(dp1
S'synergy,in'
p2
(F1
F0.00076452599388379206
I1
I0
I1
tp3
sS'with,food'
p4
(F1
F0.00076452599388379206
I0
I1
I-1
tp5
sS'mildly,hypercholesterolemic'
p6
(F1
F0.00076452599388379206
I0
I1
I-1
tp7
sS'been,assessed'
p8
(F1
F0.00076452599388379206
I0
I1
I-1
tp9
sS'date,there'
p10
(F1
F0.00076452599388379206
I0
I1
I-1
tp11
sS'no,information'
p12
(F1
F0.00076452599388379206
I0
I1
I-1
tp13
sS'vs,difference'
p14
(F1
F0.00076452599388379206
I0
I1
I-1
tp15
sS'that,rat'
p16
(F1
F0.00076452599388379206
I0
I1
I-1
tp17
sS'with,and'
p18
(F0.38461538461538464
F0.0038226299694189602
I9
I4
I5
tp19
sS'fever,severe'
p20
(F1
F0.00076452599388379206
I1
I0
I1
tp21
sS'aspirin,should'
p22
(F1
F0.0015290519877675841
I2
I0
I2
tp23
sS'coadministering,with'
p24
(F1
F0.00076452599388379206
I1
I0
I1
tp25
sS'signaling,pathways'
p26
(F1
F0.00076452599388379206
I1
I0
I1
tp27
sS'of,concentrations'
p28
(F1
F0.0015290519877675841
I2
I0
I2
tp29
sS'because,no'
p30
(F1
F0.00076452599388379206
I0
I1
I-1
tp31
sS'supplements,and'
p32
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp33
sS'the,natriuretic'
p34
(F1
F0.00076452599388379206
I1
I0
I1
tp35
sS'renal,secretion'
p36
(F1
F0.00076452599388379206
I1
I0
I1
tp37
sS'appropriate,observation'
p38
(F1
F0.00076452599388379206
I1
I0
I1
tp39
sS'receiving,than'
p40
(F1
F0.00076452599388379206
I0
I1
I-1
tp41
sS'bases,via'
p42
(F1
F0.00076452599388379206
I1
I0
I1
tp43
sS'vehicle,group'
p44
(F1
F0.00076452599388379206
I0
I1
I-1
tp45
sS'drugs,careful'
p46
(F1
F0.00076452599388379206
I1
I0
I1
tp47
sS'in,children'
p48
(F1
F0.0015290519877675841
I2
I0
I2
tp49
sS'please,note'
p50
(F1
F0.00076452599388379206
I1
I0
I1
tp51
sS'emptying,symlin'
p52
(F1
F0.00076452599388379206
I1
I0
I1
tp53
sS'inhibitors,the'
p54
(F1
F0.0015290519877675841
I2
I0
I2
tp55
sS'administration,to'
p56
(F1
F0.00076452599388379206
I1
I0
I1
tp57
sS'patient,initiates'
p58
(F1
F0.00076452599388379206
I1
I0
I1
tp59
sS'records,of'
p60
(F1
F0.00076452599388379206
I0
I1
I-1
tp61
sS'matrix,degrading'
p62
(F1
F0.00076452599388379206
I0
I1
I-1
tp63
sS'detail,below'
p64
(F1
F0.00076452599388379206
I1
I0
I1
tp65
sS'or,failed'
p66
(F1
F0.00076452599388379206
I1
I0
I1
tp67
sS'by,of'
p68
(F1
F0.00076452599388379206
I1
I0
I1
tp69
sS'oral,clinically'
p70
(F1
F0.00076452599388379206
I1
I0
I1
tp71
sS'other,cholinesterase'
p72
(F1
F0.00076452599388379206
I1
I0
I1
tp73
sS'herceptin,treatment'
p74
(F1
F0.00076452599388379206
I1
I0
I1
tp75
sS'not,isolate'
p76
(F1
F0.00076452599388379206
I1
I0
I1
tp77
sS'half-lives,all'
p78
(F1
F0.00076452599388379206
I1
I0
I1
tp79
sS'glasses,of'
p80
(F1
F0.00076452599388379206
I0
I1
I-1
tp81
sS'reacts,faster'
p82
(F1
F0.00076452599388379206
I1
I0
I1
tp83
sS'abt-737,a'
p84
(F1
F0.00076452599388379206
I1
I0
I1
tp85
sS'lines,that'
p86
(F1
F0.00076452599388379206
I0
I1
I-1
tp87
sS'agents,since'
p88
(F1
F0.00076452599388379206
I1
I0
I1
tp89
sS'a,significant'
p90
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp91
sS'sites,thus'
p92
(F1
F0.00076452599388379206
I1
I0
I1
tp93
sS'isozyme,including'
p94
(F1
F0.00076452599388379206
I1
I0
I1
tp95
sS'odds,ratio'
p96
(F1
F0.00076452599388379206
I1
I0
I1
tp97
sS'drugs,is'
p98
(F0
F0
I1
I1
I0
tp99
sS'since,bacteriostatic'
p100
(F1
F0.00076452599388379206
I1
I0
I1
tp101
sS'enhanced,by'
p102
(F1
F0.0015290519877675841
I2
I0
I2
tp103
sS'bananas,should'
p104
(F1
F0.00076452599388379206
I1
I0
I1
tp105
sS'possibly,by'
p106
(F1
F0.00076452599388379206
I1
I0
I1
tp107
sS'can,result'
p108
(F1
F0.00076452599388379206
I1
I0
I1
tp109
sS'cannot,be'
p110
(F1
F0.00076452599388379206
I1
I0
I1
tp111
sS'drugs,in'
p112
(F1
F0.0030581039755351682
I4
I0
I4
tp113
sS'lyase,than'
p114
(F1
F0.00076452599388379206
I0
I1
I-1
tp115
sS'and,who'
p116
(F1
F0.00076452599388379206
I1
I0
I1
tp117
sS'of,cognitive'
p118
(F1
F0.00076452599388379206
I1
I0
I1
tp119
sS'and,show'
p120
(F1
F0.00076452599388379206
I1
I0
I1
tp121
sS'clinical,dosage'
p122
(F1
F0.00076452599388379206
I1
I0
I1
tp123
sS'adverse,interactions'
p124
(F1
F0.0015290519877675841
I0
I2
I-2
tp125
sS'and,symptoms'
p126
(F0
F0
I1
I1
I0
tp127
sS'durations,of'
p128
(F1
F0.00076452599388379206
I1
I0
I1
tp129
sS'carbachol,may'
p130
(F1
F0.00076452599388379206
I1
I0
I1
tp131
sS'the,intensity'
p132
(F1
F0.00076452599388379206
I1
I0
I1
tp133
sS'of,proton'
p134
(F1
F0.00076452599388379206
I0
I1
I-1
tp135
sS'concentrations,of'
p136
(F0.1111111111111111
F0.00076452599388379206
I5
I4
I1
tp137
sS'we,demonstrated'
p138
(F1
F0.00076452599388379206
I1
I0
I1
tp139
sS'bound,to'
p140
(F1
F0.00076452599388379206
I0
I1
I-1
tp141
sS'de,pointe'
p142
(F1
F0.00076452599388379206
I1
I0
I1
tp143
sS'data,indicate'
p144
(F1
F0.0022935779816513763
I3
I0
I3
tp145
sS'in,all'
p146
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp147
sS'a,g'
p148
(F1
F0.00076452599388379206
I1
I0
I1
tp149
sS'mg,three'
p150
(F1
F0.0061162079510703364
I0
I8
I-8
tp151
sS'showed,a'
p152
(F1
F0.00076452599388379206
I1
I0
I1
tp153
sS'thiabendazole,may'
p154
(F1
F0.00076452599388379206
I1
I0
I1
tp155
sS'enhanced,green'
p156
(F1
F0.00076452599388379206
I0
I1
I-1
tp157
sS'is,ingested'
p158
(F1
F0.00076452599388379206
I1
I0
I1
tp159
sS'their,normal'
p160
(F1
F0.00076452599388379206
I1
I0
I1
tp161
sS'patients,already'
p162
(F1
F0.00076452599388379206
I1
I0
I1
tp163
sS'care,should'
p164
(F1
F0.00076452599388379206
I1
I0
I1
tp165
sS'clinical,practice'
p166
(F1
F0.00076452599388379206
I0
I1
I-1
tp167
sS'tricyclic,antidepressant'
p168
(F1
F0.00076452599388379206
I0
I1
I-1
tp169
sS'been,spontaneous'
p170
(F1
F0.00076452599388379206
I1
I0
I1
tp171
sS'with,high-dose'
p172
(F1
F0.0015290519877675841
I2
I0
I2
tp173
sS'control,sirna'
p174
(F1
F0.00076452599388379206
I0
I1
I-1
tp175
sS'given,twice'
p176
(F1
F0.0015290519877675841
I0
I2
I-2
tp177
sS'hypotension,and'
p178
(F1
F0.00076452599388379206
I1
I0
I1
tp179
sS'are,no'
p180
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp181
sS'containing,or'
p182
(F1
F0.00076452599388379206
I1
I0
I1
tp183
sS'combined,with'
p184
(F0
F0
I2
I2
I0
tp185
sS'influenza,vaccines'
p186
(F1
F0.00076452599388379206
I0
I1
I-1
tp187
sS'ketoconazole,an'
p188
(F1
F0.00076452599388379206
I1
I0
I1
tp189
sS'skelaxin,may'
p190
(F1
F0.00076452599388379206
I1
I0
I1
tp191
sS'combination,with'
p192
(F0.125
F0.0015290519877675841
I9
I7
I2
tp193
sS'class,drugs'
p194
(F1
F0.00076452599388379206
I1
I0
I1
tp195
sS'tomography,dopamine'
p196
(F1
F0.00076452599388379206
I1
I0
I1
tp197
sS'levothyroxine,sodium'
p198
(F1
F0.00076452599388379206
I0
I1
I-1
tp199
sS'with,nitrous'
p200
(F1
F0.00076452599388379206
I0
I1
I-1
tp201
sS'conducted,sanctura'
p202
(F1
F0.00076452599388379206
I1
I0
I1
tp203
sS'iib,iiia'
p204
(F1
F0.00076452599388379206
I1
I0
I1
tp205
sS'although,mivacron'
p206
(F1
F0.00076452599388379206
I0
I1
I-1
tp207
sS'contraction,that'
p208
(F1
F0.00076452599388379206
I0
I1
I-1
tp209
sS'agents,after'
p210
(F1
F0.00076452599388379206
I1
I0
I1
tp211
sS'and,cdk1'
p212
(F0
F0
I1
I1
I0
tp213
sS'medicines,to'
p214
(F1
F0.00076452599388379206
I0
I1
I-1
tp215
sS'subjects,mean'
p216
(F1
F0.00076452599388379206
I1
I0
I1
tp217
sS'with,treatment'
p218
(F1
F0.00076452599388379206
I0
I1
I-1
tp219
sS'metabolic,clearance'
p220
(F1
F0.00076452599388379206
I1
I0
I1
tp221
sS'proamatine,has'
p222
(F1
F0.00076452599388379206
I0
I1
I-1
tp223
sS'an,animal'
p224
(F1
F0.00076452599388379206
I1
I0
I1
tp225
sS'has,some'
p226
(F1
F0.00076452599388379206
I1
I0
I1
tp227
sS'serum,level'
p228
(F1
F0.0015290519877675841
I2
I0
I2
tp229
sS'hepatic,enzyme'
p230
(F1
F0.00076452599388379206
I1
I0
I1
tp231
sS'to,subjects'
p232
(F1
F0.0015290519877675841
I2
I0
I2
tp233
sS'with,anticholinergics'
p234
(F1
F0.00076452599388379206
I1
I0
I1
tp235
sS'pharmacodynamics,prothrombin'
p236
(F1
F0.00076452599388379206
I0
I1
I-1
tp237
sS'and,effient'
p238
(F1
F0.00076452599388379206
I0
I1
I-1
tp239
sS'diabetes,drug'
p240
(F1
F0.00076452599388379206
I1
I0
I1
tp241
sS'bid,for'
p242
(F1
F0.0015290519877675841
I2
I0
I2
tp243
sS'with,prothrombin'
p244
(F1
F0.00076452599388379206
I1
I0
I1
tp245
sS'was,a'
p246
(F0
F0
I1
I1
I0
tp247
sS'killed,virus'
p248
(F1
F0.00076452599388379206
I1
I0
I1
tp249
sS'especially,ssri'
p250
(F1
F0.00076452599388379206
I1
I0
I1
tp251
sS'antagonists,such'
p252
(F1
F0.0015290519877675841
I2
I0
I2
tp253
sS'days,a'
p254
(F1
F0.00076452599388379206
I1
I0
I1
tp255
sS'a,tricyclic'
p256
(F1
F0.00076452599388379206
I0
I1
I-1
tp257
sS'cortical,steroids'
p258
(F1
F0.00076452599388379206
I0
I1
I-1
tp259
sS'preliminary,evidence'
p260
(F1
F0.00076452599388379206
I1
I0
I1
tp261
sS'both,the'
p262
(F1
F0.00076452599388379206
I0
I1
I-1
tp263
sS'erythema,and'
p264
(F1
F0.00076452599388379206
I1
I0
I1
tp265
sS'a,terminal'
p266
(F1
F0.00076452599388379206
I0
I1
I-1
tp267
sS'agent,for'
p268
(F1
F0.00076452599388379206
I1
I0
I1
tp269
sS'symlin,and'
p270
(F0
F0
I1
I1
I0
tp271
sS'to,increased'
p272
(F1
F0.0038226299694189602
I5
I0
I5
tp273
sS'barbiturates,and'
p274
(F1
F0.00076452599388379206
I0
I1
I-1
tp275
sS'ipth,and'
p276
(F1
F0.00076452599388379206
I1
I0
I1
tp277
sS'cns,effects'
p278
(F1
F0.0015290519877675841
I2
I0
I2
tp279
sS'days,respectively'
p280
(F1
F0.00076452599388379206
I1
I0
I1
tp281
sS'folic,acid'
p282
(F1
F0.00076452599388379206
I1
I0
I1
tp283
sS'of,in'
p284
(F0.25
F0.0015290519877675841
I5
I3
I2
tp285
sS'moxifloxacin,and'
p286
(F0
F0
I1
I1
I0
tp287
sS'eg,or'
p288
(F1
F0.00076452599388379206
I1
I0
I1
tp289
sS'after,b-acetyldigoxin'
p290
(F1
F0.00076452599388379206
I0
I1
I-1
tp291
sS'of,it'
p292
(F1
F0.0015290519877675841
I2
I0
I2
tp293
sS'of,is'
p294
(F0.5
F0.0015290519877675841
I3
I1
I2
tp295
sS'ropivacaine,should'
p296
(F1
F0.00076452599388379206
I1
I0
I1
tp297
sS'a,and'
p298
(F1
F0.00076452599388379206
I0
I1
I-1
tp299
sS'xenical,should'
p300
(F1
F0.00076452599388379206
I1
I0
I1
tp301
sS'significant,pharmacokinetic'
p302
(F1
F0.00076452599388379206
I0
I1
I-1
tp303
sS'oral,no'
p304
(F1
F0.00076452599388379206
I0
I1
I-1
tp305
sS'an,adverse'
p306
(F1
F0.00076452599388379206
I1
I0
I1
tp307
sS'or,nephrotoxic'
p308
(F1
F0.00076452599388379206
I0
I1
I-1
tp309
sS'plate,test'
p310
(F1
F0.00076452599388379206
I1
I0
I1
tp311
sS'produce,a'
p312
(F1
F0.00076452599388379206
I1
I0
I1
tp313
sS'cellular,thiol'
p314
(F1
F0.00076452599388379206
I0
I1
I-1
tp315
sS'discontinuing,therapy'
p316
(F1
F0.00076452599388379206
I0
I1
I-1
tp317
sS'patients,n'
p318
(F0
F0
I1
I1
I0
tp319
sS'the,records'
p320
(F1
F0.00076452599388379206
I0
I1
I-1
tp321
sS'bp,with'
p322
(F1
F0.00076452599388379206
I0
I1
I-1
tp323
sS'adrenergic,agents'
p324
(F1
F0.0015290519877675841
I2
I0
I2
tp325
sS'increase,plasma'
p326
(F1
F0.0015290519877675841
I2
I0
I2
tp327
sS'orally,active'
p328
(F1
F0.00076452599388379206
I0
I1
I-1
tp329
sS'maleate,is'
p330
(F1
F0.00076452599388379206
I1
I0
I1
tp331
sS'a,woman'
p332
(F1
F0.00076452599388379206
I0
I1
I-1
tp333
sS'discontinuing,mexitil'
p334
(F1
F0.00076452599388379206
I1
I0
I1
tp335
sS'when,co-administered'
p336
(F1
F0.00076452599388379206
I0
I1
I-1
tp337
sS'during,concomitant'
p338
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp339
sS'alter,pharmacokinetics'
p340
(F1
F0.00076452599388379206
I0
I1
I-1
tp341
sS'osteocalcin,a'
p342
(F1
F0.00076452599388379206
I0
I1
I-1
tp343
sS'clopidogrel-treated,patients'
p344
(F1
F0.00076452599388379206
I0
I1
I-1
tp345
sS'were,also'
p346
(F1
F0.00076452599388379206
I0
I1
I-1
tp347
sS'should,avoid'
p348
(F1
F0.00076452599388379206
I1
I0
I1
tp349
sS'antidiabetic,drugs'
p350
(F1
F0.00076452599388379206
I1
I0
I1
tp351
sS'rats,neonatal'
p352
(F1
F0.00076452599388379206
I1
I0
I1
tp353
sS'cotreatment,with'
p354
(F1
F0.00076452599388379206
I1
I0
I1
tp355
sS'in,studies'
p356
(F1
F0.00076452599388379206
I0
I1
I-1
tp357
sS'acute,toxicity'
p358
(F1
F0.00076452599388379206
I0
I1
I-1
tp359
sS'glutathione,and'
p360
(F1
F0.00076452599388379206
I0
I1
I-1
tp361
sS'benzodiazepines,which'
p362
(F1
F0.00076452599388379206
I1
I0
I1
tp363
sS'ie,some'
p364
(F1
F0.00076452599388379206
I1
I0
I1
tp365
sS'hepatic,cytochrome'
p366
(F1
F0.00076452599388379206
I0
I1
I-1
tp367
sS'purpose,of'
p368
(F1
F0.0015290519877675841
I0
I2
I-2
tp369
sS'these,effects'
p370
(F0
F0
I1
I1
I0
tp371
sS'with,lower'
p372
(F1
F0.00076452599388379206
I1
I0
I1
tp373
sS'arrested,at'
p374
(F1
F0.00076452599388379206
I0
I1
I-1
tp375
sS'perfusion,of'
p376
(F1
F0.00076452599388379206
I1
I0
I1
tp377
sS'agents,structurally'
p378
(F1
F0.00076452599388379206
I1
I0
I1
tp379
sS'cmax,in'
p380
(F1
F0.00076452599388379206
I1
I0
I1
tp381
sS'elicits,a'
p382
(F1
F0.00076452599388379206
I1
I0
I1
tp383
sS'gastrointestinal,symptoms'
p384
(F1
F0.00076452599388379206
I1
I0
I1
tp385
sS'taken,a'
p386
(F1
F0.00076452599388379206
I1
I0
I1
tp387
sS'time,should'
p388
(F1
F0.00076452599388379206
I1
I0
I1
tp389
sS'measurements,of'
p390
(F1
F0.00076452599388379206
I1
I0
I1
tp391
sS'mg,were'
p392
(F1
F0.0015290519877675841
I0
I2
I-2
tp393
sS'used,when'
p394
(F1
F0.0030581039755351682
I4
I0
I4
tp395
sS'of,days'
p396
(F1
F0.00076452599388379206
I1
I0
I1
tp397
sS'nsaids,have'
p398
(F1
F0.00076452599388379206
I1
I0
I1
tp399
sS'one,hour'
p400
(F1
F0.00076452599388379206
I1
I0
I1
tp401
sS'exposure,following'
p402
(F1
F0.00076452599388379206
I0
I1
I-1
tp403
sS'patients,there'
p404
(F1
F0.00076452599388379206
I0
I1
I-1
tp405
sS'but,only'
p406
(F1
F0.00076452599388379206
I0
I1
I-1
tp407
sS'oral,adjuvant'
p408
(F1
F0.00076452599388379206
I0
I1
I-1
tp409
sS'increased,prothrombin'
p410
(F1
F0.00076452599388379206
I1
I0
I1
tp411
sS'may,lead'
p412
(F0.5
F0.0015290519877675841
I3
I1
I2
tp413
sS'kg,body'
p414
(F1
F0.00076452599388379206
I0
I1
I-1
tp415
sS'development,of'
p416
(F1
F0.00076452599388379206
I0
I1
I-1
tp417
sS'administrations,of'
p418
(F1
F0.00076452599388379206
I1
I0
I1
tp419
sS'reported,during'
p420
(F1
F0.00076452599388379206
I1
I0
I1
tp421
sS'fraction,control'
p422
(F1
F0.00076452599388379206
I0
I1
I-1
tp423
sS'effectiveness,of'
p424
(F0.5
F0.0015290519877675841
I3
I1
I2
tp425
sS'the,addition'
p426
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp427
sS'found,antagonism'
p428
(F1
F0.00076452599388379206
I1
I0
I1
tp429
sS'fenofibrate,in'
p430
(F1
F0.00076452599388379206
I1
I0
I1
tp431
sS'crm197,induced'
p432
(F1
F0.00076452599388379206
I1
I0
I1
tp433
sS'exposure,to'
p434
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp435
sS'with,ventricular'
p436
(F1
F0.00076452599388379206
I0
I1
I-1
tp437
sS'known,at'
p438
(F1
F0.00076452599388379206
I0
I1
I-1
tp439
sS'however,and'
p440
(F1
F0.00076452599388379206
I0
I1
I-1
tp441
sS'curve,of'
p442
(F1
F0.00076452599388379206
I0
I1
I-1
tp443
sS'p450,a4'
p444
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp445
sS'p450,a6'
p446
(F1
F0.00076452599388379206
I0
I1
I-1
tp447
sS'smoking,may'
p448
(F1
F0.00076452599388379206
I0
I1
I-1
tp449
sS'also,prolonged'
p450
(F1
F0.00076452599388379206
I1
I0
I1
tp451
sS'phenytoin,carbamazepine'
p452
(F1
F0.00076452599388379206
I1
I0
I1
tp453
sS'metopirone,is'
p454
(F1
F0.00076452599388379206
I1
I0
I1
tp455
sS'clinical,effects'
p456
(F1
F0.00076452599388379206
I0
I1
I-1
tp457
sS'dopaminergic,and'
p458
(F0
F0
I1
I1
I0
tp459
sS'interactions,should'
p460
(F1
F0.00076452599388379206
I0
I1
I-1
tp461
sS'with,such'
p462
(F1
F0.00076452599388379206
I0
I1
I-1
tp463
sS'initiates,or'
p464
(F1
F0.00076452599388379206
I1
I0
I1
tp465
sS'of,chemotherapy'
p466
(F1
F0.00076452599388379206
I1
I0
I1
tp467
sS'multiple,myeloma'
p468
(F1
F0.00076452599388379206
I0
I1
I-1
tp469
sS'comes,from'
p470
(F1
F0.00076452599388379206
I1
I0
I1
tp471
sS'since,celontin'
p472
(F1
F0.00076452599388379206
I1
I0
I1
tp473
sS'decreased,dasatinib-'
p474
(F1
F0.00076452599388379206
I0
I1
I-1
tp475
sS'rats,there'
p476
(F1
F0.00076452599388379206
I0
I1
I-1
tp477
sS'with,alone'
p478
(F1
F0.00076452599388379206
I1
I0
I1
tp479
sS'anesthetics,phenothiazines'
p480
(F1
F0.00076452599388379206
I1
I0
I1
tp481
sS'the,or'
p482
(F0.5
F0.0015290519877675841
I3
I1
I2
tp483
sS'pressor,amines'
p484
(F1
F0.0015290519877675841
I2
I0
I2
tp485
sS'studies,demonstrate'
p486
(F1
F0.00076452599388379206
I1
I0
I1
tp487
sS'and,avian'
p488
(F1
F0.00076452599388379206
I0
I1
I-1
tp489
sS'not,been'
p490
(F0.23076923076923078
F0.0022935779816513763
I5
I8
I-3
tp491
sS'kip1,enhanced'
p492
(F1
F0.00076452599388379206
I1
I0
I1
tp493
sS'the,potent'
p494
(F1
F0.00076452599388379206
I1
I0
I1
tp495
sS'solutions,containing'
p496
(F1
F0.00076452599388379206
I0
I1
I-1
tp497
sS'somnolence,drowsiness'
p498
(F1
F0.00076452599388379206
I1
I0
I1
tp499
sS'patient,receiving'
p500
(F1
F0.00076452599388379206
I1
I0
I1
tp501
sS'inhibitor,synergistically'
p502
(F1
F0.00076452599388379206
I1
I0
I1
tp503
sS'zidovudine,competitively'
p504
(F1
F0.00076452599388379206
I1
I0
I1
tp505
sS'carboptic,isopto'
p506
(F1
F0.00076452599388379206
I1
I0
I1
tp507
sS'british,national'
p508
(F1
F0.00076452599388379206
I0
I1
I-1
tp509
sS'and,international'
p510
(F1
F0.00076452599388379206
I1
I0
I1
tp511
sS'vasopressors,particularly'
p512
(F1
F0.0015290519877675841
I2
I0
I2
tp513
sS'medications,can'
p514
(F1
F0.00076452599388379206
I1
I0
I1
tp515
sS'with,vasoconstrictor'
p516
(F1
F0.00076452599388379206
I0
I1
I-1
tp517
sS'inr,or'
p518
(F1
F0.0015290519877675841
I2
I0
I2
tp519
sS'up,to'
p520
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp521
sS'activity,of'
p522
(F0.1111111111111111
F0.00076452599388379206
I5
I4
I1
tp523
sS'and,grapefruit'
p524
(F1
F0.00076452599388379206
I1
I0
I1
tp525
sS'to,plasma'
p526
(F1
F0.00076452599388379206
I0
I1
I-1
tp527
sS'uptake,cellular'
p528
(F1
F0.00076452599388379206
I0
I1
I-1
tp529
sS'known,inhibitor'
p530
(F0
F0
I1
I1
I0
tp531
sS'also,which'
p532
(F1
F0.00076452599388379206
I1
I0
I1
tp533
sS'at,all'
p534
(F1
F0.0015290519877675841
I2
I0
I2
tp535
sS'was,found'
p536
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp537
sS'also,be'
p538
(F1
F0.0015290519877675841
I2
I0
I2
tp539
sS'be,required'
p540
(F1
F0.00076452599388379206
I1
I0
I1
tp541
sS'before,hot'
p542
(F1
F0.00076452599388379206
I0
I1
I-1
tp543
sS'clinical,studies'
p544
(F1
F0.0022935779816513763
I3
I0
I3
tp545
sS'involving,cyp2d6'
p546
(F1
F0.00076452599388379206
I0
I1
I-1
tp547
sS'administering,mitotane'
p548
(F1
F0.00076452599388379206
I1
I0
I1
tp549
sS'and,can'
p550
(F1
F0.0022935779816513763
I3
I0
I3
tp551
sS'coumarin-type,have'
p552
(F1
F0.00076452599388379206
I1
I0
I1
tp553
sS'potent,cytochrome'
p554
(F1
F0.0022935779816513763
I3
I0
I3
tp555
sS'on,cmax'
p556
(F1
F0.00076452599388379206
I1
I0
I1
tp557
sS'when,feldene'
p558
(F1
F0.00076452599388379206
I1
I0
I1
tp559
sS'intake,before'
p560
(F1
F0.00076452599388379206
I0
I1
I-1
tp561
sS'competition,for'
p562
(F1
F0.00076452599388379206
I0
I1
I-1
tp563
sS'or,potentiate'
p564
(F1
F0.0015290519877675841
I2
I0
I2
tp565
sS'subtherapeutic,levels'
p566
(F1
F0.00076452599388379206
I1
I0
I1
tp567
sS'calcium,does'
p568
(F1
F0.00076452599388379206
I0
I1
I-1
tp569
sS'qtc,interval'
p570
(F0
F0
I1
I1
I0
tp571
sS'enzymes,may'
p572
(F1
F0.00076452599388379206
I0
I1
I-1
tp573
sS'usage,with'
p574
(F1
F0.00076452599388379206
I1
I0
I1
tp575
sS'of,wine'
p576
(F1
F0.00076452599388379206
I0
I1
I-1
tp577
sS'heme,and'
p578
(F1
F0.00076452599388379206
I0
I1
I-1
tp579
sS'recur,in'
p580
(F1
F0.00076452599388379206
I0
I1
I-1
tp581
sS'suggested,the'
p582
(F1
F0.00076452599388379206
I1
I0
I1
tp583
sS'coadministered,coadministration'
p584
(F1
F0.00076452599388379206
I1
I0
I1
tp585
sS'against,the'
p586
(F1
F0.00076452599388379206
I0
I1
I-1
tp587
sS'or,are'
p588
(F1
F0.0022935779816513763
I3
I0
I3
tp589
sS'the,breakdown'
p590
(F1
F0.00076452599388379206
I1
I0
I1
tp591
sS'or,medications'
p592
(F1
F0.00076452599388379206
I1
I0
I1
tp593
sS'co-administered,drugs'
p594
(F1
F0.00076452599388379206
I0
I1
I-1
tp595
sS'application,in'
p596
(F1
F0.00076452599388379206
I0
I1
I-1
tp597
sS'with,different'
p598
(F1
F0.00076452599388379206
I1
I0
I1
tp599
sS'we,elucidated'
p600
(F1
F0.00076452599388379206
I0
I1
I-1
tp601
sS'r-,and'
p602
(F1
F0.00076452599388379206
I0
I1
I-1
tp603
sS'be,a'
p604
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp605
sS'indications,for'
p606
(F1
F0.00076452599388379206
I0
I1
I-1
tp607
sS'vitamin,supplements'
p608
(F1
F0.00076452599388379206
I1
I0
I1
tp609
sS'desired,level'
p610
(F1
F0.00076452599388379206
I1
I0
I1
tp611
sS'mice,while'
p612
(F1
F0.00076452599388379206
I1
I0
I1
tp613
sS'results,in'
p614
(F0.5
F0.0015290519877675841
I3
I1
I2
tp615
sS'potential,interactions'
p616
(F0
F0
I1
I1
I0
tp617
sS'if,replacement'
p618
(F1
F0.00076452599388379206
I0
I1
I-1
tp619
sS'and,alone'
p620
(F1
F0.00076452599388379206
I0
I1
I-1
tp621
sS'may,develop'
p622
(F0
F0
I1
I1
I0
tp623
sS'confusion,disorientation'
p624
(F1
F0.00076452599388379206
I1
I0
I1
tp625
sS'mobic,patients'
p626
(F1
F0.00076452599388379206
I1
I0
I1
tp627
sS'directly,on'
p628
(F1
F0.00076452599388379206
I1
I0
I1
tp629
sS'lomefloxacin,reacts'
p630
(F1
F0.00076452599388379206
I1
I0
I1
tp631
sS'sulfonamides,concurrent'
p632
(F1
F0.00076452599388379206
I1
I0
I1
tp633
sS'other,chemotherapeutic'
p634
(F1
F0.00076452599388379206
I0
I1
I-1
tp635
sS'experiments,gsls'
p636
(F1
F0.00076452599388379206
I0
I1
I-1
tp637
sS'significant,increase'
p638
(F1
F0.0030581039755351682
I4
I0
I4
tp639
sS'enhance,toxicity'
p640
(F1
F0.00076452599388379206
I1
I0
I1
tp641
sS'concomitantly,with'
p642
(F0.875
F0.010703363914373088
I15
I1
I14
tp643
sS'on,various'
p644
(F1
F0.00076452599388379206
I0
I1
I-1
tp645
sS'to,potentially'
p646
(F1
F0.00076452599388379206
I1
I0
I1
tp647
sS'other,hdac'
p648
(F1
F0.00076452599388379206
I1
I0
I1
tp649
sS'the,sirna'
p650
(F1
F0.00076452599388379206
I0
I1
I-1
tp651
sS'they,have'
p652
(F1
F0.00076452599388379206
I0
I1
I-1
tp653
sS'infusion,rate'
p654
(F1
F0.00076452599388379206
I1
I0
I1
tp655
sS'lyase,greatly'
p656
(F1
F0.00076452599388379206
I0
I1
I-1
tp657
sS'in,ethinyl'
p658
(F1
F0.00076452599388379206
I1
I0
I1
tp659
sS'day,males'
p660
(F1
F0.00076452599388379206
I0
I1
I-1
tp661
sS'as,striatal'
p662
(F1
F0.00076452599388379206
I1
I0
I1
tp663
sS'inhibitor,aminobenzotriazole'
p664
(F1
F0.00076452599388379206
I0
I1
I-1
tp665
sS'or,januvia'
p666
(F1
F0.00076452599388379206
I0
I1
I-1
tp667
sS'to,decline'
p668
(F1
F0.00076452599388379206
I0
I1
I-1
tp669
sS'enzymes,improves'
p670
(F1
F0.00076452599388379206
I0
I1
I-1
tp671
sS'causing,an'
p672
(F1
F0.00076452599388379206
I1
I0
I1
tp673
sS'indicating,a'
p674
(F1
F0.00076452599388379206
I0
I1
I-1
tp675
sS'significantly,modified'
p676
(F1
F0.00076452599388379206
I0
I1
I-1
tp677
sS'clearance,increased'
p678
(F1
F0.00076452599388379206
I1
I0
I1
tp679
sS'activity,sympathomimetic'
p680
(F1
F0.00076452599388379206
I1
I0
I1
tp681
sS'by,however'
p682
(F1
F0.00076452599388379206
I0
I1
I-1
tp683
sS'be,provided'
p684
(F1
F0.00076452599388379206
I1
I0
I1
tp685
sS'dexmedetomidine-induced,antinociception'
p686
(F1
F0.00076452599388379206
I0
I1
I-1
tp687
sS'cationic,transport'
p688
(F1
F0.0015290519877675841
I2
I0
I2
tp689
sS'vitro,activity'
p690
(F1
F0.0015290519877675841
I0
I2
I-2
tp691
sS'or,has'
p692
(F1
F0.00076452599388379206
I0
I1
I-1
tp693
sS'significant,synergism'
p694
(F1
F0.00076452599388379206
I1
I0
I1
tp695
sS'the,volume'
p696
(F1
F0.00076452599388379206
I0
I1
I-1
tp697
sS'or,had'
p698
(F1
F0.00076452599388379206
I1
I0
I1
tp699
sS'cyp3a4,significantly'
p700
(F1
F0.00076452599388379206
I1
I0
I1
tp701
sS'reproduce,the'
p702
(F1
F0.00076452599388379206
I0
I1
I-1
tp703
sS'doses,generally'
p704
(F1
F0.00076452599388379206
I0
I1
I-1
tp705
sS'when,administered'
p706
(F1
F0.0045871559633027525
I6
I0
I6
tp707
sS'ra,patients'
p708
(F1
F0.00076452599388379206
I0
I1
I-1
tp709
sS'not,demonstrated'
p710
(F1
F0.00076452599388379206
I0
I1
I-1
tp711
sS'in,any'
p712
(F1
F0.0015290519877675841
I0
I2
I-2
tp713
sS'in,and'
p714
(F1
F0.00076452599388379206
I1
I0
I1
tp715
sS'associated,with'
p716
(F0.46666666666666667
F0.0053516819571865441
I11
I4
I7
tp717
sS'other,short-acting'
p718
(F1
F0.00076452599388379206
I1
I0
I1
tp719
sS'caution,should'
p720
(F0.66666666666666663
F0.0061162079510703364
I10
I2
I8
tp721
sS'have,produced'
p722
(F1
F0.00076452599388379206
I1
I0
I1
tp723
sS'diabetes,mellitus'
p724
(F1
F0.00076452599388379206
I1
I0
I1
tp725
sS'during,treatment'
p726
(F1
F0.00076452599388379206
I1
I0
I1
tp727
sS'emulsion,does'
p728
(F1
F0.00076452599388379206
I0
I1
I-1
tp729
sS'between,tamsulosin'
p730
(F1
F0.00076452599388379206
I0
I1
I-1
tp731
sS'second,day'
p732
(F1
F0.00076452599388379206
I1
I0
I1
tp733
sS'those,started'
p734
(F1
F0.00076452599388379206
I1
I0
I1
tp735
sS'the,side'
p736
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp737
sS'intravenous,premedication'
p738
(F1
F0.00076452599388379206
I1
I0
I1
tp739
sS'in,onset'
p740
(F1
F0.00076452599388379206
I0
I1
I-1
tp741
sS'herceptin,improved'
p742
(F1
F0.00076452599388379206
I1
I0
I1
tp743
sS'acid,a'
p744
(F1
F0.00076452599388379206
I0
I1
I-1
tp745
sS'approximately,glasses'
p746
(F1
F0.00076452599388379206
I0
I1
I-1
tp747
sS'with,prevention'
p748
(F1
F0.00076452599388379206
I1
I0
I1
tp749
sS'pediatric,oncology'
p750
(F1
F0.00076452599388379206
I0
I1
I-1
tp751
sS'patients,the'
p752
(F1
F0.00076452599388379206
I1
I0
I1
tp753
sS'rheumatoid,arthritis'
p754
(F1
F0.0022935779816513763
I0
I3
I-3
tp755
sS'no,dosage'
p756
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp757
sS'gsls,may'
p758
(F1
F0.00076452599388379206
I0
I1
I-1
tp759
sS'parenteral,demonstrated'
p760
(F1
F0.00076452599388379206
I1
I0
I1
tp761
sS'marrow,depression'
p762
(F1
F0.00076452599388379206
I1
I0
I1
tp763
sS'or,concurrent'
p764
(F1
F0.00076452599388379206
I1
I0
I1
tp765
sS'local,have'
p766
(F1
F0.00076452599388379206
I0
I1
I-1
tp767
sS'terfenadine,cisapride'
p768
(F1
F0.00076452599388379206
I1
I0
I1
tp769
sS'mixing,symlin'
p770
(F1
F0.00076452599388379206
I1
I0
I1
tp771
sS'and,its'
p772
(F1
F0.0022935779816513763
I0
I3
I-3
tp773
sS'caused,deaths'
p774
(F1
F0.00076452599388379206
I1
I0
I1
tp775
sS'to,chickens'
p776
(F1
F0.00076452599388379206
I1
I0
I1
tp777
sS'provided,as'
p778
(F1
F0.00076452599388379206
I1
I0
I1
tp779
sS'torsades,de'
p780
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp781
sS'these,are'
p782
(F1
F0.00076452599388379206
I1
I0
I1
tp783
sS'in,metabolism'
p784
(F1
F0.0015290519877675841
I2
I0
I2
tp785
sS'considered,necessary'
p786
(F1
F0.00076452599388379206
I1
I0
I1
tp787
sS'steroids,or'
p788
(F1
F0.00076452599388379206
I0
I1
I-1
tp789
sS'range,of'
p790
(F1
F0.0015290519877675841
I0
I2
I-2
tp791
sS'small,studies'
p792
(F1
F0.00076452599388379206
I1
I0
I1
tp793
sS'before,or'
p794
(F1
F0.00076452599388379206
I0
I1
I-1
tp795
sS'serum,concentrations'
p796
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp797
sS'included,thyroid'
p798
(F1
F0.00076452599388379206
I0
I1
I-1
tp799
sS'immediately,prior'
p800
(F1
F0.00076452599388379206
I1
I0
I1
tp801
sS'with,resulted'
p802
(F1
F0.0015290519877675841
I2
I0
I2
tp803
sS'human,plasma'
p804
(F1
F0.00076452599388379206
I0
I1
I-1
tp805
sS'enzyme,care'
p806
(F1
F0.00076452599388379206
I1
I0
I1
tp807
sS'of,target'
p808
(F0
F0
I1
I1
I0
tp809
sS'evaluated,how'
p810
(F1
F0.00076452599388379206
I0
I1
I-1
tp811
sS'greater,potentiation'
p812
(F1
F0.00076452599388379206
I0
I1
I-1
tp813
sS'values,within'
p814
(F1
F0.00076452599388379206
I1
I0
I1
tp815
sS'acid,should'
p816
(F1
F0.00076452599388379206
I0
I1
I-1
tp817
sS'concurrent,mexitil'
p818
(F1
F0.00076452599388379206
I0
I1
I-1
tp819
sS'to,analyze'
p820
(F1
F0.00076452599388379206
I0
I1
I-1
tp821
sS'effects,such'
p822
(F1
F0.00076452599388379206
I1
I0
I1
tp823
sS'was,carried'
p824
(F1
F0.00076452599388379206
I0
I1
I-1
tp825
sS'ganciclovir,may'
p826
(F1
F0.00076452599388379206
I0
I1
I-1
tp827
sS'present,an'
p828
(F1
F0.00076452599388379206
I1
I0
I1
tp829
sS'anticoagulation,and'
p830
(F1
F0.00076452599388379206
I0
I1
I-1
tp831
sS'vivo,drug-drug'
p832
(F1
F0.0015290519877675841
I0
I2
I-2
tp833
sS'of,meq'
p834
(F1
F0.00076452599388379206
I1
I0
I1
tp835
sS'but,the'
p836
(F1
F0.0015290519877675841
I2
I0
I2
tp837
sS'anti-cancer,drugs'
p838
(F1
F0.00076452599388379206
I1
I0
I1
tp839
sS'antifungals,bleeding'
p840
(F1
F0.00076452599388379206
I1
I0
I1
tp841
sS'disc,diffusion'
p842
(F1
F0.00076452599388379206
I1
I0
I1
tp843
sS'a,dznep'
p844
(F1
F0.00076452599388379206
I0
I1
I-1
tp845
sS'of,p27'
p846
(F0
F0
I2
I2
I0
tp847
sS'in,healthy'
p848
(F0.25
F0.0015290519877675841
I3
I5
I-2
tp849
sS'concurrently,may'
p850
(F1
F0.00076452599388379206
I1
I0
I1
tp851
sS'dose-dependent,growth'
p852
(F1
F0.00076452599388379206
I0
I1
I-1
tp853
sS'changes,of'
p854
(F1
F0.00076452599388379206
I0
I1
I-1
tp855
sS'between,mivacron'
p856
(F1
F0.00076452599388379206
I0
I1
I-1
tp857
sS'with,zerit'
p858
(F1
F0.00076452599388379206
I1
I0
I1
tp859
sS'from,adequate'
p860
(F1
F0.00076452599388379206
I0
I1
I-1
tp861
sS'increase,salt'
p862
(F1
F0.00076452599388379206
I0
I1
I-1
tp863
sS'drugs,being'
p864
(F1
F0.00076452599388379206
I0
I1
I-1
tp865
sS'with,ethacrynic'
p866
(F1
F0.00076452599388379206
I1
I0
I1
tp867
sS'if,in'
p868
(F1
F0.00076452599388379206
I1
I0
I1
tp869
sS'respiratory,depression'
p870
(F1
F0.0030581039755351682
I4
I0
I4
tp871
sS'of,src'
p872
(F0
F0
I1
I1
I0
tp873
sS's,active'
p874
(F1
F0.00076452599388379206
I1
I0
I1
tp875
sS'and,represents'
p876
(F1
F0.00076452599388379206
I1
I0
I1
tp877
sS'glycoside,regimen'
p878
(F1
F0.00076452599388379206
I0
I1
I-1
tp879
sS'shown,antitumor'
p880
(F1
F0.00076452599388379206
I0
I1
I-1
tp881
sS'non-human,primate'
p882
(F1
F0.00076452599388379206
I1
I0
I1
tp883
sS'phenytoin,in'
p884
(F1
F0.00076452599388379206
I0
I1
I-1
tp885
sS'if,is'
p886
(F1
F0.0015290519877675841
I2
I0
I2
tp887
sS'also,added'
p888
(F1
F0.00076452599388379206
I0
I1
I-1
tp889
sS'metolazone,as'
p890
(F1
F0.00076452599388379206
I1
I0
I1
tp891
sS'marked,shrinkage'
p892
(F1
F0.00076452599388379206
I1
I0
I1
tp893
sS'of,compounds'
p894
(F1
F0.00076452599388379206
I1
I0
I1
tp895
sS'an,appropriate'
p896
(F1
F0.00076452599388379206
I0
I1
I-1
tp897
sS'premedications,such'
p898
(F1
F0.00076452599388379206
I0
I1
I-1
tp899
sS'active,renal'
p900
(F1
F0.00076452599388379206
I0
I1
I-1
tp901
sS'in,exposure'
p902
(F1
F0.00076452599388379206
I0
I1
I-1
tp903
sS'or,induction'
p904
(F1
F0.00076452599388379206
I0
I1
I-1
tp905
sS'by,hepatic'
p906
(F0
F0
I1
I1
I0
tp907
sS'adverse,effects'
p908
(F1
F0.00076452599388379206
I1
I0
I1
tp909
sS'injection,polymyxin'
p910
(F1
F0.00076452599388379206
I0
I1
I-1
tp911
sS'anti-resorptive,response'
p912
(F1
F0.00076452599388379206
I1
I0
I1
tp913
sS'essential,hypertension'
p914
(F1
F0.00076452599388379206
I1
I0
I1
tp915
sS'enhances,herceptin-mediated'
p916
(F1
F0.00076452599388379206
I1
I0
I1
tp917
sS'particularly,in'
p918
(F1
F0.00076452599388379206
I1
I0
I1
tp919
sS'the,retinal'
p920
(F1
F0.00076452599388379206
I0
I1
I-1
tp921
sS'serious,adverse'
p922
(F1
F0.00076452599388379206
I0
I1
I-1
tp923
sS'not,otherwise'
p924
(F1
F0.00076452599388379206
I0
I1
I-1
tp925
sS'of,uveitis'
p926
(F1
F0.00076452599388379206
I1
I0
I1
tp927
sS'month,after'
p928
(F1
F0.00076452599388379206
I1
I0
I1
tp929
sS'was,overexpressed'
p930
(F1
F0.00076452599388379206
I1
I0
I1
tp931
sS'for,may'
p932
(F1
F0.00076452599388379206
I1
I0
I1
tp933
sS'bleeding,complications'
p934
(F1
F0.00076452599388379206
I1
I0
I1
tp935
sS'unusually,large'
p936
(F1
F0.00076452599388379206
I1
I0
I1
tp937
sS'with,ultram'
p938
(F1
F0.00076452599388379206
I0
I1
I-1
tp939
sS'the,molecular'
p940
(F1
F0.00076452599388379206
I1
I0
I1
tp941
sS'not,alter'
p942
(F0.81818181818181823
F0.0068807339449541288
I1
I10
I-9
tp943
sS'decreased,due'
p944
(F1
F0.00076452599388379206
I1
I0
I1
tp945
sS'ssris,have'
p946
(F1
F0.00076452599388379206
I1
I0
I1
tp947
sS'for,myocardial'
p948
(F1
F0.00076452599388379206
I0
I1
I-1
tp949
sS'cmax,of'
p950
(F1
F0.00076452599388379206
I1
I0
I1
tp951
sS'an,estrogen'
p952
(F1
F0.00076452599388379206
I0
I1
I-1
tp953
sS'none,of'
p954
(F1
F0.00076452599388379206
I1
I0
I1
tp955
sS'and,cyp1a2'
p956
(F1
F0.00076452599388379206
I0
I1
I-1
tp957
sS'taking,the'
p958
(F1
F0.00076452599388379206
I1
I0
I1
tp959
sS'be,observed'
p960
(F1
F0.0022935779816513763
I3
I0
I3
tp961
sS'pointes,in'
p962
(F1
F0.00076452599388379206
I1
I0
I1
tp963
sS'noted,using'
p964
(F1
F0.00076452599388379206
I0
I1
I-1
tp965
sS'the,starting'
p966
(F1
F0.00076452599388379206
I0
I1
I-1
tp967
sS'by,approximately'
p968
(F1
F0.0015290519877675841
I2
I0
I2
tp969
sS'and,stimulant'
p970
(F1
F0.00076452599388379206
I0
I1
I-1
tp971
sS'anabolic,may'
p972
(F1
F0.00076452599388379206
I1
I0
I1
tp973
sS'the,delivery'
p974
(F1
F0.00076452599388379206
I1
I0
I1
tp975
sS'receiving,and'
p976
(F1
F0.0030581039755351682
I4
I0
I4
tp977
sS'inhibitor,activity'
p978
(F1
F0.00076452599388379206
I0
I1
I-1
tp979
sS'of,multiple'
p980
(F0
F0
I1
I1
I0
tp981
sS'furthermore,in'
p982
(F1
F0.00076452599388379206
I1
I0
I1
tp983
sS's,pharmacokinetics'
p984
(F1
F0.00076452599388379206
I1
I0
I1
tp985
sS'bleeding,upon'
p986
(F1
F0.00076452599388379206
I1
I0
I1
tp987
sS'food,interactions'
p988
(F1
F0.00076452599388379206
I1
I0
I1
tp989
sS'gastrointestinal,absorption'
p990
(F1
F0.00076452599388379206
I1
I0
I1
tp991
sS'zemuron,mg'
p992
(F1
F0.00076452599388379206
I0
I1
I-1
tp993
sS'normal,healthy'
p994
(F1
F0.00076452599388379206
I1
I0
I1
tp995
sS'or,high'
p996
(F1
F0.00076452599388379206
I0
I1
I-1
tp997
sS'day,but'
p998
(F1
F0.00076452599388379206
I1
I0
I1
tp999
sS'efficacy,and'
p1000
(F1
F0.00076452599388379206
I0
I1
I-1
tp1001
sS'therapy,resulting'
p1002
(F1
F0.00076452599388379206
I1
I0
I1
tp1003
sS'with,hmg-coa'
p1004
(F1
F0.00076452599388379206
I0
I1
I-1
tp1005
sS'concurrent,ingestion'
p1006
(F1
F0.00076452599388379206
I0
I1
I-1
tp1007
sS'as,given'
p1008
(F1
F0.00076452599388379206
I1
I0
I1
tp1009
sS'tolectin,to'
p1010
(F1
F0.00076452599388379206
I1
I0
I1
tp1011
sS'that,myfortic'
p1012
(F1
F0.0015290519877675841
I2
I0
I2
tp1013
sS'period,of'
p1014
(F1
F0.00076452599388379206
I1
I0
I1
tp1015
sS'enhances,the'
p1016
(F1
F0.0015290519877675841
I2
I0
I2
tp1017
sS'absorption,that'
p1018
(F1
F0.00076452599388379206
I0
I1
I-1
tp1019
sS'plasma,vitamin'
p1020
(F1
F0.00076452599388379206
I1
I0
I1
tp1021
sS'the,difference'
p1022
(F1
F0.00076452599388379206
I0
I1
I-1
tp1023
sS'of,milligrams'
p1024
(F1
F0.00076452599388379206
I0
I1
I-1
tp1025
sS'remeron,has'
p1026
(F1
F0.00076452599388379206
I1
I0
I1
tp1027
sS'test,of'
p1028
(F1
F0.00076452599388379206
I0
I1
I-1
tp1029
sS'the,in'
p1030
(F1
F0.0015290519877675841
I0
I2
I-2
tp1031
sS'were,all'
p1032
(F1
F0.00076452599388379206
I1
I0
I1
tp1033
sS'minimal,increase'
p1034
(F1
F0.00076452599388379206
I1
I0
I1
tp1035
sS'been,postmarketing'
p1036
(F1
F0.00076452599388379206
I1
I0
I1
tp1037
sS'not,known'
p1038
(F1
F0.0015290519877675841
I0
I2
I-2
tp1039
sS'fluorescent,protein'
p1040
(F1
F0.00076452599388379206
I0
I1
I-1
tp1041
sS'but,also'
p1042
(F1
F0.00076452599388379206
I1
I0
I1
tp1043
sS'the,case'
p1044
(F1
F0.00076452599388379206
I1
I0
I1
tp1045
sS'increase,of'
p1046
(F1
F0.00076452599388379206
I1
I0
I1
tp1047
sS'unnecessary,when'
p1048
(F1
F0.00076452599388379206
I0
I1
I-1
tp1049
sS'drugs,having'
p1050
(F0
F0
I1
I1
I0
tp1051
sS'increase,or'
p1052
(F1
F0.00076452599388379206
I1
I0
I1
tp1053
sS'significantly,increase'
p1054
(F1
F0.0015290519877675841
I2
I0
I2
tp1055
sS'medicines,for'
p1056
(F1
F0.00076452599388379206
I0
I1
I-1
tp1057
sS'in,two'
p1058
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp1059
sS'parenteral,solutions'
p1060
(F1
F0.00076452599388379206
I0
I1
I-1
tp1061
sS'vitro,assay'
p1062
(F1
F0.00076452599388379206
I1
I0
I1
tp1063
sS'and,displaced'
p1064
(F1
F0.00076452599388379206
I1
I0
I1
tp1065
sS'are,known'
p1066
(F1
F0.00076452599388379206
I1
I0
I1
tp1067
sS'dose-related,myelotoxicity'
p1068
(F1
F0.00076452599388379206
I1
I0
I1
tp1069
sS'convulsions,have'
p1070
(F1
F0.00076452599388379206
I1
I0
I1
tp1071
sS'users,who'
p1072
(F1
F0.00076452599388379206
I1
I0
I1
tp1073
sS'that,dopamine'
p1074
(F1
F0.00076452599388379206
I1
I0
I1
tp1075
sS'live,organism'
p1076
(F1
F0.00076452599388379206
I1
I0
I1
tp1077
sS'contraindicated,should'
p1078
(F1
F0.00076452599388379206
I0
I1
I-1
tp1079
sS'of,inhibition'
p1080
(F1
F0.00076452599388379206
I1
I0
I1
tp1081
sS'accordingly,patients'
p1082
(F1
F0.0015290519877675841
I2
I0
I2
tp1083
sS'with,alcohol'
p1084
(F1
F0.00076452599388379206
I1
I0
I1
tp1085
sS'to,sensitize'
p1086
(F1
F0.00076452599388379206
I0
I1
I-1
tp1087
sS'bacteriostatic,may'
p1088
(F1
F0.0015290519877675841
I2
I0
I2
tp1089
sS'thiazide,diuretics'
p1090
(F1
F0.00076452599388379206
I1
I0
I1
tp1091
sS'with,qt'
p1092
(F1
F0.00076452599388379206
I1
I0
I1
tp1093
sS'to,influence'
p1094
(F1
F0.00076452599388379206
I1
I0
I1
tp1095
sS'and,for'
p1096
(F1
F0.00076452599388379206
I1
I0
I1
tp1097
sS'fact,that'
p1098
(F1
F0.00076452599388379206
I0
I1
I-1
tp1099
sS'which,are'
p1100
(F1
F0.0015290519877675841
I2
I0
I2
tp1101
sS'glyburide,in'
p1102
(F1
F0.00076452599388379206
I0
I1
I-1
tp1103
sS'fu,has'
p1104
(F1
F0.00076452599388379206
I0
I1
I-1
tp1105
sS'suppression,compared'
p1106
(F1
F0.00076452599388379206
I1
I0
I1
tp1107
sS'clinical,pharmacokinetics'
p1108
(F1
F0.00076452599388379206
I0
I1
I-1
tp1109
sS'subject,of'
p1110
(F1
F0.00076452599388379206
I0
I1
I-1
tp1111
sS'of,fewer'
p1112
(F1
F0.00076452599388379206
I1
I0
I1
tp1113
sS'decrease,in'
p1114
(F0.45454545454545453
F0.0038226299694189602
I8
I3
I5
tp1115
sS'with,was'
p1116
(F1
F0.0015290519877675841
I0
I2
I-2
tp1117
sS'on,treatment'
p1118
(F1
F0.00076452599388379206
I1
I0
I1
tp1119
sS'not,result'
p1120
(F1
F0.0015290519877675841
I0
I2
I-2
tp1121
sS'of,neurons'
p1122
(F1
F0.00076452599388379206
I1
I0
I1
tp1123
sS'tablets,and'
p1124
(F1
F0.00076452599388379206
I1
I0
I1
tp1125
sS'intubation,the'
p1126
(F1
F0.00076452599388379206
I0
I1
I-1
tp1127
sS'of,organic'
p1128
(F0
F0
I1
I1
I0
tp1129
sS'or,severe'
p1130
(F1
F0.00076452599388379206
I1
I0
I1
tp1131
sS'tunel,assay'
p1132
(F1
F0.00076452599388379206
I0
I1
I-1
tp1133
sS'inhibited,at'
p1134
(F1
F0.00076452599388379206
I1
I0
I1
tp1135
sS'occurrences,have'
p1136
(F1
F0.00076452599388379206
I0
I1
I-1
tp1137
sS'reported,rarely'
p1138
(F1
F0.00076452599388379206
I1
I0
I1
tp1139
sS'chloride,on'
p1140
(F1
F0.00076452599388379206
I1
I0
I1
tp1141
sS'that,markedly'
p1142
(F1
F0.00076452599388379206
I1
I0
I1
tp1143
sS'areas,under'
p1144
(F1
F0.00076452599388379206
I0
I1
I-1
tp1145
sS'metabolism,decreased'
p1146
(F1
F0.0015290519877675841
I0
I2
I-2
tp1147
sS'vaccines,are'
p1148
(F1
F0.00076452599388379206
I1
I0
I1
tp1149
sS'the,serum'
p1150
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp1151
sS'a,theoretical'
p1152
(F1
F0.00076452599388379206
I1
I0
I1
tp1153
sS'mice,with'
p1154
(F1
F0.00076452599388379206
I1
I0
I1
tp1155
sS'effect,appeared'
p1156
(F1
F0.00076452599388379206
I0
I1
I-1
tp1157
sS'survived,with'
p1158
(F1
F0.00076452599388379206
I0
I1
I-1
tp1159
sS'received,low-dose'
p1160
(F1
F0.00076452599388379206
I0
I1
I-1
tp1161
sS'lapatinib,may'
p1162
(F1
F0.00076452599388379206
I0
I1
I-1
tp1163
sS'acetate,with'
p1164
(F1
F0.00076452599388379206
I0
I1
I-1
tp1165
sS'lower,respectively'
p1166
(F1
F0.00076452599388379206
I1
I0
I1
tp1167
sS'the,duration'
p1168
(F1
F0.00076452599388379206
I1
I0
I1
tp1169
sS'cci-779,in'
p1170
(F1
F0.00076452599388379206
I0
I1
I-1
tp1171
sS'a,group'
p1172
(F1
F0.00076452599388379206
I0
I1
I-1
tp1173
sS'ovulation-suppressing,action'
p1174
(F1
F0.00076452599388379206
I0
I1
I-1
tp1175
sS'treating,urinary'
p1176
(F1
F0.00076452599388379206
I0
I1
I-1
tp1177
sS'these,drugs'
p1178
(F0.5
F0.0030581039755351682
I6
I2
I4
tp1179
sS'are,concurrently'
p1180
(F1
F0.00076452599388379206
I1
I0
I1
tp1181
sS'the,positive'
p1182
(F1
F0.00076452599388379206
I0
I1
I-1
tp1183
sS'apnea,seizures'
p1184
(F1
F0.00076452599388379206
I1
I0
I1
tp1185
sS'therapeutic,agents'
p1186
(F1
F0.00076452599388379206
I1
I0
I1
tp1187
sS'vaccinations,with'
p1188
(F1
F0.00076452599388379206
I1
I0
I1
tp1189
sS'where,compatibility'
p1190
(F1
F0.00076452599388379206
I0
I1
I-1
tp1191
sS'methotrexate,a'
p1192
(F1
F0.00076452599388379206
I0
I1
I-1
tp1193
sS'mg,qid'
p1194
(F0
F0
I1
I1
I0
tp1195
sS'caution,in'
p1196
(F1
F0.0045871559633027525
I6
I0
I6
tp1197
sS'with,feldene'
p1198
(F1
F0.00076452599388379206
I1
I0
I1
tp1199
sS'influence,of'
p1200
(F1
F0.0022935779816513763
I0
I3
I-3
tp1201
sS'caution,is'
p1202
(F1
F0.0030581039755351682
I4
I0
I4
tp1203
sS'injection,to'
p1204
(F1
F0.0015290519877675841
I0
I2
I-2
tp1205
sS'investigate,whether'
p1206
(F1
F0.00076452599388379206
I0
I1
I-1
tp1207
sS'megestrol,acetate'
p1208
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp1209
sS'inhibitors,or'
p1210
(F0
F0
I3
I3
I0
tp1211
sS'multiple,dose'
p1212
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp1213
sS'inhibitors,on'
p1214
(F1
F0.00076452599388379206
I0
I1
I-1
tp1215
sS'inhibitors,of'
p1216
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp1217
sS'certain,interact'
p1218
(F1
F0.00076452599388379206
I1
I0
I1
tp1219
sS'crossover,steady'
p1220
(F1
F0.00076452599388379206
I0
I1
I-1
tp1221
sS'cytochrome,p-450'
p1222
(F1
F0.00076452599388379206
I0
I1
I-1
tp1223
sS'on,mptp-evoked'
p1224
(F1
F0.00076452599388379206
I0
I1
I-1
tp1225
sS'plasma,cholinesterase'
p1226
(F1
F0.00076452599388379206
I1
I0
I1
tp1227
sS'number,of'
p1228
(F1
F0.0022935779816513763
I3
I0
I3
tp1229
sS'volunteers,to'
p1230
(F1
F0.00076452599388379206
I0
I1
I-1
tp1231
sS'hplc,and'
p1232
(F1
F0.00076452599388379206
I0
I1
I-1
tp1233
sS'locomotion,in'
p1234
(F1
F0.00076452599388379206
I1
I0
I1
tp1235
sS'zetia,with'
p1236
(F1
F0.00076452599388379206
I1
I0
I1
tp1237
sS'diuretics,aceon'
p1238
(F1
F0.00076452599388379206
I0
I1
I-1
tp1239
sS'curves,self-reported'
p1240
(F1
F0.00076452599388379206
I0
I1
I-1
tp1241
sS'others,supplements'
p1242
(F1
F0.00076452599388379206
I0
I1
I-1
tp1243
sS'agent,alone'
p1244
(F1
F0.00076452599388379206
I1
I0
I1
tp1245
sS'bp,quicker'
p1246
(F1
F0.00076452599388379206
I1
I0
I1
tp1247
sS'dopaminergic,neurons'
p1248
(F1
F0.00076452599388379206
I1
I0
I1
tp1249
sS'no,proven'
p1250
(F1
F0.00076452599388379206
I0
I1
I-1
tp1251
sS'control,was'
p1252
(F1
F0.00076452599388379206
I0
I1
I-1
tp1253
sS'bind,bile'
p1254
(F0
F0
I1
I1
I0
tp1255
sS'evista,and'
p1256
(F1
F0.00076452599388379206
I0
I1
I-1
tp1257
sS'interactions,of'
p1258
(F1
F0.0022935779816513763
I0
I3
I-3
tp1259
sS'ascertain,the'
p1260
(F1
F0.00076452599388379206
I0
I1
I-1
tp1261
sS'alter,serum'
p1262
(F1
F0.00076452599388379206
I1
I0
I1
tp1263
sS'be,hazardous'
p1264
(F1
F0.00076452599388379206
I1
I0
I1
tp1265
sS'to,treat'
p1266
(F1
F0.00076452599388379206
I1
I0
I1
tp1267
sS'have,no'
p1268
(F1
F0.00076452599388379206
I0
I1
I-1
tp1269
sS'drugs,tricyclic'
p1270
(F1
F0.00076452599388379206
I1
I0
I1
tp1271
sS'n,nonsteroidal'
p1272
(F1
F0.00076452599388379206
I0
I1
I-1
tp1273
sS'the,hmg-coa'
p1274
(F1
F0.00076452599388379206
I0
I1
I-1
tp1275
sS'profound,and'
p1276
(F1
F0.00076452599388379206
I1
I0
I1
tp1277
sS'conclusion,we'
p1278
(F1
F0.00076452599388379206
I1
I0
I1
tp1279
sS'day,a'
p1280
(F1
F0.00076452599388379206
I0
I1
I-1
tp1281
sS'patients,took'
p1282
(F1
F0.00076452599388379206
I1
I0
I1
tp1283
sS'the,qtc'
p1284
(F0
F0
I1
I1
I0
tp1285
sS'probenecid,concurrent'
p1286
(F1
F0.00076452599388379206
I1
I0
I1
tp1287
sS'dyscrasia,can'
p1288
(F1
F0.00076452599388379206
I1
I0
I1
tp1289
sS'additive,sedation'
p1290
(F1
F0.00076452599388379206
I1
I0
I1
tp1291
sS'component,in'
p1292
(F1
F0.00076452599388379206
I1
I0
I1
tp1293
sS'overall,exposure'
p1294
(F1
F0.00076452599388379206
I1
I0
I1
tp1295
sS'depression,which'
p1296
(F1
F0.00076452599388379206
I1
I0
I1
tp1297
sS'live,attenuated'
p1298
(F1
F0.00076452599388379206
I1
I0
I1
tp1299
sS'plasma,proteins'
p1300
(F1
F0.0015290519877675841
I0
I2
I-2
tp1301
sS'cytochrome,p4501a2'
p1302
(F1
F0.00076452599388379206
I1
I0
I1
tp1303
sS'efficiently,suppressed'
p1304
(F1
F0.00076452599388379206
I1
I0
I1
tp1305
sS'action,cholinesterase'
p1306
(F1
F0.00076452599388379206
I1
I0
I1
tp1307
sS'mg,heme'
p1308
(F1
F0.00076452599388379206
I0
I1
I-1
tp1309
sS'experiment,oral'
p1310
(F1
F0.00076452599388379206
I0
I1
I-1
tp1311
sS'pointes,have'
p1312
(F1
F0.00076452599388379206
I0
I1
I-1
tp1313
sS'tpmt,enzyme'
p1314
(F1
F0.00076452599388379206
I1
I0
I1
tp1315
sS'cross-resistance,with'
p1316
(F1
F0.00076452599388379206
I0
I1
I-1
tp1317
sS'organism,vaccines'
p1318
(F1
F0.00076452599388379206
I1
I0
I1
tp1319
sS'can,occur'
p1320
(F1
F0.00076452599388379206
I1
I0
I1
tp1321
sS'contraceptives,in'
p1322
(F1
F0.0015290519877675841
I0
I2
I-2
tp1323
sS'similar,increases'
p1324
(F1
F0.00076452599388379206
I1
I0
I1
tp1325
sS'negative,control'
p1326
(F1
F0.00076452599388379206
I0
I1
I-1
tp1327
sS'disorientation,respiratory'
p1328
(F1
F0.00076452599388379206
I1
I0
I1
tp1329
sS'anticholinesterase,agents'
p1330
(F1
F0.00076452599388379206
I1
I0
I1
tp1331
sS'or,pharmacodynamics'
p1332
(F1
F0.0015290519877675841
I0
I2
I-2
tp1333
sS'in,reduced'
p1334
(F1
F0.00076452599388379206
I1
I0
I1
tp1335
sS'yl,ethynyl'
p1336
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp1337
sS'further,elucidate'
p1338
(F1
F0.00076452599388379206
I0
I1
I-1
tp1339
sS'however,in'
p1340
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1341
sS'were,carried'
p1342
(F1
F0.00076452599388379206
I0
I1
I-1
tp1343
sS'this,was'
p1344
(F1
F0.0015290519877675841
I0
I2
I-2
tp1345
sS'through,p27'
p1346
(F1
F0.00076452599388379206
I1
I0
I1
tp1347
sS'absorption,may'
p1348
(F1
F0.00076452599388379206
I1
I0
I1
tp1349
sS'elimination,half-life'
p1350
(F1
F0.00076452599388379206
I1
I0
I1
tp1351
sS'in,inr'
p1352
(F1
F0.0015290519877675841
I2
I0
I2
tp1353
sS'which,was'
p1354
(F1
F0.0015290519877675841
I2
I0
I2
tp1355
sS'violations,in'
p1356
(F1
F0.00076452599388379206
I0
I1
I-1
tp1357
sS'regarding,the'
p1358
(F1
F0.00076452599388379206
I0
I1
I-1
tp1359
sS'indicating,that'
p1360
(F1
F0.00076452599388379206
I0
I1
I-1
tp1361
sS'neonatal,treatment'
p1362
(F0
F0
I1
I1
I0
tp1363
sS'careful,monitoring'
p1364
(F1
F0.0038226299694189602
I5
I0
I5
tp1365
sS'geometric,mean'
p1366
(F1
F0.00076452599388379206
I1
I0
I1
tp1367
sS'to,warrant'
p1368
(F1
F0.00076452599388379206
I0
I1
I-1
tp1369
sS'salt,and'
p1370
(F1
F0.00076452599388379206
I0
I1
I-1
tp1371
sS'with,opioid'
p1372
(F1
F0.00076452599388379206
I1
I0
I1
tp1373
sS'therefore,it'
p1374
(F1
F0.00076452599388379206
I1
I0
I1
tp1375
sS'after,interaction'
p1376
(F1
F0.00076452599388379206
I0
I1
I-1
tp1377
sS'who,have'
p1378
(F1
F0.00076452599388379206
I1
I0
I1
tp1379
sS'that,dasatinib-mediated'
p1380
(F1
F0.00076452599388379206
I1
I0
I1
tp1381
sS'distinct,synergistic'
p1382
(F1
F0.00076452599388379206
I0
I1
I-1
tp1383
sS'not,exceed'
p1384
(F1
F0.00076452599388379206
I1
I0
I1
tp1385
sS'can,enhance'
p1386
(F1
F0.00076452599388379206
I1
I0
I1
tp1387
sS'this,has'
p1388
(F1
F0.00076452599388379206
I1
I0
I1
tp1389
sS'rimmer,and'
p1390
(F1
F0.00076452599388379206
I1
I0
I1
tp1391
sS'substituted,imidazole'
p1392
(F1
F0.00076452599388379206
I1
I0
I1
tp1393
sS'renal,tubular'
p1394
(F0
F0
I2
I2
I0
tp1395
sS'are,recommended'
p1396
(F1
F0.00076452599388379206
I1
I0
I1
tp1397
sS'with,antiplatelet'
p1398
(F1
F0.00076452599388379206
I1
I0
I1
tp1399
sS'of,like'
p1400
(F1
F0.00076452599388379206
I0
I1
I-1
tp1401
sS'no,cross-resistance'
p1402
(F1
F0.00076452599388379206
I0
I1
I-1
tp1403
sS'as,post-marketing'
p1404
(F1
F0.00076452599388379206
I1
I0
I1
tp1405
sS'or,sequential'
p1406
(F1
F0.0015290519877675841
I0
I2
I-2
tp1407
sS'induce,or'
p1408
(F1
F0.0015290519877675841
I0
I2
I-2
tp1409
sS'inhibitors,calcium'
p1410
(F1
F0.00076452599388379206
I1
I0
I1
tp1411
sS'impairment,their'
p1412
(F1
F0.00076452599388379206
I0
I1
I-1
tp1413
sS'the,presence'
p1414
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp1415
sS'of,pediatric'
p1416
(F1
F0.00076452599388379206
I0
I1
I-1
tp1417
sS'including,hyaluronan'
p1418
(F1
F0.00076452599388379206
I0
I1
I-1
tp1419
sS'base,is'
p1420
(F1
F0.00076452599388379206
I1
I0
I1
tp1421
sS'depressant,tca'
p1422
(F1
F0.00076452599388379206
I1
I0
I1
tp1423
sS'other,alpha-adrenergic'
p1424
(F0
F0
I1
I1
I0
tp1425
sS'the,following'
p1426
(F0.1111111111111111
F0.00076452599388379206
I4
I5
I-1
tp1427
sS'decreases,the'
p1428
(F1
F0.0022935779816513763
I3
I0
I3
tp1429
sS'phase,i'
p1430
(F1
F0.00076452599388379206
I0
I1
I-1
tp1431
sS'the,marked'
p1432
(F1
F0.00076452599388379206
I1
I0
I1
tp1433
sS'antihypertensive,effect'
p1434
(F1
F0.0015290519877675841
I2
I0
I2
tp1435
sS'with,no'
p1436
(F1
F0.00076452599388379206
I1
I0
I1
tp1437
sS'colistimethate,salts'
p1438
(F1
F0.00076452599388379206
I1
I0
I1
tp1439
sS'ci,or'
p1440
(F1
F0.00076452599388379206
I1
I0
I1
tp1441
sS'or,discontinues'
p1442
(F1
F0.00076452599388379206
I1
I0
I1
tp1443
sS'toxicity,towards'
p1444
(F1
F0.00076452599388379206
I1
I0
I1
tp1445
sS'anorexia,tachypnea'
p1446
(F1
F0.00076452599388379206
I1
I0
I1
tp1447
sS's,disease'
p1448
(F1
F0.00076452599388379206
I1
I0
I1
tp1449
sS'decreases,up'
p1450
(F1
F0.00076452599388379206
I0
I1
I-1
tp1451
sS'a,role'
p1452
(F1
F0.00076452599388379206
I0
I1
I-1
tp1453
sS'following,precautions'
p1454
(F1
F0.00076452599388379206
I1
I0
I1
tp1455
sS'which,could'
p1456
(F1
F0.00076452599388379206
I1
I0
I1
tp1457
sS'isolated,effect'
p1458
(F1
F0.00076452599388379206
I1
I0
I1
tp1459
sS'inhibitor,and'
p1460
(F1
F0.00076452599388379206
I0
I1
I-1
tp1461
sS'with,patients'
p1462
(F1
F0.00076452599388379206
I1
I0
I1
tp1463
sS'possible,although'
p1464
(F1
F0.00076452599388379206
I1
I0
I1
tp1465
sS'evidence,for'
p1466
(F0
F0
I1
I1
I0
tp1467
sS'monitor,blood'
p1468
(F1
F0.00076452599388379206
I1
I0
I1
tp1469
sS'cardiac,events'
p1470
(F1
F0.00076452599388379206
I1
I0
I1
tp1471
sS'reduce,serum'
p1472
(F1
F0.00076452599388379206
I1
I0
I1
tp1473
sS'the,evidence'
p1474
(F1
F0.00076452599388379206
I1
I0
I1
tp1475
sS'the,anti-resorptive'
p1476
(F1
F0.00076452599388379206
I1
I0
I1
tp1477
sS'with,ethinyl'
p1478
(F1
F0.00076452599388379206
I1
I0
I1
tp1479
sS'for,signs'
p1480
(F1
F0.00076452599388379206
I1
I0
I1
tp1481
sS'src,family'
p1482
(F1
F0.00076452599388379206
I1
I0
I1
tp1483
sS'potent,inhibitor'
p1484
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1485
sS'include,certain'
p1486
(F1
F0.00076452599388379206
I1
I0
I1
tp1487
sS'sites,will'
p1488
(F1
F0.00076452599388379206
I0
I1
I-1
tp1489
sS'the,cytochrome'
p1490
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp1491
sS'study,demonstrated'
p1492
(F1
F0.0015290519877675841
I2
I0
I2
tp1493
sS'sufficient,to'
p1494
(F1
F0.00076452599388379206
I1
I0
I1
tp1495
sS'for,for'
p1496
(F1
F0.00076452599388379206
I0
I1
I-1
tp1497
sS'a,variety'
p1498
(F1
F0.0015290519877675841
I0
I2
I-2
tp1499
sS'possible,should'
p1500
(F1
F0.00076452599388379206
I1
I0
I1
tp1501
sS'tofranil,anafranil'
p1502
(F1
F0.00076452599388379206
I0
I1
I-1
tp1503
sS'to,improve'
p1504
(F1
F0.00076452599388379206
I0
I1
I-1
tp1505
sS'the,low'
p1506
(F1
F0.00076452599388379206
I0
I1
I-1
tp1507
sS'concealed,inefficacy'
p1508
(F1
F0.0015290519877675841
I2
I0
I2
tp1509
sS'interactions,between'
p1510
(F1
F0.00076452599388379206
I0
I1
I-1
tp1511
sS'succinate,tablets'
p1512
(F1
F0.00076452599388379206
I1
I0
I1
tp1513
sS'exhibited,dose-dependent'
p1514
(F1
F0.00076452599388379206
I0
I1
I-1
tp1515
sS'following,categories'
p1516
(F1
F0.00076452599388379206
I1
I0
I1
tp1517
sS'a,clinically-relevant'
p1518
(F1
F0.00076452599388379206
I0
I1
I-1
tp1519
sS'live,virus'
p1520
(F1
F0.00076452599388379206
I1
I0
I1
tp1521
sS'may,have'
p1522
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp1523
sS'induction,leading'
p1524
(F1
F0.00076452599388379206
I1
I0
I1
tp1525
sS'result,of'
p1526
(F0
F0
I2
I2
I0
tp1527
sS'to,maintain'
p1528
(F1
F0.00076452599388379206
I0
I1
I-1
tp1529
sS'evaluated,mechanisms'
p1530
(F1
F0.00076452599388379206
I0
I1
I-1
tp1531
sS'transplant,patient'
p1532
(F1
F0.00076452599388379206
I1
I0
I1
tp1533
sS'used,premedications'
p1534
(F1
F0.00076452599388379206
I0
I1
I-1
tp1535
sS'and,cysteine'
p1536
(F1
F0.00076452599388379206
I0
I1
I-1
tp1537
sS'published,data'
p1538
(F1
F0.00076452599388379206
I1
I0
I1
tp1539
sS'thrombocytopenia,and'
p1540
(F1
F0.00076452599388379206
I1
I0
I1
tp1541
sS'a,database'
p1542
(F1
F0.00076452599388379206
I0
I1
I-1
tp1543
sS'absorption,mainly'
p1544
(F1
F0.00076452599388379206
I1
I0
I1
tp1545
sS'adjustment,when'
p1546
(F1
F0.00076452599388379206
I0
I1
I-1
tp1547
sS'divalproex,sodium'
p1548
(F1
F0.00076452599388379206
I0
I1
I-1
tp1549
sS'with,nexavar'
p1550
(F1
F0.00076452599388379206
I1
I0
I1
tp1551
sS'discontinuing,the'
p1552
(F1
F0.00076452599388379206
I1
I0
I1
tp1553
sS'slowly,titrated'
p1554
(F1
F0.00076452599388379206
I0
I1
I-1
tp1555
sS'counteracted,when'
p1556
(F1
F0.00076452599388379206
I1
I0
I1
tp1557
sS'systemic,and'
p1558
(F1
F0.00076452599388379206
I1
I0
I1
tp1559
sS'proven,preventive'
p1560
(F1
F0.00076452599388379206
I0
I1
I-1
tp1561
sS'pyridine,versus'
p1562
(F1
F0.00076452599388379206
I0
I1
I-1
tp1563
sS'target,bp'
p1564
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1565
sS'not,bear'
p1566
(F1
F0.00076452599388379206
I1
I0
I1
tp1567
sS'metabolism,the'
p1568
(F1
F0.00076452599388379206
I0
I1
I-1
tp1569
sS'for,tubular'
p1570
(F1
F0.00076452599388379206
I0
I1
I-1
tp1571
sS'increase,in'
p1572
(F0.81818181818181823
F0.013761467889908258
I20
I2
I18
tp1573
sS'furosemide,clinical'
p1574
(F1
F0.00076452599388379206
I1
I0
I1
tp1575
sS'hydroxylase-positive,neurons'
p1576
(F1
F0.00076452599388379206
I1
I0
I1
tp1577
sS'blockers,n'
p1578
(F1
F0.00076452599388379206
I0
I1
I-1
tp1579
sS'nitrous,oxide'
p1580
(F1
F0.00076452599388379206
I0
I1
I-1
tp1581
sS'of,interaction'
p1582
(F0
F0
I1
I1
I0
tp1583
sS'possibly,enhancing'
p1584
(F1
F0.00076452599388379206
I1
I0
I1
tp1585
sS'to,significantly'
p1586
(F1
F0.00076452599388379206
I1
I0
I1
tp1587
sS'inhibition,such'
p1588
(F1
F0.00076452599388379206
I0
I1
I-1
tp1589
sS'resistant,to'
p1590
(F1
F0.0015290519877675841
I0
I2
I-2
tp1591
sS'be,administered'
p1592
(F0.63636363636363635
F0.0053516819571865441
I9
I2
I7
tp1593
sS'actin,promoter'
p1594
(F1
F0.00076452599388379206
I0
I1
I-1
tp1595
sS'in,this'
p1596
(F1
F0.0015290519877675841
I0
I2
I-2
tp1597
sS'study,has'
p1598
(F1
F0.00076452599388379206
I1
I0
I1
tp1599
sS'enterohepatic,cycling'
p1600
(F1
F0.00076452599388379206
I1
I0
I1
tp1601
sS'emission,tomography'
p1602
(F1
F0.00076452599388379206
I1
I0
I1
tp1603
sS'has,no'
p1604
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1605
sS'almost,loss'
p1606
(F1
F0.00076452599388379206
I1
I0
I1
tp1607
sS'vma,vanillylmandelic'
p1608
(F1
F0.00076452599388379206
I0
I1
I-1
tp1609
sS'vivo,the'
p1610
(F1
F0.00076452599388379206
I1
I0
I1
tp1611
sS'dznep,insensitivity'
p1612
(F1
F0.00076452599388379206
I1
I0
I1
tp1613
sS'of,gastric'
p1614
(F1
F0.00076452599388379206
I1
I0
I1
tp1615
sS'cns,depressants'
p1616
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp1617
sS'mg,maximum'
p1618
(F1
F0.00076452599388379206
I0
I1
I-1
tp1619
sS'hmg-coa,reductase'
p1620
(F1
F0.0022935779816513763
I0
I3
I-3
tp1621
sS'the,four'
p1622
(F1
F0.00076452599388379206
I1
I0
I1
tp1623
sS'stereoisomers,has'
p1624
(F1
F0.00076452599388379206
I0
I1
I-1
tp1625
sS'other,highly'
p1626
(F1
F0.0015290519877675841
I2
I0
I2
tp1627
sS'agents,have'
p1628
(F1
F0.0015290519877675841
I0
I2
I-2
tp1629
sS'not,likely'
p1630
(F1
F0.00076452599388379206
I0
I1
I-1
tp1631
sS'hormones,sedative'
p1632
(F1
F0.00076452599388379206
I0
I1
I-1
tp1633
sS'from,this'
p1634
(F1
F0.00076452599388379206
I1
I0
I1
tp1635
sS'azole-type,antifungal'
p1636
(F1
F0.00076452599388379206
I1
I0
I1
tp1637
sS'inhibition,and'
p1638
(F1
F0.00076452599388379206
I0
I1
I-1
tp1639
sS'the,cyp2c19'
p1640
(F1
F0.00076452599388379206
I1
I0
I1
tp1641
sS'the,clinical'
p1642
(F1
F0.00076452599388379206
I0
I1
I-1
tp1643
sS'of,urinary'
p1644
(F1
F0.00076452599388379206
I1
I0
I1
tp1645
sS'basic,media'
p1646
(F1
F0.00076452599388379206
I1
I0
I1
tp1647
sS'pharmacodynamic,interactions'
p1648
(F1
F0.00076452599388379206
I0
I1
I-1
tp1649
sS'the,tests'
p1650
(F1
F0.00076452599388379206
I0
I1
I-1
tp1651
sS'therapy,may'
p1652
(F1
F0.0015290519877675841
I2
I0
I2
tp1653
sS'note,that'
p1654
(F1
F0.00076452599388379206
I1
I0
I1
tp1655
sS'loss,in'
p1656
(F1
F0.00076452599388379206
I0
I1
I-1
tp1657
sS'ingestion,of'
p1658
(F1
F0.00076452599388379206
I0
I1
I-1
tp1659
sS'animals,almost'
p1660
(F1
F0.00076452599388379206
I1
I0
I1
tp1661
sS'dosages,of'
p1662
(F1
F0.00076452599388379206
I1
I0
I1
tp1663
sS'before,to'
p1664
(F1
F0.00076452599388379206
I0
I1
I-1
tp1665
sS'the,precocene'
p1666
(F1
F0.00076452599388379206
I0
I1
I-1
tp1667
sS'our,objective'
p1668
(F1
F0.00076452599388379206
I0
I1
I-1
tp1669
sS'following,seven'
p1670
(F1
F0.00076452599388379206
I0
I1
I-1
tp1671
sS'and,dznep'
p1672
(F1
F0.00076452599388379206
I1
I0
I1
tp1673
sS'in,male'
p1674
(F1
F0.00076452599388379206
I0
I1
I-1
tp1675
sS'also,evaluated'
p1676
(F1
F0.00076452599388379206
I0
I1
I-1
tp1677
sS'unaffected,in'
p1678
(F1
F0.00076452599388379206
I0
I1
I-1
tp1679
sS'patients,usp'
p1680
(F1
F0.00076452599388379206
I0
I1
I-1
tp1681
sS'administered,safely'
p1682
(F1
F0.00076452599388379206
I0
I1
I-1
tp1683
sS'with,post-mortem'
p1684
(F1
F0.00076452599388379206
I1
I0
I1
tp1685
sS'mean,pharmacokinetic'
p1686
(F1
F0.00076452599388379206
I1
I0
I1
tp1687
sS'immunocompromised,individuals'
p1688
(F1
F0.00076452599388379206
I1
I0
I1
tp1689
sS'the,high'
p1690
(F1
F0.00076452599388379206
I1
I0
I1
tp1691
sS'treatment,increased'
p1692
(F1
F0.00076452599388379206
I1
I0
I1
tp1693
sS'treatment,increases'
p1694
(F1
F0.00076452599388379206
I1
I0
I1
tp1695
sS'and,others'
p1696
(F1
F0.00076452599388379206
I0
I1
I-1
tp1697
sS'of,antinociception'
p1698
(F1
F0.00076452599388379206
I1
I0
I1
tp1699
sS'inhibitor,effectiveness'
p1700
(F1
F0.00076452599388379206
I0
I1
I-1
tp1701
sS'of,cyp2c8'
p1702
(F1
F0.00076452599388379206
I1
I0
I1
tp1703
sS'drugs,of'
p1704
(F1
F0.0015290519877675841
I2
I0
I2
tp1705
sS'day,in'
p1706
(F1
F0.00076452599388379206
I0
I1
I-1
tp1707
sS'drugs,on'
p1708
(F1
F0.00076452599388379206
I0
I1
I-1
tp1709
sS'association,with'
p1710
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1711
sS'drugs,or'
p1712
(F1
F0.00076452599388379206
I1
I0
I1
tp1713
sS'and,up'
p1714
(F1
F0.00076452599388379206
I1
I0
I1
tp1715
sS'in,association'
p1716
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp1717
sS'of,psychotic'
p1718
(F1
F0.00076452599388379206
I1
I0
I1
tp1719
sS'used,neuromuscular'
p1720
(F1
F0.00076452599388379206
I0
I1
I-1
tp1721
sS'hyaluronan,lyase'
p1722
(F1
F0.0015290519877675841
I0
I2
I-2
tp1723
sS'enhance,the'
p1724
(F1
F0.0038226299694189602
I5
I0
I5
tp1725
sS'ovarian,cancer'
p1726
(F0
F0
I1
I1
I0
tp1727
sS'the,secretion'
p1728
(F1
F0.00076452599388379206
I1
I0
I1
tp1729
sS'skelid,are'
p1730
(F1
F0.00076452599388379206
I1
I0
I1
tp1731
sS'emulsion,may'
p1732
(F1
F0.00076452599388379206
I1
I0
I1
tp1733
sS'mpag,concentrations'
p1734
(F1
F0.00076452599388379206
I0
I1
I-1
tp1735
sS'taking,other'
p1736
(F1
F0.00076452599388379206
I1
I0
I1
tp1737
sS'administration,because'
p1738
(F1
F0.00076452599388379206
I0
I1
I-1
tp1739
sS'population,pharmacokinetic'
p1740
(F0
F0
I1
I1
I0
tp1741
sS'reports,of'
p1742
(F0.66666666666666663
F0.0061162079510703364
I10
I2
I8
tp1743
sS'of,cerezyme'
p1744
(F1
F0.00076452599388379206
I1
I0
I1
tp1745
sS'demonstrate,that'
p1746
(F1
F0.00076452599388379206
I1
I0
I1
tp1747
sS'chronically,administered'
p1748
(F1
F0.00076452599388379206
I1
I0
I1
tp1749
sS'increase,certain'
p1750
(F1
F0.00076452599388379206
I1
I0
I1
tp1751
sS'motor,skills'
p1752
(F1
F0.0015290519877675841
I2
I0
I2
tp1753
sS'clearance,of'
p1754
(F1
F0.010703363914373088
I14
I0
I14
tp1755
sS'acids,via'
p1756
(F1
F0.00076452599388379206
I0
I1
I-1
tp1757
sS'neurons,in'
p1758
(F1
F0.00076452599388379206
I1
I0
I1
tp1759
sS'to,initiation'
p1760
(F1
F0.00076452599388379206
I1
I0
I1
tp1761
sS'not,prolong'
p1762
(F1
F0.00076452599388379206
I0
I1
I-1
tp1763
sS'appeared,to'
p1764
(F1
F0.0015290519877675841
I2
I0
I2
tp1765
sS'drugs,rivastigmine'
p1766
(F1
F0.00076452599388379206
I0
I1
I-1
tp1767
sS'supplemental,vitamin'
p1768
(F1
F0.00076452599388379206
I0
I1
I-1
tp1769
sS'counts,of'
p1770
(F1
F0.00076452599388379206
I1
I0
I1
tp1771
sS'be,expected'
p1772
(F0.14285714285714285
F0.00076452599388379206
I4
I3
I1
tp1773
sS'deaths,in'
p1774
(F1
F0.00076452599388379206
I1
I0
I1
tp1775
sS'of,potential'
p1776
(F1
F0.00076452599388379206
I1
I0
I1
tp1777
sS'imidazole,drugs'
p1778
(F1
F0.00076452599388379206
I1
I0
I1
tp1779
sS'been,shown'
p1780
(F0.5
F0.0015290519877675841
I3
I1
I2
tp1781
sS'report,the'
p1782
(F1
F0.00076452599388379206
I1
I0
I1
tp1783
sS'whereas,arrested'
p1784
(F1
F0.00076452599388379206
I0
I1
I-1
tp1785
sS'min,caution'
p1786
(F1
F0.00076452599388379206
I1
I0
I1
tp1787
sS'different,anti-cancer'
p1788
(F1
F0.00076452599388379206
I1
I0
I1
tp1789
sS'growth,and'
p1790
(F1
F0.00076452599388379206
I1
I0
I1
tp1791
sS'at,mg'
p1792
(F1
F0.0030581039755351682
I0
I4
I-4
tp1793
sS'patients,studied'
p1794
(F1
F0.00076452599388379206
I0
I1
I-1
tp1795
sS'barbiturates,tricyclic'
p1796
(F1
F0.00076452599388379206
I1
I0
I1
tp1797
sS'normal-weight,subjects'
p1798
(F1
F0.0038226299694189602
I0
I5
I-5
tp1799
sS'toxicity,the'
p1800
(F1
F0.00076452599388379206
I0
I1
I-1
tp1801
sS'add,to'
p1802
(F1
F0.00076452599388379206
I1
I0
I1
tp1803
sS'and,resulting'
p1804
(F1
F0.00076452599388379206
I1
I0
I1
tp1805
sS'but,not'
p1806
(F1
F0.0015290519877675841
I2
I0
I2
tp1807
sS'taking,drugs'
p1808
(F1
F0.00076452599388379206
I1
I0
I1
tp1809
sS'anti-inflammatory,agents'
p1810
(F1
F0.00076452599388379206
I1
I0
I1
tp1811
sS'or,with'
p1812
(F0
F0
I1
I1
I0
tp1813
sS'an,enhanced'
p1814
(F1
F0.00076452599388379206
I1
I0
I1
tp1815
sS'streptokinase,alone'
p1816
(F1
F0.00076452599388379206
I1
I0
I1
tp1817
sS'in,treating'
p1818
(F1
F0.00076452599388379206
I0
I1
I-1
tp1819
sS'of,ovarian'
p1820
(F1
F0.00076452599388379206
I1
I0
I1
tp1821
sS'of,adjusted'
p1822
(F1
F0.00076452599388379206
I1
I0
I1
tp1823
sS'prescribed,xenical'
p1824
(F1
F0.00076452599388379206
I1
I0
I1
tp1825
sS'toxicity,which'
p1826
(F1
F0.00076452599388379206
I1
I0
I1
tp1827
sS'the,auc'
p1828
(F0
F0
I2
I2
I0
tp1829
sS'protective,effect'
p1830
(F0
F0
I1
I1
I0
tp1831
sS'thus,elevating'
p1832
(F1
F0.00076452599388379206
I1
I0
I1
tp1833
sS'myfortic,the'
p1834
(F1
F0.00076452599388379206
I1
I0
I1
tp1835
sS'each,group'
p1836
(F1
F0.00076452599388379206
I0
I1
I-1
tp1837
sS'necessary,to'
p1838
(F0
F0
I1
I1
I0
tp1839
sS'evista,is'
p1840
(F1
F0.0015290519877675841
I2
I0
I2
tp1841
sS'are,metabolised'
p1842
(F1
F0.00076452599388379206
I1
I0
I1
tp1843
sS'were,routinely'
p1844
(F1
F0.00076452599388379206
I0
I1
I-1
tp1845
sS'during,administration'
p1846
(F1
F0.00076452599388379206
I1
I0
I1
tp1847
sS'sodium,colistimethate'
p1848
(F1
F0.00076452599388379206
I1
I0
I1
tp1849
sS'kip1,bcl-2'
p1850
(F1
F0.00076452599388379206
I0
I1
I-1
tp1851
sS'state,that'
p1852
(F1
F0.00076452599388379206
I1
I0
I1
tp1853
sS'oral,and'
p1854
(F1
F0.00076452599388379206
I1
I0
I1
tp1855
sS'frequency,and'
p1856
(F1
F0.0015290519877675841
I2
I0
I2
tp1857
sS'diminished,by'
p1858
(F1
F0.00076452599388379206
I1
I0
I1
tp1859
sS'acid,to'
p1860
(F1
F0.0015290519877675841
I2
I0
I2
tp1861
sS'of,detrol'
p1862
(F1
F0.00076452599388379206
I1
I0
I1
tp1863
sS'severe,bone'
p1864
(F1
F0.00076452599388379206
I1
I0
I1
tp1865
sS'stable,regimen'
p1866
(F1
F0.00076452599388379206
I0
I1
I-1
tp1867
sS'may,induce'
p1868
(F1
F0.00076452599388379206
I1
I0
I1
tp1869
sS'cause,any'
p1870
(F1
F0.00076452599388379206
I0
I1
I-1
tp1871
sS'woman,of'
p1872
(F1
F0.00076452599388379206
I0
I1
I-1
tp1873
sS'may,experience'
p1874
(F1
F0.00076452599388379206
I1
I0
I1
tp1875
sS'ovarian,function'
p1876
(F1
F0.00076452599388379206
I1
I0
I1
tp1877
sS'depression,neurotoxic'
p1878
(F1
F0.00076452599388379206
I1
I0
I1
tp1879
sS'warranted,appropriate'
p1880
(F1
F0.00076452599388379206
I1
I0
I1
tp1881
sS'amphotericin,b'
p1882
(F1
F0.00076452599388379206
I0
I1
I-1
tp1883
sS'approximately,probably'
p1884
(F1
F0.00076452599388379206
I0
I1
I-1
tp1885
sS'to,several'
p1886
(F1
F0.00076452599388379206
I0
I1
I-1
tp1887
sS'nephrotoxic,drugs'
p1888
(F1
F0.00076452599388379206
I0
I1
I-1
tp1889
sS'pressure,after'
p1890
(F1
F0.00076452599388379206
I1
I0
I1
tp1891
sS'daily,based'
p1892
(F1
F0.0030581039755351682
I0
I4
I-4
tp1893
sS'interval,following'
p1894
(F1
F0.00076452599388379206
I0
I1
I-1
tp1895
sS'ripe,cheese'
p1896
(F1
F0.00076452599388379206
I1
I0
I1
tp1897
sS'urinary,alkalizing'
p1898
(F1
F0.00076452599388379206
I1
I0
I1
tp1899
sS'concomitantly,should'
p1900
(F1
F0.0022935779816513763
I3
I0
I3
tp1901
sS'day,study'
p1902
(F1
F0.00076452599388379206
I0
I1
I-1
tp1903
sS'we,retrospectively'
p1904
(F1
F0.00076452599388379206
I0
I1
I-1
tp1905
sS'confirmed,in-vivo'
p1906
(F1
F0.00076452599388379206
I0
I1
I-1
tp1907
sS'of,various'
p1908
(F1
F0.00076452599388379206
I1
I0
I1
tp1909
sS'anesthesia,and'
p1910
(F1
F0.0015290519877675841
I2
I0
I2
tp1911
sS'a,calcineurin'
p1912
(F1
F0.00076452599388379206
I0
I1
I-1
tp1913
sS'uveitis,in'
p1914
(F1
F0.00076452599388379206
I1
I0
I1
tp1915
sS'day,yielded'
p1916
(F1
F0.00076452599388379206
I1
I0
I1
tp1917
sS'were,conditioned'
p1918
(F1
F0.00076452599388379206
I1
I0
I1
tp1919
sS'sequential,administrations'
p1920
(F1
F0.00076452599388379206
I1
I0
I1
tp1921
sS'fu,and'
p1922
(F1
F0.00076452599388379206
I0
I1
I-1
tp1923
sS'cholestyramine,cholestyramine'
p1924
(F1
F0.00076452599388379206
I1
I0
I1
tp1925
sS'vaccination,was'
p1926
(F1
F0.00076452599388379206
I1
I0
I1
tp1927
sS'when,coadministering'
p1928
(F1
F0.00076452599388379206
I1
I0
I1
tp1929
sS'following,resulted'
p1930
(F1
F0.00076452599388379206
I1
I0
I1
tp1931
sS'observed,data'
p1932
(F1
F0.00076452599388379206
I1
I0
I1
tp1933
sS'therapy,and'
p1934
(F1
F0.0015290519877675841
I0
I2
I-2
tp1935
sS'combination,in'
p1936
(F1
F0.00076452599388379206
I0
I1
I-1
tp1937
sS'the,psychostimulant'
p1938
(F1
F0.00076452599388379206
I0
I1
I-1
tp1939
sS'compounds,may'
p1940
(F1
F0.00076452599388379206
I1
I0
I1
tp1941
sS'to,human'
p1942
(F1
F0.00076452599388379206
I0
I1
I-1
tp1943
sS'ferrous,gluconate'
p1944
(F1
F0.00076452599388379206
I1
I0
I1
tp1945
sS'concentrations,increased'
p1946
(F1
F0.00076452599388379206
I1
I0
I1
tp1947
sS'drug,adamantyl'
p1948
(F1
F0.00076452599388379206
I0
I1
I-1
tp1949
sS'patients,for'
p1950
(F1
F0.0022935779816513763
I3
I0
I3
tp1951
sS'administration,vitamin'
p1952
(F1
F0.00076452599388379206
I0
I1
I-1
tp1953
sS'muscular,rigidity'
p1954
(F1
F0.00076452599388379206
I1
I0
I1
tp1955
sS'no,drug'
p1956
(F1
F0.00076452599388379206
I0
I1
I-1
tp1957
sS'administered,one'
p1958
(F1
F0.00076452599388379206
I1
I0
I1
tp1959
sS'sedation,which'
p1960
(F1
F0.00076452599388379206
I1
I0
I1
tp1961
sS'mobic,therapy'
p1962
(F1
F0.00076452599388379206
I1
I0
I1
tp1963
sS'inoculated,with'
p1964
(F1
F0.00076452599388379206
I1
I0
I1
tp1965
sS'ml,the'
p1966
(F1
F0.00076452599388379206
I1
I0
I1
tp1967
sS'montelukast,at'
p1968
(F1
F0.0015290519877675841
I0
I2
I-2
tp1969
sS'especially,in'
p1970
(F1
F0.00076452599388379206
I0
I1
I-1
tp1971
sS'compound,and'
p1972
(F1
F0.00076452599388379206
I1
I0
I1
tp1973
sS'have,received'
p1974
(F1
F0.00076452599388379206
I1
I0
I1
tp1975
sS'particularly,eg'
p1976
(F1
F0.00076452599388379206
I1
I0
I1
tp1977
sS'formulations,of'
p1978
(F1
F0.00076452599388379206
I1
I0
I1
tp1979
sS'of,agents'
p1980
(F1
F0.00076452599388379206
I0
I1
I-1
tp1981
sS'with,confirmed'
p1982
(F1
F0.00076452599388379206
I1
I0
I1
tp1983
sS'warfarin,anticoagulant'
p1984
(F1
F0.00076452599388379206
I1
I0
I1
tp1985
sS'drug,classes'
p1986
(F1
F0.00076452599388379206
I1
I0
I1
tp1987
sS'relapsed,multiple'
p1988
(F1
F0.00076452599388379206
I0
I1
I-1
tp1989
sS'with,low'
p1990
(F1
F0.00076452599388379206
I0
I1
I-1
tp1991
sS'flomax,capsules'
p1992
(F0
F0
I2
I2
I0
tp1993
sS'closely,monitored'
p1994
(F1
F0.0015290519877675841
I2
I0
I2
tp1995
sS'receiving,xenical'
p1996
(F1
F0.0030581039755351682
I0
I4
I-4
tp1997
sS'plavix,and'
p1998
(F1
F0.00076452599388379206
I0
I1
I-1
tp1999
sS'effect,while'
p2000
(F1
F0.00076452599388379206
I1
I0
I1
tp2001
sS'estrogen,antagonist'
p2002
(F1
F0.00076452599388379206
I0
I1
I-1
tp2003
sS'there,are'
p2004
(F0
F0
I3
I3
I0
tp2005
sS'monitoring,when'
p2006
(F1
F0.0015290519877675841
I2
I0
I2
tp2007
sS'u251,to'
p2008
(F1
F0.00076452599388379206
I0
I1
I-1
tp2009
sS'phenothiazines,other'
p2010
(F1
F0.00076452599388379206
I1
I0
I1
tp2011
sS'and,paclitaxel-induced'
p2012
(F1
F0.00076452599388379206
I0
I1
I-1
tp2013
sS'certain,ergot'
p2014
(F1
F0.00076452599388379206
I0
I1
I-1
tp2015
sS'studies,the'
p2016
(F1
F0.00076452599388379206
I0
I1
I-1
tp2017
sS'of,reinfarction'
p2018
(F1
F0.00076452599388379206
I0
I1
I-1
tp2019
sS'concomitant,with'
p2020
(F1
F0.00076452599388379206
I1
I0
I1
tp2021
sS'achieve,target'
p2022
(F1
F0.00076452599388379206
I1
I0
I1
tp2023
sS'daily,dose'
p2024
(F1
F0.0015290519877675841
I2
I0
I2
tp2025
sS'other,should'
p2026
(F1
F0.00076452599388379206
I1
I0
I1
tp2027
sS'before,and'
p2028
(F1
F0.00076452599388379206
I0
I1
I-1
tp2029
sS'charcoal,because'
p2030
(F1
F0.00076452599388379206
I1
I0
I1
tp2031
sS'zemuron,is'
p2032
(F1
F0.00076452599388379206
I1
I0
I1
tp2033
sS'mouse,vs'
p2034
(F1
F0.00076452599388379206
I1
I0
I1
tp2035
sS'digoxin,there'
p2036
(F1
F0.00076452599388379206
I1
I0
I1
tp2037
sS'of,azole'
p2038
(F1
F0.00076452599388379206
I1
I0
I1
tp2039
sS'tumor,response'
p2040
(F1
F0.00076452599388379206
I1
I0
I1
tp2041
sS'events,including'
p2042
(F1
F0.00076452599388379206
I1
I0
I1
tp2043
sS'cdna,encoding'
p2044
(F1
F0.00076452599388379206
I0
I1
I-1
tp2045
sS'particularly,the'
p2046
(F1
F0.00076452599388379206
I1
I0
I1
tp2047
sS'outcome,in'
p2048
(F1
F0.00076452599388379206
I0
I1
I-1
tp2049
sS'cns,depression-producing'
p2050
(F1
F0.00076452599388379206
I1
I0
I1
tp2051
sS'nonsteroidal,anti-inflammatory'
p2052
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2053
sS'to,ai'
p2054
(F1
F0.00076452599388379206
I1
I0
I1
tp2055
sS'renal,clearance'
p2056
(F1
F0.0015290519877675841
I2
I0
I2
tp2057
sS'for,days'
p2058
(F0.63636363636363635
F0.0053516819571865441
I2
I9
I-7
tp2059
sS'antifungal,agents'
p2060
(F1
F0.00076452599388379206
I1
I0
I1
tp2061
sS'by,injection'
p2062
(F1
F0.00076452599388379206
I0
I1
I-1
tp2063
sS'cycle,at'
p2064
(F1
F0.00076452599388379206
I0
I1
I-1
tp2065
sS'herceptin-refractory,her2-positive'
p2066
(F1
F0.00076452599388379206
I1
I0
I1
tp2067
sS'including,feldene'
p2068
(F1
F0.00076452599388379206
I1
I0
I1
tp2069
sS'proton,pump'
p2070
(F0.42857142857142855
F0.0022935779816513763
I2
I5
I-3
tp2071
sS'striatal,intensity'
p2072
(F1
F0.00076452599388379206
I1
I0
I1
tp2073
sS'such,compounds'
p2074
(F1
F0.00076452599388379206
I1
I0
I1
tp2075
sS'potassium-sparing,diuretics'
p2076
(F1
F0.0015290519877675841
I0
I2
I-2
tp2077
sS'hiv-positive,woman'
p2078
(F1
F0.0015290519877675841
I2
I0
I2
tp2079
sS'compassionate,use'
p2080
(F1
F0.00076452599388379206
I0
I1
I-1
tp2081
sS'and,cotreatment'
p2082
(F1
F0.00076452599388379206
I1
I0
I1
tp2083
sS'decreases,oral'
p2084
(F1
F0.00076452599388379206
I1
I0
I1
tp2085
sS'decreased,absorption'
p2086
(F1
F0.00076452599388379206
I0
I1
I-1
tp2087
sS'estrogens,hydroxychloroquine'
p2088
(F1
F0.00076452599388379206
I0
I1
I-1
tp2089
sS'when,zetia'
p2090
(F1
F0.00076452599388379206
I0
I1
I-1
tp2091
sS'the,ovulation-suppressing'
p2092
(F1
F0.00076452599388379206
I0
I1
I-1
tp2093
sS'either,or'
p2094
(F1
F0.0030581039755351682
I0
I4
I-4
tp2095
sS'as,concentrated'
p2096
(F1
F0.00076452599388379206
I0
I1
I-1
tp2097
sS'hazardous,when'
p2098
(F1
F0.00076452599388379206
I1
I0
I1
tp2099
sS'by,oral'
p2100
(F1
F0.00076452599388379206
I0
I1
I-1
tp2101
sS'only,female'
p2102
(F1
F0.00076452599388379206
I0
I1
I-1
tp2103
sS'terbinafine,increases'
p2104
(F1
F0.00076452599388379206
I1
I0
I1
tp2105
sS'maintain,a'
p2106
(F1
F0.00076452599388379206
I0
I1
I-1
tp2107
sS'either,of'
p2108
(F1
F0.0022935779816513763
I0
I3
I-3
tp2109
sS'toxicity,by'
p2110
(F1
F0.00076452599388379206
I1
I0
I1
tp2111
sS'administering,nexavar'
p2112
(F1
F0.00076452599388379206
I1
I0
I1
tp2113
sS'vitro,but'
p2114
(F1
F0.00076452599388379206
I1
I0
I1
tp2115
sS'be,respiratory'
p2116
(F1
F0.00076452599388379206
I1
I0
I1
tp2117
sS'certain,monoamine'
p2118
(F1
F0.00076452599388379206
I1
I0
I1
tp2119
sS'tablets,for'
p2120
(F1
F0.00076452599388379206
I1
I0
I1
tp2121
sS'reducing,plasma'
p2122
(F1
F0.00076452599388379206
I0
I1
I-1
tp2123
sS'two,experimental'
p2124
(F1
F0.00076452599388379206
I0
I1
I-1
tp2125
sS'agents,simultaneous'
p2126
(F1
F0.00076452599388379206
I1
I0
I1
tp2127
sS'when,ace'
p2128
(F1
F0.00076452599388379206
I0
I1
I-1
tp2129
sS'methergine,maleate'
p2130
(F1
F0.00076452599388379206
I1
I0
I1
tp2131
sS'k,absorption'
p2132
(F1
F0.00076452599388379206
I1
I0
I1
tp2133
sS'intravitreal,injection'
p2134
(F1
F0.00076452599388379206
I0
I1
I-1
tp2135
sS'higher,and'
p2136
(F1
F0.00076452599388379206
I0
I1
I-1
tp2137
sS'given,concomitantly'
p2138
(F1
F0.0030581039755351682
I4
I0
I4
tp2139
sS'reactivity,as'
p2140
(F1
F0.00076452599388379206
I1
I0
I1
tp2141
sS'from,to'
p2142
(F1
F0.0022935779816513763
I3
I0
I3
tp2143
sS'family,inhibitor'
p2144
(F1
F0.00076452599388379206
I1
I0
I1
tp2145
sS'tested,therapeutically'
p2146
(F1
F0.00076452599388379206
I1
I0
I1
tp2147
sS'herceptin,clearance'
p2148
(F1
F0.00076452599388379206
I1
I0
I1
tp2149
sS'interactions,for'
p2150
(F1
F0.0015290519877675841
I2
I0
I2
tp2151
sS'diflucan,reduces'
p2152
(F1
F0.00076452599388379206
I1
I0
I1
tp2153
sS'administered,following'
p2154
(F1
F0.00076452599388379206
I1
I0
I1
tp2155
sS'carnitine,elicits'
p2156
(F1
F0.00076452599388379206
I1
I0
I1
tp2157
sS'prolong,the'
p2158
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2159
sS'of,any'
p2160
(F1
F0.00076452599388379206
I0
I1
I-1
tp2161
sS'acute,and'
p2162
(F1
F0.00076452599388379206
I0
I1
I-1
tp2163
sS'the,anionic'
p2164
(F1
F0.00076452599388379206
I1
I0
I1
tp2165
sS'blockers,increase'
p2166
(F1
F0.00076452599388379206
I1
I0
I1
tp2167
sS'diflucan,taken'
p2168
(F1
F0.00076452599388379206
I1
I0
I1
tp2169
sS'aspirin,and'
p2170
(F1
F0.00076452599388379206
I1
I0
I1
tp2171
sS'sulfamethoxazole,may'
p2172
(F1
F0.00076452599388379206
I1
I0
I1
tp2173
sS'compatibility,has'
p2174
(F1
F0.00076452599388379206
I0
I1
I-1
tp2175
sS'volunteers,n'
p2176
(F1
F0.00076452599388379206
I0
I1
I-1
tp2177
sS'conjunction,with'
p2178
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp2179
sS'below,oral'
p2180
(F1
F0.00076452599388379206
I1
I0
I1
tp2181
sS'mg,m2'
p2182
(F0
F0
I1
I1
I0
tp2183
sS'avoided,and'
p2184
(F1
F0.00076452599388379206
I1
I0
I1
tp2185
sS'binding,of'
p2186
(F1
F0.00076452599388379206
I0
I1
I-1
tp2187
sS'inhibitors,has'
p2188
(F1
F0.00076452599388379206
I0
I1
I-1
tp2189
sS'of,and'
p2190
(F0.52941176470588236
F0.020642201834862386
I39
I12
I27
tp2191
sS'the,variability'
p2192
(F1
F0.00076452599388379206
I0
I1
I-1
tp2193
sS'sulfamethizole,may'
p2194
(F1
F0.00076452599388379206
I1
I0
I1
tp2195
sS'dznep,insensitive'
p2196
(F1
F0.00076452599388379206
I1
I0
I1
tp2197
sS'of,hb-egf'
p2198
(F1
F0.0015290519877675841
I0
I2
I-2
tp2199
sS'nph,and'
p2200
(F1
F0.00076452599388379206
I1
I0
I1
tp2201
sS'tested,for'
p2202
(F1
F0.00076452599388379206
I0
I1
I-1
tp2203
sS'into,the'
p2204
(F1
F0.00076452599388379206
I0
I1
I-1
tp2205
sS'on,who'
p2206
(F1
F0.00076452599388379206
I1
I0
I1
tp2207
sS'or,sedation'
p2208
(F0
F0
I1
I1
I0
tp2209
sS'animal,data'
p2210
(F1
F0.00076452599388379206
I1
I0
I1
tp2211
sS'we,found'
p2212
(F1
F0.00076452599388379206
I1
I0
I1
tp2213
sS'toxicity,have'
p2214
(F0
F0
I1
I1
I0
tp2215
sS'extend,the'
p2216
(F1
F0.00076452599388379206
I1
I0
I1
tp2217
sS'alone,average'
p2218
(F1
F0.00076452599388379206
I1
I0
I1
tp2219
sS'increased,rate'
p2220
(F1
F0.00076452599388379206
I1
I0
I1
tp2221
sS'pressor,effect'
p2222
(F1
F0.0015290519877675841
I2
I0
I2
tp2223
sS'that,bcl-2'
p2224
(F1
F0.00076452599388379206
I1
I0
I1
tp2225
sS'of,aceon'
p2226
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2227
sS'that,can'
p2228
(F1
F0.0015290519877675841
I2
I0
I2
tp2229
sS'pharmacokinetic,drug'
p2230
(F1
F0.00076452599388379206
I1
I0
I1
tp2231
sS'controlled,study'
p2232
(F1
F0.0015290519877675841
I2
I0
I2
tp2233
sS'five,different'
p2234
(F1
F0.00076452599388379206
I0
I1
I-1
tp2235
sS'n,extensive'
p2236
(F1
F0.00076452599388379206
I0
I1
I-1
tp2237
sS'antinociceptive,activity'
p2238
(F1
F0.00076452599388379206
I1
I0
I1
tp2239
sS'to,oral'
p2240
(F1
F0.00076452599388379206
I1
I0
I1
tp2241
sS'group,vehicle'
p2242
(F1
F0.00076452599388379206
I0
I1
I-1
tp2243
sS'of,concomitantly'
p2244
(F1
F0.00076452599388379206
I1
I0
I1
tp2245
sS'day,of'
p2246
(F1
F0.0015290519877675841
I2
I0
I2
tp2247
sS'the,clearance'
p2248
(F0.7142857142857143
F0.0076452599388379203
I12
I2
I10
tp2249
sS'agitation,and'
p2250
(F1
F0.00076452599388379206
I1
I0
I1
tp2251
sS'carried,out'
p2252
(F1
F0.0015290519877675841
I0
I2
I-2
tp2253
sS'the,same'
p2254
(F1
F0.0030581039755351682
I4
I0
I4
tp2255
sS'day,or'
p2256
(F1
F0.00076452599388379206
I1
I0
I1
tp2257
sS'and,does'
p2258
(F1
F0.00076452599388379206
I0
I1
I-1
tp2259
sS'of,anticoagulants'
p2260
(F1
F0.00076452599388379206
I1
I0
I1
tp2261
sS'in,rabbits'
p2262
(F1
F0.00076452599388379206
I0
I1
I-1
tp2263
sS'metabolism,and'
p2264
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp2265
sS'vaccines,may'
p2266
(F1
F0.00076452599388379206
I1
I0
I1
tp2267
sS'enzyme,inhibition'
p2268
(F1
F0.00076452599388379206
I0
I1
I-1
tp2269
sS'of,fertility'
p2270
(F1
F0.00076452599388379206
I0
I1
I-1
tp2271
sS'kg,significantly'
p2272
(F1
F0.00076452599388379206
I1
I0
I1
tp2273
sS'adjustment,of'
p2274
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp2275
sS'symptoms,of'
p2276
(F0
F0
I1
I1
I0
tp2277
sS'mptp-evoked,behavior'
p2278
(F1
F0.00076452599388379206
I0
I1
I-1
tp2279
sS'variability,in'
p2280
(F0
F0
I1
I1
I0
tp2281
sS'miochol,and'
p2282
(F1
F0.00076452599388379206
I1
I0
I1
tp2283
sS'clearance,ml'
p2284
(F1
F0.00076452599388379206
I1
I0
I1
tp2285
sS'a5,a7'
p2286
(F1
F0.00076452599388379206
I1
I0
I1
tp2287
sS'commonly,used'
p2288
(F1
F0.0015290519877675841
I0
I2
I-2
tp2289
sS'diminished,nonheme'
p2290
(F1
F0.00076452599388379206
I1
I0
I1
tp2291
sS'observed,between'
p2292
(F0
F0
I1
I1
I0
tp2293
sS'of,normal-weight'
p2294
(F1
F0.00076452599388379206
I0
I1
I-1
tp2295
sS'that,stimulate'
p2296
(F1
F0.00076452599388379206
I1
I0
I1
tp2297
sS'weight,subjects'
p2298
(F1
F0.00076452599388379206
I0
I1
I-1
tp2299
sS'with,overexpression'
p2300
(F1
F0.00076452599388379206
I1
I0
I1
tp2301
sS'plasma,bismuth'
p2302
(F1
F0.00076452599388379206
I1
I0
I1
tp2303
sS'medication,which'
p2304
(F1
F0.00076452599388379206
I1
I0
I1
tp2305
sS'dose,and'
p2306
(F1
F0.00076452599388379206
I0
I1
I-1
tp2307
sS'and,thus'
p2308
(F1
F0.0030581039755351682
I4
I0
I4
tp2309
sS'lower,levels'
p2310
(F1
F0.00076452599388379206
I1
I0
I1
tp2311
sS'demonstrate,qt'
p2312
(F1
F0.00076452599388379206
I1
I0
I1
tp2313
sS'in,cellular'
p2314
(F1
F0.00076452599388379206
I0
I1
I-1
tp2315
sS'for,pheochromocytoma'
p2316
(F1
F0.00076452599388379206
I0
I1
I-1
tp2317
sS'suppression,of'
p2318
(F1
F0.00076452599388379206
I1
I0
I1
tp2319
sS'with,caution'
p2320
(F1
F0.0068807339449541288
I9
I0
I9
tp2321
sS'on,prothrombin'
p2322
(F1
F0.00076452599388379206
I0
I1
I-1
tp2323
sS'a,pharmacokinetic'
p2324
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp2325
sS'we,concluded'
p2326
(F1
F0.00076452599388379206
I1
I0
I1
tp2327
sS'competitive,inhibition'
p2328
(F1
F0.00076452599388379206
I0
I1
I-1
tp2329
sS'until,a'
p2330
(F1
F0.00076452599388379206
I1
I0
I1
tp2331
sS'with,have'
p2332
(F0
F0
I1
I1
I0
tp2333
sS'low-dose,and'
p2334
(F1
F0.00076452599388379206
I0
I1
I-1
tp2335
sS'are,birth'
p2336
(F1
F0.00076452599388379206
I0
I1
I-1
tp2337
sS'other,similar'
p2338
(F1
F0.00076452599388379206
I1
I0
I1
tp2339
sS'with,hypertensive'
p2340
(F1
F0.00076452599388379206
I0
I1
I-1
tp2341
sS'cyp1a2,via'
p2342
(F1
F0.00076452599388379206
I0
I1
I-1
tp2343
sS'necessary,until'
p2344
(F1
F0.00076452599388379206
I1
I0
I1
tp2345
sS'commonly,employed'
p2346
(F1
F0.00076452599388379206
I0
I1
I-1
tp2347
sS'anticoagulants,prothrombin'
p2348
(F1
F0.00076452599388379206
I1
I0
I1
tp2349
sS'activity,live'
p2350
(F1
F0.00076452599388379206
I1
I0
I1
tp2351
sS'short,elimination'
p2352
(F1
F0.00076452599388379206
I1
I0
I1
tp2353
sS'therapy,i'
p2354
(F1
F0.00076452599388379206
I0
I1
I-1
tp2355
sS'phentermine,hydrochloride'
p2356
(F1
F0.00076452599388379206
I1
I0
I1
tp2357
sS'in,rheumatoid'
p2358
(F1
F0.00076452599388379206
I0
I1
I-1
tp2359
sS'is,clinically'
p2360
(F1
F0.00076452599388379206
I1
I0
I1
tp2361
sS'as,with'
p2362
(F1
F0.0015290519877675841
I2
I0
I2
tp2363
sS'with,mobic'
p2364
(F1
F0.00076452599388379206
I1
I0
I1
tp2365
sS'antacids,absorption'
p2366
(F1
F0.00076452599388379206
I1
I0
I1
tp2367
sS'needed,with'
p2368
(F1
F0.00076452599388379206
I0
I1
I-1
tp2369
sS'bleeding,events'
p2370
(F1
F0.00076452599388379206
I1
I0
I1
tp2371
sS'extrapolated,to'
p2372
(F1
F0.00076452599388379206
I1
I0
I1
tp2373
sS'a,controlled'
p2374
(F1
F0.0015290519877675841
I2
I0
I2
tp2375
sS'the,total'
p2376
(F0
F0
I1
I1
I0
tp2377
sS'patient,controlled'
p2378
(F1
F0.00076452599388379206
I1
I0
I1
tp2379
sS'of,lbh589'
p2380
(F1
F0.00076452599388379206
I0
I1
I-1
tp2381
sS'competing,for'
p2382
(F1
F0.00076452599388379206
I1
I0
I1
tp2383
sS'crm197,plus'
p2384
(F1
F0.00076452599388379206
I1
I0
I1
tp2385
sS'however,increased'
p2386
(F1
F0.00076452599388379206
I1
I0
I1
tp2387
sS'study,evaluated'
p2388
(F1
F0.00076452599388379206
I0
I1
I-1
tp2389
sS'methylprednisolone,may'
p2390
(F1
F0.00076452599388379206
I1
I0
I1
tp2391
sS'would,not'
p2392
(F1
F0.00076452599388379206
I0
I1
I-1
tp2393
sS'antiplatelet,drug'
p2394
(F1
F0.00076452599388379206
I1
I0
I1
tp2395
sS'mcf7,following'
p2396
(F1
F0.00076452599388379206
I1
I0
I1
tp2397
sS'either,sirnas'
p2398
(F1
F0.00076452599388379206
I1
I0
I1
tp2399
sS'enzymes,the'
p2400
(F1
F0.00076452599388379206
I0
I1
I-1
tp2401
sS'feldene,is'
p2402
(F1
F0.00076452599388379206
I1
I0
I1
tp2403
sS'fst,in'
p2404
(F1
F0.00076452599388379206
I0
I1
I-1
tp2405
sS'be,given'
p2406
(F1
F0.0030581039755351682
I4
I0
I4
tp2407
sS'ability,to'
p2408
(F1
F0.00076452599388379206
I1
I0
I1
tp2409
sS'hiv,protease'
p2410
(F1
F0.00076452599388379206
I0
I1
I-1
tp2411
sS'causes,a'
p2412
(F1
F0.0022935779816513763
I3
I0
I3
tp2413
sS'theophylline-containing,drugs'
p2414
(F1
F0.00076452599388379206
I1
I0
I1
tp2415
sS'of,qt'
p2416
(F1
F0.00076452599388379206
I0
I1
I-1
tp2417
sS'p450,cp450'
p2418
(F1
F0.00076452599388379206
I1
I0
I1
tp2419
sS'xl,was'
p2420
(F1
F0.00076452599388379206
I1
I0
I1
tp2421
sS'riboflavin,alcohol'
p2422
(F1
F0.00076452599388379206
I1
I0
I1
tp2423
sS'values,for'
p2424
(F1
F0.0015290519877675841
I2
I0
I2
tp2425
sS'd6,inhibitors'
p2426
(F1
F0.00076452599388379206
I1
I0
I1
tp2427
sS'on,day'
p2428
(F1
F0.00076452599388379206
I0
I1
I-1
tp2429
sS'if,this'
p2430
(F1
F0.00076452599388379206
I0
I1
I-1
tp2431
sS'hypothyroidism,on'
p2432
(F1
F0.00076452599388379206
I1
I0
I1
tp2433
sS'kinases,on'
p2434
(F1
F0.00076452599388379206
I0
I1
I-1
tp2435
sS'of,dopamine'
p2436
(F1
F0.00076452599388379206
I1
I0
I1
tp2437
sS'respectively,lesser'
p2438
(F1
F0.00076452599388379206
I1
I0
I1
tp2439
sS'after,discontinuing'
p2440
(F1
F0.00076452599388379206
I1
I0
I1
tp2441
sS'qid,can'
p2442
(F1
F0.00076452599388379206
I1
I0
I1
tp2443
sS'stereological,counts'
p2444
(F1
F0.00076452599388379206
I1
I0
I1
tp2445
sS'finding,that'
p2446
(F1
F0.00076452599388379206
I1
I0
I1
tp2447
sS'effects,on'
p2448
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp2449
sS'a4,enzyme'
p2450
(F1
F0.0015290519877675841
I2
I0
I2
tp2451
sS'doses,up'
p2452
(F1
F0.0022935779816513763
I0
I3
I-3
tp2453
sS'of,subjects'
p2454
(F1
F0.00076452599388379206
I1
I0
I1
tp2455
sS'effects,of'
p2456
(F0.31707317073170732
F0.0099388379204892966
I27
I14
I13
tp2457
sS'increases,cytochrome'
p2458
(F1
F0.00076452599388379206
I1
I0
I1
tp2459
sS'rare,serious'
p2460
(F1
F0.00076452599388379206
I1
I0
I1
tp2461
sS'changes,in'
p2462
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp2463
sS'altabax,is'
p2464
(F1
F0.00076452599388379206
I0
I1
I-1
tp2465
sS'exhibits,anti-proliferative'
p2466
(F1
F0.00076452599388379206
I1
I0
I1
tp2467
sS'trials,concomitantly'
p2468
(F1
F0.00076452599388379206
I0
I1
I-1
tp2469
sS'local,since'
p2470
(F1
F0.00076452599388379206
I1
I0
I1
tp2471
sS'potent,cyp3a'
p2472
(F1
F0.00076452599388379206
I0
I1
I-1
tp2473
sS'mean,dose'
p2474
(F1
F0.00076452599388379206
I0
I1
I-1
tp2475
sS'medications,with'
p2476
(F1
F0.00076452599388379206
I1
I0
I1
tp2477
sS'other,indications'
p2478
(F1
F0.00076452599388379206
I1
I0
I1
tp2479
sS'the,neuromuscular'
p2480
(F0.5
F0.0015290519877675841
I3
I1
I2
tp2481
sS'when,proamatine'
p2482
(F1
F0.00076452599388379206
I1
I0
I1
tp2483
sS'tests,when'
p2484
(F1
F0.00076452599388379206
I1
I0
I1
tp2485
sS'the,fact'
p2486
(F1
F0.00076452599388379206
I0
I1
I-1
tp2487
sS'of,curariform'
p2488
(F1
F0.00076452599388379206
I1
I0
I1
tp2489
sS'i,and'
p2490
(F0
F0
I1
I1
I0
tp2491
sS'a,multiple'
p2492
(F1
F0.00076452599388379206
I1
I0
I1
tp2493
sS'and,showed'
p2494
(F1
F0.00076452599388379206
I0
I1
I-1
tp2495
sS'any,concomitantly'
p2496
(F1
F0.00076452599388379206
I1
I0
I1
tp2497
sS'affect,other'
p2498
(F1
F0.00076452599388379206
I0
I1
I-1
tp2499
sS'magnesium-containing,when'
p2500
(F1
F0.00076452599388379206
I1
I0
I1
tp2501
sS'on,auc0-24hr'
p2502
(F1
F0.0030581039755351682
I0
I4
I-4
tp2503
sS'antagonism,between'
p2504
(F1
F0.00076452599388379206
I1
I0
I1
tp2505
sS'aminoglutethimide,administered'
p2506
(F1
F0.00076452599388379206
I1
I0
I1
tp2507
sS'creatinine,is'
p2508
(F1
F0.00076452599388379206
I1
I0
I1
tp2509
sS'assay,induced'
p2510
(F1
F0.00076452599388379206
I1
I0
I1
tp2511
sS'are,receiving'
p2512
(F0
F0
I1
I1
I0
tp2513
sS'with,essential'
p2514
(F1
F0.00076452599388379206
I1
I0
I1
tp2515
sS'locomotor,inhibitory'
p2516
(F1
F0.00076452599388379206
I1
I0
I1
tp2517
sS'synergism,was'
p2518
(F1
F0.0015290519877675841
I2
I0
I2
tp2519
sS'emergence,agitation'
p2520
(F1
F0.00076452599388379206
I0
I1
I-1
tp2521
sS'also,affect'
p2522
(F1
F0.00076452599388379206
I1
I0
I1
tp2523
sS'cholestyramine,and'
p2524
(F1
F0.00076452599388379206
I0
I1
I-1
tp2525
sS'vasospasm,leading'
p2526
(F1
F0.00076452599388379206
I0
I1
I-1
tp2527
sS'amines,is'
p2528
(F1
F0.0015290519877675841
I2
I0
I2
tp2529
sS'myfortic,with'
p2530
(F1
F0.0015290519877675841
I2
I0
I2
tp2531
sS'in,renal'
p2532
(F1
F0.00076452599388379206
I1
I0
I1
tp2533
sS'chemotherapy,tumor'
p2534
(F1
F0.00076452599388379206
I1
I0
I1
tp2535
sS'pharmacokinetics,are'
p2536
(F1
F0.00076452599388379206
I0
I1
I-1
tp2537
sS'anti-vitamin,k'
p2538
(F1
F0.00076452599388379206
I1
I0
I1
tp2539
sS'aminobenzotriazole,abt'
p2540
(F1
F0.00076452599388379206
I0
I1
I-1
tp2541
sS'mellitus,being'
p2542
(F1
F0.00076452599388379206
I1
I0
I1
tp2543
sS'been,conducted'
p2544
(F1
F0.00076452599388379206
I1
I0
I1
tp2545
sS'the,sulfonylurea'
p2546
(F1
F0.00076452599388379206
I1
I0
I1
tp2547
sS'both,acetic'
p2548
(F1
F0.00076452599388379206
I1
I0
I1
tp2549
sS'concurrently,administered'
p2550
(F1
F0.0015290519877675841
I2
I0
I2
tp2551
sS'hormonal,contraceptives'
p2552
(F1
F0.00076452599388379206
I0
I1
I-1
tp2553
sS'agents,were'
p2554
(F1
F0.00076452599388379206
I1
I0
I1
tp2555
sS'changes,has'
p2556
(F1
F0.00076452599388379206
I1
I0
I1
tp2557
sS'toxicity,has'
p2558
(F1
F0.0015290519877675841
I2
I0
I2
tp2559
sS'consideration,in'
p2560
(F1
F0.00076452599388379206
I1
I0
I1
tp2561
sS'this,enzyme'
p2562
(F1
F0.00076452599388379206
I0
I1
I-1
tp2563
sS'agents,oxandrolone'
p2564
(F1
F0.00076452599388379206
I1
I0
I1
tp2565
sS'initiating,or'
p2566
(F1
F0.00076452599388379206
I1
I0
I1
tp2567
sS'be,counteracted'
p2568
(F1
F0.00076452599388379206
I1
I0
I1
tp2569
sS'peg-intron,once'
p2570
(F1
F0.00076452599388379206
I1
I0
I1
tp2571
sS'administering,with'
p2572
(F1
F0.00076452599388379206
I1
I0
I1
tp2573
sS'soltab,with'
p2574
(F1
F0.00076452599388379206
I0
I1
I-1
tp2575
sS'fold,in'
p2576
(F1
F0.00076452599388379206
I1
I0
I1
tp2577
sS'gastrointestinal,effects'
p2578
(F1
F0.00076452599388379206
I0
I1
I-1
tp2579
sS'administration,decreased'
p2580
(F1
F0.00076452599388379206
I1
I0
I1
tp2581
sS'pharmacokinetic,interaction'
p2582
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp2583
sS'sites,notably'
p2584
(F1
F0.00076452599388379206
I1
I0
I1
tp2585
sS'and,extent'
p2586
(F1
F0.00076452599388379206
I0
I1
I-1
tp2587
sS'by,some'
p2588
(F1
F0.00076452599388379206
I1
I0
I1
tp2589
sS'may,counteract'
p2590
(F1
F0.00076452599388379206
I1
I0
I1
tp2591
sS'ace,inhibitors'
p2592
(F0.5
F0.0015290519877675841
I3
I1
I2
tp2593
sS'coumarin-type,interactions'
p2594
(F1
F0.00076452599388379206
I1
I0
I1
tp2595
sS'secretion,population'
p2596
(F1
F0.00076452599388379206
I1
I0
I1
tp2597
sS'of,atropinization'
p2598
(F1
F0.00076452599388379206
I1
I0
I1
tp2599
sS'being,given'
p2600
(F1
F0.00076452599388379206
I0
I1
I-1
tp2601
sS'of,neuromuscular'
p2602
(F1
F0.00076452599388379206
I1
I0
I1
tp2603
sS'spontaneous,reports'
p2604
(F1
F0.00076452599388379206
I1
I0
I1
tp2605
sS'exelon,tartrate'
p2606
(F1
F0.00076452599388379206
I0
I1
I-1
tp2607
sS'studies,between'
p2608
(F1
F0.00076452599388379206
I0
I1
I-1
tp2609
sS'in,other'
p2610
(F1
F0.00076452599388379206
I1
I0
I1
tp2611
sS'mexitil,dose'
p2612
(F1
F0.00076452599388379206
I1
I0
I1
tp2613
sS'purpura,has'
p2614
(F1
F0.00076452599388379206
I0
I1
I-1
tp2615
sS'be,treated'
p2616
(F1
F0.00076452599388379206
I1
I0
I1
tp2617
sS'in,plasma'
p2618
(F0.55555555555555558
F0.0038226299694189602
I7
I2
I5
tp2619
sS'the,acute'
p2620
(F1
F0.00076452599388379206
I0
I1
I-1
tp2621
sS'ea,in'
p2622
(F1
F0.00076452599388379206
I1
I0
I1
tp2623
sS'other,muscle'
p2624
(F1
F0.00076452599388379206
I0
I1
I-1
tp2625
sS'nutritional,status'
p2626
(F1
F0.00076452599388379206
I0
I1
I-1
tp2627
sS'is,increased'
p2628
(F1
F0.0022935779816513763
I3
I0
I3
tp2629
sS'plasma,parathyroid'
p2630
(F1
F0.00076452599388379206
I0
I1
I-1
tp2631
sS'tell,your'
p2632
(F1
F0.00076452599388379206
I0
I1
I-1
tp2633
sS'sympathomimetic,pressor'
p2634
(F1
F0.0015290519877675841
I2
I0
I2
tp2635
sS'diffusion,tests'
p2636
(F1
F0.00076452599388379206
I1
I0
I1
tp2637
sS'elavil,asendin'
p2638
(F1
F0.00076452599388379206
I0
I1
I-1
tp2639
sS'that,causes'
p2640
(F1
F0.00076452599388379206
I1
I0
I1
tp2641
sS'are,capable'
p2642
(F1
F0.0015290519877675841
I2
I0
I2
tp2643
sS'from,has'
p2644
(F1
F0.00076452599388379206
I1
I0
I1
tp2645
sS'that,caused'
p2646
(F1
F0.00076452599388379206
I1
I0
I1
tp2647
sS'and,vs'
p2648
(F1
F0.00076452599388379206
I1
I0
I1
tp2649
sS'when,initiating'
p2650
(F1
F0.00076452599388379206
I1
I0
I1
tp2651
sS'significant,changes'
p2652
(F1
F0.0015290519877675841
I0
I2
I-2
tp2653
sS'healthy,volunteers'
p2654
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp2655
sS'apoptosis,by'
p2656
(F1
F0.00076452599388379206
I1
I0
I1
tp2657
sS'dose,from'
p2658
(F1
F0.00076452599388379206
I0
I1
I-1
tp2659
sS'furosemide,and'
p2660
(F1
F0.00076452599388379206
I1
I0
I1
tp2661
sS'reductions,of'
p2662
(F1
F0.00076452599388379206
I1
I0
I1
tp2663
sS'the,pharmacokinetics'
p2664
(F1
F0.0084097859327217118
I0
I11
I-11
tp2665
sS'injections,mg'
p2666
(F1
F0.00076452599388379206
I0
I1
I-1
tp2667
sS'with,infusion'
p2668
(F1
F0.00076452599388379206
I1
I0
I1
tp2669
sS'dose,containing'
p2670
(F1
F0.00076452599388379206
I0
I1
I-1
tp2671
sS'can,also'
p2672
(F1
F0.00076452599388379206
I1
I0
I1
tp2673
sS'oxide,to'
p2674
(F1
F0.00076452599388379206
I0
I1
I-1
tp2675
sS'rivastigmine,is'
p2676
(F1
F0.00076452599388379206
I0
I1
I-1
tp2677
sS'temperature,has'
p2678
(F1
F0.00076452599388379206
I1
I0
I1
tp2679
sS'resulted,in'
p2680
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp2681
sS'ingested,on'
p2682
(F1
F0.00076452599388379206
I0
I1
I-1
tp2683
sS'in,methyl-4'
p2684
(F1
F0.0015290519877675841
I2
I0
I2
tp2685
sS'prevent,graft-versus'
p2686
(F1
F0.00076452599388379206
I1
I0
I1
tp2687
sS'guanethidine,although'
p2688
(F1
F0.00076452599388379206
I1
I0
I1
tp2689
sS'extrapyramidal,effects'
p2690
(F1
F0.00076452599388379206
I1
I0
I1
tp2691
sS'pamelor,tofranil'
p2692
(F1
F0.00076452599388379206
I0
I1
I-1
tp2693
sS'significantly,higher'
p2694
(F0
F0
I1
I1
I0
tp2695
sS'used,cautiously'
p2696
(F1
F0.0030581039755351682
I4
I0
I4
tp2697
sS'overexpression,of'
p2698
(F1
F0.00076452599388379206
I1
I0
I1
tp2699
sS'constipation,which'
p2700
(F1
F0.00076452599388379206
I1
I0
I1
tp2701
sS'src,and'
p2702
(F1
F0.00076452599388379206
I0
I1
I-1
tp2703
sS'to,establish'
p2704
(F1
F0.00076452599388379206
I0
I1
I-1
tp2705
sS'are,secreted'
p2706
(F1
F0.00076452599388379206
I1
I0
I1
tp2707
sS'occasions,with'
p2708
(F1
F0.00076452599388379206
I1
I0
I1
tp2709
sS'affect,the'
p2710
(F0.5
F0.0030581039755351682
I2
I6
I-4
tp2711
sS'gsls,at'
p2712
(F1
F0.00076452599388379206
I0
I1
I-1
tp2713
sS'birth,control'
p2714
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2715
sS'relating,to'
p2716
(F1
F0.00076452599388379206
I1
I0
I1
tp2717
sS'causing,too'
p2718
(F1
F0.00076452599388379206
I1
I0
I1
tp2719
sS'other,potent'
p2720
(F1
F0.0015290519877675841
I2
I0
I2
tp2721
sS'between,these'
p2722
(F1
F0.00076452599388379206
I0
I1
I-1
tp2723
sS'system,also'
p2724
(F1
F0.00076452599388379206
I1
I0
I1
tp2725
sS'of,bleeding'
p2726
(F1
F0.0030581039755351682
I4
I0
I4
tp2727
sS'decrease,or'
p2728
(F1
F0.00076452599388379206
I1
I0
I1
tp2729
sS'or,cholinergic'
p2730
(F1
F0.00076452599388379206
I1
I0
I1
tp2731
sS'elevating,the'
p2732
(F1
F0.00076452599388379206
I1
I0
I1
tp2733
sS'daily,and'
p2734
(F1
F0.00076452599388379206
I1
I0
I1
tp2735
sS'depressants,can'
p2736
(F1
F0.0015290519877675841
I2
I0
I2
tp2737
sS'rifampicin,in'
p2738
(F1
F0.00076452599388379206
I1
I0
I1
tp2739
sS'mg,of'
p2740
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2741
sS'mg,on'
p2742
(F1
F0.0015290519877675841
I0
I2
I-2
tp2743
sS'improve,immunization'
p2744
(F1
F0.00076452599388379206
I0
I1
I-1
tp2745
sS'mg,or'
p2746
(F1
F0.00076452599388379206
I1
I0
I1
tp2747
sS'media,whereas'
p2748
(F1
F0.00076452599388379206
I1
I0
I1
tp2749
sS'pointes,and'
p2750
(F1
F0.00076452599388379206
I1
I0
I1
tp2751
sS'clinical,relevance'
p2752
(F1
F0.00076452599388379206
I0
I1
I-1
tp2753
sS'that,altered'
p2754
(F1
F0.00076452599388379206
I1
I0
I1
tp2755
sS'agent,dtic'
p2756
(F1
F0.00076452599388379206
I0
I1
I-1
tp2757
sS'of,metabolites'
p2758
(F1
F0.00076452599388379206
I1
I0
I1
tp2759
sS'altering,concentrations'
p2760
(F1
F0.00076452599388379206
I1
I0
I1
tp2761
sS'methicillin-resistant,staphylococcus'
p2762
(F1
F0.00076452599388379206
I0
I1
I-1
tp2763
sS'hyaluronidase,may'
p2764
(F1
F0.00076452599388379206
I1
I0
I1
tp2765
sS'may,influence'
p2766
(F1
F0.00076452599388379206
I1
I0
I1
tp2767
sS'analgesics,i'
p2768
(F1
F0.00076452599388379206
I1
I0
I1
tp2769
sS'daily,or'
p2770
(F1
F0.00076452599388379206
I0
I1
I-1
tp2771
sS'similar,to'
p2772
(F0
F0
I2
I2
I0
tp2773
sS'behavioural,observations'
p2774
(F1
F0.00076452599388379206
I1
I0
I1
tp2775
sS'human,serum'
p2776
(F0
F0
I1
I1
I0
tp2777
sS'invega,should'
p2778
(F1
F0.00076452599388379206
I1
I0
I1
tp2779
sS'adjustment,for'
p2780
(F1
F0.00076452599388379206
I1
I0
I1
tp2781
sS'monitor,patients'
p2782
(F1
F0.0015290519877675841
I2
I0
I2
tp2783
sS'of,cardiac'
p2784
(F1
F0.00076452599388379206
I1
I0
I1
tp2785
sS'primarily,metabolized'
p2786
(F1
F0.00076452599388379206
I0
I1
I-1
tp2787
sS'reported,in'
p2788
(F0.5
F0.0045871559633027525
I9
I3
I6
tp2789
sS'in,shorter'
p2790
(F1
F0.00076452599388379206
I1
I0
I1
tp2791
sS'sedative,activity'
p2792
(F1
F0.00076452599388379206
I1
I0
I1
tp2793
sS'but,significant'
p2794
(F1
F0.00076452599388379206
I1
I0
I1
tp2795
sS'and,other'
p2796
(F0.69999999999999996
F0.010703363914373088
I17
I3
I14
tp2797
sS'for,induction'
p2798
(F1
F0.00076452599388379206
I1
I0
I1
tp2799
sS'selegiline,in'
p2800
(F1
F0.00076452599388379206
I0
I1
I-1
tp2801
sS'exert,particular'
p2802
(F1
F0.00076452599388379206
I1
I0
I1
tp2803
sS'tended,to'
p2804
(F0
F0
I1
I1
I0
tp2805
sS'adjustment,is'
p2806
(F1
F0.00076452599388379206
I0
I1
I-1
tp2807
sS'was,lower'
p2808
(F1
F0.00076452599388379206
I1
I0
I1
tp2809
sS'randomized,blinded'
p2810
(F1
F0.00076452599388379206
I0
I1
I-1
tp2811
sS'of,diprivan'
p2812
(F1
F0.0015290519877675841
I2
I0
I2
tp2813
sS'zolinza,concomitantly'
p2814
(F1
F0.00076452599388379206
I1
I0
I1
tp2815
sS'monitored,and'
p2816
(F1
F0.00076452599388379206
I1
I0
I1
tp2817
sS'alpha-adrenergic,blocking'
p2818
(F0
F0
I1
I1
I0
tp2819
sS'symptoms,in'
p2820
(F1
F0.00076452599388379206
I0
I1
I-1
tp2821
sS'changes,to'
p2822
(F1
F0.00076452599388379206
I0
I1
I-1
tp2823
sS'curcumin,can'
p2824
(F1
F0.00076452599388379206
I0
I1
I-1
tp2825
sS'therapy,with'
p2826
(F1
F0.0030581039755351682
I4
I0
I4
tp2827
sS'cellular,glutathione'
p2828
(F1
F0.00076452599388379206
I0
I1
I-1
tp2829
sS'which,convert'
p2830
(F1
F0.00076452599388379206
I0
I1
I-1
tp2831
sS'amplifies,the'
p2832
(F1
F0.00076452599388379206
I1
I0
I1
tp2833
sS'of,five'
p2834
(F1
F0.00076452599388379206
I0
I1
I-1
tp2835
sS'we,present'
p2836
(F1
F0.0015290519877675841
I2
I0
I2
tp2837
sS'minutes,range'
p2838
(F1
F0.00076452599388379206
I0
I1
I-1
tp2839
sS'might,be'
p2840
(F1
F0.0022935779816513763
I3
I0
I3
tp2841
sS'examination,of'
p2842
(F1
F0.00076452599388379206
I1
I0
I1
tp2843
sS'was,noticeably'
p2844
(F1
F0.00076452599388379206
I0
I1
I-1
tp2845
sS'the,first'
p2846
(F1
F0.0022935779816513763
I3
I0
I3
tp2847
sS'drug,s'
p2848
(F1
F0.00076452599388379206
I1
I0
I1
tp2849
sS'rr,and'
p2850
(F1
F0.00076452599388379206
I0
I1
I-1
tp2851
sS'negatively,regulating'
p2852
(F1
F0.00076452599388379206
I1
I0
I1
tp2853
sS'isolated,rat'
p2854
(F1
F0.00076452599388379206
I1
I0
I1
tp2855
sS'the,data'
p2856
(F1
F0.00076452599388379206
I0
I1
I-1
tp2857
sS'interactions,it'
p2858
(F1
F0.00076452599388379206
I1
I0
I1
tp2859
sS'receptors,or'
p2860
(F1
F0.00076452599388379206
I1
I0
I1
tp2861
sS'treatment,on'
p2862
(F1
F0.00076452599388379206
I0
I1
I-1
tp2863
sS'radiolabeled,drug'
p2864
(F1
F0.00076452599388379206
I0
I1
I-1
tp2865
sS'bid,with'
p2866
(F1
F0.00076452599388379206
I1
I0
I1
tp2867
sS'treatment,of'
p2868
(F0
F0
I3
I3
I0
tp2869
sS'at,an'
p2870
(F1
F0.00076452599388379206
I1
I0
I1
tp2871
sS'rendered,parkinsonian'
p2872
(F1
F0.00076452599388379206
I0
I1
I-1
tp2873
sS'epistaxis,gastrointestinal'
p2874
(F1
F0.00076452599388379206
I1
I0
I1
tp2875
sS'two-fold,decrease'
p2876
(F1
F0.00076452599388379206
I1
I0
I1
tp2877
sS'titrated,to'
p2878
(F1
F0.00076452599388379206
I0
I1
I-1
tp2879
sS'to,amide-type'
p2880
(F1
F0.00076452599388379206
I1
I0
I1
tp2881
sS'nalidixic,acid'
p2882
(F1
F0.00076452599388379206
I1
I0
I1
tp2883
sS'mofetil,inhibit'
p2884
(F1
F0.00076452599388379206
I1
I0
I1
tp2885
sS'mexitil,lowered'
p2886
(F1
F0.00076452599388379206
I1
I0
I1
tp2887
sS'lipoic,acid'
p2888
(F1
F0.00076452599388379206
I0
I1
I-1
tp2889
sS'using,locomotor'
p2890
(F1
F0.00076452599388379206
I0
I1
I-1
tp2891
sS'when,ditropan'
p2892
(F1
F0.00076452599388379206
I1
I0
I1
tp2893
sS'st,johns'
p2894
(F1
F0.00076452599388379206
I1
I0
I1
tp2895
sS'who,received'
p2896
(F1
F0.00076452599388379206
I0
I1
I-1
tp2897
sS'the,pharmacokinetic'
p2898
(F0.40000000000000002
F0.0030581039755351682
I3
I7
I-4
tp2899
sS'uncontrolled,hy-per'
p2900
(F1
F0.00076452599388379206
I0
I1
I-1
tp2901
sS'may,occasionally'
p2902
(F1
F0.00076452599388379206
I1
I0
I1
tp2903
sS'metabolized,by'
p2904
(F0.27272727272727271
F0.0022935779816513763
I4
I7
I-3
tp2905
sS'tests,there'
p2906
(F1
F0.00076452599388379206
I0
I1
I-1
tp2907
sS'may,also'
p2908
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp2909
sS'study,published'
p2910
(F1
F0.00076452599388379206
I1
I0
I1
tp2911
sS'consistent,with'
p2912
(F1
F0.00076452599388379206
I1
I0
I1
tp2913
sS'cells,treated'
p2914
(F1
F0.00076452599388379206
I1
I0
I1
tp2915
sS'and,u251'
p2916
(F1
F0.00076452599388379206
I0
I1
I-1
tp2917
sS'at,least'
p2918
(F0.5
F0.0015290519877675841
I3
I1
I2
tp2919
sS'that,irreversibly'
p2920
(F1
F0.00076452599388379206
I1
I0
I1
tp2921
sS'relative,concentration'
p2922
(F1
F0.00076452599388379206
I1
I0
I1
tp2923
sS'the,oral'
p2924
(F0
F0
I1
I1
I0
tp2925
sS'were,administered'
p2926
(F0
F0
I1
I1
I0
tp2927
sS'products,with'
p2928
(F1
F0.00076452599388379206
I1
I0
I1
tp2929
sS's-ketamine,is'
p2930
(F1
F0.00076452599388379206
I1
I0
I1
tp2931
sS'required,and'
p2932
(F1
F0.00076452599388379206
I1
I0
I1
tp2933
sS'marrow,depressants'
p2934
(F1
F0.00076452599388379206
I1
I0
I1
tp2935
sS'confidence,interval'
p2936
(F1
F0.00076452599388379206
I1
I0
I1
tp2937
sS'zemuron,before'
p2938
(F1
F0.00076452599388379206
I0
I1
I-1
tp2939
sS'macrolide,including'
p2940
(F1
F0.00076452599388379206
I1
I0
I1
tp2941
sS'was,administered'
p2942
(F0.14285714285714285
F0.00076452599388379206
I4
I3
I1
tp2943
sS'and,toxicity'
p2944
(F1
F0.00076452599388379206
I1
I0
I1
tp2945
sS'interrupted,close'
p2946
(F1
F0.00076452599388379206
I1
I0
I1
tp2947
sS'by,remeron'
p2948
(F1
F0.0015290519877675841
I2
I0
I2
tp2949
sS'used,with'
p2950
(F0.63636363636363635
F0.0053516819571865441
I9
I2
I7
tp2951
sS'occurs,with'
p2952
(F0
F0
I1
I1
I0
tp2953
sS'following,the'
p2954
(F1
F0.0015290519877675841
I2
I0
I2
tp2955
sS'recommended,for'
p2956
(F1
F0.00076452599388379206
I1
I0
I1
tp2957
sS'in,breast'
p2958
(F1
F0.00076452599388379206
I1
I0
I1
tp2959
sS'trials,of'
p2960
(F0
F0
I1
I1
I0
tp2961
sS'g,and'
p2962
(F1
F0.0015290519877675841
I0
I2
I-2
tp2963
sS'or,cautiously'
p2964
(F1
F0.00076452599388379206
I0
I1
I-1
tp2965
sS'initially,activated'
p2966
(F1
F0.00076452599388379206
I1
I0
I1
tp2967
sS'using,in'
p2968
(F1
F0.00076452599388379206
I0
I1
I-1
tp2969
sS'and,serum'
p2970
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp2971
sS'concluded,that'
p2972
(F1
F0.0015290519877675841
I2
I0
I2
tp2973
sS'from,plasma'
p2974
(F0
F0
I1
I1
I0
tp2975
sS'inhibition,by'
p2976
(F1
F0.00076452599388379206
I1
I0
I1
tp2977
sS'patients,to'
p2978
(F1
F0.0022935779816513763
I3
I0
I3
tp2979
sS'antidepressants,may'
p2980
(F1
F0.00076452599388379206
I1
I0
I1
tp2981
sS'lines,hela'
p2982
(F1
F0.00076452599388379206
I0
I1
I-1
tp2983
sS'with,fixed'
p2984
(F1
F0.00076452599388379206
I0
I1
I-1
tp2985
sS'salicylate,drugs'
p2986
(F1
F0.00076452599388379206
I1
I0
I1
tp2987
sS'paclitaxel-induced,apoptosis'
p2988
(F0
F0
I1
I1
I0
tp2989
sS'was,minutes'
p2990
(F1
F0.00076452599388379206
I0
I1
I-1
tp2991
sS'alcohol,concomitant'
p2992
(F1
F0.00076452599388379206
I1
I0
I1
tp2993
sS'kg,group'
p2994
(F1
F0.00076452599388379206
I0
I1
I-1
tp2995
sS't-all,cell'
p2996
(F1
F0.00076452599388379206
I0
I1
I-1
tp2997
sS'in,total'
p2998
(F1
F0.00076452599388379206
I0
I1
I-1
tp2999
sS'concomitantly,as'
p3000
(F1
F0.00076452599388379206
I1
I0
I1
tp3001
sS'k,activity'
p3002
(F1
F0.00076452599388379206
I1
I0
I1
tp3003
sS'decreased,with'
p3004
(F1
F0.00076452599388379206
I1
I0
I1
tp3005
sS't790m,and'
p3006
(F1
F0.00076452599388379206
I1
I0
I1
tp3007
sS'intense,and'
p3008
(F1
F0.00076452599388379206
I1
I0
I1
tp3009
sS'which,blocks'
p3010
(F1
F0.00076452599388379206
I1
I0
I1
tp3011
sS'data,on'
p3012
(F1
F0.00076452599388379206
I0
I1
I-1
tp3013
sS'patient,should'
p3014
(F1
F0.00076452599388379206
I1
I0
I1
tp3015
sS'the,absorption'
p3016
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp3017
sS'of,action'
p3018
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3019
sS'suggests,that'
p3020
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp3021
sS'the,they'
p3022
(F1
F0.00076452599388379206
I1
I0
I1
tp3023
sS'and,insulin'
p3024
(F1
F0.00076452599388379206
I1
I0
I1
tp3025
sS'aggrastat,in'
p3026
(F1
F0.00076452599388379206
I1
I0
I1
tp3027
sS'eldepryl,and'
p3028
(F1
F0.00076452599388379206
I1
I0
I1
tp3029
sS'infarction,in'
p3030
(F1
F0.00076452599388379206
I0
I1
I-1
tp3031
sS'particularly,at'
p3032
(F1
F0.00076452599388379206
I1
I0
I1
tp3033
sS'suitable,anticoagulation'
p3034
(F1
F0.00076452599388379206
I1
I0
I1
tp3035
sS'of,their'
p3036
(F1
F0.0022935779816513763
I3
I0
I3
tp3037
sS'since,mexitil'
p3038
(F1
F0.00076452599388379206
I0
I1
I-1
tp3039
sS'statistically,significant'
p3040
(F1
F0.0015290519877675841
I2
I0
I2
tp3041
sS'care,in'
p3042
(F1
F0.00076452599388379206
I1
I0
I1
tp3043
sS'cns,depression'
p3044
(F1
F0.00076452599388379206
I0
I1
I-1
tp3045
sS'higher,concentrations'
p3046
(F1
F0.0015290519877675841
I0
I2
I-2
tp3047
sS'and,however'
p3048
(F1
F0.00076452599388379206
I1
I0
I1
tp3049
sS'acidic,media'
p3050
(F1
F0.00076452599388379206
I1
I0
I1
tp3051
sS'clinical,and'
p3052
(F1
F0.00076452599388379206
I1
I0
I1
tp3053
sS'cyp2d6,cyp1a2'
p3054
(F1
F0.00076452599388379206
I0
I1
I-1
tp3055
sS'forced,expression'
p3056
(F1
F0.00076452599388379206
I1
I0
I1
tp3057
sS'control,values'
p3058
(F1
F0.00076452599388379206
I1
I0
I1
tp3059
sS'regular,nph'
p3060
(F1
F0.00076452599388379206
I1
I0
I1
tp3061
sS'of,major'
p3062
(F1
F0.00076452599388379206
I1
I0
I1
tp3063
sS'g,dose'
p3064
(F1
F0.00076452599388379206
I1
I0
I1
tp3065
sS'giving,class'
p3066
(F1
F0.00076452599388379206
I1
I0
I1
tp3067
sS'forced,swimming'
p3068
(F1
F0.00076452599388379206
I0
I1
I-1
tp3069
sS'of,achievement'
p3070
(F1
F0.00076452599388379206
I0
I1
I-1
tp3071
sS'attributed,to'
p3072
(F1
F0.00076452599388379206
I1
I0
I1
tp3073
sS'general,other'
p3074
(F1
F0.00076452599388379206
I0
I1
I-1
tp3075
sS'previously,reported'
p3076
(F1
F0.00076452599388379206
I1
I0
I1
tp3077
sS'isopto,carbachol'
p3078
(F1
F0.00076452599388379206
I1
I0
I1
tp3079
sS'diuretics,furosemide'
p3080
(F1
F0.00076452599388379206
I1
I0
I1
tp3081
sS'decrease,the'
p3082
(F1
F0.0053516819571865441
I7
I0
I7
tp3083
sS'no,pharmacokinetic'
p3084
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3085
sS'weakness,hyperreflexia'
p3086
(F1
F0.00076452599388379206
I1
I0
I1
tp3087
sS'were,unaffected'
p3088
(F1
F0.0022935779816513763
I0
I3
I-3
tp3089
sS'whether,the'
p3090
(F1
F0.0022935779816513763
I0
I3
I-3
tp3091
sS'day,treatment'
p3092
(F1
F0.00076452599388379206
I0
I1
I-1
tp3093
sS'heart,medicines'
p3094
(F1
F0.00076452599388379206
I1
I0
I1
tp3095
sS'tnkase,were'
p3096
(F1
F0.00076452599388379206
I0
I1
I-1
tp3097
sS'but,magnesium-aluminum'
p3098
(F1
F0.00076452599388379206
I1
I0
I1
tp3099
sS'platelet,reactivity'
p3100
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3101
sS'block,may'
p3102
(F1
F0.00076452599388379206
I1
I0
I1
tp3103
sS'is,introduced'
p3104
(F1
F0.00076452599388379206
I1
I0
I1
tp3105
sS'and,apparent'
p3106
(F1
F0.00076452599388379206
I1
I0
I1
tp3107
sS'cause,marrow'
p3108
(F1
F0.00076452599388379206
I1
I0
I1
tp3109
sS'central,nervous'
p3110
(F1
F0.0030581039755351682
I4
I0
I4
tp3111
sS'intravenous,dose'
p3112
(F1
F0.00076452599388379206
I0
I1
I-1
tp3113
sS'metabolised,by'
p3114
(F1
F0.00076452599388379206
I1
I0
I1
tp3115
sS'at,a'
p3116
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp3117
sS'in,oral'
p3118
(F1
F0.00076452599388379206
I0
I1
I-1
tp3119
sS'some,drugs'
p3120
(F1
F0.00076452599388379206
I1
I0
I1
tp3121
sS'large,and'
p3122
(F1
F0.00076452599388379206
I0
I1
I-1
tp3123
sS'their,serum'
p3124
(F1
F0.00076452599388379206
I1
I0
I1
tp3125
sS'to,use'
p3126
(F1
F0.00076452599388379206
I1
I0
I1
tp3127
sS'study,indicate'
p3128
(F1
F0.00076452599388379206
I1
I0
I1
tp3129
sS'induced,toxicity'
p3130
(F1
F0.00076452599388379206
I1
I0
I1
tp3131
sS'synergism,is'
p3132
(F1
F0.00076452599388379206
I1
I0
I1
tp3133
sS'when,concomitantly'
p3134
(F1
F0.00076452599388379206
I1
I0
I1
tp3135
sS'and,could'
p3136
(F1
F0.00076452599388379206
I1
I0
I1
tp3137
sS'reaction,reports'
p3138
(F1
F0.00076452599388379206
I1
I0
I1
tp3139
sS'the,exposure'
p3140
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3141
sS'with,bcl-2'
p3142
(F1
F0.00076452599388379206
I0
I1
I-1
tp3143
sS'demonstrated,in'
p3144
(F1
F0.00076452599388379206
I1
I0
I1
tp3145
sS'combination,therapy'
p3146
(F1
F0.00076452599388379206
I1
I0
I1
tp3147
sS'and,to'
p3148
(F0
F0
I2
I2
I0
tp3149
sS'was,potentiated'
p3150
(F1
F0.00076452599388379206
I1
I0
I1
tp3151
sS'transporter,and'
p3152
(F1
F0.00076452599388379206
I1
I0
I1
tp3153
sS'therapeutic,effect'
p3154
(F1
F0.00076452599388379206
I0
I1
I-1
tp3155
sS'in,greater'
p3156
(F1
F0.00076452599388379206
I1
I0
I1
tp3157
sS'growth,more'
p3158
(F1
F0.00076452599388379206
I1
I0
I1
tp3159
sS'the,standard'
p3160
(F1
F0.00076452599388379206
I0
I1
I-1
tp3161
sS'proamatine,cardiac'
p3162
(F1
F0.00076452599388379206
I1
I0
I1
tp3163
sS'conducted,in'
p3164
(F0.66666666666666663
F0.0030581039755351682
I1
I5
I-4
tp3165
sS'levels,returned'
p3166
(F1
F0.00076452599388379206
I1
I0
I1
tp3167
sS'advisable,to'
p3168
(F1
F0.0015290519877675841
I2
I0
I2
tp3169
sS'were,exposed'
p3170
(F0
F0
I1
I1
I0
tp3171
sS'was,measured'
p3172
(F1
F0.00076452599388379206
I0
I1
I-1
tp3173
sS'inhibit,the'
p3174
(F0.66666666666666663
F0.0061162079510703364
I10
I2
I8
tp3175
sS'was,delivered'
p3176
(F1
F0.00076452599388379206
I0
I1
I-1
tp3177
sS'gene,expression'
p3178
(F1
F0.00076452599388379206
I0
I1
I-1
tp3179
sS'chemet,is'
p3180
(F1
F0.00076452599388379206
I0
I1
I-1
tp3181
sS'critical,determinant'
p3182
(F1
F0.00076452599388379206
I1
I0
I1
tp3183
sS'vitamins,such'
p3184
(F1
F0.00076452599388379206
I1
I0
I1
tp3185
sS'by,administration'
p3186
(F1
F0.00076452599388379206
I0
I1
I-1
tp3187
sS'demonstrated,appropriateness'
p3188
(F1
F0.00076452599388379206
I1
I0
I1
tp3189
sS'a4,it'
p3190
(F1
F0.00076452599388379206
I1
I0
I1
tp3191
sS'an,increased'
p3192
(F0.5
F0.0030581039755351682
I6
I2
I4
tp3193
sS'thrombocytopenia,increased'
p3194
(F1
F0.0015290519877675841
I0
I2
I-2
tp3195
sS'potential,for'
p3196
(F0.14285714285714285
F0.00076452599388379206
I4
I3
I1
tp3197
sS'decreased,seizure'
p3198
(F1
F0.00076452599388379206
I1
I0
I1
tp3199
sS'an,increases'
p3200
(F1
F0.00076452599388379206
I0
I1
I-1
tp3201
sS'result,in'
p3202
(F0.52941176470588236
F0.0068807339449541288
I13
I4
I9
tp3203
sS'patients,with'
p3204
(F0.17647058823529413
F0.0022935779816513763
I10
I7
I3
tp3205
sS'are,potentiated'
p3206
(F1
F0.0015290519877675841
I2
I0
I2
tp3207
sS'taken,especially'
p3208
(F1
F0.00076452599388379206
I1
I0
I1
tp3209
sS'g,kg'
p3210
(F0
F0
I1
I1
I0
tp3211
sS'channel,antagonists'
p3212
(F1
F0.00076452599388379206
I1
I0
I1
tp3213
sS'chicken,actin'
p3214
(F1
F0.00076452599388379206
I0
I1
I-1
tp3215
sS'with,are'
p3216
(F1
F0.00076452599388379206
I0
I1
I-1
tp3217
sS'furthermore,the'
p3218
(F1
F0.00076452599388379206
I1
I0
I1
tp3219
sS'reasonable,to'
p3220
(F1
F0.0015290519877675841
I2
I0
I2
tp3221
sS'or,reverse'
p3222
(F1
F0.00076452599388379206
I0
I1
I-1
tp3223
sS'following,oral'
p3224
(F1
F0.0015290519877675841
I2
I0
I2
tp3225
sS'ergot,alkaloids'
p3226
(F1
F0.00076452599388379206
I0
I1
I-1
tp3227
sS'for,interaction'
p3228
(F1
F0.00076452599388379206
I0
I1
I-1
tp3229
sS'and,rifampicin'
p3230
(F1
F0.00076452599388379206
I1
I0
I1
tp3231
sS'full,examination'
p3232
(F1
F0.00076452599388379206
I1
I0
I1
tp3233
sS'p,lt'
p3234
(F1
F0.00076452599388379206
I0
I1
I-1
tp3235
sS'depressants,including'
p3236
(F0
F0
I1
I1
I0
tp3237
sS'theoretical,basis'
p3238
(F1
F0.00076452599388379206
I1
I0
I1
tp3239
sS'cyp3a4,i'
p3240
(F1
F0.00076452599388379206
I1
I0
I1
tp3241
sS'mg,in'
p3242
(F1
F0.0015290519877675841
I2
I0
I2
tp3243
sS'or,other'
p3244
(F0.5714285714285714
F0.0061162079510703364
I11
I3
I8
tp3245
sS'loss,of'
p3246
(F1
F0.0015290519877675841
I2
I0
I2
tp3247
sS'low-dose,added'
p3248
(F1
F0.00076452599388379206
I1
I0
I1
tp3249
sS'lesser,number'
p3250
(F1
F0.00076452599388379206
I1
I0
I1
tp3251
sS'impairment,of'
p3252
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3253
sS'the,base-secreting'
p3254
(F1
F0.00076452599388379206
I1
I0
I1
tp3255
sS'in,r-warfarin'
p3256
(F1
F0.00076452599388379206
I1
I0
I1
tp3257
sS'of,metabolism'
p3258
(F1
F0.0015290519877675841
I2
I0
I2
tp3259
sS'daily,mg'
p3260
(F1
F0.00076452599388379206
I0
I1
I-1
tp3261
sS'trental,has'
p3262
(F1
F0.00076452599388379206
I0
I1
I-1
tp3263
sS'administering,tolectin'
p3264
(F1
F0.00076452599388379206
I1
I0
I1
tp3265
sS'effect,and'
p3266
(F1
F0.00076452599388379206
I0
I1
I-1
tp3267
sS'that,could'
p3268
(F1
F0.00076452599388379206
I1
I0
I1
tp3269
sS'added,sometimes'
p3270
(F1
F0.00076452599388379206
I0
I1
I-1
tp3271
sS'cyp3a4,inhibition'
p3272
(F1
F0.00076452599388379206
I0
I1
I-1
tp3273
sS'mitotane,to'
p3274
(F1
F0.00076452599388379206
I1
I0
I1
tp3275
sS'avoid,taking'
p3276
(F1
F0.00076452599388379206
I1
I0
I1
tp3277
sS'adrenal,cortical'
p3278
(F1
F0.00076452599388379206
I0
I1
I-1
tp3279
sS'antibody-dependent,cellular'
p3280
(F0
F0
I1
I1
I0
tp3281
sS'of,valproic'
p3282
(F1
F0.0015290519877675841
I2
I0
I2
tp3283
sS'antiplatelets,after'
p3284
(F1
F0.00076452599388379206
I0
I1
I-1
tp3285
sS'profiles,of'
p3286
(F1
F0.0015290519877675841
I0
I2
I-2
tp3287
sS'after,a'
p3288
(F1
F0.00076452599388379206
I0
I1
I-1
tp3289
sS'pharmacologic,studies'
p3290
(F1
F0.00076452599388379206
I1
I0
I1
tp3291
sS'antidepressant,drugs'
p3292
(F1
F0.00076452599388379206
I1
I0
I1
tp3293
sS'hormonal,agents'
p3294
(F1
F0.00076452599388379206
I1
I0
I1
tp3295
sS'with,salt-retaining'
p3296
(F1
F0.00076452599388379206
I0
I1
I-1
tp3297
sS'increase,platelet'
p3298
(F1
F0.00076452599388379206
I1
I0
I1
tp3299
sS'capsules,may'
p3300
(F1
F0.00076452599388379206
I1
I0
I1
tp3301
sS'a,total'
p3302
(F1
F0.00076452599388379206
I0
I1
I-1
tp3303
sS'been,described'
p3304
(F1
F0.00076452599388379206
I1
I0
I1
tp3305
sS'with,absorption'
p3306
(F1
F0.00076452599388379206
I1
I0
I1
tp3307
sS'mesylate,is'
p3308
(F1
F0.00076452599388379206
I0
I1
I-1
tp3309
sS'system,drugs'
p3310
(F1
F0.00076452599388379206
I0
I1
I-1
tp3311
sS'pt,should'
p3312
(F1
F0.00076452599388379206
I1
I0
I1
tp3313
sS'anticipated,it'
p3314
(F1
F0.00076452599388379206
I1
I0
I1
tp3315
sS'in,dznep'
p3316
(F1
F0.00076452599388379206
I1
I0
I1
tp3317
sS'enzymes,including'
p3318
(F1
F0.00076452599388379206
I0
I1
I-1
tp3319
sS'combinations,in'
p3320
(F1
F0.00076452599388379206
I1
I0
I1
tp3321
sS'inhibits,some'
p3322
(F1
F0.00076452599388379206
I1
I0
I1
tp3323
sS'attenuating,some'
p3324
(F1
F0.00076452599388379206
I0
I1
I-1
tp3325
sS'n,males'
p3326
(F1
F0.00076452599388379206
I1
I0
I1
tp3327
sS'cancer,or'
p3328
(F1
F0.00076452599388379206
I0
I1
I-1
tp3329
sS'inr,international'
p3330
(F1
F0.0015290519877675841
I0
I2
I-2
tp3331
sS'effects,with'
p3332
(F1
F0.00076452599388379206
I0
I1
I-1
tp3333
sS'of,trental'
p3334
(F1
F0.00076452599388379206
I1
I0
I1
tp3335
sS'experiment,the'
p3336
(F1
F0.00076452599388379206
I1
I0
I1
tp3337
sS'additive,with'
p3338
(F1
F0.0030581039755351682
I4
I0
I4
tp3339
sS'model,three'
p3340
(F1
F0.00076452599388379206
I0
I1
I-1
tp3341
sS'antagonist,methyl-1'
p3342
(F0
F0
I1
I1
I0
tp3343
sS'in,drug-interaction'
p3344
(F1
F0.00076452599388379206
I0
I1
I-1
tp3345
sS'radiation,therapy'
p3346
(F1
F0.00076452599388379206
I1
I0
I1
tp3347
sS'at,g1'
p3348
(F1
F0.00076452599388379206
I0
I1
I-1
tp3349
sS'efficacy,may'
p3350
(F1
F0.00076452599388379206
I1
I0
I1
tp3351
sS'other,antihypertensive'
p3352
(F1
F0.0022935779816513763
I3
I0
I3
tp3353
sS'by,increasing'
p3354
(F1
F0.00076452599388379206
I1
I0
I1
tp3355
sS'clearance,is'
p3356
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3357
sS'more,time'
p3358
(F1
F0.00076452599388379206
I0
I1
I-1
tp3359
sS'show,additive'
p3360
(F1
F0.00076452599388379206
I1
I0
I1
tp3361
sS'of,anesthesia'
p3362
(F1
F0.00076452599388379206
I1
I0
I1
tp3363
sS'terbinafine,clearance'
p3364
(F0
F0
I1
I1
I0
tp3365
sS'if,administered'
p3366
(F1
F0.0015290519877675841
I2
I0
I2
tp3367
sS'elevated,parent'
p3368
(F1
F0.00076452599388379206
I1
I0
I1
tp3369
sS'cause,unusually'
p3370
(F1
F0.00076452599388379206
I1
I0
I1
tp3371
sS'to,that'
p3372
(F0
F0
I1
I1
I0
tp3373
sS'and,smoking'
p3374
(F1
F0.00076452599388379206
I0
I1
I-1
tp3375
sS'however,the'
p3376
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp3377
sS'report,in'
p3378
(F1
F0.00076452599388379206
I1
I0
I1
tp3379
sS'on,gastrointestinal'
p3380
(F1
F0.00076452599388379206
I1
I0
I1
tp3381
sS'recently,may'
p3382
(F1
F0.00076452599388379206
I1
I0
I1
tp3383
sS'by,this'
p3384
(F1
F0.00076452599388379206
I0
I1
I-1
tp3385
sS'the,mitomycin-c'
p3386
(F1
F0.00076452599388379206
I1
I0
I1
tp3387
sS'shown,to'
p3388
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp3389
sS'the,hospital'
p3390
(F1
F0.00076452599388379206
I0
I1
I-1
tp3391
sS'tobi,patients'
p3392
(F1
F0.00076452599388379206
I1
I0
I1
tp3393
sS'aluminum-,or'
p3394
(F1
F0.00076452599388379206
I1
I0
I1
tp3395
sS'is,partially'
p3396
(F1
F0.00076452599388379206
I1
I0
I1
tp3397
sS'for,are'
p3398
(F1
F0.00076452599388379206
I0
I1
I-1
tp3399
sS'myfortic,and'
p3400
(F0
F0
I1
I1
I0
tp3401
sS'a,shimadzu'
p3402
(F1
F0.00076452599388379206
I0
I1
I-1
tp3403
sS'parent,levels'
p3404
(F1
F0.00076452599388379206
I1
I0
I1
tp3405
sS'genentech,beta'
p3406
(F1
F0.00076452599388379206
I1
I0
I1
tp3407
sS'antihypertensive,drugs'
p3408
(F1
F0.0015290519877675841
I2
I0
I2
tp3409
sS'inhibit,plasma'
p3410
(F1
F0.00076452599388379206
I1
I0
I1
tp3411
sS'risk,is'
p3412
(F1
F0.00076452599388379206
I0
I1
I-1
tp3413
sS'oral,coumarin-type'
p3414
(F1
F0.00076452599388379206
I1
I0
I1
tp3415
sS'and,gp'
p3416
(F1
F0.00076452599388379206
I1
I0
I1
tp3417
sS'are,less'
p3418
(F1
F0.00076452599388379206
I0
I1
I-1
tp3419
sS'were,decreases'
p3420
(F1
F0.00076452599388379206
I0
I1
I-1
tp3421
sS'improves,retinal'
p3422
(F1
F0.00076452599388379206
I0
I1
I-1
tp3423
sS'occurred,in'
p3424
(F1
F0.00076452599388379206
I1
I0
I1
tp3425
sS'the,metabolic'
p3426
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3427
sS'the,efficacy'
p3428
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3429
sS'may,occur'
p3430
(F0
F0
I1
I1
I0
tp3431
sS'of,wales'
p3432
(F1
F0.00076452599388379206
I1
I0
I1
tp3433
sS'other,complications'
p3434
(F1
F0.00076452599388379206
I1
I0
I1
tp3435
sS'system,with'
p3436
(F1
F0.00076452599388379206
I0
I1
I-1
tp3437
sS'orally,doses'
p3438
(F1
F0.00076452599388379206
I0
I1
I-1
tp3439
sS'mi,when'
p3440
(F1
F0.00076452599388379206
I0
I1
I-1
tp3441
sS'bear,directly'
p3442
(F1
F0.00076452599388379206
I1
I0
I1
tp3443
sS'xanthine,derivatives'
p3444
(F1
F0.00076452599388379206
I1
I0
I1
tp3445
sS'male,and'
p3446
(F1
F0.00076452599388379206
I0
I1
I-1
tp3447
sS'results,if'
p3448
(F1
F0.00076452599388379206
I0
I1
I-1
tp3449
sS'and,are'
p3450
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp3451
sS'a,prolongation'
p3452
(F1
F0.00076452599388379206
I1
I0
I1
tp3453
sS'creatinine,clearance'
p3454
(F1
F0.00076452599388379206
I1
I0
I1
tp3455
sS'much,study'
p3456
(F1
F0.00076452599388379206
I0
I1
I-1
tp3457
sS'hospitalized,in'
p3458
(F1
F0.00076452599388379206
I0
I1
I-1
tp3459
sS'those,in'
p3460
(F1
F0.0015290519877675841
I0
I2
I-2
tp3461
sS'and,bleeding'
p3462
(F1
F0.00076452599388379206
I1
I0
I1
tp3463
sS'day,females'
p3464
(F1
F0.00076452599388379206
I0
I1
I-1
tp3465
sS'of,nonmatched'
p3466
(F1
F0.00076452599388379206
I0
I1
I-1
tp3467
sS'when,are'
p3468
(F1
F0.00076452599388379206
I1
I0
I1
tp3469
sS'ischemia,of'
p3470
(F1
F0.00076452599388379206
I0
I1
I-1
tp3471
sS'with,dornase'
p3472
(F1
F0.00076452599388379206
I1
I0
I1
tp3473
sS'its,carboxylated'
p3474
(F1
F0.00076452599388379206
I0
I1
I-1
tp3475
sS'acid,artificial'
p3476
(F1
F0.00076452599388379206
I0
I1
I-1
tp3477
sS'experienced,a'
p3478
(F1
F0.00076452599388379206
I1
I0
I1
tp3479
sS'renal,excretion'
p3480
(F1
F0.0015290519877675841
I0
I2
I-2
tp3481
sS'g1,phase'
p3482
(F1
F0.00076452599388379206
I0
I1
I-1
tp3483
sS'bronchodilators,should'
p3484
(F1
F0.0015290519877675841
I2
I0
I2
tp3485
sS'blood,glucose'
p3486
(F1
F0.00076452599388379206
I1
I0
I1
tp3487
sS'weeks,was'
p3488
(F1
F0.00076452599388379206
I1
I0
I1
tp3489
sS'related,compounds'
p3490
(F1
F0.00076452599388379206
I1
I0
I1
tp3491
sS'when,methergine'
p3492
(F1
F0.00076452599388379206
I1
I0
I1
tp3493
sS'combination,of'
p3494
(F0.75
F0.0045871559633027525
I7
I1
I6
tp3495
sS'therefore,as'
p3496
(F1
F0.00076452599388379206
I1
I0
I1
tp3497
sS'on,deb'
p3498
(F1
F0.00076452599388379206
I1
I0
I1
tp3499
sS'of,megestrol'
p3500
(F0
F0
I1
I1
I0
tp3501
sS'will,compete'
p3502
(F1
F0.00076452599388379206
I0
I1
I-1
tp3503
sS'affect,absorption'
p3504
(F1
F0.00076452599388379206
I1
I0
I1
tp3505
sS'in,humans'
p3506
(F1
F0.00076452599388379206
I0
I1
I-1
tp3507
sS'noticeably,influence'
p3508
(F1
F0.00076452599388379206
I0
I1
I-1
tp3509
sS'in,prolongation'
p3510
(F1
F0.00076452599388379206
I1
I0
I1
tp3511
sS'lbh589,an'
p3512
(F1
F0.00076452599388379206
I0
I1
I-1
tp3513
sS'levodopa,carbidopa'
p3514
(F1
F0.00076452599388379206
I0
I1
I-1
tp3515
sS'a,p450'
p3516
(F1
F0.00076452599388379206
I0
I1
I-1
tp3517
sS'and,of'
p3518
(F1
F0.00076452599388379206
I0
I1
I-1
tp3519
sS'not,reproduce'
p3520
(F1
F0.00076452599388379206
I0
I1
I-1
tp3521
sS'and,on'
p3522
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3523
sS'important,effects'
p3524
(F1
F0.00076452599388379206
I0
I1
I-1
tp3525
sS'effects,may'
p3526
(F1
F0.0022935779816513763
I3
I0
I3
tp3527
sS'and,or'
p3528
(F0.375
F0.0045871559633027525
I11
I5
I6
tp3529
sS'single-dose,pharmacokinetics'
p3530
(F1
F0.00076452599388379206
I0
I1
I-1
tp3531
sS'gsls,was'
p3532
(F1
F0.00076452599388379206
I1
I0
I1
tp3533
sS'this,interaction'
p3534
(F1
F0.00076452599388379206
I1
I0
I1
tp3535
sS'increase,blood'
p3536
(F1
F0.00076452599388379206
I0
I1
I-1
tp3537
sS'include,divalproex'
p3538
(F1
F0.00076452599388379206
I0
I1
I-1
tp3539
sS'sedative,effects'
p3540
(F1
F0.0022935779816513763
I3
I0
I3
tp3541
sS'insulin,the'
p3542
(F1
F0.00076452599388379206
I1
I0
I1
tp3543
sS'the,elevation'
p3544
(F1
F0.00076452599388379206
I0
I1
I-1
tp3545
sS'prothrombin,activity'
p3546
(F1
F0.00076452599388379206
I1
I0
I1
tp3547
sS'agonist,it'
p3548
(F1
F0.00076452599388379206
I1
I0
I1
tp3549
sS'antagonists,drugs'
p3550
(F1
F0.00076452599388379206
I1
I0
I1
tp3551
sS'that,diflucan'
p3552
(F1
F0.00076452599388379206
I1
I0
I1
tp3553
sS'of,some'
p3554
(F1
F0.00076452599388379206
I0
I1
I-1
tp3555
sS'of,gene'
p3556
(F1
F0.00076452599388379206
I0
I1
I-1
tp3557
sS'not,change'
p3558
(F1
F0.0015290519877675841
I0
I2
I-2
tp3559
sS'therefore,flomax'
p3560
(F1
F0.00076452599388379206
I1
I0
I1
tp3561
sS'cause,unpredictable'
p3562
(F1
F0.00076452599388379206
I1
I0
I1
tp3563
sS'elimination,of'
p3564
(F1
F0.00076452599388379206
I1
I0
I1
tp3565
sS'virus,may'
p3566
(F1
F0.00076452599388379206
I1
I0
I1
tp3567
sS'levels,therapeutic'
p3568
(F1
F0.00076452599388379206
I1
I0
I1
tp3569
sS'vitro,evidence'
p3570
(F1
F0.00076452599388379206
I1
I0
I1
tp3571
sS'exposure,were'
p3572
(F1
F0.00076452599388379206
I1
I0
I1
tp3573
sS'daily,doses'
p3574
(F1
F0.0022935779816513763
I0
I3
I-3
tp3575
sS'additional,birth'
p3576
(F1
F0.00076452599388379206
I1
I0
I1
tp3577
sS'amide-type,local'
p3578
(F1
F0.00076452599388379206
I1
I0
I1
tp3579
sS'cause,clinically'
p3580
(F1
F0.0015290519877675841
I0
I2
I-2
tp3581
sS'having,mixed'
p3582
(F1
F0.00076452599388379206
I0
I1
I-1
tp3583
sS'twice,daily'
p3584
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp3585
sS'p450,inhibition'
p3586
(F1
F0.00076452599388379206
I0
I1
I-1
tp3587
sS'to,may'
p3588
(F1
F0.0015290519877675841
I2
I0
I2
tp3589
sS'maximum,recommended'
p3590
(F1
F0.00076452599388379206
I0
I1
I-1
tp3591
sS'in,ovarian'
p3592
(F1
F0.00076452599388379206
I0
I1
I-1
tp3593
sS'studies,that'
p3594
(F1
F0.00076452599388379206
I1
I0
I1
tp3595
sS'chronic,model'
p3596
(F1
F0.00076452599388379206
I0
I1
I-1
tp3597
sS'of,pain'
p3598
(F1
F0.00076452599388379206
I1
I0
I1
tp3599
sS'ai,vaccination'
p3600
(F1
F0.00076452599388379206
I1
I0
I1
tp3601
sS'the,gastrointestinal'
p3602
(F1
F0.00076452599388379206
I0
I1
I-1
tp3603
sS'is,purported'
p3604
(F1
F0.00076452599388379206
I1
I0
I1
tp3605
sS'following,classes'
p3606
(F1
F0.00076452599388379206
I0
I1
I-1
tp3607
sS'skelid,by'
p3608
(F1
F0.00076452599388379206
I1
I0
I1
tp3609
sS'of,forced'
p3610
(F1
F0.00076452599388379206
I0
I1
I-1
tp3611
sS'studied,and'
p3612
(F1
F0.0015290519877675841
I2
I0
I2
tp3613
sS'volume,contraction'
p3614
(F1
F0.00076452599388379206
I0
I1
I-1
tp3615
sS'measured,bp'
p3616
(F1
F0.00076452599388379206
I1
I0
I1
tp3617
sS'nondepolarizing,agents'
p3618
(F1
F0.00076452599388379206
I1
I0
I1
tp3619
sS'crossover,study'
p3620
(F1
F0.0015290519877675841
I0
I2
I-2
tp3621
sS'doses,between'
p3622
(F1
F0.0015290519877675841
I0
I2
I-2
tp3623
sS'the,cns-depressant'
p3624
(F1
F0.00076452599388379206
I1
I0
I1
tp3625
sS'toxicity,when'
p3626
(F1
F0.0015290519877675841
I2
I0
I2
tp3627
sS'administered,with'
p3628
(F0.2857142857142857
F0.0030581039755351682
I9
I5
I4
tp3629
sS'herceptin-mediated,antibody-dependent'
p3630
(F0
F0
I1
I1
I0
tp3631
sS'vs,but'
p3632
(F1
F0.00076452599388379206
I1
I0
I1
tp3633
sS'and,bronchospasm'
p3634
(F1
F0.00076452599388379206
I1
I0
I1
tp3635
sS'of,isolated'
p3636
(F1
F0.00076452599388379206
I1
I0
I1
tp3637
sS'the,single-dose'
p3638
(F1
F0.00076452599388379206
I0
I1
I-1
tp3639
sS'that,coadministration'
p3640
(F1
F0.0015290519877675841
I2
I0
I2
tp3641
sS'sirna,knockdown'
p3642
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3643
sS'gi,bleeding'
p3644
(F1
F0.00076452599388379206
I1
I0
I1
tp3645
sS'bronchospasm,killed'
p3646
(F1
F0.00076452599388379206
I1
I0
I1
tp3647
sS'with,anticholinergic'
p3648
(F1
F0.00076452599388379206
I1
I0
I1
tp3649
sS'agonist,antagonist'
p3650
(F1
F0.00076452599388379206
I1
I0
I1
tp3651
sS'to,affect'
p3652
(F1
F0.0045871559633027525
I0
I6
I-6
tp3653
sS'the,two'
p3654
(F1
F0.0015290519877675841
I0
I2
I-2
tp3655
sS'herceptin,in'
p3656
(F1
F0.00076452599388379206
I0
I1
I-1
tp3657
sS'single,use'
p3658
(F1
F0.00076452599388379206
I0
I1
I-1
tp3659
sS'mutagenesis,impairment'
p3660
(F1
F0.00076452599388379206
I0
I1
I-1
tp3661
sS'results,revealed'
p3662
(F1
F0.00076452599388379206
I0
I1
I-1
tp3663
sS'parameters,for'
p3664
(F1
F0.00076452599388379206
I1
I0
I1
tp3665
sS'female,controls'
p3666
(F1
F0.00076452599388379206
I0
I1
I-1
tp3667
sS'given,the'
p3668
(F0
F0
I1
I1
I0
tp3669
sS'used,the'
p3670
(F1
F0.00076452599388379206
I1
I0
I1
tp3671
sS'and,carboptic'
p3672
(F1
F0.00076452599388379206
I1
I0
I1
tp3673
sS'administered,alone'
p3674
(F0
F0
I1
I1
I0
tp3675
sS'a4,inhibitors'
p3676
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3677
sS'population,as'
p3678
(F1
F0.00076452599388379206
I1
I0
I1
tp3679
sS'are,prescribed'
p3680
(F1
F0.00076452599388379206
I1
I0
I1
tp3681
sS'resistance,to'
p3682
(F1
F0.00076452599388379206
I1
I0
I1
tp3683
sS'biotransformation,of'
p3684
(F1
F0.0015290519877675841
I0
I2
I-2
tp3685
sS'used,concomitantly'
p3686
(F1
F0.0022935779816513763
I3
I0
I3
tp3687
sS'of,ointment'
p3688
(F1
F0.00076452599388379206
I1
I0
I1
tp3689
sS'from,small'
p3690
(F1
F0.00076452599388379206
I1
I0
I1
tp3691
sS'via,renal'
p3692
(F1
F0.00076452599388379206
I1
I0
I1
tp3693
sS'cyp450,enzyme'
p3694
(F1
F0.00076452599388379206
I1
I0
I1
tp3695
sS'synergism,of'
p3696
(F1
F0.00076452599388379206
I1
I0
I1
tp3697
sS'with,significantly'
p3698
(F1
F0.00076452599388379206
I1
I0
I1
tp3699
sS'tetrahydropyridine,toxicity'
p3700
(F1
F0.00076452599388379206
I1
I0
I1
tp3701
sS'dornase,alfa'
p3702
(F1
F0.00076452599388379206
I1
I0
I1
tp3703
sS'nonheme,absorption'
p3704
(F1
F0.00076452599388379206
I1
I0
I1
tp3705
sS'induce,metabolism'
p3706
(F1
F0.0015290519877675841
I2
I0
I2
tp3707
sS'without,unexpected'
p3708
(F1
F0.00076452599388379206
I0
I1
I-1
tp3709
sS'enhance,or'
p3710
(F1
F0.0015290519877675841
I2
I0
I2
tp3711
sS'and,h'
p3712
(F1
F0.00076452599388379206
I0
I1
I-1
tp3713
sS'and,n'
p3714
(F1
F0.0015290519877675841
I0
I2
I-2
tp3715
sS'other,potentially'
p3716
(F1
F0.00076452599388379206
I0
I1
I-1
tp3717
sS'of,hypertensive'
p3718
(F1
F0.00076452599388379206
I1
I0
I1
tp3719
sS'and,a'
p3720
(F1
F0.0022935779816513763
I3
I0
I3
tp3721
sS'and,g'
p3722
(F1
F0.00076452599388379206
I0
I1
I-1
tp3723
sS'of,concomitant'
p3724
(F1
F0.00076452599388379206
I0
I1
I-1
tp3725
sS'and,p'
p3726
(F1
F0.00076452599388379206
I0
I1
I-1
tp3727
sS'labeling,for'
p3728
(F1
F0.00076452599388379206
I0
I1
I-1
tp3729
sS'of,zolinza'
p3730
(F1
F0.00076452599388379206
I1
I0
I1
tp3731
sS'show,that'
p3732
(F1
F0.0015290519877675841
I0
I2
I-2
tp3733
sS'benzodiazepines,following'
p3734
(F1
F0.00076452599388379206
I1
I0
I1
tp3735
sS'normal,weight'
p3736
(F1
F0.00076452599388379206
I0
I1
I-1
tp3737
sS'this,single'
p3738
(F1
F0.00076452599388379206
I1
I0
I1
tp3739
sS'reduce,plasma'
p3740
(F1
F0.00076452599388379206
I1
I0
I1
tp3741
sS'volunteers,tended'
p3742
(F1
F0.00076452599388379206
I1
I0
I1
tp3743
sS'receiving,doses'
p3744
(F1
F0.00076452599388379206
I1
I0
I1
tp3745
sS'strong,inhibitor'
p3746
(F1
F0.00076452599388379206
I1
I0
I1
tp3747
sS'evaluate,whether'
p3748
(F1
F0.0015290519877675841
I0
I2
I-2
tp3749
sS'of,three'
p3750
(F1
F0.00076452599388379206
I0
I1
I-1
tp3751
sS'gastric,acid'
p3752
(F1
F0.00076452599388379206
I1
I0
I1
tp3753
sS'methenamine,efficacy'
p3754
(F1
F0.00076452599388379206
I1
I0
I1
tp3755
sS'you,cannot'
p3756
(F1
F0.00076452599388379206
I1
I0
I1
tp3757
sS'intravenous,and'
p3758
(F1
F0.00076452599388379206
I1
I0
I1
tp3759
sS'lethargy,coma'
p3760
(F1
F0.00076452599388379206
I1
I0
I1
tp3761
sS'a4,or'
p3762
(F1
F0.00076452599388379206
I0
I1
I-1
tp3763
sS'could,synergistically'
p3764
(F1
F0.00076452599388379206
I1
I0
I1
tp3765
sS'the,most'
p3766
(F0
F0
I1
I1
I0
tp3767
sS'decrease,arterial'
p3768
(F1
F0.0015290519877675841
I2
I0
I2
tp3769
sS'time,may'
p3770
(F1
F0.00076452599388379206
I1
I0
I1
tp3771
sS'hypokalemia,and'
p3772
(F1
F0.00076452599388379206
I0
I1
I-1
tp3773
sS'pulmozyme,genentech'
p3774
(F1
F0.00076452599388379206
I1
I0
I1
tp3775
sS'and,following'
p3776
(F1
F0.00076452599388379206
I0
I1
I-1
tp3777
sS'with,paget'
p3778
(F1
F0.00076452599388379206
I1
I0
I1
tp3779
sS'low-dose,in'
p3780
(F1
F0.00076452599388379206
I0
I1
I-1
tp3781
sS'salicylic,acid'
p3782
(F1
F0.00076452599388379206
I1
I0
I1
tp3783
sS'binding,sites'
p3784
(F0
F0
I1
I1
I0
tp3785
sS'from,that'
p3786
(F1
F0.00076452599388379206
I1
I0
I1
tp3787
sS'with,measurement'
p3788
(F1
F0.00076452599388379206
I0
I1
I-1
tp3789
sS'diminish,the'
p3790
(F1
F0.0022935779816513763
I3
I0
I3
tp3791
sS'p,but'
p3792
(F1
F0.00076452599388379206
I0
I1
I-1
tp3793
sS'postmarketing,reports'
p3794
(F1
F0.00076452599388379206
I1
I0
I1
tp3795
sS'p,as'
p3796
(F1
F0.00076452599388379206
I0
I1
I-1
tp3797
sS's,ability'
p3798
(F1
F0.00076452599388379206
I1
I0
I1
tp3799
sS'the,glucuronidation'
p3800
(F1
F0.00076452599388379206
I1
I0
I1
tp3801
sS'saline,saline'
p3802
(F1
F0.00076452599388379206
I0
I1
I-1
tp3803
sS'control,methods'
p3804
(F1
F0.00076452599388379206
I1
I0
I1
tp3805
sS'as,and'
p3806
(F0.625
F0.0076452599388379203
I13
I3
I10
tp3807
sS'auc,were'
p3808
(F1
F0.0015290519877675841
I2
I0
I2
tp3809
sS'examples,of'
p3810
(F1
F0.00076452599388379206
I0
I1
I-1
tp3811
sS'up-regulation,of'
p3812
(F0
F0
I1
I1
I0
tp3813
sS'leads,to'
p3814
(F1
F0.00076452599388379206
I1
I0
I1
tp3815
sS'has,displayed'
p3816
(F1
F0.00076452599388379206
I1
I0
I1
tp3817
sS'concurrently,with'
p3818
(F0.59999999999999998
F0.0045871559633027525
I8
I2
I6
tp3819
sS'mg,kg'
p3820
(F0.73333333333333328
F0.0084097859327217118
I2
I13
I-11
tp3821
sS'prolonged,by'
p3822
(F1
F0.00076452599388379206
I1
I0
I1
tp3823
sS'program,mexitil'
p3824
(F1
F0.00076452599388379206
I0
I1
I-1
tp3825
sS'or,local'
p3826
(F1
F0.0015290519877675841
I0
I2
I-2
tp3827
sS'profile,of'
p3828
(F1
F0.0022935779816513763
I0
I3
I-3
tp3829
sS'elevations,in'
p3830
(F1
F0.00076452599388379206
I1
I0
I1
tp3831
sS'treatment,did'
p3832
(F1
F0.00076452599388379206
I1
I0
I1
tp3833
sS'leaf,saponins'
p3834
(F1
F0.0015290519877675841
I0
I2
I-2
tp3835
sS'is,in'
p3836
(F1
F0.00076452599388379206
I1
I0
I1
tp3837
sS'half-life,of'
p3838
(F1
F0.0015290519877675841
I2
I0
I2
tp3839
sS'high,fever'
p3840
(F1
F0.00076452599388379206
I1
I0
I1
tp3841
sS'increased,inr'
p3842
(F1
F0.00076452599388379206
I1
I0
I1
tp3843
sS'diuretics,in'
p3844
(F1
F0.00076452599388379206
I1
I0
I1
tp3845
sS'no,known'
p3846
(F1
F0.00076452599388379206
I1
I0
I1
tp3847
sS'is,usually'
p3848
(F1
F0.00076452599388379206
I1
I0
I1
tp3849
sS'is,improved'
p3850
(F1
F0.00076452599388379206
I1
I0
I1
tp3851
sS'antagonize,the'
p3852
(F1
F0.0038226299694189602
I5
I0
I5
tp3853
sS'hepatotoxicity,has'
p3854
(F1
F0.00076452599388379206
I1
I0
I1
tp3855
sS'of,dznep'
p3856
(F1
F0.00076452599388379206
I1
I0
I1
tp3857
sS'seizures,such'
p3858
(F1
F0.00076452599388379206
I0
I1
I-1
tp3859
sS'receiving,high-dose'
p3860
(F1
F0.00076452599388379206
I1
I0
I1
tp3861
sS'these,include'
p3862
(F1
F0.00076452599388379206
I0
I1
I-1
tp3863
sS'occurrence,of'
p3864
(F1
F0.0015290519877675841
I2
I0
I2
tp3865
sS'with,cns'
p3866
(F1
F0.00076452599388379206
I1
I0
I1
tp3867
sS'astemizole,the'
p3868
(F1
F0.00076452599388379206
I1
I0
I1
tp3869
sS'other,and'
p3870
(F1
F0.00076452599388379206
I0
I1
I-1
tp3871
sS'brilinta,better'
p3872
(F1
F0.00076452599388379206
I0
I1
I-1
tp3873
sS'achieve,appropriate'
p3874
(F1
F0.00076452599388379206
I1
I0
I1
tp3875
sS'avoid,and'
p3876
(F1
F0.00076452599388379206
I1
I0
I1
tp3877
sS'damage,of'
p3878
(F1
F0.00076452599388379206
I0
I1
I-1
tp3879
sS'clearances,similar'
p3880
(F1
F0.00076452599388379206
I0
I1
I-1
tp3881
sS'ingested,mg'
p3882
(F1
F0.00076452599388379206
I0
I1
I-1
tp3883
sS'to,and'
p3884
(F0
F0
I2
I2
I0
tp3885
sS'chickens,inoculated'
p3886
(F1
F0.00076452599388379206
I1
I0
I1
tp3887
sS'enzymes,such'
p3888
(F1
F0.0015290519877675841
I2
I0
I2
tp3889
sS'as,wine'
p3890
(F1
F0.00076452599388379206
I1
I0
I1
tp3891
sS'relaxants,or'
p3892
(F1
F0.00076452599388379206
I0
I1
I-1
tp3893
sS'liver,model'
p3894
(F1
F0.00076452599388379206
I1
I0
I1
tp3895
sS'pyridine-treated,monkeys'
p3896
(F1
F0.00076452599388379206
I1
I0
I1
tp3897
sS'antiepileptic,drugs'
p3898
(F1
F0.00076452599388379206
I1
I0
I1
tp3899
sS'synergistic,antinociception'
p3900
(F1
F0.00076452599388379206
I1
I0
I1
tp3901
sS'time,and'
p3902
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp3903
sS'antibiotics,and'
p3904
(F1
F0.00076452599388379206
I0
I1
I-1
tp3905
sS'pravastatin,in'
p3906
(F1
F0.00076452599388379206
I0
I1
I-1
tp3907
sS'be,precipitated'
p3908
(F1
F0.00076452599388379206
I1
I0
I1
tp3909
sS'receiving,can'
p3910
(F1
F0.00076452599388379206
I1
I0
I1
tp3911
sS'small,but'
p3912
(F1
F0.00076452599388379206
I1
I0
I1
tp3913
sS'an,hmg-coa'
p3914
(F1
F0.00076452599388379206
I0
I1
I-1
tp3915
sS'daily,with'
p3916
(F1
F0.00076452599388379206
I1
I0
I1
tp3917
sS'least,hour'
p3918
(F1
F0.00076452599388379206
I1
I0
I1
tp3919
sS'on,appears'
p3920
(F1
F0.00076452599388379206
I1
I0
I1
tp3921
sS'dznep,could'
p3922
(F1
F0.00076452599388379206
I1
I0
I1
tp3923
sS'of,antihypertensive'
p3924
(F1
F0.00076452599388379206
I1
I0
I1
tp3925
sS'of,extra'
p3926
(F1
F0.00076452599388379206
I0
I1
I-1
tp3927
sS'oral,hormone'
p3928
(F1
F0.00076452599388379206
I0
I1
I-1
tp3929
sS'interval,in'
p3930
(F0
F0
I1
I1
I0
tp3931
sS'nexavar,resulted'
p3932
(F1
F0.00076452599388379206
I1
I0
I1
tp3933
sS'this,study'
p3934
(F0.75
F0.0045871559633027525
I1
I7
I-6
tp3935
sS'properties,may'
p3936
(F1
F0.00076452599388379206
I0
I1
I-1
tp3937
sS'cyp3a,isozymes'
p3938
(F1
F0.00076452599388379206
I1
I0
I1
tp3939
sS'psychotic,episodes'
p3940
(F1
F0.00076452599388379206
I1
I0
I1
tp3941
sS'and,theophylline-containing'
p3942
(F1
F0.00076452599388379206
I1
I0
I1
tp3943
sS'and,female'
p3944
(F1
F0.00076452599388379206
I0
I1
I-1
tp3945
sS'of,both'
p3946
(F1
F0.0015290519877675841
I2
I0
I2
tp3947
sS'of,reproductive'
p3948
(F1
F0.00076452599388379206
I0
I1
I-1
tp3949
sS'secreted,could'
p3950
(F1
F0.00076452599388379206
I1
I0
I1
tp3951
sS'was,muted'
p3952
(F1
F0.00076452599388379206
I0
I1
I-1
tp3953
sS'additionally,in'
p3954
(F1
F0.00076452599388379206
I1
I0
I1
tp3955
sS'of,cylert'
p3956
(F1
F0.00076452599388379206
I0
I1
I-1
tp3957
sS'have,not'
p3958
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp3959
sS'the,drug-paired'
p3960
(F1
F0.00076452599388379206
I0
I1
I-1
tp3961
sS'on,mycophenolate'
p3962
(F1
F0.00076452599388379206
I0
I1
I-1
tp3963
sS'values,with'
p3964
(F1
F0.00076452599388379206
I0
I1
I-1
tp3965
sS'alimta,in'
p3966
(F1
F0.00076452599388379206
I1
I0
I1
tp3967
sS'other,suitable'
p3968
(F1
F0.00076452599388379206
I1
I0
I1
tp3969
sS'mouth,and'
p3970
(F1
F0.00076452599388379206
I1
I0
I1
tp3971
sS'increased,incidence'
p3972
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp3973
sS'caffeine,and'
p3974
(F1
F0.00076452599388379206
I1
I0
I1
tp3975
sS'the,initiation'
p3976
(F1
F0.0015290519877675841
I2
I0
I2
tp3977
sS'drs,rimmer'
p3978
(F1
F0.00076452599388379206
I1
I0
I1
tp3979
sS'first,few'
p3980
(F1
F0.00076452599388379206
I1
I0
I1
tp3981
sS'sulfoxone,may'
p3982
(F1
F0.00076452599388379206
I1
I0
I1
tp3983
sS'auc,and'
p3984
(F1
F0.0038226299694189602
I5
I0
I5
tp3985
sS'well,before'
p3986
(F1
F0.00076452599388379206
I1
I0
I1
tp3987
sS'on,metabolism'
p3988
(F1
F0.00076452599388379206
I1
I0
I1
tp3989
sS'investigate,the'
p3990
(F1
F0.00076452599388379206
I0
I1
I-1
tp3991
sS'marrow,transplant'
p3992
(F1
F0.00076452599388379206
I1
I0
I1
tp3993
sS'potentiated,in'
p3994
(F1
F0.0015290519877675841
I2
I0
I2
tp3995
sS'other,oral'
p3996
(F1
F0.00076452599388379206
I1
I0
I1
tp3997
sS'herceptin-refractory,to'
p3998
(F1
F0.00076452599388379206
I0
I1
I-1
tp3999
sS'specific,drug'
p4000
(F1
F0.00076452599388379206
I1
I0
I1
tp4001
sS'corresponded,to'
p4002
(F1
F0.00076452599388379206
I0
I1
I-1
tp4003
sS'inducer,and'
p4004
(F1
F0.00076452599388379206
I1
I0
I1
tp4005
sS'in,rats'
p4006
(F1
F0.0022935779816513763
I0
I3
I-3
tp4007
sS'depth,of'
p4008
(F1
F0.00076452599388379206
I0
I1
I-1
tp4009
sS'diuretics,excessive'
p4010
(F1
F0.00076452599388379206
I0
I1
I-1
tp4011
sS'pr,qrs'
p4012
(F1
F0.00076452599388379206
I0
I1
I-1
tp4013
sS'which,may'
p4014
(F1
F0.0030581039755351682
I4
I0
I4
tp4015
sS'subjects,showed'
p4016
(F1
F0.00076452599388379206
I0
I1
I-1
tp4017
sS'cellular,cytotoxicity'
p4018
(F1
F0.00076452599388379206
I1
I0
I1
tp4019
sS'and,there'
p4020
(F1
F0.00076452599388379206
I1
I0
I1
tp4021
sS'between,mg'
p4022
(F1
F0.00076452599388379206
I0
I1
I-1
tp4023
sS'are,unnecessary'
p4024
(F1
F0.00076452599388379206
I0
I1
I-1
tp4025
sS'acetate,were'
p4026
(F1
F0.00076452599388379206
I0
I1
I-1
tp4027
sS'place,preference'
p4028
(F1
F0.00076452599388379206
I0
I1
I-1
tp4029
sS'bcl-2,family'
p4030
(F1
F0.00076452599388379206
I1
I0
I1
tp4031
sS'dtic,and'
p4032
(F1
F0.0015290519877675841
I0
I2
I-2
tp4033
sS'may,enhance'
p4034
(F1
F0.0053516819571865441
I7
I0
I7
tp4035
sS'nose,may'
p4036
(F1
F0.00076452599388379206
I1
I0
I1
tp4037
sS'periodic,serum'
p4038
(F1
F0.00076452599388379206
I1
I0
I1
tp4039
sS'streptokinase,causes'
p4040
(F1
F0.00076452599388379206
I1
I0
I1
tp4041
sS'chronic,hepatitis'
p4042
(F1
F0.00076452599388379206
I1
I0
I1
tp4043
sS'the,cell'
p4044
(F0
F0
I1
I1
I0
tp4045
sS'of,cyp2d6'
p4046
(F1
F0.00076452599388379206
I0
I1
I-1
tp4047
sS'such,a'
p4048
(F0
F0
I1
I1
I0
tp4049
sS'minor,bleeding'
p4050
(F1
F0.00076452599388379206
I1
I0
I1
tp4051
sS'pharmacokinetic,studies'
p4052
(F1
F0.0015290519877675841
I0
I2
I-2
tp4053
sS'motility,are'
p4054
(F1
F0.00076452599388379206
I1
I0
I1
tp4055
sS'of,bcl-2'
p4056
(F1
F0.0022935779816513763
I3
I0
I3
tp4057
sS'and,mg'
p4058
(F0.14285714285714285
F0.00076452599388379206
I3
I4
I-1
tp4059
sS'observed,in'
p4060
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp4061
sS'either,to'
p4062
(F1
F0.00076452599388379206
I0
I1
I-1
tp4063
sS'stable,digitalis'
p4064
(F1
F0.00076452599388379206
I0
I1
I-1
tp4065
sS'increase,their'
p4066
(F1
F0.00076452599388379206
I1
I0
I1
tp4067
sS'beneficial,effects'
p4068
(F1
F0.00076452599388379206
I1
I0
I1
tp4069
sS'way,crossover'
p4070
(F1
F0.00076452599388379206
I0
I1
I-1
tp4071
sS'drops,or'
p4072
(F1
F0.00076452599388379206
I1
I0
I1
tp4073
sS'or,side'
p4074
(F1
F0.00076452599388379206
I1
I0
I1
tp4075
sS'and,dna'
p4076
(F1
F0.0015290519877675841
I0
I2
I-2
tp4077
sS'average,anticoagulant'
p4078
(F1
F0.00076452599388379206
I0
I1
I-1
tp4079
sS'be,avoided'
p4080
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp4081
sS'effects,in'
p4082
(F1
F0.0022935779816513763
I3
I0
I3
tp4083
sS'systemic,exposure'
p4084
(F1
F0.0015290519877675841
I0
I2
I-2
tp4085
sS'vindesine,can'
p4086
(F1
F0.00076452599388379206
I1
I0
I1
tp4087
sS'clinical,dose'
p4088
(F1
F0.00076452599388379206
I0
I1
I-1
tp4089
sS'tobi,should'
p4090
(F1
F0.00076452599388379206
I1
I0
I1
tp4091
sS'a,proof'
p4092
(F1
F0.00076452599388379206
I1
I0
I1
tp4093
sS'was,decreased'
p4094
(F1
F0.0030581039755351682
I4
I0
I4
tp4095
sS'the,adverse'
p4096
(F1
F0.00076452599388379206
I0
I1
I-1
tp4097
sS'wine,did'
p4098
(F1
F0.00076452599388379206
I0
I1
I-1
tp4099
sS'of,free'
p4100
(F1
F0.00076452599388379206
I0
I1
I-1
tp4101
sS'was,unaltered'
p4102
(F1
F0.00076452599388379206
I0
I1
I-1
tp4103
sS'parent,compound'
p4104
(F1
F0.00076452599388379206
I1
I0
I1
tp4105
sS'plus,formed'
p4106
(F1
F0.00076452599388379206
I1
I0
I1
tp4107
sS'level,subsequent'
p4108
(F1
F0.00076452599388379206
I1
I0
I1
tp4109
sS'since,these'
p4110
(F1
F0.00076452599388379206
I1
I0
I1
tp4111
sS'human,liver'
p4112
(F1
F0.00076452599388379206
I0
I1
I-1
tp4113
sS'quicker,achievement'
p4114
(F1
F0.00076452599388379206
I1
I0
I1
tp4115
sS'melatonin,may'
p4116
(F1
F0.00076452599388379206
I1
I0
I1
tp4117
sS'of,ketoconazole-mediated'
p4118
(F1
F0.00076452599388379206
I0
I1
I-1
tp4119
sS'the,result'
p4120
(F1
F0.0015290519877675841
I0
I2
I-2
tp4121
sS'use,appears'
p4122
(F1
F0.00076452599388379206
I1
I0
I1
tp4123
sS'could,elicit'
p4124
(F1
F0.00076452599388379206
I1
I0
I1
tp4125
sS'of,its'
p4126
(F1
F0.00076452599388379206
I0
I1
I-1
tp4127
sS'the,due'
p4128
(F1
F0.00076452599388379206
I0
I1
I-1
tp4129
sS'recommended,terfenadine'
p4130
(F1
F0.00076452599388379206
I1
I0
I1
tp4131
sS'children,with'
p4132
(F1
F0.00076452599388379206
I1
I0
I1
tp4133
sS'pk,analysis'
p4134
(F1
F0.00076452599388379206
I0
I1
I-1
tp4135
sS'inducers,such'
p4136
(F1
F0.0030581039755351682
I4
I0
I4
tp4137
sS'a,minimal'
p4138
(F1
F0.0022935779816513763
I3
I0
I3
tp4139
sS'change,in'
p4140
(F0.42857142857142855
F0.0022935779816513763
I2
I5
I-3
tp4141
sS'medications,certain'
p4142
(F1
F0.00076452599388379206
I1
I0
I1
tp4143
sS'it,will'
p4144
(F1
F0.00076452599388379206
I0
I1
I-1
tp4145
sS'to,decrease'
p4146
(F0
F0
I1
I1
I0
tp4147
sS'earlier,than'
p4148
(F1
F0.00076452599388379206
I1
I0
I1
tp4149
sS'throughout,the'
p4150
(F1
F0.00076452599388379206
I0
I1
I-1
tp4151
sS'pump,inhibitors'
p4152
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp4153
sS'breast,cancer'
p4154
(F0.14285714285714285
F0.00076452599388379206
I4
I3
I1
tp4155
sS'cerebral,ischemia'
p4156
(F1
F0.00076452599388379206
I0
I1
I-1
tp4157
sS'specific,metabotropic'
p4158
(F1
F0.00076452599388379206
I0
I1
I-1
tp4159
sS'to,subtherapeutic'
p4160
(F1
F0.00076452599388379206
I1
I0
I1
tp4161
sS'drugs,antiarrhythmic'
p4162
(F1
F0.00076452599388379206
I1
I0
I1
tp4163
sS'dryness,of'
p4164
(F1
F0.00076452599388379206
I1
I0
I1
tp4165
sS'vs,ml'
p4166
(F1
F0.00076452599388379206
I1
I0
I1
tp4167
sS'inhibitors,have'
p4168
(F1
F0.00076452599388379206
I1
I0
I1
tp4169
sS'or,ferrous'
p4170
(F1
F0.00076452599388379206
I1
I0
I1
tp4171
sS'activated,charcoal'
p4172
(F1
F0.00076452599388379206
I1
I0
I1
tp4173
sS'that,combined'
p4174
(F1
F0.00076452599388379206
I1
I0
I1
tp4175
sS'levels,bioavailability'
p4176
(F1
F0.00076452599388379206
I1
I0
I1
tp4177
sS'cyp3a,inhibitors'
p4178
(F1
F0.0015290519877675841
I0
I2
I-2
tp4179
sS'either,pharmacokinetics'
p4180
(F1
F0.00076452599388379206
I0
I1
I-1
tp4181
sS'patients,under'
p4182
(F1
F0.00076452599388379206
I0
I1
I-1
tp4183
sS'indicated,are'
p4184
(F1
F0.00076452599388379206
I1
I0
I1
tp4185
sS'day,times'
p4186
(F1
F0.0015290519877675841
I0
I2
I-2
tp4187
sS'sedation,the'
p4188
(F1
F0.00076452599388379206
I1
I0
I1
tp4189
sS'releases,catecholamines'
p4190
(F1
F0.00076452599388379206
I1
I0
I1
tp4191
sS'metabolite,and'
p4192
(F1
F0.00076452599388379206
I0
I1
I-1
tp4193
sS'and,adjustment'
p4194
(F1
F0.00076452599388379206
I1
I0
I1
tp4195
sS'mofetil,given'
p4196
(F1
F0.00076452599388379206
I1
I0
I1
tp4197
sS'corticosteroids,or'
p4198
(F1
F0.00076452599388379206
I0
I1
I-1
tp4199
sS'dosing,of'
p4200
(F1
F0.00076452599388379206
I0
I1
I-1
tp4201
sS'requirements,for'
p4202
(F1
F0.00076452599388379206
I1
I0
I1
tp4203
sS'particular,focus'
p4204
(F1
F0.00076452599388379206
I0
I1
I-1
tp4205
sS'less,potent'
p4206
(F1
F0.00076452599388379206
I0
I1
I-1
tp4207
sS'there,were'
p4208
(F1
F0.00076452599388379206
I0
I1
I-1
tp4209
sS'of,each'
p4210
(F1
F0.00076452599388379206
I1
I0
I1
tp4211
sS'inactivated,ai'
p4212
(F1
F0.00076452599388379206
I1
I0
I1
tp4213
sS'intestinal,absorption'
p4214
(F1
F0.0015290519877675841
I2
I0
I2
tp4215
sS'fluconazole,tablets'
p4216
(F1
F0.00076452599388379206
I1
I0
I1
tp4217
sS'exposure,observed'
p4218
(F1
F0.00076452599388379206
I0
I1
I-1
tp4219
sS'mg,day'
p4220
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp4221
sS'median,duration'
p4222
(F1
F0.00076452599388379206
I0
I1
I-1
tp4223
sS'after,initiating'
p4224
(F1
F0.00076452599388379206
I1
I0
I1
tp4225
sS's-warfarin,half-life'
p4226
(F1
F0.00076452599388379206
I1
I0
I1
tp4227
sS'hepatitis,c'
p4228
(F1
F0.00076452599388379206
I1
I0
I1
tp4229
sS'and,pr'
p4230
(F1
F0.00076452599388379206
I0
I1
I-1
tp4231
sS'a,selective'
p4232
(F1
F0.0015290519877675841
I2
I0
I2
tp4233
sS'compared,to'
p4234
(F1
F0.0030581039755351682
I4
I0
I4
tp4235
sS'we,also'
p4236
(F0
F0
I1
I1
I0
tp4237
sS'inducers,of'
p4238
(F0.5
F0.0015290519877675841
I3
I1
I2
tp4239
sS'recommended,when'
p4240
(F1
F0.0022935779816513763
I3
I0
I3
tp4241
sS'slightly,shorter'
p4242
(F1
F0.00076452599388379206
I1
I0
I1
tp4243
sS'loop,diuretics'
p4244
(F1
F0.00076452599388379206
I1
I0
I1
tp4245
sS'been,large'
p4246
(F1
F0.00076452599388379206
I0
I1
I-1
tp4247
sS'herceptin,resulted'
p4248
(F1
F0.00076452599388379206
I1
I0
I1
tp4249
sS'occasionally,experience'
p4250
(F1
F0.00076452599388379206
I1
I0
I1
tp4251
sS'an,isolated'
p4252
(F1
F0.00076452599388379206
I1
I0
I1
tp4253
sS'and,group'
p4254
(F1
F0.00076452599388379206
I0
I1
I-1
tp4255
sS'fat-soluble,vitamin'
p4256
(F1
F0.00076452599388379206
I1
I0
I1
tp4257
sS'performed,to'
p4258
(F1
F0.00076452599388379206
I0
I1
I-1
tp4259
sS'that,oral'
p4260
(F1
F0.00076452599388379206
I1
I0
I1
tp4261
sS'anticoagulants,metolazone'
p4262
(F1
F0.00076452599388379206
I1
I0
I1
tp4263
sS'treatment,also'
p4264
(F1
F0.00076452599388379206
I1
I0
I1
tp4265
sS'cognitive,and'
p4266
(F1
F0.00076452599388379206
I1
I0
I1
tp4267
sS'function,has'
p4268
(F1
F0.00076452599388379206
I1
I0
I1
tp4269
sS'phenobarbital,which'
p4270
(F1
F0.0015290519877675841
I0
I2
I-2
tp4271
sS'of,streptase'
p4272
(F1
F0.00076452599388379206
I0
I1
I-1
tp4273
sS'requirements,may'
p4274
(F1
F0.00076452599388379206
I1
I0
I1
tp4275
sS'that,there'
p4276
(F1
F0.00076452599388379206
I0
I1
I-1
tp4277
sS'not,considered'
p4278
(F1
F0.00076452599388379206
I0
I1
I-1
tp4279
sS'to,depress'
p4280
(F1
F0.00076452599388379206
I1
I0
I1
tp4281
sS'blood,pressure'
p4282
(F0
F0
I2
I2
I0
tp4283
sS'compared,with'
p4284
(F0.1111111111111111
F0.00076452599388379206
I5
I4
I1
tp4285
sS'to,streptokinase'
p4286
(F1
F0.00076452599388379206
I1
I0
I1
tp4287
sS'g,of'
p4288
(F1
F0.00076452599388379206
I0
I1
I-1
tp4289
sS'taken,while'
p4290
(F1
F0.00076452599388379206
I1
I0
I1
tp4291
sS'metabolized,eliminated'
p4292
(F1
F0.00076452599388379206
I1
I0
I1
tp4293
sS'compete,with'
p4294
(F0
F0
I1
I1
I0
tp4295
sS'the,stomach'
p4296
(F1
F0.00076452599388379206
I1
I0
I1
tp4297
sS'as,sulfate'
p4298
(F1
F0.00076452599388379206
I1
I0
I1
tp4299
sS'produce,additive'
p4300
(F1
F0.00076452599388379206
I0
I1
I-1
tp4301
sS'increased,with'
p4302
(F1
F0.00076452599388379206
I1
I0
I1
tp4303
sS'decrease,plasma'
p4304
(F1
F0.00076452599388379206
I1
I0
I1
tp4305
sS'certain,primarily'
p4306
(F1
F0.00076452599388379206
I0
I1
I-1
tp4307
sS'that,did'
p4308
(F1
F0.00076452599388379206
I1
I0
I1
tp4309
sS'intramuscular,methyl-4'
p4310
(F1
F0.00076452599388379206
I0
I1
I-1
tp4311
sS'the,abraded'
p4312
(F1
F0.00076452599388379206
I1
I0
I1
tp4313
sS'reported,confusion'
p4314
(F1
F0.00076452599388379206
I1
I0
I1
tp4315
sS'mao,inhibitors'
p4316
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp4317
sS'sensitization,to'
p4318
(F1
F0.00076452599388379206
I0
I1
I-1
tp4319
sS'or,its'
p4320
(F1
F0.00076452599388379206
I0
I1
I-1
tp4321
sS'hospitalization,for'
p4322
(F0
F0
I1
I1
I0
tp4323
sS'and,particularly'
p4324
(F1
F0.00076452599388379206
I1
I0
I1
tp4325
sS'pantoprazole,has'
p4326
(F1
F0.00076452599388379206
I1
I0
I1
tp4327
sS'mg,oral'
p4328
(F1
F0.00076452599388379206
I0
I1
I-1
tp4329
sS'reductions,in'
p4330
(F1
F0.00076452599388379206
I0
I1
I-1
tp4331
sS'for,mice'
p4332
(F1
F0.00076452599388379206
I0
I1
I-1
tp4333
sS'protein,binding'
p4334
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp4335
sS'melena,have'
p4336
(F1
F0.00076452599388379206
I1
I0
I1
tp4337
sS'when,coadministered'
p4338
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp4339
sS'of,which'
p4340
(F1
F0.00076452599388379206
I1
I0
I1
tp4341
sS'in,adult'
p4342
(F1
F0.00076452599388379206
I0
I1
I-1
tp4343
sS'antiarrhythmic,agents'
p4344
(F1
F0.00076452599388379206
I1
I0
I1
tp4345
sS'by,cytochrome'
p4346
(F1
F0.00076452599388379206
I0
I1
I-1
tp4347
sS'one,month'
p4348
(F1
F0.00076452599388379206
I1
I0
I1
tp4349
sS'to,therapy'
p4350
(F1
F0.00076452599388379206
I0
I1
I-1
tp4351
sS'especially,those'
p4352
(F1
F0.00076452599388379206
I1
I0
I1
tp4353
sS'edta,is'
p4354
(F1
F0.00076452599388379206
I1
I0
I1
tp4355
sS'patients,concurrently'
p4356
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp4357
sS'taken,concurrently'
p4358
(F1
F0.0015290519877675841
I2
I0
I2
tp4359
sS'hb-egf,cross-reacting'
p4360
(F1
F0.00076452599388379206
I0
I1
I-1
tp4361
sS'component,of'
p4362
(F1
F0.00076452599388379206
I0
I1
I-1
tp4363
sS'cross-resistance,between'
p4364
(F1
F0.00076452599388379206
I1
I0
I1
tp4365
sS'mtt,radiolabeled'
p4366
(F1
F0.00076452599388379206
I0
I1
I-1
tp4367
sS'of,mpag'
p4368
(F1
F0.00076452599388379206
I0
I1
I-1
tp4369
sS'of,proamatine'
p4370
(F1
F0.0015290519877675841
I2
I0
I2
tp4371
sS'is,unaffected'
p4372
(F0
F0
I1
I1
I0
tp4373
sS'and,mobic'
p4374
(F1
F0.00076452599388379206
I1
I0
I1
tp4375
sS'of,fu'
p4376
(F1
F0.00076452599388379206
I1
I0
I1
tp4377
sS'the,impairment'
p4378
(F1
F0.0015290519877675841
I2
I0
I2
tp4379
sS'and,agents'
p4380
(F1
F0.00076452599388379206
I1
I0
I1
tp4381
sS'be,diminished'
p4382
(F1
F0.00076452599388379206
I1
I0
I1
tp4383
sS'subjects,the'
p4384
(F1
F0.00076452599388379206
I0
I1
I-1
tp4385
sS'studies,indicate'
p4386
(F1
F0.0015290519877675841
I2
I0
I2
tp4387
sS'level,of'
p4388
(F0
F0
I1
I1
I0
tp4389
sS'interactions,with'
p4390
(F0
F0
I4
I4
I0
tp4391
sS'males,and'
p4392
(F1
F0.00076452599388379206
I0
I1
I-1
tp4393
sS'as,other'
p4394
(F1
F0.0015290519877675841
I2
I0
I2
tp4395
sS'insensitivity,might'
p4396
(F1
F0.00076452599388379206
I1
I0
I1
tp4397
sS'pathways,involving'
p4398
(F1
F0.00076452599388379206
I0
I1
I-1
tp4399
sS'interpreted,according'
p4400
(F1
F0.00076452599388379206
I0
I1
I-1
tp4401
sS'possible,the'
p4402
(F1
F0.00076452599388379206
I0
I1
I-1
tp4403
sS'rats,and'
p4404
(F1
F0.0015290519877675841
I0
I2
I-2
tp4405
sS'determinations,of'
p4406
(F1
F0.00076452599388379206
I1
I0
I1
tp4407
sS'levels,may'
p4408
(F0
F0
I1
I1
I0
tp4409
sS'suspension,test'
p4410
(F1
F0.00076452599388379206
I0
I1
I-1
tp4411
sS'cardiac,arrhythmias'
p4412
(F1
F0.0015290519877675841
I2
I0
I2
tp4413
sS'not,have'
p4414
(F1
F0.0015290519877675841
I0
I2
I-2
tp4415
sS'other,narcotic'
p4416
(F1
F0.00076452599388379206
I1
I0
I1
tp4417
sS'to,parent'
p4418
(F1
F0.00076452599388379206
I1
I0
I1
tp4419
sS'drugs,such'
p4420
(F0.80000000000000004
F0.0061162079510703364
I9
I1
I8
tp4421
sS'coeruleus,a5'
p4422
(F1
F0.00076452599388379206
I1
I0
I1
tp4423
sS'elimination,half-lives'
p4424
(F1
F0.00076452599388379206
I1
I0
I1
tp4425
sS'normal-weight,mildly'
p4426
(F1
F0.00076452599388379206
I0
I1
I-1
tp4427
sS'be,concluded'
p4428
(F1
F0.00076452599388379206
I1
I0
I1
tp4429
sS'all,the'
p4430
(F1
F0.00076452599388379206
I0
I1
I-1
tp4431
sS'to,date'
p4432
(F1
F0.00076452599388379206
I0
I1
I-1
tp4433
sS'when,diflucan'
p4434
(F1
F0.00076452599388379206
I1
I0
I1
tp4435
sS'to,toxicity'
p4436
(F1
F0.00076452599388379206
I0
I1
I-1
tp4437
sS'cyp,interactions'
p4438
(F1
F0.00076452599388379206
I0
I1
I-1
tp4439
sS'nsaids,should'
p4440
(F1
F0.00076452599388379206
I1
I0
I1
tp4441
sS'indicate,a'
p4442
(F1
F0.00076452599388379206
I1
I0
I1
tp4443
sS'and,oral'
p4444
(F1
F0.0015290519877675841
I0
I2
I-2
tp4445
sS'extra,thoracic'
p4446
(F1
F0.00076452599388379206
I0
I1
I-1
tp4447
sS'probenecid,competes'
p4448
(F1
F0.00076452599388379206
I1
I0
I1
tp4449
sS'beta,adrenergic'
p4450
(F1
F0.0038226299694189602
I5
I0
I5
tp4451
sS'overall,mean'
p4452
(F1
F0.00076452599388379206
I1
I0
I1
tp4453
sS'in,administering'
p4454
(F0
F0
I1
I1
I0
tp4455
sS'therapeutic,target'
p4456
(F1
F0.00076452599388379206
I0
I1
I-1
tp4457
sS'cyp3a4,isozymes'
p4458
(F1
F0.0015290519877675841
I2
I0
I2
tp4459
sS'interaction,between'
p4460
(F0.5
F0.0045871559633027525
I3
I9
I-6
tp4461
sS'that,reduce'
p4462
(F1
F0.00076452599388379206
I1
I0
I1
tp4463
sS'bioavailability,of'
p4464
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp4465
sS'although,such'
p4466
(F0
F0
I1
I1
I0
tp4467
sS'of,blood'
p4468
(F1
F0.00076452599388379206
I1
I0
I1
tp4469
sS'for,lenalidomide-cci'
p4470
(F1
F0.00076452599388379206
I0
I1
I-1
tp4471
sS'the,human'
p4472
(F1
F0.0038226299694189602
I0
I5
I-5
tp4473
sS'until,normal'
p4474
(F1
F0.00076452599388379206
I0
I1
I-1
tp4475
sS'times,a'
p4476
(F0.55555555555555558
F0.0038226299694189602
I2
I7
I-5
tp4477
sS'be,carefully'
p4478
(F1
F0.0015290519877675841
I2
I0
I2
tp4479
sS'not,increase'
p4480
(F0
F0
I1
I1
I0
tp4481
sS'are,depressed'
p4482
(F1
F0.00076452599388379206
I1
I0
I1
tp4483
sS'all,significantly'
p4484
(F1
F0.00076452599388379206
I1
I0
I1
tp4485
sS'blockers,selective'
p4486
(F1
F0.00076452599388379206
I0
I1
I-1
tp4487
sS'response,for'
p4488
(F1
F0.00076452599388379206
I0
I1
I-1
tp4489
sS'been,rare'
p4490
(F1
F0.00076452599388379206
I0
I1
I-1
tp4491
sS'plasma,protein-binding'
p4492
(F1
F0.00076452599388379206
I1
I0
I1
tp4493
sS'both,based'
p4494
(F1
F0.00076452599388379206
I0
I1
I-1
tp4495
sS'were,increased'
p4496
(F1
F0.0015290519877675841
I2
I0
I2
tp4497
sS'of,hey'
p4498
(F1
F0.00076452599388379206
I1
I0
I1
tp4499
sS'depression,hypotension'
p4500
(F1
F0.00076452599388379206
I1
I0
I1
tp4501
sS'cdk1,suggest'
p4502
(F1
F0.00076452599388379206
I1
I0
I1
tp4503
sS'further,electrocardiographic'
p4504
(F1
F0.00076452599388379206
I0
I1
I-1
tp4505
sS'when,xenical'
p4506
(F1
F0.00076452599388379206
I1
I0
I1
tp4507
sS'some,may'
p4508
(F1
F0.00076452599388379206
I1
I0
I1
tp4509
sS'to,during'
p4510
(F1
F0.00076452599388379206
I1
I0
I1
tp4511
sS'interaction,oral'
p4512
(F1
F0.00076452599388379206
I0
I1
I-1
tp4513
sS'pregnancies,on'
p4514
(F1
F0.00076452599388379206
I1
I0
I1
tp4515
sS'agents,and'
p4516
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp4517
sS'of,methicillin-resistant'
p4518
(F1
F0.0015290519877675841
I0
I2
I-2
tp4519
sS'sulfonylurea,should'
p4520
(F1
F0.00076452599388379206
I1
I0
I1
tp4521
sS'magnesium-aluminum,containing'
p4522
(F1
F0.00076452599388379206
I1
I0
I1
tp4523
sS'cell,layer'
p4524
(F1
F0.00076452599388379206
I0
I1
I-1
tp4525
sS'obstipation,even'
p4526
(F1
F0.00076452599388379206
I1
I0
I1
tp4527
sS'rats,demonstrated'
p4528
(F1
F0.00076452599388379206
I0
I1
I-1
tp4529
sS'of,tritec'
p4530
(F1
F0.00076452599388379206
I1
I0
I1
tp4531
sS'we,tested'
p4532
(F1
F0.00076452599388379206
I0
I1
I-1
tp4533
sS'sulfate,or'
p4534
(F1
F0.0015290519877675841
I2
I0
I2
tp4535
sS'all,incubation'
p4536
(F1
F0.00076452599388379206
I1
I0
I1
tp4537
sS'the,level'
p4538
(F1
F0.00076452599388379206
I0
I1
I-1
tp4539
sS'lines,with'
p4540
(F0
F0
I1
I1
I0
tp4541
sS'a,second'
p4542
(F1
F0.00076452599388379206
I1
I0
I1
tp4543
sS'partially,metabolized'
p4544
(F1
F0.00076452599388379206
I1
I0
I1
tp4545
sS'advised,for'
p4546
(F1
F0.00076452599388379206
I1
I0
I1
tp4547
sS'analogues,a'
p4548
(F1
F0.00076452599388379206
I1
I0
I1
tp4549
sS'returned,to'
p4550
(F0
F0
I1
I1
I0
tp4551
sS'while,their'
p4552
(F1
F0.00076452599388379206
I1
I0
I1
tp4553
sS'performed,in'
p4554
(F1
F0.00076452599388379206
I0
I1
I-1
tp4555
sS'relationship,between'
p4556
(F1
F0.00076452599388379206
I1
I0
I1
tp4557
sS'are,significantly'
p4558
(F1
F0.00076452599388379206
I0
I1
I-1
tp4559
sS'severe,obstipation'
p4560
(F1
F0.00076452599388379206
I1
I0
I1
tp4561
sS'cardiac,glycosides'
p4562
(F1
F0.00076452599388379206
I1
I0
I1
tp4563
sS'pointe,as'
p4564
(F1
F0.00076452599388379206
I1
I0
I1
tp4565
sS'pills,anti-infective'
p4566
(F1
F0.00076452599388379206
I1
I0
I1
tp4567
sS'with,plavix'
p4568
(F1
F0.00076452599388379206
I0
I1
I-1
tp4569
sS'and,ethinyl'
p4570
(F1
F0.00076452599388379206
I0
I1
I-1
tp4571
sS'and,total'
p4572
(F1
F0.00076452599388379206
I0
I1
I-1
tp4573
sS'the,interaction'
p4574
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp4575
sS'and,anticholinesterase'
p4576
(F1
F0.00076452599388379206
I1
I0
I1
tp4577
sS'of,these'
p4578
(F0.20000000000000001
F0.0022935779816513763
I9
I6
I3
tp4579
sS'affecting,hepatic'
p4580
(F1
F0.00076452599388379206
I0
I1
I-1
tp4581
sS'folinic,acid'
p4582
(F1
F0.00076452599388379206
I0
I1
I-1
tp4583
sS'base-secreting,system'
p4584
(F1
F0.00076452599388379206
I1
I0
I1
tp4585
sS'drugs,have'
p4586
(F1
F0.00076452599388379206
I1
I0
I1
tp4587
sS'was,detected'
p4588
(F1
F0.00076452599388379206
I1
I0
I1
tp4589
sS'hydroxide,when'
p4590
(F1
F0.00076452599388379206
I1
I0
I1
tp4591
sS'we,sought'
p4592
(F1
F0.00076452599388379206
I0
I1
I-1
tp4593
sS'ea,signs'
p4594
(F1
F0.00076452599388379206
I0
I1
I-1
tp4595
sS'arrhythmia,including'
p4596
(F1
F0.00076452599388379206
I0
I1
I-1
tp4597
sS'under,treatment'
p4598
(F1
F0.00076452599388379206
I0
I1
I-1
tp4599
sS'egfr,t790m'
p4600
(F0
F0
I1
I1
I0
tp4601
sS'with,recommended'
p4602
(F1
F0.00076452599388379206
I1
I0
I1
tp4603
sS'capsules,should'
p4604
(F1
F0.0015290519877675841
I2
I0
I2
tp4605
sS'to,ascertain'
p4606
(F1
F0.00076452599388379206
I0
I1
I-1
tp4607
sS'to,attenuate'
p4608
(F1
F0.00076452599388379206
I0
I1
I-1
tp4609
sS'with,increases'
p4610
(F1
F0.00076452599388379206
I1
I0
I1
tp4611
sS'in,those'
p4612
(F1
F0.00076452599388379206
I0
I1
I-1
tp4613
sS'avoid,giving'
p4614
(F1
F0.00076452599388379206
I1
I0
I1
tp4615
sS'decreased,in'
p4616
(F1
F0.00076452599388379206
I0
I1
I-1
tp4617
sS'with,increased'
p4618
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp4619
sS'may,potentiate'
p4620
(F1
F0.0022935779816513763
I3
I0
I3
tp4621
sS'injected,with'
p4622
(F1
F0.00076452599388379206
I0
I1
I-1
tp4623
sS'short-acting,beta'
p4624
(F1
F0.00076452599388379206
I1
I0
I1
tp4625
sS'care,must'
p4626
(F1
F0.00076452599388379206
I1
I0
I1
tp4627
sS'several,days'
p4628
(F1
F0.00076452599388379206
I0
I1
I-1
tp4629
sS'treatment,should'
p4630
(F1
F0.00076452599388379206
I1
I0
I1
tp4631
sS'fludrocortisone,acetate'
p4632
(F1
F0.00076452599388379206
I0
I1
I-1
tp4633
sS'intravenous,has'
p4634
(F1
F0.00076452599388379206
I1
I0
I1
tp4635
sS'concomitantly,receiving'
p4636
(F1
F0.00076452599388379206
I1
I0
I1
tp4637
sS'has,the'
p4638
(F1
F0.00076452599388379206
I1
I0
I1
tp4639
sS'those,methods'
p4640
(F1
F0.00076452599388379206
I0
I1
I-1
tp4641
sS'the,analgesic'
p4642
(F1
F0.00076452599388379206
I1
I0
I1
tp4643
sS'and,histamine-like'
p4644
(F1
F0.00076452599388379206
I1
I0
I1
tp4645
sS'from,the'
p4646
(F1
F0.00076452599388379206
I1
I0
I1
tp4647
sS'steady,state'
p4648
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp4649
sS'test,tst'
p4650
(F1
F0.00076452599388379206
I0
I1
I-1
tp4651
sS'rigidity,severe'
p4652
(F1
F0.00076452599388379206
I1
I0
I1
tp4653
sS'with,alimta'
p4654
(F1
F0.00076452599388379206
I1
I0
I1
tp4655
sS'transcriptase,inhibitors'
p4656
(F1
F0.00076452599388379206
I0
I1
I-1
tp4657
sS'kip1,in'
p4658
(F1
F0.00076452599388379206
I1
I0
I1
tp4659
sS'and,confusional'
p4660
(F1
F0.00076452599388379206
I1
I0
I1
tp4661
sS'both,sj'
p4662
(F1
F0.00076452599388379206
I0
I1
I-1
tp4663
sS'crisis,has'
p4664
(F1
F0.00076452599388379206
I1
I0
I1
tp4665
sS'aav2,containing'
p4666
(F1
F0.00076452599388379206
I0
I1
I-1
tp4667
sS'appeared,less'
p4668
(F1
F0.00076452599388379206
I0
I1
I-1
tp4669
sS'sodium,valproic'
p4670
(F1
F0.00076452599388379206
I0
I1
I-1
tp4671
sS'elderly,may'
p4672
(F1
F0.00076452599388379206
I1
I0
I1
tp4673
sS'neurotoxin,methyl-4'
p4674
(F1
F0.00076452599388379206
I0
I1
I-1
tp4675
sS'discontinued,well'
p4676
(F1
F0.00076452599388379206
I1
I0
I1
tp4677
sS'increased,in'
p4678
(F0.5
F0.0015290519877675841
I3
I1
I2
tp4679
sS'was,aimed'
p4680
(F1
F0.00076452599388379206
I0
I1
I-1
tp4681
sS'infinity,auc'
p4682
(F1
F0.00076452599388379206
I1
I0
I1
tp4683
sS'an,important'
p4684
(F1
F0.00076452599388379206
I1
I0
I1
tp4685
sS'inhibitors,there'
p4686
(F1
F0.00076452599388379206
I0
I1
I-1
tp4687
sS'but,this'
p4688
(F1
F0.00076452599388379206
I1
I0
I1
tp4689
sS'heparinase,iii'
p4690
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp4691
sS'by,when'
p4692
(F1
F0.0015290519877675841
I2
I0
I2
tp4693
sS'response,in'
p4694
(F1
F0.00076452599388379206
I0
I1
I-1
tp4695
sS'and,related'
p4696
(F1
F0.00076452599388379206
I1
I0
I1
tp4697
sS'or,magnesium-containing'
p4698
(F1
F0.00076452599388379206
I1
I0
I1
tp4699
sS'these,isozymes'
p4700
(F1
F0.00076452599388379206
I0
I1
I-1
tp4701
sS'two,controlled'
p4702
(F1
F0.00076452599388379206
I0
I1
I-1
tp4703
sS'impairs,the'
p4704
(F1
F0.00076452599388379206
I1
I0
I1
tp4705
sS'for,growth'
p4706
(F1
F0.00076452599388379206
I0
I1
I-1
tp4707
sS'a,multidose'
p4708
(F1
F0.00076452599388379206
I1
I0
I1
tp4709
sS'taking,remeron'
p4710
(F1
F0.00076452599388379206
I1
I0
I1
tp4711
sS'administered,medication'
p4712
(F1
F0.00076452599388379206
I1
I0
I1
tp4713
sS'with,doses'
p4714
(F1
F0.00076452599388379206
I1
I0
I1
tp4715
sS'oral,antidiabetic'
p4716
(F1
F0.00076452599388379206
I1
I0
I1
tp4717
sS'combination,compared'
p4718
(F1
F0.00076452599388379206
I1
I0
I1
tp4719
sS'apparent,total'
p4720
(F1
F0.00076452599388379206
I1
I0
I1
tp4721
sS'kg,p'
p4722
(F1
F0.00076452599388379206
I0
I1
I-1
tp4723
sS'hour,after'
p4724
(F1
F0.0015290519877675841
I2
I0
I2
tp4725
sS'after,caused'
p4726
(F1
F0.00076452599388379206
I1
I0
I1
tp4727
sS'in,hospitalized'
p4728
(F1
F0.00076452599388379206
I0
I1
I-1
tp4729
sS'possible,drug'
p4730
(F1
F0.00076452599388379206
I1
I0
I1
tp4731
sS'were,tested'
p4732
(F1
F0.00076452599388379206
I1
I0
I1
tp4733
sS'taking,this'
p4734
(F1
F0.00076452599388379206
I0
I1
I-1
tp4735
sS'by,discontinuing'
p4736
(F1
F0.00076452599388379206
I0
I1
I-1
tp4737
sS'and,tolerability'
p4738
(F1
F0.00076452599388379206
I0
I1
I-1
tp4739
sS'metabolite,profile'
p4740
(F1
F0.00076452599388379206
I0
I1
I-1
tp4741
sS'transferase-mediated,dutp'
p4742
(F1
F0.00076452599388379206
I0
I1
I-1
tp4743
sS'can,reduce'
p4744
(F1
F0.00076452599388379206
I1
I0
I1
tp4745
sS'a,drug-drug'
p4746
(F0
F0
I1
I1
I0
tp4747
sS'tumors,in'
p4748
(F0
F0
I1
I1
I0
tp4749
sS'its,active'
p4750
(F1
F0.00076452599388379206
I0
I1
I-1
tp4751
sS'that,chronic'
p4752
(F0
F0
I1
I1
I0
tp4753
sS'regarding,potential'
p4754
(F1
F0.00076452599388379206
I1
I0
I1
tp4755
sS'are,concomitantly'
p4756
(F1
F0.00076452599388379206
I1
I0
I1
tp4757
sS'dopamine,antagonists'
p4758
(F1
F0.0015290519877675841
I2
I0
I2
tp4759
sS'may,reduce'
p4760
(F1
F0.0030581039755351682
I4
I0
I4
tp4761
sS'dasatinib-mediated,induction'
p4762
(F1
F0.00076452599388379206
I1
I0
I1
tp4763
sS'half,because'
p4764
(F1
F0.00076452599388379206
I1
I0
I1
tp4765
sS'and,multiple'
p4766
(F1
F0.00076452599388379206
I0
I1
I-1
tp4767
sS'typically,torsades'
p4768
(F1
F0.00076452599388379206
I1
I0
I1
tp4769
sS'have,demonstrated'
p4770
(F1
F0.00076452599388379206
I1
I0
I1
tp4771
sS'ganglion,cell'
p4772
(F1
F0.00076452599388379206
I0
I1
I-1
tp4773
sS'alone,for'
p4774
(F1
F0.00076452599388379206
I1
I0
I1
tp4775
sS'necessary,eg'
p4776
(F1
F0.00076452599388379206
I1
I0
I1
tp4777
sS'adrenergic,aerosol'
p4778
(F1
F0.0015290519877675841
I2
I0
I2
tp4779
sS'been,reported'
p4780
(F0.70588235294117652
F0.01834862385321101
I29
I5
I24
tp4781
sS'or,there'
p4782
(F1
F0.00076452599388379206
I0
I1
I-1
tp4783
sS'increased,effect'
p4784
(F1
F0.0015290519877675841
I0
I2
I-2
tp4785
sS'demonstrated,adverse'
p4786
(F1
F0.00076452599388379206
I1
I0
I1
tp4787
sS'agents,may'
p4788
(F1
F0.0061162079510703364
I8
I0
I8
tp4789
sS'possible,interactions'
p4790
(F1
F0.0015290519877675841
I0
I2
I-2
tp4791
sS'time,with'
p4792
(F1
F0.00076452599388379206
I1
I0
I1
tp4793
sS'a,chicken'
p4794
(F1
F0.00076452599388379206
I0
I1
I-1
tp4795
sS'serum,antibody'
p4796
(F1
F0.00076452599388379206
I1
I0
I1
tp4797
sS'agents,mao'
p4798
(F1
F0.00076452599388379206
I1
I0
I1
tp4799
sS'thiazide,beta'
p4800
(F1
F0.00076452599388379206
I0
I1
I-1
tp4801
sS'the,methyl-4'
p4802
(F1
F0.0015290519877675841
I2
I0
I2
tp4803
sS'the,methyl-1'
p4804
(F1
F0.00076452599388379206
I1
I0
I1
tp4805
sS'increased,fold'
p4806
(F1
F0.0015290519877675841
I2
I0
I2
tp4807
sS'revealed,that'
p4808
(F1
F0.00076452599388379206
I0
I1
I-1
tp4809
sS'human,non-small'
p4810
(F1
F0.00076452599388379206
I1
I0
I1
tp4811
sS'of,heparinase'
p4812
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp4813
sS'are,unknown'
p4814
(F1
F0.00076452599388379206
I1
I0
I1
tp4815
sS'isozymes,caution'
p4816
(F1
F0.00076452599388379206
I1
I0
I1
tp4817
sS'for,precocene'
p4818
(F1
F0.00076452599388379206
I0
I1
I-1
tp4819
sS'some,can'
p4820
(F1
F0.00076452599388379206
I1
I0
I1
tp4821
sS'likely,the'
p4822
(F1
F0.00076452599388379206
I0
I1
I-1
tp4823
sS'substrate,for'
p4824
(F1
F0.00076452599388379206
I0
I1
I-1
tp4825
sS's-ketamine,should'
p4826
(F1
F0.00076452599388379206
I1
I0
I1
tp4827
sS'that,releases'
p4828
(F1
F0.00076452599388379206
I1
I0
I1
tp4829
sS'dissolving,dosage'
p4830
(F1
F0.00076452599388379206
I1
I0
I1
tp4831
sS'la,is'
p4832
(F1
F0.00076452599388379206
I1
I0
I1
tp4833
sS'cancer,cells'
p4834
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp4835
sS'influenced,by'
p4836
(F1
F0.00076452599388379206
I0
I1
I-1
tp4837
sS'and,coumarin-type'
p4838
(F1
F0.00076452599388379206
I1
I0
I1
tp4839
sS'with,common'
p4840
(F1
F0.00076452599388379206
I0
I1
I-1
tp4841
sS'is,advised'
p4842
(F1
F0.0015290519877675841
I2
I0
I2
tp4843
sS'onset,intensity'
p4844
(F1
F0.00076452599388379206
I0
I1
I-1
tp4845
sS'qt,interval'
p4846
(F0
F0
I2
I2
I0
tp4847
sS'be,adjusted'
p4848
(F1
F0.0015290519877675841
I2
I0
I2
tp4849
sS'is,therefore'
p4850
(F1
F0.00076452599388379206
I1
I0
I1
tp4851
sS'prolongation,and'
p4852
(F1
F0.0015290519877675841
I2
I0
I2
tp4853
sS'and,cci-779'
p4854
(F1
F0.00076452599388379206
I0
I1
I-1
tp4855
sS'carbidopa,levodopa'
p4856
(F1
F0.00076452599388379206
I0
I1
I-1
tp4857
sS'and,must'
p4858
(F1
F0.00076452599388379206
I0
I1
I-1
tp4859
sS'relevance,for'
p4860
(F1
F0.00076452599388379206
I0
I1
I-1
tp4861
sS'vaccination,and'
p4862
(F1
F0.00076452599388379206
I1
I0
I1
tp4863
sS'cells,mcf7'
p4864
(F1
F0.00076452599388379206
I1
I0
I1
tp4865
sS'clearance,in'
p4866
(F1
F0.0015290519877675841
I2
I0
I2
tp4867
sS'four,times'
p4868
(F1
F0.0015290519877675841
I2
I0
I2
tp4869
sS'hepatic,metabolism'
p4870
(F1
F0.0022935779816513763
I0
I3
I-3
tp4871
sS'mobic,is'
p4872
(F0
F0
I1
I1
I0
tp4873
sS'and,abt-737'
p4874
(F1
F0.00076452599388379206
I1
I0
I1
tp4875
sS'events,bruising'
p4876
(F1
F0.00076452599388379206
I1
I0
I1
tp4877
sS'general,or'
p4878
(F1
F0.00076452599388379206
I0
I1
I-1
tp4879
sS'regulating,bcl-2'
p4880
(F1
F0.00076452599388379206
I1
I0
I1
tp4881
sS'mykrox,tablets'
p4882
(F1
F0.00076452599388379206
I1
I0
I1
tp4883
sS'been,studied'
p4884
(F0
F0
I2
I2
I0
tp4885
sS'significantly,affect'
p4886
(F1
F0.00076452599388379206
I0
I1
I-1
tp4887
sS'the,drug'
p4888
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp4889
sS'combinations,of'
p4890
(F1
F0.00076452599388379206
I0
I1
I-1
tp4891
sS'concomitant,administration'
p4892
(F0.63636363636363635
F0.010703363914373088
I18
I4
I14
tp4893
sS'weeks,of'
p4894
(F1
F0.00076452599388379206
I1
I0
I1
tp4895
sS'to,did'
p4896
(F1
F0.00076452599388379206
I0
I1
I-1
tp4897
sS'although,no'
p4898
(F1
F0.00076452599388379206
I1
I0
I1
tp4899
sS'increased,response'
p4900
(F1
F0.0015290519877675841
I0
I2
I-2
tp4901
sS'placebo,in'
p4902
(F1
F0.00076452599388379206
I0
I1
I-1
tp4903
sS'often,needed'
p4904
(F1
F0.00076452599388379206
I1
I0
I1
tp4905
sS'decrease,bioavailability'
p4906
(F1
F0.00076452599388379206
I1
I0
I1
tp4907
sS'be,used'
p4908
(F0.77777777777777779
F0.016055045871559634
I24
I3
I21
tp4909
sS'receiving,both'
p4910
(F1
F0.00076452599388379206
I1
I0
I1
tp4911
sS'john,s'
p4912
(F1
F0.0015290519877675841
I2
I0
I2
tp4913
sS'a,way'
p4914
(F1
F0.00076452599388379206
I0
I1
I-1
tp4915
sS'increased,the'
p4916
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp4917
sS'metabolism,it'
p4918
(F1
F0.00076452599388379206
I1
I0
I1
tp4919
sS'and,mycophenolate'
p4920
(F0
F0
I1
I1
I0
tp4921
sS'metabolism,in'
p4922
(F1
F0.00076452599388379206
I1
I0
I1
tp4923
sS'zavesca,appeared'
p4924
(F1
F0.00076452599388379206
I1
I0
I1
tp4925
sS'of,increasing'
p4926
(F1
F0.00076452599388379206
I0
I1
I-1
tp4927
sS'while,the'
p4928
(F1
F0.00076452599388379206
I1
I0
I1
tp4929
sS'cyps,a6'
p4930
(F1
F0.00076452599388379206
I0
I1
I-1
tp4931
sS'nsaids,may'
p4932
(F1
F0.0015290519877675841
I2
I0
I2
tp4933
sS'the,hypoprothrombinemic'
p4934
(F1
F0.00076452599388379206
I1
I0
I1
tp4935
sS'with,streptokinase'
p4936
(F1
F0.00076452599388379206
I0
I1
I-1
tp4937
sS'diprivan,injectable'
p4938
(F0
F0
I2
I2
I0
tp4939
sS'plasma,prothrombin'
p4940
(F1
F0.00076452599388379206
I1
I0
I1
tp4941
sS'and,until'
p4942
(F1
F0.00076452599388379206
I1
I0
I1
tp4943
sS'formal,study'
p4944
(F1
F0.0015290519877675841
I0
I2
I-2
tp4945
sS'detected,in'
p4946
(F1
F0.00076452599388379206
I1
I0
I1
tp4947
sS'the,british'
p4948
(F1
F0.00076452599388379206
I0
I1
I-1
tp4949
sS'in,departments'
p4950
(F1
F0.00076452599388379206
I0
I1
I-1
tp4951
sS'or,causing'
p4952
(F1
F0.00076452599388379206
I1
I0
I1
tp4953
sS'ingested,with'
p4954
(F1
F0.00076452599388379206
I1
I0
I1
tp4955
sS'asendin,sinequan'
p4956
(F1
F0.00076452599388379206
I0
I1
I-1
tp4957
sS'point,which'
p4958
(F1
F0.00076452599388379206
I1
I0
I1
tp4959
sS'combination,was'
p4960
(F1
F0.0022935779816513763
I0
I3
I-3
tp4961
sS'conditioned,place'
p4962
(F1
F0.0015290519877675841
I0
I2
I-2
tp4963
sS'depress,plasma'
p4964
(F1
F0.00076452599388379206
I1
I0
I1
tp4965
sS'been,observed'
p4966
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp4967
sS'as,elavil'
p4968
(F1
F0.00076452599388379206
I0
I1
I-1
tp4969
sS'resulting,in'
p4970
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp4971
sS'following,agents'
p4972
(F1
F0.00076452599388379206
I1
I0
I1
tp4973
sS'pergolide,mesylate'
p4974
(F1
F0.00076452599388379206
I0
I1
I-1
tp4975
sS'and,protease'
p4976
(F1
F0.00076452599388379206
I0
I1
I-1
tp4977
sS'abl,kinases'
p4978
(F0
F0
I1
I1
I0
tp4979
sS'control,of'
p4980
(F1
F0.0015290519877675841
I0
I2
I-2
tp4981
sS'with,but'
p4982
(F1
F0.0015290519877675841
I0
I2
I-2
tp4983
sS'by,exposure'
p4984
(F1
F0.00076452599388379206
I1
I0
I1
tp4985
sS'potassium-sparing,or'
p4986
(F1
F0.00076452599388379206
I1
I0
I1
tp4987
sS'of,crm197'
p4988
(F0
F0
I1
I1
I0
tp4989
sS'oral,are'
p4990
(F1
F0.00076452599388379206
I1
I0
I1
tp4991
sS'of,subsequent'
p4992
(F1
F0.00076452599388379206
I0
I1
I-1
tp4993
sS'pr,intervals'
p4994
(F1
F0.00076452599388379206
I0
I1
I-1
tp4995
sS'detrol,la'
p4996
(F1
F0.00076452599388379206
I1
I0
I1
tp4997
sS'also,had'
p4998
(F1
F0.00076452599388379206
I1
I0
I1
tp4999
sS'agonists,has'
p5000
(F1
F0.00076452599388379206
I0
I1
I-1
tp5001
sS'barbiturates,may'
p5002
(F1
F0.00076452599388379206
I1
I0
I1
tp5003
sS'a,concomitant'
p5004
(F1
F0.00076452599388379206
I1
I0
I1
tp5005
sS'although,a'
p5006
(F1
F0.00076452599388379206
I1
I0
I1
tp5007
sS'rifabutin,there'
p5008
(F1
F0.00076452599388379206
I1
I0
I1
tp5009
sS'is,coadministered'
p5010
(F0
F0
I1
I1
I0
tp5011
sS'different,drugs'
p5012
(F1
F0.00076452599388379206
I1
I0
I1
tp5013
sS'heme,at'
p5014
(F1
F0.00076452599388379206
I0
I1
I-1
tp5015
sS'studies,demonstrated'
p5016
(F1
F0.00076452599388379206
I0
I1
I-1
tp5017
sS'given,that'
p5018
(F1
F0.00076452599388379206
I1
I0
I1
tp5019
sS'profiles,similar'
p5020
(F1
F0.00076452599388379206
I1
I0
I1
tp5021
sS'heme,as'
p5022
(F1
F0.00076452599388379206
I0
I1
I-1
tp5023
sS'or,platelet'
p5024
(F1
F0.00076452599388379206
I1
I0
I1
tp5025
sS'interactions,effect'
p5026
(F1
F0.00076452599388379206
I0
I1
I-1
tp5027
sS'prior,use'
p5028
(F1
F0.00076452599388379206
I1
I0
I1
tp5029
sS'le,is'
p5030
(F1
F0.00076452599388379206
I1
I0
I1
tp5031
sS'episodes,when'
p5032
(F1
F0.00076452599388379206
I1
I0
I1
tp5033
sS'experience,an'
p5034
(F1
F0.00076452599388379206
I1
I0
I1
tp5035
sS'it,should'
p5036
(F1
F0.0015290519877675841
I2
I0
I2
tp5037
sS'and,concomitant'
p5038
(F1
F0.00076452599388379206
I1
I0
I1
tp5039
sS'of,solid'
p5040
(F1
F0.00076452599388379206
I0
I1
I-1
tp5041
sS'a,change'
p5042
(F1
F0.0015290519877675841
I2
I0
I2
tp5043
sS'decreased,the'
p5044
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp5045
sS'single,agent'
p5046
(F1
F0.00076452599388379206
I1
I0
I1
tp5047
sS'experience,as'
p5048
(F1
F0.00076452599388379206
I1
I0
I1
tp5049
sS'hypertension,suggests'
p5050
(F1
F0.00076452599388379206
I1
I0
I1
tp5051
sS'multidose,study'
p5052
(F1
F0.00076452599388379206
I1
I0
I1
tp5053
sS'ziagen,twice'
p5054
(F1
F0.00076452599388379206
I1
I0
I1
tp5055
sS'of,precocene'
p5056
(F0
F0
I1
I1
I0
tp5057
sS'dose,produced'
p5058
(F1
F0.00076452599388379206
I1
I0
I1
tp5059
sS'phases,the'
p5060
(F1
F0.00076452599388379206
I0
I1
I-1
tp5061
sS'patients,treated'
p5062
(F0.5
F0.0015290519877675841
I3
I1
I2
tp5063
sS'received,to'
p5064
(F1
F0.00076452599388379206
I1
I0
I1
tp5065
sS'with,a'
p5066
(F0.23076923076923078
F0.0022935779816513763
I8
I5
I3
tp5067
sS'of,since'
p5068
(F1
F0.00076452599388379206
I1
I0
I1
tp5069
sS'liver,slices'
p5070
(F1
F0.00076452599388379206
I0
I1
I-1
tp5071
sS'of,biotransformation'
p5072
(F1
F0.00076452599388379206
I0
I1
I-1
tp5073
sS'this,diminution'
p5074
(F1
F0.00076452599388379206
I1
I0
I1
tp5075
sS'trimethoprim,may'
p5076
(F1
F0.00076452599388379206
I1
I0
I1
tp5077
sS'been,investigated'
p5078
(F1
F0.00076452599388379206
I0
I1
I-1
tp5079
sS'interactions,may'
p5080
(F1
F0.00076452599388379206
I1
I0
I1
tp5081
sS'for,compounds'
p5082
(F1
F0.00076452599388379206
I0
I1
I-1
tp5083
sS'of,predominantly'
p5084
(F1
F0.00076452599388379206
I0
I1
I-1
tp5085
sS'transduction,following'
p5086
(F1
F0.00076452599388379206
I0
I1
I-1
tp5087
sS'interact,with'
p5088
(F0.53846153846153844
F0.0053516819571865441
I10
I3
I7
tp5089
sS'of,were'
p5090
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp5091
sS'use,of'
p5092
(F0.47368421052631576
F0.020642201834862386
I42
I15
I27
tp5093
sS'and,is'
p5094
(F0.5
F0.0015290519877675841
I3
I1
I2
tp5095
sS'of,much'
p5096
(F1
F0.00076452599388379206
I0
I1
I-1
tp5097
sS'precipitate,bradycardia'
p5098
(F1
F0.00076452599388379206
I1
I0
I1
tp5099
sS'use,on'
p5100
(F1
F0.00076452599388379206
I0
I1
I-1
tp5101
sS'to,women'
p5102
(F1
F0.00076452599388379206
I1
I0
I1
tp5103
sS'indications,that'
p5104
(F1
F0.00076452599388379206
I1
I0
I1
tp5105
sS'the,aim'
p5106
(F1
F0.00076452599388379206
I0
I1
I-1
tp5107
sS'on,herceptin-mediated'
p5108
(F1
F0.00076452599388379206
I0
I1
I-1
tp5109
sS'tubular,secretion'
p5110
(F0.25
F0.0015290519877675841
I5
I3
I2
tp5111
sS'and,in'
p5112
(F0
F0
I5
I5
I0
tp5113
sS'monitoring,of'
p5114
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp5115
sS'confirmed,congenital'
p5116
(F1
F0.00076452599388379206
I1
I0
I1
tp5117
sS'of,containing'
p5118
(F1
F0.00076452599388379206
I0
I1
I-1
tp5119
sS'neulasta,should'
p5120
(F1
F0.00076452599388379206
I1
I0
I1
tp5121
sS'of,neurotoxin'
p5122
(F1
F0.00076452599388379206
I0
I1
I-1
tp5123
sS'these,subjects'
p5124
(F1
F0.00076452599388379206
I0
I1
I-1
tp5125
sS'expression,and'
p5126
(F1
F0.00076452599388379206
I1
I0
I1
tp5127
sS'failure,in'
p5128
(F1
F0.00076452599388379206
I1
I0
I1
tp5129
sS'foods,with'
p5130
(F1
F0.00076452599388379206
I1
I0
I1
tp5131
sS'wort,and'
p5132
(F1
F0.00076452599388379206
I1
I0
I1
tp5133
sS'males,the'
p5134
(F1
F0.00076452599388379206
I1
I0
I1
tp5135
sS'expression,of'
p5136
(F1
F0.00076452599388379206
I0
I1
I-1
tp5137
sS'that,are'
p5138
(F0.27272727272727271
F0.0022935779816513763
I7
I4
I3
tp5139
sS'of,cimetidine'
p5140
(F1
F0.00076452599388379206
I1
I0
I1
tp5141
sS'one,renal'
p5142
(F1
F0.00076452599388379206
I1
I0
I1
tp5143
sS'dose,pharmacodynamics'
p5144
(F1
F0.00076452599388379206
I0
I1
I-1
tp5145
sS'an,approach'
p5146
(F1
F0.00076452599388379206
I1
I0
I1
tp5147
sS'are,not'
p5148
(F0.14285714285714285
F0.00076452599388379206
I3
I4
I-1
tp5149
sS'kg,of'
p5150
(F1
F0.00076452599388379206
I0
I1
I-1
tp5151
sS'imexon,and'
p5152
(F1
F0.00076452599388379206
I1
I0
I1
tp5153
sS'of,ergotamine-containing'
p5154
(F1
F0.00076452599388379206
I1
I0
I1
tp5155
sS'or,changing'
p5156
(F1
F0.00076452599388379206
I1
I0
I1
tp5157
sS'mild,to'
p5158
(F1
F0.0015290519877675841
I2
I0
I2
tp5159
sS'is,possible'
p5160
(F1
F0.0015290519877675841
I2
I0
I2
tp5161
sS'the,deazaneplanocin'
p5162
(F1
F0.00076452599388379206
I0
I1
I-1
tp5163
sS'known,to'
p5164
(F0
F0
I3
I3
I0
tp5165
sS'be,additive'
p5166
(F1
F0.0038226299694189602
I5
I0
I5
tp5167
sS'after,topical'
p5168
(F1
F0.00076452599388379206
I1
I0
I1
tp5169
sS'and,performance'
p5170
(F1
F0.00076452599388379206
I0
I1
I-1
tp5171
sS'absence,and'
p5172
(F1
F0.00076452599388379206
I0
I1
I-1
tp5173
sS'pt,has'
p5174
(F1
F0.00076452599388379206
I1
I0
I1
tp5175
sS'patients,being'
p5176
(F1
F0.00076452599388379206
I1
I0
I1
tp5177
sS'day,after'
p5178
(F1
F0.00076452599388379206
I1
I0
I1
tp5179
sS'bile,acids'
p5180
(F0
F0
I1
I1
I0
tp5181
sS'drug-drug,interactions'
p5182
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp5183
sS'with,topical'
p5184
(F1
F0.00076452599388379206
I0
I1
I-1
tp5185
sS'ethinyl,estradiol-'
p5186
(F1
F0.00076452599388379206
I1
I0
I1
tp5187
sS'of,profound'
p5188
(F1
F0.00076452599388379206
I1
I0
I1
tp5189
sS'than,when'
p5190
(F1
F0.00076452599388379206
I1
I0
I1
tp5191
sS'medical,treatment'
p5192
(F1
F0.00076452599388379206
I0
I1
I-1
tp5193
sS'event,profile'
p5194
(F1
F0.00076452599388379206
I0
I1
I-1
tp5195
sS'is,sequence'
p5196
(F1
F0.00076452599388379206
I1
I0
I1
tp5197
sS'be,metabolized'
p5198
(F0
F0
I1
I1
I0
tp5199
sS'chondroitin,abc'
p5200
(F1
F0.0015290519877675841
I0
I2
I-2
tp5201
sS'thiazides,may'
p5202
(F1
F0.0015290519877675841
I2
I0
I2
tp5203
sS'drug,has'
p5204
(F1
F0.00076452599388379206
I0
I1
I-1
tp5205
sS'when,concomitant'
p5206
(F0
F0
I1
I1
I0
tp5207
sS'trimethoprim,given'
p5208
(F1
F0.00076452599388379206
I1
I0
I1
tp5209
sS'mixed,with'
p5210
(F1
F0.00076452599388379206
I1
I0
I1
tp5211
sS'attenuated,vaccines'
p5212
(F1
F0.00076452599388379206
I1
I0
I1
tp5213
sS'higher,serum'
p5214
(F1
F0.00076452599388379206
I1
I0
I1
tp5215
sS'two,combinations'
p5216
(F1
F0.00076452599388379206
I1
I0
I1
tp5217
sS'also,found'
p5218
(F1
F0.00076452599388379206
I1
I0
I1
tp5219
sS'or,extent'
p5220
(F0
F0
I1
I1
I0
tp5221
sS'not,in'
p5222
(F1
F0.0015290519877675841
I2
I0
I2
tp5223
sS'predictable,dose-related'
p5224
(F1
F0.00076452599388379206
I1
I0
I1
tp5225
sS'may,require'
p5226
(F1
F0.0038226299694189602
I5
I0
I5
tp5227
sS'inhibited,tumor'
p5228
(F1
F0.00076452599388379206
I1
I0
I1
tp5229
sS'test,for'
p5230
(F1
F0.00076452599388379206
I0
I1
I-1
tp5231
sS'and,from'
p5232
(F1
F0.00076452599388379206
I1
I0
I1
tp5233
sS'mcf7,and'
p5234
(F1
F0.00076452599388379206
I0
I1
I-1
tp5235
sS'mycamine,and'
p5236
(F1
F0.00076452599388379206
I0
I1
I-1
tp5237
sS'agents,increased'
p5238
(F1
F0.0015290519877675841
I0
I2
I-2
tp5239
sS'one,case'
p5240
(F1
F0.0015290519877675841
I2
I0
I2
tp5241
sS'after,other'
p5242
(F1
F0.00076452599388379206
I0
I1
I-1
tp5243
sS'were,observed'
p5244
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp5245
sS'binding,site'
p5246
(F1
F0.00076452599388379206
I0
I1
I-1
tp5247
sS'in,cyclosporine-treated'
p5248
(F0
F0
I1
I1
I0
tp5249
sS'apoptosis,compared'
p5250
(F1
F0.00076452599388379206
I0
I1
I-1
tp5251
sS'or,increasing'
p5252
(F1
F0.00076452599388379206
I1
I0
I1
tp5253
sS'distinct,and'
p5254
(F1
F0.00076452599388379206
I1
I0
I1
tp5255
sS'demonstrated,an'
p5256
(F1
F0.00076452599388379206
I1
I0
I1
tp5257
sS'mutation,were'
p5258
(F1
F0.00076452599388379206
I0
I1
I-1
tp5259
sS'dose,to'
p5260
(F1
F0.0015290519877675841
I2
I0
I2
tp5261
sS'tamsulosin,hci'
p5262
(F1
F0.00076452599388379206
I0
I1
I-1
tp5263
sS'study,found'
p5264
(F1
F0.00076452599388379206
I1
I0
I1
tp5265
sS'chronic,dosing'
p5266
(F1
F0.00076452599388379206
I0
I1
I-1
tp5267
sS'being,and'
p5268
(F1
F0.00076452599388379206
I0
I1
I-1
tp5269
sS'glutamate,receptor'
p5270
(F0
F0
I1
I1
I0
tp5271
sS'it,was'
p5272
(F1
F0.0030581039755351682
I4
I0
I4
tp5273
sS'data,suggest'
p5274
(F1
F0.00076452599388379206
I1
I0
I1
tp5275
sS'diuretics,patients'
p5276
(F1
F0.00076452599388379206
I1
I0
I1
tp5277
sS'oral,has'
p5278
(F1
F0.00076452599388379206
I1
I0
I1
tp5279
sS'another,study'
p5280
(F1
F0.00076452599388379206
I1
I0
I1
tp5281
sS'its,addition'
p5282
(F1
F0.00076452599388379206
I0
I1
I-1
tp5283
sS'of,mometasone'
p5284
(F1
F0.00076452599388379206
I1
I0
I1
tp5285
sS'sirna,sub-g1'
p5286
(F1
F0.00076452599388379206
I0
I1
I-1
tp5287
sS'certain,and'
p5288
(F1
F0.0015290519877675841
I2
I0
I2
tp5289
sS'the,therapeutic'
p5290
(F0
F0
I1
I1
I0
tp5291
sS'with,oral'
p5292
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp5293
sS'interactions,women'
p5294
(F1
F0.00076452599388379206
I1
I0
I1
tp5295
sS'a,narrow'
p5296
(F1
F0.00076452599388379206
I0
I1
I-1
tp5297
sS'dose,oral'
p5298
(F1
F0.00076452599388379206
I1
I0
I1
tp5299
sS'drugs,known'
p5300
(F1
F0.0015290519877675841
I0
I2
I-2
tp5301
sS'depressant,effects'
p5302
(F1
F0.0022935779816513763
I3
I0
I3
tp5303
sS's-adenosylhomocysteine,adohcy'
p5304
(F1
F0.00076452599388379206
I0
I1
I-1
tp5305
sS'and,increases'
p5306
(F1
F0.00076452599388379206
I1
I0
I1
tp5307
sS'carcinogenicity,study'
p5308
(F1
F0.0015290519877675841
I0
I2
I-2
tp5309
sS'the,basis'
p5310
(F1
F0.0015290519877675841
I2
I0
I2
tp5311
sS'the,finding'
p5312
(F1
F0.00076452599388379206
I1
I0
I1
tp5313
sS'to,assure'
p5314
(F1
F0.00076452599388379206
I1
I0
I1
tp5315
sS'is,significantly'
p5316
(F1
F0.00076452599388379206
I0
I1
I-1
tp5317
sS'and,increased'
p5318
(F0
F0
I1
I1
I0
tp5319
sS'aspirin,rimantadine'
p5320
(F1
F0.00076452599388379206
I0
I1
I-1
tp5321
sS'swimming,test'
p5322
(F1
F0.00076452599388379206
I0
I1
I-1
tp5323
sS'concentrations,and'
p5324
(F1
F0.0030581039755351682
I4
I0
I4
tp5325
sS'in,delayed'
p5326
(F1
F0.00076452599388379206
I1
I0
I1
tp5327
sS'not,recommended'
p5328
(F1
F0.0030581039755351682
I4
I0
I4
tp5329
sS'were,significantly'
p5330
(F1
F0.00076452599388379206
I0
I1
I-1
tp5331
sS'plasma,kinetics'
p5332
(F1
F0.00076452599388379206
I0
I1
I-1
tp5333
sS'isozymes,cytochrome'
p5334
(F1
F0.00076452599388379206
I1
I0
I1
tp5335
sS'competes,with'
p5336
(F1
F0.0015290519877675841
I2
I0
I2
tp5337
sS'thus,decrease'
p5338
(F1
F0.0015290519877675841
I2
I0
I2
tp5339
sS'because,have'
p5340
(F1
F0.00076452599388379206
I1
I0
I1
tp5341
sS'prior,administration'
p5342
(F1
F0.00076452599388379206
I1
I0
I1
tp5343
sS'studied,the'
p5344
(F1
F0.00076452599388379206
I1
I0
I1
tp5345
sS'by,cyp'
p5346
(F1
F0.00076452599388379206
I1
I0
I1
tp5347
sS'with,concurrent'
p5348
(F1
F0.0015290519877675841
I2
I0
I2
tp5349
sS'on,serotonin'
p5350
(F1
F0.00076452599388379206
I0
I1
I-1
tp5351
sS'phenyl-1,tetrahydropyridine'
p5352
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp5353
sS'and,vitamin'
p5354
(F1
F0.0015290519877675841
I2
I0
I2
tp5355
sS'mg,qd'
p5356
(F1
F0.00076452599388379206
I1
I0
I1
tp5357
sS'of,either'
p5358
(F1
F0.0045871559633027525
I0
I6
I-6
tp5359
sS'theophylline,plasma'
p5360
(F1
F0.00076452599388379206
I1
I0
I1
tp5361
sS'of,sanctura'
p5362
(F0
F0
I1
I1
I0
tp5363
sS'the,like'
p5364
(F1
F0.00076452599388379206
I0
I1
I-1
tp5365
sS'elimination,because'
p5366
(F1
F0.00076452599388379206
I0
I1
I-1
tp5367
sS'inhibitors,such'
p5368
(F1
F0.00076452599388379206
I1
I0
I1
tp5369
sS'the,roles'
p5370
(F1
F0.00076452599388379206
I0
I1
I-1
tp5371
sS'due,to'
p5372
(F0.5
F0.0045871559633027525
I9
I3
I6
tp5373
sS'by,but'
p5374
(F1
F0.0015290519877675841
I2
I0
I2
tp5375
sS'of,altabax'
p5376
(F1
F0.00076452599388379206
I0
I1
I-1
tp5377
sS'bp,in'
p5378
(F1
F0.00076452599388379206
I1
I0
I1
tp5379
sS'interactions,the'
p5380
(F1
F0.0015290519877675841
I0
I2
I-2
tp5381
sS'with,their'
p5382
(F1
F0.00076452599388379206
I1
I0
I1
tp5383
sS's-ketamine,after'
p5384
(F1
F0.00076452599388379206
I0
I1
I-1
tp5385
sS'anticoagulants,interaction'
p5386
(F1
F0.00076452599388379206
I0
I1
I-1
tp5387
sS'selective,serotonin'
p5388
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp5389
sS'volume,per'
p5390
(F1
F0.00076452599388379206
I1
I0
I1
tp5391
sS'locomotor,sensitization'
p5392
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp5393
sS'prescribing,isoenzyme'
p5394
(F1
F0.00076452599388379206
I1
I0
I1
tp5395
sS'some,drug'
p5396
(F1
F0.00076452599388379206
I0
I1
I-1
tp5397
sS'mequitazine,can'
p5398
(F1
F0.00076452599388379206
I1
I0
I1
tp5399
sS'has,also'
p5400
(F1
F0.00076452599388379206
I1
I0
I1
tp5401
sS'of,neonatal'
p5402
(F1
F0.00076452599388379206
I0
I1
I-1
tp5403
sS'enzyme,inducer'
p5404
(F1
F0.00076452599388379206
I1
I0
I1
tp5405
sS'incremental,ldl-c'
p5406
(F1
F0.00076452599388379206
I1
I0
I1
tp5407
sS'as,marplan'
p5408
(F1
F0.00076452599388379206
I1
I0
I1
tp5409
sS'a,xenical'
p5410
(F1
F0.00076452599388379206
I1
I0
I1
tp5411
sS'alcohol,impairs'
p5412
(F1
F0.00076452599388379206
I1
I0
I1
tp5413
sS'history,of'
p5414
(F1
F0.00076452599388379206
I1
I0
I1
tp5415
sS'c9,or'
p5416
(F1
F0.00076452599388379206
I0
I1
I-1
tp5417
sS'ferrous,sulfate'
p5418
(F1
F0.0015290519877675841
I2
I0
I2
tp5419
sS'p,respectively'
p5420
(F1
F0.00076452599388379206
I1
I0
I1
tp5421
sS'slow,the'
p5422
(F1
F0.00076452599388379206
I1
I0
I1
tp5423
sS'of,by'
p5424
(F1
F0.0022935779816513763
I3
I0
I3
tp5425
sS'daily,fro'
p5426
(F1
F0.00076452599388379206
I0
I1
I-1
tp5427
sS'to,assess'
p5428
(F0
F0
I1
I1
I0
tp5429
sS'mpa,were'
p5430
(F1
F0.00076452599388379206
I1
I0
I1
tp5431
sS'of,bw'
p5432
(F1
F0.00076452599388379206
I0
I1
I-1
tp5433
sS'to,employ'
p5434
(F1
F0.0015290519877675841
I2
I0
I2
tp5435
sS'closely,for'
p5436
(F1
F0.0015290519877675841
I2
I0
I2
tp5437
sS'and,because'
p5438
(F1
F0.00076452599388379206
I1
I0
I1
tp5439
sS'b,or'
p5440
(F1
F0.0015290519877675841
I0
I2
I-2
tp5441
sS'mometasone,furoate'
p5442
(F1
F0.00076452599388379206
I1
I0
I1
tp5443
sS'transplant,patients'
p5444
(F0.5
F0.0015290519877675841
I3
I1
I2
tp5445
sS'terbinafine,decreases'
p5446
(F1
F0.00076452599388379206
I1
I0
I1
tp5447
sS'of,low-dose'
p5448
(F1
F0.00076452599388379206
I1
I0
I1
tp5449
sS'multiple,metastatic'
p5450
(F1
F0.00076452599388379206
I1
I0
I1
tp5451
sS'the,possibility'
p5452
(F0.5
F0.0015290519877675841
I3
I1
I2
tp5453
sS'by,a'
p5454
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp5455
sS'to,preclude'
p5456
(F1
F0.00076452599388379206
I1
I0
I1
tp5457
sS'methyl-1,thiazol-4'
p5458
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp5459
sS'that,the'
p5460
(F0.27272727272727271
F0.0022935779816513763
I7
I4
I3
tp5461
sS'total,intravenous'
p5462
(F1
F0.00076452599388379206
I0
I1
I-1
tp5463
sS'or,similar'
p5464
(F1
F0.00076452599388379206
I1
I0
I1
tp5465
sS'or,supplements'
p5466
(F1
F0.00076452599388379206
I1
I0
I1
tp5467
sS'a,single'
p5468
(F0.5
F0.0045871559633027525
I3
I9
I-6
tp5469
sS'mechanisms,of'
p5470
(F1
F0.00076452599388379206
I0
I1
I-1
tp5471
sS'i,trial'
p5472
(F1
F0.00076452599388379206
I0
I1
I-1
tp5473
sS'rabbits,treated'
p5474
(F1
F0.00076452599388379206
I0
I1
I-1
tp5475
sS'absorption,dosage'
p5476
(F1
F0.00076452599388379206
I1
I0
I1
tp5477
sS'data,from'
p5478
(F1
F0.0015290519877675841
I2
I0
I2
tp5479
sS'interval,ci'
p5480
(F1
F0.00076452599388379206
I1
I0
I1
tp5481
sS'limits,the'
p5482
(F1
F0.00076452599388379206
I1
I0
I1
tp5483
sS'vivo,cyp3a'
p5484
(F1
F0.00076452599388379206
I0
I1
I-1
tp5485
sS'drug,uptake'
p5486
(F1
F0.00076452599388379206
I0
I1
I-1
tp5487
sS'metabolism,of'
p5488
(F0.17647058823529413
F0.0022935779816513763
I10
I7
I3
tp5489
sS'progression-free,survival'
p5490
(F1
F0.00076452599388379206
I1
I0
I1
tp5491
sS'pharmacokinetic,study'
p5492
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp5493
sS'ethanol,decreases'
p5494
(F1
F0.00076452599388379206
I1
I0
I1
tp5495
sS'theophylline,terfenadine'
p5496
(F1
F0.00076452599388379206
I1
I0
I1
tp5497
sS'for,optimal'
p5498
(F1
F0.00076452599388379206
I0
I1
I-1
tp5499
sS'with,relapsed'
p5500
(F1
F0.00076452599388379206
I0
I1
I-1
tp5501
sS'unchanged,mexitil'
p5502
(F1
F0.00076452599388379206
I1
I0
I1
tp5503
sS'microsomal,enzyme'
p5504
(F1
F0.00076452599388379206
I1
I0
I1
tp5505
sS'but,greatly'
p5506
(F1
F0.00076452599388379206
I1
I0
I1
tp5507
sS'displace,from'
p5508
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp5509
sS'pharmacokinetic,interactions'
p5510
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp5511
sS'parnate,or'
p5512
(F1
F0.00076452599388379206
I1
I0
I1
tp5513
sS'a,inhibitors'
p5514
(F1
F0.00076452599388379206
I1
I0
I1
tp5515
sS'cmax,by'
p5516
(F1
F0.00076452599388379206
I1
I0
I1
tp5517
sS'd,vitamin'
p5518
(F1
F0.00076452599388379206
I0
I1
I-1
tp5519
sS'hours,and'
p5520
(F1
F0.0015290519877675841
I2
I0
I2
tp5521
sS'by,up-regulation'
p5522
(F0
F0
I1
I1
I0
tp5523
sS'an,elevation'
p5524
(F1
F0.00076452599388379206
I1
I0
I1
tp5525
sS'exelon,drugs'
p5526
(F1
F0.00076452599388379206
I0
I1
I-1
tp5527
sS'hours,of'
p5528
(F1
F0.00076452599388379206
I1
I0
I1
tp5529
sS'was,observed'
p5530
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp5531
sS'test,point'
p5532
(F1
F0.00076452599388379206
I1
I0
I1
tp5533
sS'no,change'
p5534
(F1
F0.0015290519877675841
I0
I2
I-2
tp5535
sS'daily,increased'
p5536
(F1
F0.00076452599388379206
I1
I0
I1
tp5537
sS'that,alter'
p5538
(F1
F0.0030581039755351682
I4
I0
I4
tp5539
sS'first,test'
p5540
(F1
F0.00076452599388379206
I1
I0
I1
tp5541
sS'the,pregnancy'
p5542
(F1
F0.00076452599388379206
I0
I1
I-1
tp5543
sS'and,nose'
p5544
(F1
F0.00076452599388379206
I1
I0
I1
tp5545
sS'without,causing'
p5546
(F1
F0.00076452599388379206
I1
I0
I1
tp5547
sS'patients,have'
p5548
(F1
F0.00076452599388379206
I0
I1
I-1
tp5549
sS'spent,in'
p5550
(F1
F0.00076452599388379206
I0
I1
I-1
tp5551
sS'not,to'
p5552
(F1
F0.00076452599388379206
I0
I1
I-1
tp5553
sS'of,are'
p5554
(F0
F0
I2
I2
I0
tp5555
sS'hot,plate'
p5556
(F0
F0
I1
I1
I0
tp5557
sS'increase,serum'
p5558
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp5559
sS'coma,and'
p5560
(F1
F0.00076452599388379206
I1
I0
I1
tp5561
sS'that,mephenytoin'
p5562
(F1
F0.00076452599388379206
I1
I0
I1
tp5563
sS'pre-dose,concentration'
p5564
(F1
F0.00076452599388379206
I1
I0
I1
tp5565
sS'concomitant,therapy'
p5566
(F1
F0.00076452599388379206
I1
I0
I1
tp5567
sS'of,potassium-sparing'
p5568
(F0
F0
I1
I1
I0
tp5569
sS'women,treated'
p5570
(F1
F0.00076452599388379206
I1
I0
I1
tp5571
sS'and,lomefloxacin'
p5572
(F1
F0.00076452599388379206
I1
I0
I1
tp5573
sS'when,t'
p5574
(F1
F0.00076452599388379206
I0
I1
I-1
tp5575
sS'metabotropic,glutamate'
p5576
(F0
F0
I1
I1
I0
tp5577
sS'tolectin,is'
p5578
(F1
F0.00076452599388379206
I1
I0
I1
tp5579
sS'when,a'
p5580
(F1
F0.0015290519877675841
I2
I0
I2
tp5581
sS'objective,of'
p5582
(F1
F0.0015290519877675841
I0
I2
I-2
tp5583
sS'respectively,in'
p5584
(F1
F0.00076452599388379206
I1
I0
I1
tp5585
sS'has,stabilized'
p5586
(F1
F0.00076452599388379206
I1
I0
I1
tp5587
sS'and,with'
p5588
(F0
F0
I1
I1
I0
tp5589
sS'for,information'
p5590
(F1
F0.00076452599388379206
I0
I1
I-1
tp5591
sS'may,increase'
p5592
(F0.69230769230769229
F0.013761467889908258
I22
I4
I18
tp5593
sS'of,healthy'
p5594
(F0
F0
I1
I1
I0
tp5595
sS'pharmacokinetics,both'
p5596
(F1
F0.00076452599388379206
I0
I1
I-1
tp5597
sS'dose,reductions'
p5598
(F1
F0.00076452599388379206
I1
I0
I1
tp5599
sS'by,intravitreal'
p5600
(F1
F0.00076452599388379206
I0
I1
I-1
tp5601
sS'behavior,violations'
p5602
(F1
F0.00076452599388379206
I0
I1
I-1
tp5603
sS'a,broad'
p5604
(F1
F0.00076452599388379206
I0
I1
I-1
tp5605
sS'therefore,physicians'
p5606
(F1
F0.0015290519877675841
I2
I0
I2
tp5607
sS'can,exert'
p5608
(F1
F0.00076452599388379206
I1
I0
I1
tp5609
sS'agents,including'
p5610
(F0
F0
I2
I2
I0
tp5611
sS'her2-positive,breast'
p5612
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp5613
sS'mean,area'
p5614
(F1
F0.00076452599388379206
I1
I0
I1
tp5615
sS'tolectin,and'
p5616
(F1
F0.00076452599388379206
I1
I0
I1
tp5617
sS'type,mao'
p5618
(F1
F0.00076452599388379206
I1
I0
I1
tp5619
sS'to,mexitil'
p5620
(F1
F0.00076452599388379206
I1
I0
I1
tp5621
sS'use,in'
p5622
(F1
F0.00076452599388379206
I1
I0
I1
tp5623
sS'tablets,in'
p5624
(F0
F0
I1
I1
I0
tp5625
sS'posicor,inhibits'
p5626
(F1
F0.00076452599388379206
I1
I0
I1
tp5627
sS'not,possible'
p5628
(F1
F0.00076452599388379206
I0
I1
I-1
tp5629
sS'were,performed'
p5630
(F1
F0.0015290519877675841
I0
I2
I-2
tp5631
sS'on,oral'
p5632
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp5633
sS'decreased,when'
p5634
(F1
F0.00076452599388379206
I1
I0
I1
tp5635
sS'tubularly,secreted'
p5636
(F1
F0.00076452599388379206
I1
I0
I1
tp5637
sS'and,especially'
p5638
(F1
F0.00076452599388379206
I1
I0
I1
tp5639
sS'the,orthostatic'
p5640
(F1
F0.00076452599388379206
I1
I0
I1
tp5641
sS'type,may'
p5642
(F1
F0.00076452599388379206
I1
I0
I1
tp5643
sS'effect,decreased'
p5644
(F1
F0.0015290519877675841
I0
I2
I-2
tp5645
sS'alter,mean'
p5646
(F1
F0.00076452599388379206
I1
I0
I1
tp5647
sS'users,had'
p5648
(F1
F0.00076452599388379206
I1
I0
I1
tp5649
sS'drugs,n'
p5650
(F1
F0.00076452599388379206
I0
I1
I-1
tp5651
sS'alter,the'
p5652
(F0.84615384615384615
F0.0084097859327217118
I1
I12
I-11
tp5653
sS'writhing,and'
p5654
(F1
F0.00076452599388379206
I1
I0
I1
tp5655
sS'or,both'
p5656
(F1
F0.0015290519877675841
I0
I2
I-2
tp5657
sS'co-administration,with'
p5658
(F1
F0.00076452599388379206
I0
I1
I-1
tp5659
sS'an,ssri'
p5660
(F1
F0.00076452599388379206
I1
I0
I1
tp5661
sS'calcium,was'
p5662
(F1
F0.00076452599388379206
I0
I1
I-1
tp5663
sS'to,increase'
p5664
(F1
F0.0045871559633027525
I6
I0
I6
tp5665
sS'but,its'
p5666
(F1
F0.0015290519877675841
I0
I2
I-2
tp5667
sS'phosphorylation,of'
p5668
(F1
F0.00076452599388379206
I1
I0
I1
tp5669
sS'the,poor'
p5670
(F1
F0.00076452599388379206
I0
I1
I-1
tp5671
sS'maximum,mg'
p5672
(F1
F0.00076452599388379206
I0
I1
I-1
tp5673
sS'drug,or'
p5674
(F1
F0.00076452599388379206
I1
I0
I1
tp5675
sS'adult,mice'
p5676
(F1
F0.00076452599388379206
I0
I1
I-1
tp5677
sS'of,renal'
p5678
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp5679
sS'of,chemet'
p5680
(F1
F0.00076452599388379206
I1
I0
I1
tp5681
sS'qt,prolongation'
p5682
(F1
F0.00076452599388379206
I0
I1
I-1
tp5683
sS'resistances,at'
p5684
(F1
F0.00076452599388379206
I0
I1
I-1
tp5685
sS'with,potent'
p5686
(F1
F0.00076452599388379206
I1
I0
I1
tp5687
sS'ldl-c,reduction'
p5688
(F1
F0.00076452599388379206
I1
I0
I1
tp5689
sS'acromegalic,patients'
p5690
(F1
F0.00076452599388379206
I1
I0
I1
tp5691
sS'in,experiment'
p5692
(F0
F0
I1
I1
I0
tp5693
sS'to,competition'
p5694
(F1
F0.00076452599388379206
I0
I1
I-1
tp5695
sS'of,has'
p5696
(F0.14285714285714285
F0.00076452599388379206
I3
I4
I-1
tp5697
sS'modified,by'
p5698
(F1
F0.00076452599388379206
I0
I1
I-1
tp5699
sS'intestines,and'
p5700
(F1
F0.00076452599388379206
I1
I0
I1
tp5701
sS'of,will'
p5702
(F1
F0.00076452599388379206
I1
I0
I1
tp5703
sS'until,blood'
p5704
(F1
F0.00076452599388379206
I1
I0
I1
tp5705
sS'antimycotic,agents'
p5706
(F1
F0.00076452599388379206
I1
I0
I1
tp5707
sS'of,fluid'
p5708
(F1
F0.00076452599388379206
I1
I0
I1
tp5709
sS'transduction,into'
p5710
(F1
F0.00076452599388379206
I0
I1
I-1
tp5711
sS'with,mycamine'
p5712
(F1
F0.00076452599388379206
I1
I0
I1
tp5713
sS'on,the'
p5714
(F0.31034482758620691
F0.0068807339449541288
I10
I19
I-9
tp5715
sS'used,together'
p5716
(F1
F0.00076452599388379206
I1
I0
I1
tp5717
sS'depression,due'
p5718
(F1
F0.00076452599388379206
I1
I0
I1
tp5719
sS'five,normal'
p5720
(F1
F0.00076452599388379206
I1
I0
I1
tp5721
sS'were,randomized'
p5722
(F1
F0.00076452599388379206
I0
I1
I-1
tp5723
sS'reduces,dopaminergic'
p5724
(F1
F0.00076452599388379206
I0
I1
I-1
tp5725
sS'after,starting'
p5726
(F1
F0.00076452599388379206
I1
I0
I1
tp5727
sS'increased,intraocular'
p5728
(F1
F0.00076452599388379206
I1
I0
I1
tp5729
sS'symlin,were'
p5730
(F1
F0.00076452599388379206
I1
I0
I1
tp5731
sS'all,cell'
p5732
(F1
F0.00076452599388379206
I1
I0
I1
tp5733
sS'were,vs'
p5734
(F1
F0.00076452599388379206
I1
I0
I1
tp5735
sS'enhanced,cytotoxicity'
p5736
(F1
F0.00076452599388379206
I1
I0
I1
tp5737
sS'exhibits,some'
p5738
(F1
F0.00076452599388379206
I1
I0
I1
tp5739
sS'the,central'
p5740
(F1
F0.00076452599388379206
I1
I0
I1
tp5741
sS'loss,was'
p5742
(F1
F0.00076452599388379206
I1
I0
I1
tp5743
sS'than,in'
p5744
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp5745
sS'adrenergic,agonists'
p5746
(F1
F0.00076452599388379206
I1
I0
I1
tp5747
sS'were,used'
p5748
(F1
F0.00076452599388379206
I0
I1
I-1
tp5749
sS'mazindol,may'
p5750
(F1
F0.00076452599388379206
I1
I0
I1
tp5751
sS'for,four'
p5752
(F1
F0.00076452599388379206
I1
I0
I1
tp5753
sS'p27,kip1'
p5754
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp5755
sS'fu,plasma'
p5756
(F1
F0.00076452599388379206
I1
I0
I1
tp5757
sS'administering,zadaxin'
p5758
(F1
F0.00076452599388379206
I1
I0
I1
tp5759
sS'chickens,intramuscularly'
p5760
(F1
F0.00076452599388379206
I0
I1
I-1
tp5761
sS'surface,expression'
p5762
(F1
F0.00076452599388379206
I0
I1
I-1
tp5763
sS'protein-binding,sites'
p5764
(F1
F0.00076452599388379206
I1
I0
I1
tp5765
sS'or,duration'
p5766
(F1
F0.00076452599388379206
I0
I1
I-1
tp5767
sS'including,is'
p5768
(F1
F0.00076452599388379206
I1
I0
I1
tp5769
sS'reports,suggest'
p5770
(F1
F0.00076452599388379206
I1
I0
I1
tp5771
sS'treatment,enhanced'
p5772
(F1
F0.00076452599388379206
I1
I0
I1
tp5773
sS'a,specific'
p5774
(F1
F0.00076452599388379206
I0
I1
I-1
tp5775
sS'to,reduce'
p5776
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp5777
sS'when,univasc'
p5778
(F1
F0.00076452599388379206
I0
I1
I-1
tp5779
sS'caution,to'
p5780
(F1
F0.0022935779816513763
I3
I0
I3
tp5781
sS'considered,in'
p5782
(F1
F0.00076452599388379206
I1
I0
I1
tp5783
sS'mg,diminished'
p5784
(F1
F0.0015290519877675841
I2
I0
I2
tp5785
sS'and,concurrent'
p5786
(F1
F0.00076452599388379206
I1
I0
I1
tp5787
sS'only,known'
p5788
(F1
F0.00076452599388379206
I1
I0
I1
tp5789
sS'administration,for'
p5790
(F1
F0.00076452599388379206
I0
I1
I-1
tp5791
sS'bleeding,risk'
p5792
(F1
F0.00076452599388379206
I0
I1
I-1
tp5793
sS'hydrochloride,may'
p5794
(F1
F0.0022935779816513763
I3
I0
I3
tp5795
sS'for,total'
p5796
(F1
F0.00076452599388379206
I0
I1
I-1
tp5797
sS'since,inhibit'
p5798
(F1
F0.00076452599388379206
I1
I0
I1
tp5799
sS'and,grams'
p5800
(F1
F0.00076452599388379206
I0
I1
I-1
tp5801
sS'in,profound'
p5802
(F1
F0.00076452599388379206
I1
I0
I1
tp5803
sS'microsomes,showed'
p5804
(F1
F0.00076452599388379206
I0
I1
I-1
tp5805
sS'with,since'
p5806
(F1
F0.00076452599388379206
I1
I0
I1
tp5807
sS'or,when'
p5808
(F1
F0.00076452599388379206
I0
I1
I-1
tp5809
sS'i,fludrocortisone'
p5810
(F1
F0.00076452599388379206
I0
I1
I-1
tp5811
sS'may,antagonize'
p5812
(F1
F0.0022935779816513763
I3
I0
I3
tp5813
sS'those,agents'
p5814
(F1
F0.00076452599388379206
I1
I0
I1
tp5815
sS'peak,plasma'
p5816
(F1
F0.00076452599388379206
I1
I0
I1
tp5817
sS'ganglionic,or'
p5818
(F1
F0.00076452599388379206
I0
I1
I-1
tp5819
sS'be,reduced'
p5820
(F1
F0.0045871559633027525
I6
I0
I6
tp5821
sS'on,drug'
p5822
(F1
F0.00076452599388379206
I0
I1
I-1
tp5823
sS'monoamine,oxidase'
p5824
(F0.55555555555555558
F0.0038226299694189602
I7
I2
I5
tp5825
sS'concomitant,treatment'
p5826
(F1
F0.0015290519877675841
I2
I0
I2
tp5827
sS'concurrent,use'
p5828
(F0.88888888888888884
F0.012232415902140673
I17
I1
I16
tp5829
sS'a,target'
p5830
(F1
F0.00076452599388379206
I0
I1
I-1
tp5831
sS'tachycardia,dryness'
p5832
(F1
F0.00076452599388379206
I1
I0
I1
tp5833
sS'decrease,levels'
p5834
(F1
F0.00076452599388379206
I1
I0
I1
tp5835
sS'sutent,with'
p5836
(F1
F0.0015290519877675841
I2
I0
I2
tp5837
sS'to,disalcid'
p5838
(F1
F0.00076452599388379206
I1
I0
I1
tp5839
sS'wort,may'
p5840
(F1
F0.00076452599388379206
I1
I0
I1
tp5841
sS'a,t-all'
p5842
(F1
F0.00076452599388379206
I1
I0
I1
tp5843
sS'nsaids,concomitant'
p5844
(F1
F0.00076452599388379206
I1
I0
I1
tp5845
sS'and,certain'
p5846
(F1
F0.0015290519877675841
I2
I0
I2
tp5847
sS'reported,to'
p5848
(F1
F0.0068807339449541288
I9
I0
I9
tp5849
sS'previously,and'
p5850
(F1
F0.00076452599388379206
I0
I1
I-1
tp5851
sS'on,coumarin-type'
p5852
(F1
F0.00076452599388379206
I1
I0
I1
tp5853
sS'necessary,it'
p5854
(F1
F0.00076452599388379206
I1
I0
I1
tp5855
sS'feasible,as'
p5856
(F1
F0.00076452599388379206
I0
I1
I-1
tp5857
sS'acetate,and'
p5858
(F0
F0
I1
I1
I0
tp5859
sS'increase,was'
p5860
(F1
F0.00076452599388379206
I1
I0
I1
tp5861
sS'with,adjustment'
p5862
(F1
F0.00076452599388379206
I0
I1
I-1
tp5863
sS'full,characterization'
p5864
(F1
F0.00076452599388379206
I1
I0
I1
tp5865
sS'and,without'
p5866
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp5867
sS'of,cyps'
p5868
(F1
F0.00076452599388379206
I0
I1
I-1
tp5869
sS'the,purpose'
p5870
(F1
F0.0015290519877675841
I0
I2
I-2
tp5871
sS'like,activity'
p5872
(F1
F0.0015290519877675841
I0
I2
I-2
tp5873
sS'lithium,increased'
p5874
(F0
F0
I1
I1
I0
tp5875
sS'analgesics,general'
p5876
(F1
F0.00076452599388379206
I1
I0
I1
tp5877
sS'out,in'
p5878
(F1
F0.00076452599388379206
I0
I1
I-1
tp5879
sS'the,anticoagulant'
p5880
(F1
F0.00076452599388379206
I0
I1
I-1
tp5881
sS'refer,to'
p5882
(F1
F0.0015290519877675841
I0
I2
I-2
tp5883
sS'acid,secretion'
p5884
(F1
F0.00076452599388379206
I1
I0
I1
tp5885
sS'concomitant,drugs'
p5886
(F1
F0.00076452599388379206
I0
I1
I-1
tp5887
sS'when,anticholinergic'
p5888
(F1
F0.00076452599388379206
I0
I1
I-1
tp5889
sS'p,mouse'
p5890
(F1
F0.00076452599388379206
I1
I0
I1
tp5891
sS'model,for'
p5892
(F1
F0.00076452599388379206
I0
I1
I-1
tp5893
sS'and,phenothiazine-type'
p5894
(F1
F0.00076452599388379206
I0
I1
I-1
tp5895
sS'eg,nitrous'
p5896
(F1
F0.00076452599388379206
I1
I0
I1
tp5897
sS'model,possibly'
p5898
(F1
F0.00076452599388379206
I1
I0
I1
tp5899
sS'that,concomitant'
p5900
(F1
F0.00076452599388379206
I1
I0
I1
tp5901
sS'is,an'
p5902
(F1
F0.00076452599388379206
I1
I0
I1
tp5903
sS'to,s'
p5904
(F1
F0.00076452599388379206
I1
I0
I1
tp5905
sS'kinases,with'
p5906
(F1
F0.00076452599388379206
I1
I0
I1
tp5907
sS'had,an'
p5908
(F1
F0.0015290519877675841
I2
I0
I2
tp5909
sS'to,a'
p5910
(F1
F0.0022935779816513763
I3
I0
I3
tp5911
sS'to,g'
p5912
(F1
F0.0015290519877675841
I2
I0
I2
tp5913
sS'flushing,and'
p5914
(F1
F0.00076452599388379206
I1
I0
I1
tp5915
sS'thiamine,loop'
p5916
(F1
F0.00076452599388379206
I1
I0
I1
tp5917
sS'respectively,than'
p5918
(F1
F0.00076452599388379206
I1
I0
I1
tp5919
sS'various,drugs'
p5920
(F1
F0.00076452599388379206
I1
I0
I1
tp5921
sS'mg,once'
p5922
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp5923
sS'agents,such'
p5924
(F1
F0.0030581039755351682
I4
I0
I4
tp5925
sS'metabolic,pathways'
p5926
(F1
F0.00076452599388379206
I0
I1
I-1
tp5927
sS'can,inhibit'
p5928
(F1
F0.0015290519877675841
I2
I0
I2
tp5929
sS'with,combined'
p5930
(F1
F0.00076452599388379206
I1
I0
I1
tp5931
sS'is,required'
p5932
(F1
F0.00076452599388379206
I0
I1
I-1
tp5933
sS'tst,in'
p5934
(F1
F0.00076452599388379206
I0
I1
I-1
tp5935
sS'premedications,or'
p5936
(F1
F0.00076452599388379206
I0
I1
I-1
tp5937
sS'mitotane,has'
p5938
(F1
F0.00076452599388379206
I1
I0
I1
tp5939
sS'required,for'
p5940
(F1
F0.00076452599388379206
I0
I1
I-1
tp5941
sS'showed,that'
p5942
(F1
F0.0022935779816513763
I0
I3
I-3
tp5943
sS'of,potentiating'
p5944
(F1
F0.00076452599388379206
I1
I0
I1
tp5945
sS'limited,evidence'
p5946
(F1
F0.00076452599388379206
I1
I0
I1
tp5947
sS'cerezyme,by'
p5948
(F1
F0.00076452599388379206
I1
I0
I1
tp5949
sS'alone,and'
p5950
(F1
F0.00076452599388379206
I0
I1
I-1
tp5951
sS'which,induces'
p5952
(F1
F0.0015290519877675841
I0
I2
I-2
tp5953
sS'an,antiproliferative'
p5954
(F1
F0.00076452599388379206
I1
I0
I1
tp5955
sS'as,determined'
p5956
(F1
F0.00076452599388379206
I0
I1
I-1
tp5957
sS'ssris,and'
p5958
(F1
F0.00076452599388379206
I0
I1
I-1
tp5959
sS'crm197,on'
p5960
(F1
F0.00076452599388379206
I0
I1
I-1
tp5961
sS'terfenadine,and'
p5962
(F1
F0.00076452599388379206
I1
I0
I1
tp5963
sS'of,adrenergic'
p5964
(F1
F0.0015290519877675841
I2
I0
I2
tp5965
sS'clinically-relevant,interaction'
p5966
(F1
F0.00076452599388379206
I0
I1
I-1
tp5967
sS'be,slowly'
p5968
(F1
F0.00076452599388379206
I0
I1
I-1
tp5969
sS'auc0-,since'
p5970
(F1
F0.00076452599388379206
I1
I0
I1
tp5971
sS'patients,chronically'
p5972
(F1
F0.00076452599388379206
I1
I0
I1
tp5973
sS'tetrahydropyridine,injections'
p5974
(F1
F0.00076452599388379206
I0
I1
I-1
tp5975
sS'any,of'
p5976
(F1
F0.0022935779816513763
I0
I3
I-3
tp5977
sS'the,average'
p5978
(F1
F0.00076452599388379206
I0
I1
I-1
tp5979
sS'this,medication'
p5980
(F1
F0.00076452599388379206
I0
I1
I-1
tp5981
sS'healthy,adults'
p5982
(F1
F0.00076452599388379206
I1
I0
I1
tp5983
sS'thus,the'
p5984
(F1
F0.00076452599388379206
I1
I0
I1
tp5985
sS'to,many'
p5986
(F1
F0.00076452599388379206
I0
I1
I-1
tp5987
sS'too,great'
p5988
(F1
F0.00076452599388379206
I1
I0
I1
tp5989
sS'a,greater'
p5990
(F1
F0.00076452599388379206
I0
I1
I-1
tp5991
sS'of,enhanced'
p5992
(F1
F0.0015290519877675841
I2
I0
I2
tp5993
sS'depression,does'
p5994
(F1
F0.00076452599388379206
I0
I1
I-1
tp5995
sS'reduced,in'
p5996
(F1
F0.0022935779816513763
I3
I0
I3
tp5997
sS'cancer,especially'
p5998
(F1
F0.00076452599388379206
I1
I0
I1
tp5999
sS'in,no'
p6000
(F1
F0.00076452599388379206
I0
I1
I-1
tp6001
sS'and,effectiveness'
p6002
(F1
F0.00076452599388379206
I0
I1
I-1
tp6003
sS'the,child'
p6004
(F1
F0.00076452599388379206
I0
I1
I-1
tp6005
sS'cimetidine,cimetidine'
p6006
(F1
F0.00076452599388379206
I1
I0
I1
tp6007
sS'was,similar'
p6008
(F1
F0.00076452599388379206
I0
I1
I-1
tp6009
sS'pharmacokinetic,and'
p6010
(F1
F0.00076452599388379206
I0
I1
I-1
tp6011
sS'severe,agitation'
p6012
(F1
F0.00076452599388379206
I1
I0
I1
tp6013
sS'an,oral'
p6014
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp6015
sS'carcinogenesis,mutagenesis'
p6016
(F1
F0.00076452599388379206
I0
I1
I-1
tp6017
sS'altered,by'
p6018
(F0
F0
I1
I1
I0
tp6019
sS'the,proton'
p6020
(F1
F0.00076452599388379206
I0
I1
I-1
tp6021
sS'and,sympathomimetic'
p6022
(F1
F0.0015290519877675841
I2
I0
I2
tp6023
sS'interactions,concomitant'
p6024
(F1
F0.00076452599388379206
I1
I0
I1
tp6025
sS'to,cause'
p6026
(F0
F0
I1
I1
I0
tp6027
sS'your,doctor'
p6028
(F1
F0.00076452599388379206
I0
I1
I-1
tp6029
sS'given,by'
p6030
(F1
F0.00076452599388379206
I0
I1
I-1
tp6031
sS'was,taking'
p6032
(F1
F0.00076452599388379206
I0
I1
I-1
tp6033
sS'these,products'
p6034
(F1
F0.00076452599388379206
I1
I0
I1
tp6035
sS'have,beneficial'
p6036
(F1
F0.00076452599388379206
I1
I0
I1
tp6037
sS'of,cytochromes'
p6038
(F1
F0.00076452599388379206
I0
I1
I-1
tp6039
sS'anticoagulant,effect'
p6040
(F1
F0.0015290519877675841
I0
I2
I-2
tp6041
sS'when,compared'
p6042
(F1
F0.00076452599388379206
I1
I0
I1
tp6043
sS'agents,that'
p6044
(F1
F0.0038226299694189602
I5
I0
I5
tp6045
sS'its,effects'
p6046
(F1
F0.00076452599388379206
I1
I0
I1
tp6047
sS'study,the'
p6048
(F1
F0.0022935779816513763
I0
I3
I-3
tp6049
sS'downward,adjustment'
p6050
(F1
F0.00076452599388379206
I1
I0
I1
tp6051
sS'tranquilizers,sedative-hypnotics'
p6052
(F1
F0.00076452599388379206
I1
I0
I1
tp6053
sS'antidepressant,such'
p6054
(F1
F0.00076452599388379206
I0
I1
I-1
tp6055
sS'and,foods'
p6056
(F1
F0.00076452599388379206
I1
I0
I1
tp6057
sS'and,days'
p6058
(F1
F0.0022935779816513763
I3
I0
I3
tp6059
sS'of,dtic'
p6060
(F1
F0.00076452599388379206
I0
I1
I-1
tp6061
sS'to,adult'
p6062
(F1
F0.00076452599388379206
I0
I1
I-1
tp6063
sS'qt,were'
p6064
(F1
F0.00076452599388379206
I0
I1
I-1
tp6065
sS'losses,of'
p6066
(F1
F0.00076452599388379206
I1
I0
I1
tp6067
sS'cause,neurologic'
p6068
(F1
F0.00076452599388379206
I1
I0
I1
tp6069
sS'adolescent,rats'
p6070
(F1
F0.00076452599388379206
I0
I1
I-1
tp6071
sS'of,demser'
p6072
(F1
F0.00076452599388379206
I1
I0
I1
tp6073
sS'solid,tumors'
p6074
(F1
F0.00076452599388379206
I0
I1
I-1
tp6075
sS'post-mortem,stereological'
p6076
(F1
F0.00076452599388379206
I1
I0
I1
tp6077
sS'with,phentermine'
p6078
(F1
F0.00076452599388379206
I1
I0
I1
tp6079
sS'or,timing'
p6080
(F1
F0.00076452599388379206
I1
I0
I1
tp6081
sS'anticoagulants,anabolic'
p6082
(F1
F0.00076452599388379206
I1
I0
I1
tp6083
sS'use,program'
p6084
(F1
F0.00076452599388379206
I0
I1
I-1
tp6085
sS'the,coadministered'
p6086
(F1
F0.00076452599388379206
I0
I1
I-1
tp6087
sS'or,precipitate'
p6088
(F1
F0.00076452599388379206
I1
I0
I1
tp6089
sS'greater,with'
p6090
(F1
F0.00076452599388379206
I1
I0
I1
tp6091
sS'tartrate,on'
p6092
(F1
F0.00076452599388379206
I0
I1
I-1
tp6093
sS'receiving,methadone-maintenance'
p6094
(F1
F0.00076452599388379206
I1
I0
I1
tp6095
sS'including,a'
p6096
(F1
F0.00076452599388379206
I0
I1
I-1
tp6097
sS'tolectin,or'
p6098
(F1
F0.00076452599388379206
I0
I1
I-1
tp6099
sS'metabolism,occurs'
p6100
(F1
F0.00076452599388379206
I1
I0
I1
tp6101
sS'the,safety'
p6102
(F1
F0.0022935779816513763
I0
I3
I-3
tp6103
sS'days,after'
p6104
(F1
F0.00076452599388379206
I1
I0
I1
tp6105
sS'of,tobi'
p6106
(F1
F0.00076452599388379206
I1
I0
I1
tp6107
sS'these,data'
p6108
(F1
F0.00076452599388379206
I1
I0
I1
tp6109
sS'reduced,approximately'
p6110
(F0
F0
I1
I1
I0
tp6111
sS'skills,produced'
p6112
(F1
F0.0015290519877675841
I2
I0
I2
tp6113
sS'incubation,schedules'
p6114
(F0
F0
I1
I1
I0
tp6115
sS'are,administered'
p6116
(F1
F0.00076452599388379206
I1
I0
I1
tp6117
sS'p450,cyp'
p6118
(F1
F0.00076452599388379206
I0
I1
I-1
tp6119
sS'when,those'
p6120
(F1
F0.00076452599388379206
I1
I0
I1
tp6121
sS'paliperidone,is'
p6122
(F1
F0.0015290519877675841
I0
I2
I-2
tp6123
sS'and,pharmacodynamic'
p6124
(F1
F0.00076452599388379206
I0
I1
I-1
tp6125
sS'who,take'
p6126
(F1
F0.00076452599388379206
I1
I0
I1
tp6127
sS'blockers,may'
p6128
(F1
F0.00076452599388379206
I1
I0
I1
tp6129
sS'of,ziagen'
p6130
(F1
F0.00076452599388379206
I1
I0
I1
tp6131
sS'observed,at'
p6132
(F0
F0
I1
I1
I0
tp6133
sS'inhibits,the'
p6134
(F1
F0.0030581039755351682
I4
I0
I4
tp6135
sS'stronger,of'
p6136
(F1
F0.00076452599388379206
I0
I1
I-1
tp6137
sS'dosing,with'
p6138
(F1
F0.00076452599388379206
I1
I0
I1
tp6139
sS'levels,reports'
p6140
(F1
F0.00076452599388379206
I1
I0
I1
tp6141
sS'isolates,of'
p6142
(F1
F0.0015290519877675841
I0
I2
I-2
tp6143
sS'after,treatment'
p6144
(F1
F0.00076452599388379206
I0
I1
I-1
tp6145
sS'is,due'
p6146
(F1
F0.00076452599388379206
I1
I0
I1
tp6147
sS'would,be'
p6148
(F0
F0
I1
I1
I0
tp6149
sS'and,eg'
p6150
(F1
F0.00076452599388379206
I0
I1
I-1
tp6151
sS'methyl-4,phenyl-1'
p6152
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp6153
sS'catecholamines,levels'
p6154
(F1
F0.00076452599388379206
I0
I1
I-1
tp6155
sS'a,synergistic'
p6156
(F1
F0.00076452599388379206
I1
I0
I1
tp6157
sS'female,rats'
p6158
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp6159
sS'mpag,hydrolysis'
p6160
(F1
F0.00076452599388379206
I0
I1
I-1
tp6161
sS'reduced,absorption'
p6162
(F1
F0.00076452599388379206
I1
I0
I1
tp6163
sS'reported,when'
p6164
(F0
F0
I1
I1
I0
tp6165
sS'all,methyl-4'
p6166
(F1
F0.00076452599388379206
I1
I0
I1
tp6167
sS'cimetidine,mg'
p6168
(F1
F0.00076452599388379206
I1
I0
I1
tp6169
sS'as,cana'
p6170
(F1
F0.00076452599388379206
I1
I0
I1
tp6171
sS'drug,concentration'
p6172
(F1
F0.00076452599388379206
I1
I0
I1
tp6173
sS'male,rats'
p6174
(F1
F0.00076452599388379206
I0
I1
I-1
tp6175
sS'inhibitors,macrolide'
p6176
(F1
F0.00076452599388379206
I0
I1
I-1
tp6177
sS'mean,peak'
p6178
(F1
F0.00076452599388379206
I1
I0
I1
tp6179
sS'the,mexitil'
p6180
(F1
F0.00076452599388379206
I1
I0
I1
tp6181
sS'parathyroidism,causes'
p6182
(F1
F0.00076452599388379206
I0
I1
I-1
tp6183
sS'may,predispose'
p6184
(F1
F0.00076452599388379206
I1
I0
I1
tp6185
sS'of,hcl'
p6186
(F1
F0.00076452599388379206
I1
I0
I1
tp6187
sS'tetrahydropyridine,methyl-1'
p6188
(F0.5
F0.0015290519877675841
I3
I1
I2
tp6189
sS'of,was'
p6190
(F0.20000000000000001
F0.0015290519877675841
I6
I4
I2
tp6191
sS'for,two'
p6192
(F1
F0.00076452599388379206
I1
I0
I1
tp6193
sS'and,anesthetic'
p6194
(F1
F0.00076452599388379206
I1
I0
I1
tp6195
sS'to,ng'
p6196
(F1
F0.00076452599388379206
I1
I0
I1
tp6197
sS'of,but'
p6198
(F1
F0.0015290519877675841
I2
I0
I2
tp6199
sS'of,fat-soluble'
p6200
(F1
F0.00076452599388379206
I1
I0
I1
tp6201
sS'other,nsaids'
p6202
(F1
F0.0015290519877675841
I2
I0
I2
tp6203
sS'demonstrated,a'
p6204
(F1
F0.00076452599388379206
I0
I1
I-1
tp6205
sS'that,produced'
p6206
(F1
F0.00076452599388379206
I0
I1
I-1
tp6207
sS'anticipated,and'
p6208
(F1
F0.00076452599388379206
I1
I0
I1
tp6209
sS'render,oral'
p6210
(F1
F0.0015290519877675841
I2
I0
I2
tp6211
sS'using,a'
p6212
(F1
F0.0015290519877675841
I0
I2
I-2
tp6213
sS'pending,full'
p6214
(F1
F0.0015290519877675841
I2
I0
I2
tp6215
sS'constipation,and'
p6216
(F1
F0.00076452599388379206
I1
I0
I1
tp6217
sS'significant,change'
p6218
(F1
F0.0015290519877675841
I0
I2
I-2
tp6219
sS'cylert,with'
p6220
(F1
F0.00076452599388379206
I0
I1
I-1
tp6221
sS'group,drugs'
p6222
(F1
F0.00076452599388379206
I0
I1
I-1
tp6223
sS'because,is'
p6224
(F1
F0.0015290519877675841
I0
I2
I-2
tp6225
sS'because,it'
p6226
(F0
F0
I1
I1
I0
tp6227
sS'days,following'
p6228
(F1
F0.0015290519877675841
I2
I0
I2
tp6229
sS'a,statistically'
p6230
(F1
F0.00076452599388379206
I1
I0
I1
tp6231
sS'active,tubular'
p6232
(F1
F0.0022935779816513763
I3
I0
I3
tp6233
sS'days,to'
p6234
(F1
F0.0015290519877675841
I0
I2
I-2
tp6235
sS'medications,may'
p6236
(F1
F0.00076452599388379206
I1
I0
I1
tp6237
sS'only,and'
p6238
(F1
F0.00076452599388379206
I0
I1
I-1
tp6239
sS'and,adjoining'
p6240
(F1
F0.00076452599388379206
I1
I0
I1
tp6241
sS'in,elevated'
p6242
(F1
F0.00076452599388379206
I1
I0
I1
tp6243
sS'kept,in'
p6244
(F0
F0
I1
I1
I0
tp6245
sS'effect,in'
p6246
(F1
F0.00076452599388379206
I0
I1
I-1
tp6247
sS'or,intravenous'
p6248
(F1
F0.00076452599388379206
I1
I0
I1
tp6249
sS'is,used'
p6250
(F1
F0.0022935779816513763
I3
I0
I3
tp6251
sS'relaxants,inhalational'
p6252
(F1
F0.00076452599388379206
I0
I1
I-1
tp6253
sS'in,some'
p6254
(F0
F0
I2
I2
I0
tp6255
sS'by,either'
p6256
(F1
F0.00076452599388379206
I1
I0
I1
tp6257
sS'or,ci'
p6258
(F1
F0.00076452599388379206
I1
I0
I1
tp6259
sS'avian,influenza'
p6260
(F1
F0.00076452599388379206
I0
I1
I-1
tp6261
sS'weight,in'
p6262
(F1
F0.00076452599388379206
I0
I1
I-1
tp6263
sS'a,mechanism'
p6264
(F1
F0.00076452599388379206
I1
I0
I1
tp6265
sS'study,investigates'
p6266
(F1
F0.00076452599388379206
I0
I1
I-1
tp6267
sS'reverse,the'
p6268
(F1
F0.00076452599388379206
I1
I0
I1
tp6269
sS'in,chickens'
p6270
(F1
F0.00076452599388379206
I0
I1
I-1
tp6271
sS'these,or'
p6272
(F1
F0.00076452599388379206
I1
I0
I1
tp6273
sS'succinylcholine-facilitated,tracheal'
p6274
(F1
F0.00076452599388379206
I0
I1
I-1
tp6275
sS'vanillylmandelic,acid'
p6276
(F1
F0.00076452599388379206
I0
I1
I-1
tp6277
sS'plasma,protein'
p6278
(F1
F0.00076452599388379206
I0
I1
I-1
tp6279
sS'toxicity,of'
p6280
(F0
F0
I1
I1
I0
tp6281
sS'sunitinib,exhibited'
p6282
(F1
F0.00076452599388379206
I0
I1
I-1
tp6283
sS'mivacron,before'
p6284
(F1
F0.00076452599388379206
I0
I1
I-1
tp6285
sS'high,blood'
p6286
(F1
F0.00076452599388379206
I0
I1
I-1
tp6287
sS'or,because'
p6288
(F1
F0.00076452599388379206
I1
I0
I1
tp6289
sS'the,risk'
p6290
(F0.42857142857142855
F0.0045871559633027525
I10
I4
I6
tp6291
sS'although,not'
p6292
(F1
F0.00076452599388379206
I1
I0
I1
tp6293
sS'a,test'
p6294
(F1
F0.00076452599388379206
I0
I1
I-1
tp6295
sS'sirnas,or'
p6296
(F1
F0.00076452599388379206
I1
I0
I1
tp6297
sS'phenyl-1,tetrahydropyridine-induced'
p6298
(F1
F0.00076452599388379206
I1
I0
I1
tp6299
sS'mexitil,does'
p6300
(F1
F0.00076452599388379206
I1
I0
I1
tp6301
sS'by,with'
p6302
(F1
F0.00076452599388379206
I1
I0
I1
tp6303
sS'and,tyrosine'
p6304
(F1
F0.00076452599388379206
I1
I0
I1
tp6305
sS'supplemental,analgesic'
p6306
(F1
F0.00076452599388379206
I1
I0
I1
tp6307
sS'study,at'
p6308
(F1
F0.00076452599388379206
I1
I0
I1
tp6309
sS'of,declining'
p6310
(F1
F0.00076452599388379206
I1
I0
I1
tp6311
sS'observations,were'
p6312
(F1
F0.00076452599388379206
I1
I0
I1
tp6313
sS'and,sirna'
p6314
(F1
F0.00076452599388379206
I1
I0
I1
tp6315
sS'nephrotoxicity,in'
p6316
(F1
F0.00076452599388379206
I1
I0
I1
tp6317
sS'drugs,which'
p6318
(F1
F0.0022935779816513763
I3
I0
I3
tp6319
sS'mg,did'
p6320
(F1
F0.00076452599388379206
I0
I1
I-1
tp6321
sS'is,initiated'
p6322
(F0
F0
I1
I1
I0
tp6323
sS'is,evidence'
p6324
(F1
F0.0015290519877675841
I2
I0
I2
tp6325
sS'with,ace'
p6326
(F1
F0.00076452599388379206
I1
I0
I1
tp6327
sS'lamisil,tablets'
p6328
(F1
F0.00076452599388379206
I1
I0
I1
tp6329
sS'or,agents'
p6330
(F1
F0.00076452599388379206
I1
I0
I1
tp6331
sS'also,been'
p6332
(F1
F0.00076452599388379206
I1
I0
I1
tp6333
sS'plus,enhanced'
p6334
(F1
F0.00076452599388379206
I1
I0
I1
tp6335
sS'for,weeks'
p6336
(F1
F0.00076452599388379206
I1
I0
I1
tp6337
sS'acid,together'
p6338
(F1
F0.00076452599388379206
I1
I0
I1
tp6339
sS'a,corresponding'
p6340
(F1
F0.00076452599388379206
I1
I0
I1
tp6341
sS'vectors,and'
p6342
(F1
F0.00076452599388379206
I0
I1
I-1
tp6343
sS'cause,serious'
p6344
(F1
F0.0015290519877675841
I2
I0
I2
tp6345
sS'hydroxychloroquine,sulfate'
p6346
(F1
F0.00076452599388379206
I0
I1
I-1
tp6347
sS'liver,has'
p6348
(F1
F0.00076452599388379206
I1
I0
I1
tp6349
sS'enhanced,time'
p6350
(F1
F0.00076452599388379206
I0
I1
I-1
tp6351
sS'variety,of'
p6352
(F1
F0.0015290519877675841
I0
I2
I-2
tp6353
sS'new,medication'
p6354
(F1
F0.00076452599388379206
I1
I0
I1
tp6355
sS'and,self'
p6356
(F1
F0.00076452599388379206
I1
I0
I1
tp6357
sS'kg,with'
p6358
(F1
F0.00076452599388379206
I1
I0
I1
tp6359
sS'a,enzyme'
p6360
(F1
F0.00076452599388379206
I1
I0
I1
tp6361
sS'the,p'
p6362
(F0
F0
I1
I1
I0
tp6363
sS'exposure,the'
p6364
(F1
F0.00076452599388379206
I1
I0
I1
tp6365
sS'capsules,and'
p6366
(F1
F0.00076452599388379206
I0
I1
I-1
tp6367
sS'potassium-sparing,and'
p6368
(F1
F0.00076452599388379206
I0
I1
I-1
tp6369
sS'system,may'
p6370
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6371
sS'chemotherapy,in'
p6372
(F1
F0.00076452599388379206
I1
I0
I1
tp6373
sS'the,c'
p6374
(F1
F0.00076452599388379206
I1
I0
I1
tp6375
sS'effect,was'
p6376
(F1
F0.00076452599388379206
I0
I1
I-1
tp6377
sS'receptor,antagonist'
p6378
(F0
F0
I1
I1
I0
tp6379
sS'females,times'
p6380
(F1
F0.00076452599388379206
I0
I1
I-1
tp6381
sS'hepg2,mcf7'
p6382
(F1
F0.00076452599388379206
I0
I1
I-1
tp6383
sS'target,for'
p6384
(F1
F0.00076452599388379206
I0
I1
I-1
tp6385
sS'been,used'
p6386
(F1
F0.0038226299694189602
I0
I5
I-5
tp6387
sS'cyp2d6,and'
p6388
(F1
F0.00076452599388379206
I0
I1
I-1
tp6389
sS'potentiation,of'
p6390
(F0
F0
I1
I1
I0
tp6391
sS'fewer,colonies'
p6392
(F1
F0.00076452599388379206
I1
I0
I1
tp6393
sS'containing,cdna'
p6394
(F1
F0.00076452599388379206
I0
I1
I-1
tp6395
sS'and,mpag'
p6396
(F1
F0.00076452599388379206
I0
I1
I-1
tp6397
sS'may,extend'
p6398
(F1
F0.00076452599388379206
I1
I0
I1
tp6399
sS'inr,and'
p6400
(F1
F0.0022935779816513763
I3
I0
I3
tp6401
sS'in,basic'
p6402
(F1
F0.00076452599388379206
I1
I0
I1
tp6403
sS'peripheral,adrenergic'
p6404
(F1
F0.00076452599388379206
I0
I1
I-1
tp6405
sS'appear,as'
p6406
(F1
F0.00076452599388379206
I0
I1
I-1
tp6407
sS'similar,neuromuscular'
p6408
(F1
F0.00076452599388379206
I1
I0
I1
tp6409
sS'abacavir,has'
p6410
(F1
F0.00076452599388379206
I0
I1
I-1
tp6411
sS'recombinant,human'
p6412
(F1
F0.00076452599388379206
I1
I0
I1
tp6413
sS'separate,occasions'
p6414
(F1
F0.00076452599388379206
I1
I0
I1
tp6415
sS'not,always'
p6416
(F1
F0.00076452599388379206
I0
I1
I-1
tp6417
sS'receiving,indicating'
p6418
(F1
F0.00076452599388379206
I0
I1
I-1
tp6419
sS'concentrations,are'
p6420
(F1
F0.00076452599388379206
I0
I1
I-1
tp6421
sS'also,increased'
p6422
(F1
F0.00076452599388379206
I1
I0
I1
tp6423
sS'they,should'
p6424
(F1
F0.0015290519877675841
I2
I0
I2
tp6425
sS'and,diminishing'
p6426
(F1
F0.00076452599388379206
I1
I0
I1
tp6427
sS'same,subjects'
p6428
(F1
F0.00076452599388379206
I1
I0
I1
tp6429
sS'prolonged,prothrombin'
p6430
(F1
F0.00076452599388379206
I1
I0
I1
tp6431
sS'additive,sedative'
p6432
(F1
F0.0015290519877675841
I2
I0
I2
tp6433
sS'of,hospitalization'
p6434
(F0
F0
I1
I1
I0
tp6435
sS'vivo,biotransformation'
p6436
(F1
F0.00076452599388379206
I0
I1
I-1
tp6437
sS'matched,tacrolimus-treated'
p6438
(F1
F0.00076452599388379206
I1
I0
I1
tp6439
sS'which,corresponded'
p6440
(F1
F0.00076452599388379206
I0
I1
I-1
tp6441
sS'by,commonly'
p6442
(F1
F0.00076452599388379206
I0
I1
I-1
tp6443
sS'enzyme,they'
p6444
(F1
F0.00076452599388379206
I1
I0
I1
tp6445
sS'receiving,low-dose'
p6446
(F1
F0.00076452599388379206
I0
I1
I-1
tp6447
sS'if,you'
p6448
(F0
F0
I1
I1
I0
tp6449
sS'maximum,g'
p6450
(F1
F0.00076452599388379206
I0
I1
I-1
tp6451
sS'and,rare'
p6452
(F1
F0.00076452599388379206
I1
I0
I1
tp6453
sS'having,tubal'
p6454
(F1
F0.00076452599388379206
I1
I0
I1
tp6455
sS'not,only'
p6456
(F1
F0.00076452599388379206
I1
I0
I1
tp6457
sS'of,her2-positive'
p6458
(F1
F0.00076452599388379206
I1
I0
I1
tp6459
sS'which,limits'
p6460
(F1
F0.00076452599388379206
I1
I0
I1
tp6461
sS'studies,documenting'
p6462
(F1
F0.00076452599388379206
I0
I1
I-1
tp6463
sS'rat,liver'
p6464
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6465
sS'antinociception,and'
p6466
(F1
F0.0015290519877675841
I0
I2
I-2
tp6467
sS'rimantadine,hcl'
p6468
(F1
F0.0015290519877675841
I0
I2
I-2
tp6469
sS'altered,the'
p6470
(F1
F0.00076452599388379206
I1
I0
I1
tp6471
sS'enhanced,serum'
p6472
(F1
F0.00076452599388379206
I1
I0
I1
tp6473
sS'with,coadministration'
p6474
(F1
F0.00076452599388379206
I1
I0
I1
tp6475
sS'rifampin,theophylline'
p6476
(F1
F0.00076452599388379206
I1
I0
I1
tp6477
sS'usp,modified'
p6478
(F1
F0.00076452599388379206
I0
I1
I-1
tp6479
sS'not,yet'
p6480
(F1
F0.00076452599388379206
I0
I1
I-1
tp6481
sS'revealed,the'
p6482
(F1
F0.00076452599388379206
I0
I1
I-1
tp6483
sS'with,refer'
p6484
(F1
F0.00076452599388379206
I0
I1
I-1
tp6485
sS'their,coexistence'
p6486
(F1
F0.00076452599388379206
I0
I1
I-1
tp6487
sS'small,bowel'
p6488
(F1
F0.00076452599388379206
I1
I0
I1
tp6489
sS'acetate,is'
p6490
(F1
F0.00076452599388379206
I0
I1
I-1
tp6491
sS'kg,administered'
p6492
(F1
F0.00076452599388379206
I0
I1
I-1
tp6493
sS'hydrochloride,and'
p6494
(F1
F0.0030581039755351682
I4
I0
I4
tp6495
sS'oral,by'
p6496
(F1
F0.00076452599388379206
I1
I0
I1
tp6497
sS'and,fold'
p6498
(F1
F0.00076452599388379206
I1
I0
I1
tp6499
sS'food,interaction'
p6500
(F1
F0.00076452599388379206
I0
I1
I-1
tp6501
sS'the,co-administration'
p6502
(F1
F0.00076452599388379206
I1
I0
I1
tp6503
sS'intensity,measurements'
p6504
(F1
F0.00076452599388379206
I1
I0
I1
tp6505
sS'receiving,proton'
p6506
(F1
F0.00076452599388379206
I1
I0
I1
tp6507
sS'formal,drug'
p6508
(F1
F0.00076452599388379206
I0
I1
I-1
tp6509
sS'we,suggest'
p6510
(F1
F0.00076452599388379206
I1
I0
I1
tp6511
sS'with,significant'
p6512
(F1
F0.00076452599388379206
I1
I0
I1
tp6513
sS'renal,impairment'
p6514
(F1
F0.00076452599388379206
I0
I1
I-1
tp6515
sS'that,plasma'
p6516
(F1
F0.00076452599388379206
I1
I0
I1
tp6517
sS'dosed,to'
p6518
(F1
F0.0015290519877675841
I0
I2
I-2
tp6519
sS'whom,and'
p6520
(F1
F0.0022935779816513763
I3
I0
I3
tp6521
sS'effect,relating'
p6522
(F1
F0.00076452599388379206
I1
I0
I1
tp6523
sS'interaction,and'
p6524
(F1
F0.00076452599388379206
I0
I1
I-1
tp6525
sS'supervision,should'
p6526
(F1
F0.00076452599388379206
I1
I0
I1
tp6527
sS'and,leading'
p6528
(F1
F0.00076452599388379206
I1
I0
I1
tp6529
sS'agent,is'
p6530
(F1
F0.00076452599388379206
I1
I0
I1
tp6531
sS'more,potent'
p6532
(F1
F0.00076452599388379206
I0
I1
I-1
tp6533
sS'p,o'
p6534
(F1
F0.00076452599388379206
I0
I1
I-1
tp6535
sS'p450,system'
p6536
(F1
F0.0015290519877675841
I2
I0
I2
tp6537
sS'the,peak'
p6538
(F1
F0.00076452599388379206
I1
I0
I1
tp6539
sS'ssri,such'
p6540
(F1
F0.00076452599388379206
I1
I0
I1
tp6541
sS'be,anticipated'
p6542
(F1
F0.00076452599388379206
I1
I0
I1
tp6543
sS'tumor,growth'
p6544
(F1
F0.00076452599388379206
I1
I0
I1
tp6545
sS'and,duration'
p6546
(F1
F0.00076452599388379206
I1
I0
I1
tp6547
sS'observed,closely'
p6548
(F1
F0.00076452599388379206
I1
I0
I1
tp6549
sS'the,university'
p6550
(F1
F0.00076452599388379206
I1
I0
I1
tp6551
sS'case,to'
p6552
(F1
F0.00076452599388379206
I1
I0
I1
tp6553
sS'arrested,cell'
p6554
(F1
F0.00076452599388379206
I0
I1
I-1
tp6555
sS'a,markedly'
p6556
(F1
F0.00076452599388379206
I1
I0
I1
tp6557
sS'difference,in'
p6558
(F1
F0.00076452599388379206
I0
I1
I-1
tp6559
sS'myelotoxicity,bone'
p6560
(F1
F0.00076452599388379206
I1
I0
I1
tp6561
sS'than,those'
p6562
(F1
F0.00076452599388379206
I0
I1
I-1
tp6563
sS'evidence,suggests'
p6564
(F1
F0.0015290519877675841
I2
I0
I2
tp6565
sS'potential,effects'
p6566
(F1
F0.00076452599388379206
I0
I1
I-1
tp6567
sS'inhibition,mtt'
p6568
(F1
F0.00076452599388379206
I0
I1
I-1
tp6569
sS'closely,monitor'
p6570
(F1
F0.0015290519877675841
I2
I0
I2
tp6571
sS'of,treatment'
p6572
(F0
F0
I1
I1
I0
tp6573
sS'purported,to'
p6574
(F1
F0.00076452599388379206
I1
I0
I1
tp6575
sS'between,lamisil'
p6576
(F1
F0.00076452599388379206
I1
I0
I1
tp6577
sS'with,depo-subq'
p6578
(F1
F0.00076452599388379206
I1
I0
I1
tp6579
sS'second,herceptin'
p6580
(F1
F0.00076452599388379206
I1
I0
I1
tp6581
sS'may,lower'
p6582
(F1
F0.00076452599388379206
I1
I0
I1
tp6583
sS'cp450,mediated'
p6584
(F1
F0.00076452599388379206
I1
I0
I1
tp6585
sS'feldene,since'
p6586
(F1
F0.00076452599388379206
I1
I0
I1
tp6587
sS'state,dosing'
p6588
(F1
F0.00076452599388379206
I0
I1
I-1
tp6589
sS'isozymes,have'
p6590
(F1
F0.00076452599388379206
I1
I0
I1
tp6591
sS'belladonna,alkaloids'
p6592
(F1
F0.00076452599388379206
I0
I1
I-1
tp6593
sS'and,between'
p6594
(F1
F0.00076452599388379206
I1
I0
I1
tp6595
sS'and,inr'
p6596
(F1
F0.00076452599388379206
I1
I0
I1
tp6597
sS'and,arrested'
p6598
(F1
F0.00076452599388379206
I0
I1
I-1
tp6599
sS'when,or'
p6600
(F1
F0.00076452599388379206
I1
I0
I1
tp6601
sS'an,inducer'
p6602
(F1
F0.00076452599388379206
I1
I0
I1
tp6603
sS'achieve,the'
p6604
(F1
F0.0015290519877675841
I2
I0
I2
tp6605
sS'is,additive'
p6606
(F1
F0.00076452599388379206
I1
I0
I1
tp6607
sS'stable,doses'
p6608
(F1
F0.00076452599388379206
I1
I0
I1
tp6609
sS'greater,detail'
p6610
(F1
F0.00076452599388379206
I1
I0
I1
tp6611
sS'inhaled,other'
p6612
(F1
F0.00076452599388379206
I1
I0
I1
tp6613
sS'control,at'
p6614
(F1
F0.00076452599388379206
I0
I1
I-1
tp6615
sS'and,incoordination'
p6616
(F1
F0.00076452599388379206
I1
I0
I1
tp6617
sS'reduces,methyl-4'
p6618
(F1
F0.00076452599388379206
I1
I0
I1
tp6619
sS'extracellular,matrix'
p6620
(F1
F0.00076452599388379206
I0
I1
I-1
tp6621
sS'the,breast'
p6622
(F1
F0.00076452599388379206
I1
I0
I1
tp6623
sS'absorption,by'
p6624
(F1
F0.00076452599388379206
I1
I0
I1
tp6625
sS'cisapride,other'
p6626
(F1
F0.00076452599388379206
I1
I0
I1
tp6627
sS'vaccines,by'
p6628
(F1
F0.00076452599388379206
I0
I1
I-1
tp6629
sS'although,this'
p6630
(F0
F0
I1
I1
I0
tp6631
sS'this,crossover'
p6632
(F1
F0.00076452599388379206
I0
I1
I-1
tp6633
sS'be,considered'
p6634
(F0.5
F0.0015290519877675841
I3
I1
I2
tp6635
sS'influence,the'
p6636
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp6637
sS'tetracycline,a'
p6638
(F1
F0.00076452599388379206
I1
I0
I1
tp6639
sS'published,in'
p6640
(F1
F0.00076452599388379206
I1
I0
I1
tp6641
sS'significant,reduction'
p6642
(F1
F0.00076452599388379206
I1
I0
I1
tp6643
sS'shorter,time'
p6644
(F1
F0.00076452599388379206
I1
I0
I1
tp6645
sS'at,the'
p6646
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp6647
sS'than,were'
p6648
(F1
F0.00076452599388379206
I0
I1
I-1
tp6649
sS'agent,should'
p6650
(F1
F0.00076452599388379206
I1
I0
I1
tp6651
sS'cells,alone'
p6652
(F1
F0.00076452599388379206
I0
I1
I-1
tp6653
sS'normalized,ratio'
p6654
(F0
F0
I1
I1
I0
tp6655
sS'conclusive,because'
p6656
(F1
F0.00076452599388379206
I1
I0
I1
tp6657
sS'nexavar,with'
p6658
(F1
F0.00076452599388379206
I1
I0
I1
tp6659
sS'if,short-acting'
p6660
(F1
F0.00076452599388379206
I1
I0
I1
tp6661
sS'no,effect'
p6662
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp6663
sS'and,c9'
p6664
(F1
F0.00076452599388379206
I0
I1
I-1
tp6665
sS'were,required'
p6666
(F1
F0.00076452599388379206
I0
I1
I-1
tp6667
sS'neurons,was'
p6668
(F1
F0.00076452599388379206
I1
I0
I1
tp6669
sS'in,chronic'
p6670
(F1
F0.00076452599388379206
I0
I1
I-1
tp6671
sS'aimed,to'
p6672
(F1
F0.0015290519877675841
I0
I2
I-2
tp6673
sS'of,minor'
p6674
(F1
F0.00076452599388379206
I1
I0
I1
tp6675
sS'time,spent'
p6676
(F1
F0.00076452599388379206
I0
I1
I-1
tp6677
sS'chemotherapeutic,agents'
p6678
(F1
F0.00076452599388379206
I0
I1
I-1
tp6679
sS'mpa,exposure'
p6680
(F1
F0.00076452599388379206
I0
I1
I-1
tp6681
sS'produced,an'
p6682
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6683
sS'against,isolates'
p6684
(F1
F0.00076452599388379206
I0
I1
I-1
tp6685
sS'hcl,was'
p6686
(F1
F0.00076452599388379206
I1
I0
I1
tp6687
sS'to,monitor'
p6688
(F1
F0.00076452599388379206
I1
I0
I1
tp6689
sS'toxicity,may'
p6690
(F1
F0.00076452599388379206
I1
I0
I1
tp6691
sS'cyp3a,and'
p6692
(F1
F0.00076452599388379206
I1
I0
I1
tp6693
sS'zolinza,and'
p6694
(F1
F0.00076452599388379206
I1
I0
I1
tp6695
sS'extent,of'
p6696
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp6697
sS'the,decreases'
p6698
(F1
F0.00076452599388379206
I0
I1
I-1
tp6699
sS'her2,expression'
p6700
(F1
F0.00076452599388379206
I1
I0
I1
tp6701
sS'antagonist,analgesics'
p6702
(F1
F0.00076452599388379206
I1
I0
I1
tp6703
sS'ml,min'
p6704
(F1
F0.0015290519877675841
I2
I0
I2
tp6705
sS'hormone,pth'
p6706
(F1
F0.00076452599388379206
I0
I1
I-1
tp6707
sS'with,alupent'
p6708
(F1
F0.00076452599388379206
I1
I0
I1
tp6709
sS'not,occurred'
p6710
(F1
F0.00076452599388379206
I1
I0
I1
tp6711
sS'inhibitors,including'
p6712
(F1
F0.00076452599388379206
I1
I0
I1
tp6713
sS'cyp3a4,cyp2d6'
p6714
(F1
F0.00076452599388379206
I0
I1
I-1
tp6715
sS'displaced,protein-bound'
p6716
(F1
F0.00076452599388379206
I1
I0
I1
tp6717
sS'synergistic,interaction'
p6718
(F1
F0.00076452599388379206
I1
I0
I1
tp6719
sS'cyp2d6,coadministration'
p6720
(F1
F0.00076452599388379206
I0
I1
I-1
tp6721
sS'expression,at'
p6722
(F1
F0.00076452599388379206
I1
I0
I1
tp6723
sS'parameters,i'
p6724
(F1
F0.00076452599388379206
I1
I0
I1
tp6725
sS'well,as'
p6726
(F0.5
F0.0030581039755351682
I6
I2
I4
tp6727
sS'bactericidal,action'
p6728
(F1
F0.00076452599388379206
I1
I0
I1
tp6729
sS'and,formalin'
p6730
(F1
F0.00076452599388379206
I1
I0
I1
tp6731
sS'during,coadministration'
p6732
(F1
F0.00076452599388379206
I1
I0
I1
tp6733
sS'be,potentiated'
p6734
(F0.5
F0.0015290519877675841
I3
I1
I2
tp6735
sS'caution,and'
p6736
(F1
F0.0015290519877675841
I2
I0
I2
tp6737
sS'cmax,were'
p6738
(F1
F0.00076452599388379206
I1
I0
I1
tp6739
sS'reduction,of'
p6740
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp6741
sS'function,such'
p6742
(F1
F0.0015290519877675841
I2
I0
I2
tp6743
sS'n,than'
p6744
(F1
F0.00076452599388379206
I1
I0
I1
tp6745
sS'small,number'
p6746
(F1
F0.00076452599388379206
I1
I0
I1
tp6747
sS'trental,and'
p6748
(F1
F0.00076452599388379206
I1
I0
I1
tp6749
sS'mice,group'
p6750
(F1
F0.00076452599388379206
I0
I1
I-1
tp6751
sS'stupor,muscular'
p6752
(F1
F0.00076452599388379206
I1
I0
I1
tp6753
sS'interaction,should'
p6754
(F1
F0.00076452599388379206
I1
I0
I1
tp6755
sS'by,synergism'
p6756
(F1
F0.00076452599388379206
I1
I0
I1
tp6757
sS'and,zavesca'
p6758
(F1
F0.00076452599388379206
I1
I0
I1
tp6759
sS'the,sequential'
p6760
(F1
F0.0015290519877675841
I2
I0
I2
tp6761
sS'supplement,absorption'
p6762
(F1
F0.00076452599388379206
I1
I0
I1
tp6763
sS'adult,diabetic'
p6764
(F1
F0.00076452599388379206
I0
I1
I-1
tp6765
sS'because,pergolide'
p6766
(F1
F0.00076452599388379206
I0
I1
I-1
tp6767
sS'de,pointes'
p6768
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6769
sS'was,co-administered'
p6770
(F1
F0.00076452599388379206
I0
I1
I-1
tp6771
sS'disintegrating,tablets'
p6772
(F1
F0.00076452599388379206
I0
I1
I-1
tp6773
sS'for,this'
p6774
(F1
F0.0015290519877675841
I0
I2
I-2
tp6775
sS'may,not'
p6776
(F1
F0.0015290519877675841
I0
I2
I-2
tp6777
sS'agitation,in'
p6778
(F1
F0.00076452599388379206
I0
I1
I-1
tp6779
sS'interactions,occurred'
p6780
(F1
F0.00076452599388379206
I0
I1
I-1
tp6781
sS'than,treatment'
p6782
(F1
F0.00076452599388379206
I1
I0
I1
tp6783
sS'oral,alkeran'
p6784
(F1
F0.00076452599388379206
I1
I0
I1
tp6785
sS'fold,increase'
p6786
(F1
F0.0015290519877675841
I2
I0
I2
tp6787
sS'performed,until'
p6788
(F1
F0.00076452599388379206
I0
I1
I-1
tp6789
sS'cell,cycle'
p6790
(F1
F0.0015290519877675841
I0
I2
I-2
tp6791
sS'cm3,difference'
p6792
(F1
F0.00076452599388379206
I1
I0
I1
tp6793
sS'the,aruonic'
p6794
(F1
F0.00076452599388379206
I0
I1
I-1
tp6795
sS'study,and'
p6796
(F1
F0.00076452599388379206
I1
I0
I1
tp6797
sS'or,therapy'
p6798
(F1
F0.00076452599388379206
I1
I0
I1
tp6799
sS'should,be'
p6800
(F0.68571428571428572
F0.03669724770642202
I59
I11
I48
tp6801
sS'from,hypoglycemia'
p6802
(F1
F0.00076452599388379206
I1
I0
I1
tp6803
sS'that,inhibits'
p6804
(F1
F0.00076452599388379206
I1
I0
I1
tp6805
sS'in,bone'
p6806
(F1
F0.00076452599388379206
I1
I0
I1
tp6807
sS'evaluate,the'
p6808
(F1
F0.0022935779816513763
I0
I3
I-3
tp6809
sS'furthermore,we'
p6810
(F1
F0.00076452599388379206
I1
I0
I1
tp6811
sS'drug,mg'
p6812
(F1
F0.00076452599388379206
I0
I1
I-1
tp6813
sS'is,considered'
p6814
(F1
F0.00076452599388379206
I1
I0
I1
tp6815
sS'bile,acid'
p6816
(F1
F0.00076452599388379206
I1
I0
I1
tp6817
sS'oxidase,inhibitors'
p6818
(F0.5
F0.0015290519877675841
I3
I1
I2
tp6819
sS'the,extent'
p6820
(F0
F0
I1
I1
I0
tp6821
sS'oxidase,inhibitory'
p6822
(F1
F0.00076452599388379206
I1
I0
I1
tp6823
sS'agencies,state'
p6824
(F1
F0.00076452599388379206
I1
I0
I1
tp6825
sS'inhibitors,severe'
p6826
(F1
F0.00076452599388379206
I1
I0
I1
tp6827
sS'and,nutritionally-derived'
p6828
(F1
F0.00076452599388379206
I0
I1
I-1
tp6829
sS'once,weekly'
p6830
(F1
F0.00076452599388379206
I1
I0
I1
tp6831
sS'coadministration,with'
p6832
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6833
sS'mptp,x'
p6834
(F1
F0.00076452599388379206
I0
I1
I-1
tp6835
sS'tests,for'
p6836
(F1
F0.00076452599388379206
I0
I1
I-1
tp6837
sS'toxic,effects'
p6838
(F1
F0.00076452599388379206
I1
I0
I1
tp6839
sS'before,taking'
p6840
(F1
F0.00076452599388379206
I0
I1
I-1
tp6841
sS'the,vaccination'
p6842
(F1
F0.00076452599388379206
I1
I0
I1
tp6843
sS'since,is'
p6844
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp6845
sS'increased,exposure'
p6846
(F1
F0.00076452599388379206
I1
I0
I1
tp6847
sS'nondepolarizing,neuromuscular'
p6848
(F0
F0
I1
I1
I0
tp6849
sS'treatment,are'
p6850
(F1
F0.00076452599388379206
I0
I1
I-1
tp6851
sS'of,sympathomimetic'
p6852
(F1
F0.0015290519877675841
I2
I0
I2
tp6853
sS'or,enhances'
p6854
(F1
F0.00076452599388379206
I1
I0
I1
tp6855
sS'which,a'
p6856
(F1
F0.00076452599388379206
I1
I0
I1
tp6857
sS'anesthesia,or'
p6858
(F0
F0
I1
I1
I0
tp6859
sS'oral,gavage'
p6860
(F1
F0.00076452599388379206
I0
I1
I-1
tp6861
sS'the,plasma'
p6862
(F0.23076923076923078
F0.0022935779816513763
I8
I5
I3
tp6863
sS'toxicity,and'
p6864
(F1
F0.00076452599388379206
I1
I0
I1
tp6865
sS'effient,for'
p6866
(F1
F0.00076452599388379206
I0
I1
I-1
tp6867
sS'concomitant,diflucan'
p6868
(F1
F0.00076452599388379206
I1
I0
I1
tp6869
sS'decreased,following'
p6870
(F1
F0.00076452599388379206
I1
I0
I1
tp6871
sS'complete,cross-resistance'
p6872
(F1
F0.00076452599388379206
I1
I0
I1
tp6873
sS'with,lowered'
p6874
(F1
F0.00076452599388379206
I1
I0
I1
tp6875
sS'increasing,serum'
p6876
(F0
F0
I1
I1
I0
tp6877
sS'on,these'
p6878
(F0
F0
I1
I1
I0
tp6879
sS'hormone,replacement'
p6880
(F1
F0.00076452599388379206
I0
I1
I-1
tp6881
sS'university,of'
p6882
(F1
F0.00076452599388379206
I1
I0
I1
tp6883
sS'an,acute'
p6884
(F1
F0.00076452599388379206
I0
I1
I-1
tp6885
sS'absorption,when'
p6886
(F1
F0.00076452599388379206
I1
I0
I1
tp6887
sS'found,no'
p6888
(F1
F0.00076452599388379206
I0
I1
I-1
tp6889
sS'reported,previously'
p6890
(F1
F0.00076452599388379206
I0
I1
I-1
tp6891
sS'four,drugs'
p6892
(F1
F0.00076452599388379206
I1
I0
I1
tp6893
sS'adjusted,as'
p6894
(F1
F0.00076452599388379206
I1
I0
I1
tp6895
sS'findings,suggest'
p6896
(F1
F0.00076452599388379206
I1
I0
I1
tp6897
sS'from,limited'
p6898
(F1
F0.00076452599388379206
I0
I1
I-1
tp6899
sS'tested,whether'
p6900
(F1
F0.00076452599388379206
I0
I1
I-1
tp6901
sS'for,symptoms'
p6902
(F1
F0.00076452599388379206
I1
I0
I1
tp6903
sS'streptase,streptokinase'
p6904
(F0
F0
I1
I1
I0
tp6905
sS'increased,risk'
p6906
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp6907
sS'fertility,studies'
p6908
(F1
F0.00076452599388379206
I0
I1
I-1
tp6909
sS'enhanced,paclitaxel-induced'
p6910
(F1
F0.00076452599388379206
I1
I0
I1
tp6911
sS'therapeutic,actions'
p6912
(F1
F0.00076452599388379206
I1
I0
I1
tp6913
sS'a,useful'
p6914
(F1
F0.00076452599388379206
I0
I1
I-1
tp6915
sS'expected,with'
p6916
(F1
F0.00076452599388379206
I0
I1
I-1
tp6917
sS'agonists,should'
p6918
(F1
F0.00076452599388379206
I1
I0
I1
tp6919
sS'who,initiated'
p6920
(F1
F0.00076452599388379206
I1
I0
I1
tp6921
sS'has,any'
p6922
(F1
F0.00076452599388379206
I0
I1
I-1
tp6923
sS'and,skelid'
p6924
(F1
F0.00076452599388379206
I1
I0
I1
tp6925
sS'metabolism,lowering'
p6926
(F1
F0.00076452599388379206
I1
I0
I1
tp6927
sS'initiating,adjusting'
p6928
(F1
F0.00076452599388379206
I1
I0
I1
tp6929
sS'to,occur'
p6930
(F1
F0.00076452599388379206
I0
I1
I-1
tp6931
sS'n,poor'
p6932
(F1
F0.00076452599388379206
I0
I1
I-1
tp6933
sS'the,stronger'
p6934
(F1
F0.00076452599388379206
I0
I1
I-1
tp6935
sS'while,those'
p6936
(F1
F0.00076452599388379206
I1
I0
I1
tp6937
sS'laboratory,tests'
p6938
(F1
F0.00076452599388379206
I0
I1
I-1
tp6939
sS'not,itself'
p6940
(F1
F0.00076452599388379206
I1
I0
I1
tp6941
sS'x,mg'
p6942
(F1
F0.00076452599388379206
I0
I1
I-1
tp6943
sS'the,relative'
p6944
(F1
F0.00076452599388379206
I1
I0
I1
tp6945
sS'that,ritalin'
p6946
(F1
F0.00076452599388379206
I1
I0
I1
tp6947
sS'is,reduced'
p6948
(F0
F0
I1
I1
I0
tp6949
sS'with,therapeutic'
p6950
(F1
F0.00076452599388379206
I1
I0
I1
tp6951
sS'clinical,trials'
p6952
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp6953
sS'in,a'
p6954
(F0.1875
F0.0045871559633027525
I19
I13
I6
tp6955
sS'in,day'
p6956
(F1
F0.00076452599388379206
I0
I1
I-1
tp6957
sS'in,c'
p6958
(F1
F0.00076452599388379206
I1
I0
I1
tp6959
sS'a375,melanoma'
p6960
(F1
F0.00076452599388379206
I0
I1
I-1
tp6961
sS'constipation,somnolence'
p6962
(F1
F0.00076452599388379206
I1
I0
I1
tp6963
sS'stable,renal'
p6964
(F0
F0
I1
I1
I0
tp6965
sS'patients,should'
p6966
(F1
F0.0038226299694189602
I5
I0
I5
tp6967
sS'used,concurrently'
p6968
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp6969
sS'sanctura,and'
p6970
(F1
F0.00076452599388379206
I0
I1
I-1
tp6971
sS'superior,to'
p6972
(F1
F0.00076452599388379206
I1
I0
I1
tp6973
sS'for,thc'
p6974
(F1
F0.00076452599388379206
I0
I1
I-1
tp6975
sS'decline,in'
p6976
(F1
F0.00076452599388379206
I0
I1
I-1
tp6977
sS'for,the'
p6978
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp6979
sS'and,sodium'
p6980
(F1
F0.00076452599388379206
I1
I0
I1
tp6981
sS'inhibitors,other'
p6982
(F1
F0.00076452599388379206
I1
I0
I1
tp6983
sS'mutual,inhibition'
p6984
(F1
F0.00076452599388379206
I1
I0
I1
tp6985
sS'treatment,for'
p6986
(F1
F0.0015290519877675841
I0
I2
I-2
tp6987
sS'could,potentially'
p6988
(F1
F0.00076452599388379206
I1
I0
I1
tp6989
sS'study,examined'
p6990
(F1
F0.00076452599388379206
I0
I1
I-1
tp6991
sS'for,is'
p6992
(F1
F0.00076452599388379206
I1
I0
I1
tp6993
sS'benzodiazepines,oral'
p6994
(F1
F0.00076452599388379206
I1
I0
I1
tp6995
sS'levodopa,does'
p6996
(F1
F0.00076452599388379206
I0
I1
I-1
tp6997
sS'studies,as'
p6998
(F1
F0.00076452599388379206
I1
I0
I1
tp6999
sS'rate,and'
p7000
(F0
F0
I1
I1
I0
tp7001
sS'salicylates,given'
p7002
(F1
F0.00076452599388379206
I1
I0
I1
tp7003
sS'and,analogues'
p7004
(F1
F0.00076452599388379206
I1
I0
I1
tp7005
sS'rarely,to'
p7006
(F1
F0.00076452599388379206
I1
I0
I1
tp7007
sS'mivacron,may'
p7008
(F0
F0
I1
I1
I0
tp7009
sS'h2,blockers'
p7010
(F1
F0.00076452599388379206
I0
I1
I-1
tp7011
sS'potent,cyp'
p7012
(F1
F0.0015290519877675841
I0
I2
I-2
tp7013
sS'digitalis,glycoside'
p7014
(F1
F0.00076452599388379206
I0
I1
I-1
tp7015
sS'sympathomimetic,agents'
p7016
(F1
F0.00076452599388379206
I1
I0
I1
tp7017
sS'a,week'
p7018
(F1
F0.0015290519877675841
I0
I2
I-2
tp7019
sS'chronic,treatment'
p7020
(F0
F0
I1
I1
I0
tp7021
sS'than,with'
p7022
(F0
F0
I1
I1
I0
tp7023
sS'and,local'
p7024
(F1
F0.00076452599388379206
I0
I1
I-1
tp7025
sS'administering,mobic'
p7026
(F1
F0.00076452599388379206
I1
I0
I1
tp7027
sS'of,diflucan'
p7028
(F1
F0.0015290519877675841
I2
I0
I2
tp7029
sS'interactions,there'
p7030
(F1
F0.00076452599388379206
I1
I0
I1
tp7031
sS'reduced,doses'
p7032
(F1
F0.00076452599388379206
I1
I0
I1
tp7033
sS'allowing,to'
p7034
(F1
F0.00076452599388379206
I1
I0
I1
tp7035
sS'preclude,effectiveness'
p7036
(F1
F0.00076452599388379206
I1
I0
I1
tp7037
sS'tubal,pregnancies'
p7038
(F1
F0.00076452599388379206
I1
I0
I1
tp7039
sS'digoxin,meloxicam'
p7040
(F1
F0.00076452599388379206
I0
I1
I-1
tp7041
sS'and,ace'
p7042
(F1
F0.00076452599388379206
I0
I1
I-1
tp7043
sS'with,purpura'
p7044
(F1
F0.00076452599388379206
I0
I1
I-1
tp7045
sS'mean,increase'
p7046
(F1
F0.0022935779816513763
I3
I0
I3
tp7047
sS'agents,no'
p7048
(F1
F0.00076452599388379206
I0
I1
I-1
tp7049
sS'anticholinesterases,concurrent'
p7050
(F1
F0.00076452599388379206
I1
I0
I1
tp7051
sS'zetia,is'
p7052
(F1
F0.00076452599388379206
I0
I1
I-1
tp7053
sS'common,clinical'
p7054
(F1
F0.00076452599388379206
I1
I0
I1
tp7055
sS'of,thrombotic'
p7056
(F1
F0.00076452599388379206
I1
I0
I1
tp7057
sS'the,cns'
p7058
(F1
F0.0015290519877675841
I2
I0
I2
tp7059
sS'cdk1,in'
p7060
(F1
F0.00076452599388379206
I0
I1
I-1
tp7061
sS'been,administered'
p7062
(F1
F0.00076452599388379206
I0
I1
I-1
tp7063
sS'there,have'
p7064
(F0.5
F0.0030581039755351682
I6
I2
I4
tp7065
sS'child,was'
p7066
(F1
F0.00076452599388379206
I0
I1
I-1
tp7067
sS'parathyroid,hormone'
p7068
(F1
F0.0015290519877675841
I0
I2
I-2
tp7069
sS'plasma,levels'
p7070
(F1
F0.0091743119266055051
I12
I0
I12
tp7071
sS'of,decreased'
p7072
(F1
F0.0022935779816513763
I0
I3
I-3
tp7073
sS'vs,p27'
p7074
(F1
F0.00076452599388379206
I0
I1
I-1
tp7075
sS'as,an'
p7076
(F1
F0.0015290519877675841
I2
I0
I2
tp7077
sS'min,p'
p7078
(F1
F0.00076452599388379206
I1
I0
I1
tp7079
sS'vitamin,k'
p7080
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp7081
sS'be,to'
p7082
(F1
F0.00076452599388379206
I1
I0
I1
tp7083
sS'taking,or'
p7084
(F1
F0.00076452599388379206
I1
I0
I1
tp7085
sS'slowing,the'
p7086
(F1
F0.00076452599388379206
I1
I0
I1
tp7087
sS'arrythmias,typically'
p7088
(F1
F0.00076452599388379206
I1
I0
I1
tp7089
sS'is,impaired'
p7090
(F1
F0.00076452599388379206
I1
I0
I1
tp7091
sS'b,if'
p7092
(F1
F0.00076452599388379206
I0
I1
I-1
tp7093
sS'increased,odds'
p7094
(F1
F0.00076452599388379206
I1
I0
I1
tp7095
sS'evaluated,by'
p7096
(F1
F0.00076452599388379206
I1
I0
I1
tp7097
sS'appears,to'
p7098
(F1
F0.0015290519877675841
I2
I0
I2
tp7099
sS'dosage,requirements'
p7100
(F1
F0.0015290519877675841
I2
I0
I2
tp7101
sS'vitamin,d'
p7102
(F1
F0.00076452599388379206
I0
I1
I-1
tp7103
sS'hormone,control'
p7104
(F1
F0.00076452599388379206
I0
I1
I-1
tp7105
sS'with,diprivan'
p7106
(F1
F0.00076452599388379206
I0
I1
I-1
tp7107
sS'enzymes,cyp3a4'
p7108
(F1
F0.00076452599388379206
I0
I1
I-1
tp7109
sS'rapid,onset'
p7110
(F1
F0.00076452599388379206
I1
I0
I1
tp7111
sS'augment,precocene'
p7112
(F1
F0.00076452599388379206
I1
I0
I1
tp7113
sS'supporting,experimental'
p7114
(F1
F0.00076452599388379206
I1
I0
I1
tp7115
sS'while,dosing'
p7116
(F1
F0.00076452599388379206
I1
I0
I1
tp7117
sS'anticholinergics,or'
p7118
(F1
F0.00076452599388379206
I1
I0
I1
tp7119
sS'reduce,the'
p7120
(F0.81818181818181823
F0.0068807339449541288
I10
I1
I9
tp7121
sS'sanctura,has'
p7122
(F1
F0.00076452599388379206
I1
I0
I1
tp7123
sS'infusional,fu'
p7124
(F1
F0.00076452599388379206
I0
I1
I-1
tp7125
sS'cell,lines'
p7126
(F0.25
F0.0015290519877675841
I3
I5
I-2
tp7127
sS'dna,damage'
p7128
(F1
F0.00076452599388379206
I0
I1
I-1
tp7129
sS'lead,to'
p7130
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp7131
sS'of,clinical'
p7132
(F1
F0.0015290519877675841
I0
I2
I-2
tp7133
sS'recommended,dose'
p7134
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp7135
sS'no,conclusive'
p7136
(F1
F0.00076452599388379206
I0
I1
I-1
tp7137
sS'stabilized,for'
p7138
(F1
F0.00076452599388379206
I1
I0
I1
tp7139
sS'to,lower'
p7140
(F1
F0.00076452599388379206
I1
I0
I1
tp7141
sS'and,respectively'
p7142
(F1
F0.00076452599388379206
I1
I0
I1
tp7143
sS'transporter,imaging'
p7144
(F1
F0.00076452599388379206
I1
I0
I1
tp7145
sS'more,than'
p7146
(F1
F0.00076452599388379206
I1
I0
I1
tp7147
sS'clinical,isolates'
p7148
(F1
F0.00076452599388379206
I0
I1
I-1
tp7149
sS'connection,with'
p7150
(F1
F0.00076452599388379206
I0
I1
I-1
tp7151
sS'and,noradrenergic'
p7152
(F0
F0
I1
I1
I0
tp7153
sS'also,displace'
p7154
(F1
F0.00076452599388379206
I1
I0
I1
tp7155
sS'specific,inhibitor'
p7156
(F1
F0.00076452599388379206
I0
I1
I-1
tp7157
sS'in,serum'
p7158
(F1
F0.0015290519877675841
I2
I0
I2
tp7159
sS'in,either'
p7160
(F1
F0.0030581039755351682
I0
I4
I-4
tp7161
sS'of,anticholinergic'
p7162
(F1
F0.0015290519877675841
I2
I0
I2
tp7163
sS'especially,during'
p7164
(F1
F0.00076452599388379206
I1
I0
I1
tp7165
sS'is,decreased'
p7166
(F1
F0.00076452599388379206
I1
I0
I1
tp7167
sS'other,central'
p7168
(F1
F0.0015290519877675841
I2
I0
I2
tp7169
sS'analysis,suggests'
p7170
(F0
F0
I1
I1
I0
tp7171
sS'its,administration'
p7172
(F1
F0.00076452599388379206
I1
I0
I1
tp7173
sS'zemuron,rocuronium'
p7174
(F1
F0.00076452599388379206
I0
I1
I-1
tp7175
sS'when,is'
p7176
(F1
F0.0030581039755351682
I4
I0
I4
tp7177
sS'inhibits,metabolism'
p7178
(F1
F0.00076452599388379206
I1
I0
I1
tp7179
sS'liver,microsomes'
p7180
(F1
F0.00076452599388379206
I0
I1
I-1
tp7181
sS'n,and'
p7182
(F1
F0.00076452599388379206
I0
I1
I-1
tp7183
sS'in,which'
p7184
(F1
F0.0015290519877675841
I2
I0
I2
tp7185
sS'diflucan,increases'
p7186
(F1
F0.0015290519877675841
I2
I0
I2
tp7187
sS'tiva,repeatedly'
p7188
(F1
F0.00076452599388379206
I0
I1
I-1
tp7189
sS'tracheal,intubation'
p7190
(F1
F0.00076452599388379206
I0
I1
I-1
tp7191
sS'calcium,is'
p7192
(F1
F0.00076452599388379206
I1
I0
I1
tp7193
sS't-all,and'
p7194
(F1
F0.00076452599388379206
I0
I1
I-1
tp7195
sS'cyp1a2,cyp2a6'
p7196
(F1
F0.00076452599388379206
I0
I1
I-1
tp7197
sS'seizure,threshold'
p7198
(F1
F0.00076452599388379206
I1
I0
I1
tp7199
sS'pharmacokinetic,analysis'
p7200
(F0
F0
I1
I1
I0
tp7201
sS'occurred,when'
p7202
(F1
F0.00076452599388379206
I0
I1
I-1
tp7203
sS'be,attributed'
p7204
(F1
F0.00076452599388379206
I1
I0
I1
tp7205
sS'amines,may'
p7206
(F1
F0.00076452599388379206
I1
I0
I1
tp7207
sS'acid,sequestrates'
p7208
(F1
F0.00076452599388379206
I1
I0
I1
tp7209
sS'activities,in'
p7210
(F1
F0.00076452599388379206
I0
I1
I-1
tp7211
sS'itraconazole,torsades'
p7212
(F1
F0.00076452599388379206
I1
I0
I1
tp7213
sS'analgesic,activity'
p7214
(F1
F0.00076452599388379206
I1
I0
I1
tp7215
sS'when,cells'
p7216
(F1
F0.00076452599388379206
I1
I0
I1
tp7217
sS'the,hepatic'
p7218
(F1
F0.0015290519877675841
I2
I0
I2
tp7219
sS'trials,nsaids'
p7220
(F1
F0.00076452599388379206
I1
I0
I1
tp7221
sS'not,believed'
p7222
(F1
F0.00076452599388379206
I1
I0
I1
tp7223
sS'anticholinergics,antagonize'
p7224
(F1
F0.00076452599388379206
I1
I0
I1
tp7225
sS'relevant,concentrations'
p7226
(F1
F0.0015290519877675841
I2
I0
I2
tp7227
sS'taking,magnesium-aluminum'
p7228
(F1
F0.00076452599388379206
I1
I0
I1
tp7229
sS'larger,cohorts'
p7230
(F1
F0.00076452599388379206
I0
I1
I-1
tp7231
sS'administering,vumon'
p7232
(F1
F0.00076452599388379206
I0
I1
I-1
tp7233
sS'seizure,activity'
p7234
(F1
F0.00076452599388379206
I1
I0
I1
tp7235
sS'quinpirole-free,controls'
p7236
(F0
F0
I1
I1
I0
tp7237
sS'with,congenital'
p7238
(F1
F0.00076452599388379206
I0
I1
I-1
tp7239
sS'on,dosing'
p7240
(F1
F0.00076452599388379206
I0
I1
I-1
tp7241
sS'vitro,in'
p7242
(F1
F0.0015290519877675841
I2
I0
I2
tp7243
sS'this,drug'
p7244
(F0
F0
I1
I1
I0
tp7245
sS'develop,during'
p7246
(F1
F0.00076452599388379206
I0
I1
I-1
tp7247
sS'mao-a,inhibitors'
p7248
(F1
F0.0015290519877675841
I2
I0
I2
tp7249
sS'or,topical'
p7250
(F1
F0.00076452599388379206
I0
I1
I-1
tp7251
sS'require,drug'
p7252
(F1
F0.00076452599388379206
I0
I1
I-1
tp7253
sS'the,extrapyramidal'
p7254
(F1
F0.00076452599388379206
I1
I0
I1
tp7255
sS'and,a7'
p7256
(F1
F0.00076452599388379206
I1
I0
I1
tp7257
sS'with,known'
p7258
(F1
F0.00076452599388379206
I1
I0
I1
tp7259
sS'spontaneous,accounts'
p7260
(F1
F0.00076452599388379206
I0
I1
I-1
tp7261
sS'thus,inhibits'
p7262
(F1
F0.00076452599388379206
I1
I0
I1
tp7263
sS'the,antinociceptive'
p7264
(F1
F0.00076452599388379206
I1
I0
I1
tp7265
sS'difference,cm3'
p7266
(F1
F0.00076452599388379206
I1
I0
I1
tp7267
sS'population,pk'
p7268
(F1
F0.00076452599388379206
I0
I1
I-1
tp7269
sS'about,while'
p7270
(F1
F0.00076452599388379206
I1
I0
I1
tp7271
sS'tid,to'
p7272
(F1
F0.00076452599388379206
I1
I0
I1
tp7273
sS'and,an'
p7274
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp7275
sS'by,and'
p7276
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp7277
sS'the,role'
p7278
(F1
F0.00076452599388379206
I1
I0
I1
tp7279
sS'they,are'
p7280
(F1
F0.00076452599388379206
I0
I1
I-1
tp7281
sS'may,interact'
p7282
(F1
F0.0045871559633027525
I6
I0
I6
tp7283
sS'with,longer'
p7284
(F1
F0.00076452599388379206
I1
I0
I1
tp7285
sS'by,any'
p7286
(F1
F0.00076452599388379206
I1
I0
I1
tp7287
sS'and,as'
p7288
(F1
F0.00076452599388379206
I0
I1
I-1
tp7289
sS'and,statistically'
p7290
(F1
F0.00076452599388379206
I1
I0
I1
tp7291
sS'this,may'
p7292
(F1
F0.00076452599388379206
I0
I1
I-1
tp7293
sS'in,in-vivo'
p7294
(F1
F0.00076452599388379206
I1
I0
I1
tp7295
sS'and,hydrochloride'
p7296
(F1
F0.00076452599388379206
I1
I0
I1
tp7297
sS'medicines,and'
p7298
(F1
F0.00076452599388379206
I1
I0
I1
tp7299
sS'combination,normalized'
p7300
(F1
F0.00076452599388379206
I1
I0
I1
tp7301
sS'poor,cyp2d6'
p7302
(F1
F0.00076452599388379206
I0
I1
I-1
tp7303
sS'during,or'
p7304
(F1
F0.00076452599388379206
I1
I0
I1
tp7305
sS'for,drug'
p7306
(F1
F0.00076452599388379206
I1
I0
I1
tp7307
sS'undercarboxylated,osteocalcin'
p7308
(F1
F0.00076452599388379206
I0
I1
I-1
tp7309
sS'inefficacy,of'
p7310
(F1
F0.00076452599388379206
I1
I0
I1
tp7311
sS'cyp,a4'
p7312
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7313
sS'the,synergism'
p7314
(F1
F0.00076452599388379206
I1
I0
I1
tp7315
sS'the,order'
p7316
(F1
F0.00076452599388379206
I0
I1
I-1
tp7317
sS'seen,when'
p7318
(F1
F0.00076452599388379206
I0
I1
I-1
tp7319
sS'transporter,did'
p7320
(F1
F0.00076452599388379206
I0
I1
I-1
tp7321
sS'high-dose,and'
p7322
(F1
F0.00076452599388379206
I1
I0
I1
tp7323
sS'to,avoid'
p7324
(F1
F0.0030581039755351682
I4
I0
I4
tp7325
sS'with,tacrolimus-treated'
p7326
(F1
F0.00076452599388379206
I0
I1
I-1
tp7327
sS'many,drugs'
p7328
(F1
F0.00076452599388379206
I0
I1
I-1
tp7329
sS'accelerate,the'
p7330
(F1
F0.00076452599388379206
I1
I0
I1
tp7331
sS'low,systemic'
p7332
(F1
F0.0015290519877675841
I0
I2
I-2
tp7333
sS'or,decrease'
p7334
(F1
F0.00076452599388379206
I1
I0
I1
tp7335
sS'neurotoxic,and'
p7336
(F1
F0.00076452599388379206
I0
I1
I-1
tp7337
sS'deb,induced'
p7338
(F1
F0.00076452599388379206
I1
I0
I1
tp7339
sS'and,patients'
p7340
(F1
F0.00076452599388379206
I1
I0
I1
tp7341
sS'low,doses'
p7342
(F1
F0.00076452599388379206
I0
I1
I-1
tp7343
sS'encoding,enhanced'
p7344
(F1
F0.00076452599388379206
I0
I1
I-1
tp7345
sS'the,mtor'
p7346
(F1
F0.00076452599388379206
I1
I0
I1
tp7347
sS'to,have'
p7348
(F0
F0
I1
I1
I0
tp7349
sS'receiving,most'
p7350
(F1
F0.00076452599388379206
I0
I1
I-1
tp7351
sS'drugs,for'
p7352
(F1
F0.00076452599388379206
I1
I0
I1
tp7353
sS'should,closely'
p7354
(F1
F0.0015290519877675841
I2
I0
I2
tp7355
sS'they,may'
p7356
(F1
F0.0015290519877675841
I2
I0
I2
tp7357
sS'on,a'
p7358
(F1
F0.0022935779816513763
I0
I3
I-3
tp7359
sS'antagonists,since'
p7360
(F1
F0.00076452599388379206
I1
I0
I1
tp7361
sS'and,reduce'
p7362
(F0
F0
I1
I1
I0
tp7363
sS'ephedrine,enhances'
p7364
(F1
F0.00076452599388379206
I1
I0
I1
tp7365
sS'on,s'
p7366
(F1
F0.00076452599388379206
I1
I0
I1
tp7367
sS'levels,tended'
p7368
(F1
F0.00076452599388379206
I0
I1
I-1
tp7369
sS'employed,antianginal'
p7370
(F1
F0.00076452599388379206
I0
I1
I-1
tp7371
sS'meperidine,should'
p7372
(F1
F0.00076452599388379206
I1
I0
I1
tp7373
sS'i,or'
p7374
(F1
F0.00076452599388379206
I1
I0
I1
tp7375
sS'with,dznep'
p7376
(F1
F0.00076452599388379206
I1
I0
I1
tp7377
sS'lasting,inhibition'
p7378
(F1
F0.00076452599388379206
I1
I0
I1
tp7379
sS'towards,dopaminergic'
p7380
(F1
F0.00076452599388379206
I1
I0
I1
tp7381
sS'following,a'
p7382
(F1
F0.0015290519877675841
I0
I2
I-2
tp7383
sS'the,incremental'
p7384
(F1
F0.00076452599388379206
I1
I0
I1
tp7385
sS'to,hours'
p7386
(F1
F0.00076452599388379206
I1
I0
I1
tp7387
sS'knockdown,of'
p7388
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7389
sS'gluconate,is'
p7390
(F1
F0.00076452599388379206
I1
I0
I1
tp7391
sS'contraindicated,pending'
p7392
(F1
F0.00076452599388379206
I1
I0
I1
tp7393
sS'strand,breaks'
p7394
(F1
F0.00076452599388379206
I0
I1
I-1
tp7395
sS'prothrombin,times'
p7396
(F1
F0.00076452599388379206
I1
I0
I1
tp7397
sS'administration,may'
p7398
(F1
F0.00076452599388379206
I1
I0
I1
tp7399
sS'effect,may'
p7400
(F1
F0.00076452599388379206
I1
I0
I1
tp7401
sS'autohaler,because'
p7402
(F1
F0.00076452599388379206
I1
I0
I1
tp7403
sS'bone,marrow'
p7404
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp7405
sS'natriuretic,effect'
p7406
(F1
F0.00076452599388379206
I1
I0
I1
tp7407
sS'a,much'
p7408
(F1
F0.00076452599388379206
I1
I0
I1
tp7409
sS'hepatic,enzymes'
p7410
(F1
F0.0015290519877675841
I2
I0
I2
tp7411
sS'per,mouse'
p7412
(F1
F0.00076452599388379206
I1
I0
I1
tp7413
sS'three,times'
p7414
(F1
F0.0061162079510703364
I0
I8
I-8
tp7415
sS'immunoreactivity,which'
p7416
(F1
F0.00076452599388379206
I1
I0
I1
tp7417
sS'to,result'
p7418
(F1
F0.0015290519877675841
I2
I0
I2
tp7419
sS'sirna,vs'
p7420
(F1
F0.00076452599388379206
I0
I1
I-1
tp7421
sS'parameters,of'
p7422
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7423
sS'methyldopa,does'
p7424
(F1
F0.00076452599388379206
I0
I1
I-1
tp7425
sS'newcastle,disease'
p7426
(F1
F0.00076452599388379206
I0
I1
I-1
tp7427
sS'had,no'
p7428
(F1
F0.00076452599388379206
I1
I0
I1
tp7429
sS'and,associated'
p7430
(F1
F0.00076452599388379206
I0
I1
I-1
tp7431
sS'virus,vaccines'
p7432
(F1
F0.00076452599388379206
I1
I0
I1
tp7433
sS'b2,riboflavin'
p7434
(F1
F0.00076452599388379206
I1
I0
I1
tp7435
sS'thrombopenia,with'
p7436
(F1
F0.00076452599388379206
I0
I1
I-1
tp7437
sS'streptokinase,with'
p7438
(F1
F0.00076452599388379206
I0
I1
I-1
tp7439
sS'of,spiriva'
p7440
(F1
F0.00076452599388379206
I1
I0
I1
tp7441
sS'elevate,the'
p7442
(F1
F0.00076452599388379206
I0
I1
I-1
tp7443
sS'be,of'
p7444
(F1
F0.00076452599388379206
I0
I1
I-1
tp7445
sS'post-marketing,experience'
p7446
(F1
F0.00076452599388379206
I1
I0
I1
tp7447
sS'agents,eg'
p7448
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7449
sS'with,guanethidine'
p7450
(F1
F0.00076452599388379206
I1
I0
I1
tp7451
sS'in,certain'
p7452
(F1
F0.00076452599388379206
I1
I0
I1
tp7453
sS'or,food'
p7454
(F1
F0.00076452599388379206
I1
I0
I1
tp7455
sS'h,before'
p7456
(F1
F0.00076452599388379206
I0
I1
I-1
tp7457
sS'to,those'
p7458
(F1
F0.00076452599388379206
I0
I1
I-1
tp7459
sS'tramadol,although'
p7460
(F1
F0.00076452599388379206
I1
I0
I1
tp7461
sS'tamoxifen,an'
p7462
(F1
F0.00076452599388379206
I0
I1
I-1
tp7463
sS'of,class'
p7464
(F1
F0.00076452599388379206
I1
I0
I1
tp7465
sS'studies,patients'
p7466
(F1
F0.00076452599388379206
I1
I0
I1
tp7467
sS'extensive,and'
p7468
(F1
F0.00076452599388379206
I0
I1
I-1
tp7469
sS'antinociceptive,effect'
p7470
(F1
F0.00076452599388379206
I1
I0
I1
tp7471
sS'patient,taking'
p7472
(F1
F0.00076452599388379206
I1
I0
I1
tp7473
sS'alone,or'
p7474
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7475
sS'the,day'
p7476
(F1
F0.0015290519877675841
I2
I0
I2
tp7477
sS'of,versed'
p7478
(F1
F0.00076452599388379206
I1
I0
I1
tp7479
sS'muted,compared'
p7480
(F1
F0.00076452599388379206
I0
I1
I-1
tp7481
sS'medicines,birth'
p7482
(F1
F0.00076452599388379206
I1
I0
I1
tp7483
sS'women,the'
p7484
(F1
F0.0015290519877675841
I0
I2
I-2
tp7485
sS'analyze,the'
p7486
(F1
F0.00076452599388379206
I0
I1
I-1
tp7487
sS'when,mixed'
p7488
(F1
F0.00076452599388379206
I1
I0
I1
tp7489
sS'and,mean'
p7490
(F1
F0.00076452599388379206
I1
I0
I1
tp7491
sS'which,different'
p7492
(F1
F0.00076452599388379206
I1
I0
I1
tp7493
sS'was,studied'
p7494
(F1
F0.0022935779816513763
I0
I3
I-3
tp7495
sS'these,cytochrome'
p7496
(F1
F0.00076452599388379206
I0
I1
I-1
tp7497
sS'a,dose'
p7498
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7499
sS'subsequent,to'
p7500
(F1
F0.00076452599388379206
I1
I0
I1
tp7501
sS'drug-interaction,studies'
p7502
(F1
F0.00076452599388379206
I0
I1
I-1
tp7503
sS'anticoagulants,prolongation'
p7504
(F1
F0.00076452599388379206
I1
I0
I1
tp7505
sS'if,cannot'
p7506
(F1
F0.00076452599388379206
I1
I0
I1
tp7507
sS'cyp,inhibitor'
p7508
(F1
F0.0015290519877675841
I0
I2
I-2
tp7509
sS'other,monoamine'
p7510
(F1
F0.00076452599388379206
I0
I1
I-1
tp7511
sS'less,with'
p7512
(F1
F0.00076452599388379206
I0
I1
I-1
tp7513
sS'sensitize,cells'
p7514
(F1
F0.00076452599388379206
I0
I1
I-1
tp7515
sS'cyp3a4,inhibitor'
p7516
(F1
F0.00076452599388379206
I1
I0
I1
tp7517
sS'while,taking'
p7518
(F1
F0.0015290519877675841
I2
I0
I2
tp7519
sS'b1,thiamine'
p7520
(F1
F0.00076452599388379206
I1
I0
I1
tp7521
sS'require,dose'
p7522
(F1
F0.00076452599388379206
I1
I0
I1
tp7523
sS'sodium,medroxyprogesterone'
p7524
(F1
F0.00076452599388379206
I0
I1
I-1
tp7525
sS'or,dosage'
p7526
(F1
F0.00076452599388379206
I1
I0
I1
tp7527
sS'pyridine,significantly'
p7528
(F1
F0.00076452599388379206
I1
I0
I1
tp7529
sS'and,the'
p7530
(F0.125
F0.0015290519877675841
I7
I9
I-2
tp7531
sS'abraded,skin'
p7532
(F1
F0.00076452599388379206
I1
I0
I1
tp7533
sS'gastric,ph'
p7534
(F1
F0.00076452599388379206
I1
I0
I1
tp7535
sS'sessions,during'
p7536
(F1
F0.00076452599388379206
I0
I1
I-1
tp7537
sS'juice,may'
p7538
(F1
F0.00076452599388379206
I1
I0
I1
tp7539
sS'therapy,on'
p7540
(F1
F0.00076452599388379206
I1
I0
I1
tp7541
sS'vitro,p450'
p7542
(F1
F0.00076452599388379206
I0
I1
I-1
tp7543
sS'of,increase'
p7544
(F1
F0.0015290519877675841
I2
I0
I2
tp7545
sS'platelet,function'
p7546
(F1
F0.0015290519877675841
I2
I0
I2
tp7547
sS'to,identify'
p7548
(F1
F0.00076452599388379206
I0
I1
I-1
tp7549
sS'other,non-steroidal'
p7550
(F1
F0.00076452599388379206
I1
I0
I1
tp7551
sS'of,transduction'
p7552
(F1
F0.00076452599388379206
I0
I1
I-1
tp7553
sS'our,data'
p7554
(F1
F0.00076452599388379206
I1
I0
I1
tp7555
sS'or,vehicle'
p7556
(F1
F0.00076452599388379206
I0
I1
I-1
tp7557
sS'fst,with'
p7558
(F1
F0.00076452599388379206
I0
I1
I-1
tp7559
sS'invega,to'
p7560
(F1
F0.00076452599388379206
I0
I1
I-1
tp7561
sS'with,forced'
p7562
(F1
F0.00076452599388379206
I1
I0
I1
tp7563
sS'concomitantly,administered'
p7564
(F1
F0.0030581039755351682
I4
I0
I4
tp7565
sS'studies,of'
p7566
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7567
sS'gsls,because'
p7568
(F1
F0.00076452599388379206
I0
I1
I-1
tp7569
sS'with,the'
p7570
(F0.59999999999999998
F0.0068807339449541288
I12
I3
I9
tp7571
sS'syrup,is'
p7572
(F1
F0.00076452599388379206
I1
I0
I1
tp7573
sS'anti-pseudomonal,or'
p7574
(F1
F0.00076452599388379206
I1
I0
I1
tp7575
sS'blocking,effects'
p7576
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp7577
sS'particularly,when'
p7578
(F1
F0.00076452599388379206
I1
I0
I1
tp7579
sS'to,chemotherapy'
p7580
(F1
F0.00076452599388379206
I1
I0
I1
tp7581
sS'great,a'
p7582
(F1
F0.00076452599388379206
I1
I0
I1
tp7583
sS'hela,hct116'
p7584
(F1
F0.00076452599388379206
I0
I1
I-1
tp7585
sS'therapy,when'
p7586
(F1
F0.00076452599388379206
I0
I1
I-1
tp7587
sS'with,that'
p7588
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp7589
sS'diepoxybutane,to'
p7590
(F1
F0.00076452599388379206
I0
I1
I-1
tp7591
sS'on,dexmedetomidine-induced'
p7592
(F1
F0.00076452599388379206
I0
I1
I-1
tp7593
sS'by,chronic'
p7594
(F1
F0.00076452599388379206
I0
I1
I-1
tp7595
sS'an,infant'
p7596
(F1
F0.00076452599388379206
I1
I0
I1
tp7597
sS'analgesic,agents'
p7598
(F0
F0
I1
I1
I0
tp7599
sS'thiazide,drugs'
p7600
(F1
F0.00076452599388379206
I1
I0
I1
tp7601
sS'variable,doses'
p7602
(F1
F0.00076452599388379206
I1
I0
I1
tp7603
sS'significantly,reduces'
p7604
(F1
F0.00076452599388379206
I1
I0
I1
tp7605
sS'depressants,such'
p7606
(F1
F0.00076452599388379206
I1
I0
I1
tp7607
sS'positron,emission'
p7608
(F1
F0.00076452599388379206
I1
I0
I1
tp7609
sS'at,doses'
p7610
(F0.25
F0.0015290519877675841
I3
I5
I-2
tp7611
sS'and,gastrointestinal'
p7612
(F1
F0.00076452599388379206
I1
I0
I1
tp7613
sS'approximately,following'
p7614
(F1
F0.0015290519877675841
I0
I2
I-2
tp7615
sS'is,anticipated'
p7616
(F1
F0.00076452599388379206
I1
I0
I1
tp7617
sS'few,days'
p7618
(F1
F0.00076452599388379206
I1
I0
I1
tp7619
sS'have,more'
p7620
(F1
F0.00076452599388379206
I1
I0
I1
tp7621
sS'the,zantac'
p7622
(F1
F0.00076452599388379206
I0
I1
I-1
tp7623
sS'and,within'
p7624
(F1
F0.00076452599388379206
I1
I0
I1
tp7625
sS'compounds,that'
p7626
(F1
F0.00076452599388379206
I1
I0
I1
tp7627
sS'a,course'
p7628
(F1
F0.00076452599388379206
I1
I0
I1
tp7629
sS'and,after'
p7630
(F1
F0.0015290519877675841
I0
I2
I-2
tp7631
sS'to,evaluate'
p7632
(F1
F0.0045871559633027525
I0
I6
I-6
tp7633
sS'vaccines,during'
p7634
(F1
F0.00076452599388379206
I1
I0
I1
tp7635
sS'may,accentuate'
p7636
(F1
F0.00076452599388379206
I1
I0
I1
tp7637
sS'and,generally'
p7638
(F1
F0.00076452599388379206
I1
I0
I1
tp7639
sS'both,drugs'
p7640
(F1
F0.0022935779816513763
I3
I0
I3
tp7641
sS'drugs,remarkably'
p7642
(F1
F0.00076452599388379206
I1
I0
I1
tp7643
sS'while,no'
p7644
(F1
F0.00076452599388379206
I0
I1
I-1
tp7645
sS'agents,tricyclic'
p7646
(F1
F0.00076452599388379206
I1
I0
I1
tp7647
sS'eliminated,via'
p7648
(F1
F0.00076452599388379206
I1
I0
I1
tp7649
sS'indicated,requires'
p7650
(F1
F0.00076452599388379206
I0
I1
I-1
tp7651
sS'be,advised'
p7652
(F1
F0.0022935779816513763
I3
I0
I3
tp7653
sS'the,response'
p7654
(F1
F0.00076452599388379206
I0
I1
I-1
tp7655
sS'test,should'
p7656
(F1
F0.00076452599388379206
I1
I0
I1
tp7657
sS'studies,were'
p7658
(F1
F0.00076452599388379206
I0
I1
I-1
tp7659
sS'inhibitor,maoi'
p7660
(F1
F0.00076452599388379206
I1
I0
I1
tp7661
sS'to,potentiate'
p7662
(F1
F0.00076452599388379206
I1
I0
I1
tp7663
sS'and,nitrous'
p7664
(F1
F0.00076452599388379206
I1
I0
I1
tp7665
sS'dose,requirements'
p7666
(F1
F0.00076452599388379206
I1
I0
I1
tp7667
sS'performed,the'
p7668
(F1
F0.00076452599388379206
I0
I1
I-1
tp7669
sS'in,requirement'
p7670
(F1
F0.00076452599388379206
I0
I1
I-1
tp7671
sS'were,reduced'
p7672
(F1
F0.00076452599388379206
I1
I0
I1
tp7673
sS'addition,cns'
p7674
(F1
F0.00076452599388379206
I1
I0
I1
tp7675
sS'hepatic,and'
p7676
(F1
F0.00076452599388379206
I0
I1
I-1
tp7677
sS'drugs,oral'
p7678
(F1
F0.0015290519877675841
I0
I2
I-2
tp7679
sS'has,been'
p7680
(F0.31428571428571428
F0.0084097859327217118
I23
I12
I11
tp7681
sS'enzymes,an'
p7682
(F1
F0.00076452599388379206
I0
I1
I-1
tp7683
sS'a,reduction'
p7684
(F0.40000000000000002
F0.0030581039755351682
I7
I3
I4
tp7685
sS'anti-proliferative,effects'
p7686
(F1
F0.0015290519877675841
I2
I0
I2
tp7687
sS'implanon,failure'
p7688
(F1
F0.00076452599388379206
I1
I0
I1
tp7689
sS'enhanced,locomotor'
p7690
(F1
F0.00076452599388379206
I1
I0
I1
tp7691
sS'urine,screening'
p7692
(F1
F0.00076452599388379206
I0
I1
I-1
tp7693
sS'will,influence'
p7694
(F1
F0.00076452599388379206
I1
I0
I1
tp7695
sS'alupent,metaproterenol'
p7696
(F1
F0.00076452599388379206
I1
I0
I1
tp7697
sS'after,weeks'
p7698
(F1
F0.00076452599388379206
I1
I0
I1
tp7699
sS'and,decreases'
p7700
(F1
F0.00076452599388379206
I1
I0
I1
tp7701
sS'pressor,response'
p7702
(F1
F0.0015290519877675841
I2
I0
I2
tp7703
sS'protein-bound,in'
p7704
(F1
F0.00076452599388379206
I1
I0
I1
tp7705
sS'formed,fewer'
p7706
(F1
F0.00076452599388379206
I1
I0
I1
tp7707
sS'pharmacodynamics,and'
p7708
(F1
F0.00076452599388379206
I0
I1
I-1
tp7709
sS'it,has'
p7710
(F1
F0.0015290519877675841
I2
I0
I2
tp7711
sS'mycamine,compared'
p7712
(F1
F0.0015290519877675841
I2
I0
I2
tp7713
sS'and,decreased'
p7714
(F1
F0.0022935779816513763
I3
I0
I3
tp7715
sS'increased,cns'
p7716
(F1
F0.00076452599388379206
I1
I0
I1
tp7717
sS'with,enterohepatic'
p7718
(F1
F0.00076452599388379206
I1
I0
I1
tp7719
sS'state,did'
p7720
(F1
F0.0015290519877675841
I0
I2
I-2
tp7721
sS'nick-end,labeling'
p7722
(F1
F0.00076452599388379206
I0
I1
I-1
tp7723
sS'days,resulted'
p7724
(F1
F0.00076452599388379206
I0
I1
I-1
tp7725
sS'with,care'
p7726
(F1
F0.00076452599388379206
I1
I0
I1
tp7727
sS'pyridine,treatment'
p7728
(F1
F0.00076452599388379206
I1
I0
I1
tp7729
sS'at,high'
p7730
(F1
F0.00076452599388379206
I0
I1
I-1
tp7731
sS'or,drugs'
p7732
(F0
F0
I1
I1
I0
tp7733
sS'of,gsls'
p7734
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7735
sS'drugs,diuretic-induced'
p7736
(F1
F0.00076452599388379206
I1
I0
I1
tp7737
sS'and,thiazide'
p7738
(F1
F0.00076452599388379206
I1
I0
I1
tp7739
sS'first,dose'
p7740
(F1
F0.00076452599388379206
I1
I0
I1
tp7741
sS'to,the'
p7742
(F0.17647058823529413
F0.0022935779816513763
I10
I7
I3
tp7743
sS'hiv-protease,inhibitors'
p7744
(F1
F0.00076452599388379206
I0
I1
I-1
tp7745
sS'of,nonheme'
p7746
(F1
F0.0015290519877675841
I0
I2
I-2
tp7747
sS'in-vivo,plasma'
p7748
(F1
F0.00076452599388379206
I1
I0
I1
tp7749
sS'range,considered'
p7750
(F1
F0.00076452599388379206
I1
I0
I1
tp7751
sS'although,they'
p7752
(F0
F0
I1
I1
I0
tp7753
sS'disalcid,and'
p7754
(F1
F0.00076452599388379206
I1
I0
I1
tp7755
sS'celontin,may'
p7756
(F1
F0.00076452599388379206
I1
I0
I1
tp7757
sS'carboxylated,metabolite'
p7758
(F1
F0.00076452599388379206
I0
I1
I-1
tp7759
sS'cyp2c19,a'
p7760
(F1
F0.00076452599388379206
I1
I0
I1
tp7761
sS'another,formal'
p7762
(F1
F0.00076452599388379206
I0
I1
I-1
tp7763
sS'or,were'
p7764
(F1
F0.00076452599388379206
I0
I1
I-1
tp7765
sS'contraception,and'
p7766
(F1
F0.00076452599388379206
I1
I0
I1
tp7767
sS'oral,mg'
p7768
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp7769
sS's-ketamine,with'
p7770
(F1
F0.00076452599388379206
I0
I1
I-1
tp7771
sS'of,live'
p7772
(F1
F0.00076452599388379206
I1
I0
I1
tp7773
sS't,values'
p7774
(F1
F0.00076452599388379206
I1
I0
I1
tp7775
sS'versus,methyl-4'
p7776
(F1
F0.00076452599388379206
I0
I1
I-1
tp7777
sS'and,have'
p7778
(F0
F0
I2
I2
I0
tp7779
sS'per,day'
p7780
(F1
F0.00076452599388379206
I1
I0
I1
tp7781
sS'taking,concomitant'
p7782
(F1
F0.00076452599388379206
I1
I0
I1
tp7783
sS'to,one'
p7784
(F1
F0.00076452599388379206
I1
I0
I1
tp7785
sS'meloxicam,mg'
p7786
(F1
F0.00076452599388379206
I0
I1
I-1
tp7787
sS'effect,when'
p7788
(F1
F0.0015290519877675841
I2
I0
I2
tp7789
sS'certain,may'
p7790
(F1
F0.00076452599388379206
I1
I0
I1
tp7791
sS'frequent,monitoring'
p7792
(F1
F0.00076452599388379206
I1
I0
I1
tp7793
sS'however,interactions'
p7794
(F1
F0.00076452599388379206
I1
I0
I1
tp7795
sS'multiple-dose,study'
p7796
(F1
F0.00076452599388379206
I0
I1
I-1
tp7797
sS'receiving,concomitant'
p7798
(F0
F0
I1
I1
I0
tp7799
sS'two,with'
p7800
(F1
F0.00076452599388379206
I0
I1
I-1
tp7801
sS'and,not'
p7802
(F1
F0.00076452599388379206
I1
I0
I1
tp7803
sS'pth,levels'
p7804
(F1
F0.00076452599388379206
I0
I1
I-1
tp7805
sS'thiol,content'
p7806
(F1
F0.00076452599388379206
I0
I1
I-1
tp7807
sS'proteins,caution'
p7808
(F1
F0.00076452599388379206
I0
I1
I-1
tp7809
sS'pharmacokinetic,profiles'
p7810
(F1
F0.00076452599388379206
I0
I1
I-1
tp7811
sS'inhibitors,reports'
p7812
(F1
F0.00076452599388379206
I1
I0
I1
tp7813
sS'in,clopidogrel-treated'
p7814
(F1
F0.00076452599388379206
I0
I1
I-1
tp7815
sS'or,may'
p7816
(F1
F0.0015290519877675841
I2
I0
I2
tp7817
sS'p-450,drug-metabolizing'
p7818
(F1
F0.00076452599388379206
I0
I1
I-1
tp7819
sS'mg,nonheme'
p7820
(F1
F0.00076452599388379206
I0
I1
I-1
tp7821
sS'sought,to'
p7822
(F1
F0.00076452599388379206
I0
I1
I-1
tp7823
sS'and,richens'
p7824
(F1
F0.00076452599388379206
I1
I0
I1
tp7825
sS'monkeys,rendered'
p7826
(F1
F0.00076452599388379206
I0
I1
I-1
tp7827
sS'milligrams,in'
p7828
(F1
F0.00076452599388379206
I0
I1
I-1
tp7829
sS'at,comparatively'
p7830
(F1
F0.00076452599388379206
I0
I1
I-1
tp7831
sS'sanctura,have'
p7832
(F1
F0.00076452599388379206
I1
I0
I1
tp7833
sS'as,diminished'
p7834
(F1
F0.0015290519877675841
I2
I0
I2
tp7835
sS'include,macrolide'
p7836
(F1
F0.00076452599388379206
I0
I1
I-1
tp7837
sS'methadone-maintenance,therapy'
p7838
(F1
F0.00076452599388379206
I1
I0
I1
tp7839
sS'anesthesia,other'
p7840
(F1
F0.00076452599388379206
I1
I0
I1
tp7841
sS'patients,since'
p7842
(F1
F0.00076452599388379206
I1
I0
I1
tp7843
sS'half-life,from'
p7844
(F1
F0.00076452599388379206
I1
I0
I1
tp7845
sS'lowered,the'
p7846
(F1
F0.00076452599388379206
I1
I0
I1
tp7847
sS'take,both'
p7848
(F1
F0.00076452599388379206
I1
I0
I1
tp7849
sS'strong,p450'
p7850
(F1
F0.00076452599388379206
I1
I0
I1
tp7851
sS'maintenance,of'
p7852
(F1
F0.00076452599388379206
I1
I0
I1
tp7853
sS'expected,and'
p7854
(F1
F0.00076452599388379206
I1
I0
I1
tp7855
sS'anticholinergic,activity'
p7856
(F1
F0.00076452599388379206
I1
I0
I1
tp7857
sS'pharmacological,effects'
p7858
(F1
F0.00076452599388379206
I1
I0
I1
tp7859
sS'these,medications'
p7860
(F1
F0.00076452599388379206
I0
I1
I-1
tp7861
sS'levels,be'
p7862
(F1
F0.00076452599388379206
I1
I0
I1
tp7863
sS'the,induction'
p7864
(F0
F0
I1
I1
I0
tp7865
sS'to,drugs'
p7866
(F1
F0.00076452599388379206
I0
I1
I-1
tp7867
sS'important,effect'
p7868
(F1
F0.00076452599388379206
I0
I1
I-1
tp7869
sS'chloride,miochol'
p7870
(F1
F0.00076452599388379206
I1
I0
I1
tp7871
sS'either,agent'
p7872
(F1
F0.00076452599388379206
I1
I0
I1
tp7873
sS'drugs,can'
p7874
(F1
F0.00076452599388379206
I1
I0
I1
tp7875
sS'patients,may'
p7876
(F1
F0.00076452599388379206
I1
I0
I1
tp7877
sS'avoided,in'
p7878
(F1
F0.00076452599388379206
I0
I1
I-1
tp7879
sS'steady-state,mycamine'
p7880
(F1
F0.0015290519877675841
I2
I0
I2
tp7881
sS'ascorbic,acid'
p7882
(F1
F0.00076452599388379206
I1
I0
I1
tp7883
sS'bleeding,vs'
p7884
(F1
F0.00076452599388379206
I1
I0
I1
tp7885
sS'hepatic,microsomal'
p7886
(F1
F0.00076452599388379206
I1
I0
I1
tp7887
sS'digitalized,patients'
p7888
(F1
F0.00076452599388379206
I1
I0
I1
tp7889
sS'the,isoform-specific'
p7890
(F1
F0.00076452599388379206
I0
I1
I-1
tp7891
sS'and,caused'
p7892
(F1
F0.00076452599388379206
I1
I0
I1
tp7893
sS'intravitreal,delivery'
p7894
(F1
F0.00076452599388379206
I0
I1
I-1
tp7895
sS'from,mg'
p7896
(F1
F0.00076452599388379206
I0
I1
I-1
tp7897
sS'low-dose,to'
p7898
(F1
F0.00076452599388379206
I1
I0
I1
tp7899
sS'cyclosporine,the'
p7900
(F1
F0.00076452599388379206
I1
I0
I1
tp7901
sS'noradrenergic,cell'
p7902
(F1
F0.00076452599388379206
I1
I0
I1
tp7903
sS'tumors,and'
p7904
(F1
F0.00076452599388379206
I0
I1
I-1
tp7905
sS'significant,protective'
p7906
(F1
F0.00076452599388379206
I1
I0
I1
tp7907
sS'decreased,metabolite'
p7908
(F1
F0.00076452599388379206
I1
I0
I1
tp7909
sS'this,increase'
p7910
(F1
F0.00076452599388379206
I1
I0
I1
tp7911
sS'for,example'
p7912
(F1
F0.00076452599388379206
I1
I0
I1
tp7913
sS'time,or'
p7914
(F0
F0
I1
I1
I0
tp7915
sS'drugs,from'
p7916
(F1
F0.00076452599388379206
I1
I0
I1
tp7917
sS'content,hplc'
p7918
(F1
F0.00076452599388379206
I0
I1
I-1
tp7919
sS'the,pro-oxidant'
p7920
(F1
F0.00076452599388379206
I0
I1
I-1
tp7921
sS'time,of'
p7922
(F0
F0
I1
I1
I0
tp7923
sS'interaction,study'
p7924
(F0.25
F0.0015290519877675841
I5
I3
I2
tp7925
sS'compete,for'
p7926
(F1
F0.00076452599388379206
I0
I1
I-1
tp7927
sS'vitro,studies'
p7928
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp7929
sS'because,of'
p7930
(F0.55555555555555558
F0.0038226299694189602
I7
I2
I5
tp7931
sS'of,fst'
p7932
(F1
F0.00076452599388379206
I0
I1
I-1
tp7933
sS'of,ginseng'
p7934
(F1
F0.0015290519877675841
I0
I2
I-2
tp7935
sS'emulsion,administration'
p7936
(F1
F0.00076452599388379206
I1
I0
I1
tp7937
sS'decrease,when'
p7938
(F1
F0.00076452599388379206
I0
I1
I-1
tp7939
sS'ii,acetyl-l'
p7940
(F1
F0.00076452599388379206
I1
I0
I1
tp7941
sS'concentration,was'
p7942
(F1
F0.00076452599388379206
I1
I0
I1
tp7943
sS'coumarin,and'
p7944
(F1
F0.00076452599388379206
I1
I0
I1
tp7945
sS'the,type'
p7946
(F1
F0.00076452599388379206
I1
I0
I1
tp7947
sS'and,package'
p7948
(F1
F0.00076452599388379206
I0
I1
I-1
tp7949
sS'amphetamine,locomotor'
p7950
(F1
F0.00076452599388379206
I0
I1
I-1
tp7951
sS'organogenesis,result'
p7952
(F1
F0.00076452599388379206
I0
I1
I-1
tp7953
sS'or,influence'
p7954
(F1
F0.00076452599388379206
I0
I1
I-1
tp7955
sS'to,parenteral'
p7956
(F1
F0.00076452599388379206
I0
I1
I-1
tp7957
sS'cholinomimetics,and'
p7958
(F1
F0.00076452599388379206
I1
I0
I1
tp7959
sS'potent,inhibitors'
p7960
(F1
F0.00076452599388379206
I0
I1
I-1
tp7961
sS'paliperidone,may'
p7962
(F1
F0.00076452599388379206
I1
I0
I1
tp7963
sS'certain,herbal'
p7964
(F1
F0.00076452599388379206
I0
I1
I-1
tp7965
sS'to,but'
p7966
(F1
F0.00076452599388379206
I1
I0
I1
tp7967
sS'documenting,the'
p7968
(F1
F0.00076452599388379206
I0
I1
I-1
tp7969
sS'effective,in'
p7970
(F1
F0.00076452599388379206
I0
I1
I-1
tp7971
sS'family,may'
p7972
(F1
F0.00076452599388379206
I1
I0
I1
tp7973
sS'toxicity,in'
p7974
(F1
F0.00076452599388379206
I1
I0
I1
tp7975
sS'interval,prolongation'
p7976
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp7977
sS'as,nonheme'
p7978
(F1
F0.00076452599388379206
I1
I0
I1
tp7979
sS'from,studies'
p7980
(F1
F0.00076452599388379206
I1
I0
I1
tp7981
sS'of,gastrointestinal'
p7982
(F1
F0.00076452599388379206
I1
I0
I1
tp7983
sS'bleeding,associated'
p7984
(F1
F0.00076452599388379206
I1
I0
I1
tp7985
sS'renal,function'
p7986
(F1
F0.0022935779816513763
I3
I0
I3
tp7987
sS'patients,when'
p7988
(F1
F0.00076452599388379206
I1
I0
I1
tp7989
sS'coadministered,to'
p7990
(F0
F0
I1
I1
I0
tp7991
sS'competitively,inhibits'
p7992
(F1
F0.00076452599388379206
I1
I0
I1
tp7993
sS'of,anticholinesterase'
p7994
(F1
F0.00076452599388379206
I1
I0
I1
tp7995
sS'interaction,with'
p7996
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp7997
sS'depresses,the'
p7998
(F1
F0.00076452599388379206
I1
I0
I1
tp7999
sS'of,who'
p8000
(F1
F0.00076452599388379206
I1
I0
I1
tp8001
sS'shimadzu,hplc'
p8002
(F1
F0.00076452599388379206
I0
I1
I-1
tp8003
sS'database,of'
p8004
(F1
F0.00076452599388379206
I0
I1
I-1
tp8005
sS'i,cmax'
p8006
(F1
F0.00076452599388379206
I1
I0
I1
tp8007
sS'data,demonstrate'
p8008
(F1
F0.00076452599388379206
I1
I0
I1
tp8009
sS'clinically,significant'
p8010
(F0.5
F0.0030581039755351682
I2
I6
I-4
tp8011
sS'cholestyramine,pretreatment'
p8012
(F1
F0.00076452599388379206
I1
I0
I1
tp8013
sS'reuptake,inhibitors'
p8014
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp8015
sS'woman,on'
p8016
(F1
F0.0015290519877675841
I2
I0
I2
tp8017
sS'been,established'
p8018
(F1
F0.00076452599388379206
I1
I0
I1
tp8019
sS'serotonin,and'
p8020
(F1
F0.00076452599388379206
I0
I1
I-1
tp8021
sS'depressants,the'
p8022
(F1
F0.00076452599388379206
I1
I0
I1
tp8023
sS'arrhythmias,during'
p8024
(F1
F0.0015290519877675841
I2
I0
I2
tp8025
sS'with,end-stage'
p8026
(F1
F0.00076452599388379206
I0
I1
I-1
tp8027
sS'slices,do'
p8028
(F1
F0.00076452599388379206
I0
I1
I-1
tp8029
sS'not,interfere'
p8030
(F1
F0.00076452599388379206
I0
I1
I-1
tp8031
sS'common,premedications'
p8032
(F1
F0.00076452599388379206
I0
I1
I-1
tp8033
sS'data,and'
p8034
(F1
F0.00076452599388379206
I1
I0
I1
tp8035
sS'possibility,of'
p8036
(F0.5
F0.0015290519877675841
I3
I1
I2
tp8037
sS'the,bioavailability'
p8038
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp8039
sS'that,impair'
p8040
(F1
F0.00076452599388379206
I1
I0
I1
tp8041
sS'ketoconazole,spontaneous'
p8042
(F1
F0.00076452599388379206
I1
I0
I1
tp8043
sS'demonstrated,sensitization'
p8044
(F1
F0.00076452599388379206
I0
I1
I-1
tp8045
sS'responsiveness,before'
p8046
(F1
F0.00076452599388379206
I0
I1
I-1
tp8047
sS'groups,whereas'
p8048
(F1
F0.00076452599388379206
I1
I0
I1
tp8049
sS'family,st'
p8050
(F1
F0.00076452599388379206
I1
I0
I1
tp8051
sS'model,nitrogen'
p8052
(F1
F0.00076452599388379206
I1
I0
I1
tp8053
sS'adding,to'
p8054
(F1
F0.00076452599388379206
I1
I0
I1
tp8055
sS'acute,mi'
p8056
(F1
F0.00076452599388379206
I0
I1
I-1
tp8057
sS'significantly,increases'
p8058
(F1
F0.00076452599388379206
I1
I0
I1
tp8059
sS'of,tyrosine'
p8060
(F1
F0.00076452599388379206
I1
I0
I1
tp8061
sS'whereas,treatment'
p8062
(F1
F0.00076452599388379206
I1
I0
I1
tp8063
sS'concomitantly,treated'
p8064
(F1
F0.00076452599388379206
I0
I1
I-1
tp8065
sS'gel,is'
p8066
(F1
F0.00076452599388379206
I0
I1
I-1
tp8067
sS'affect,invega'
p8068
(F1
F0.00076452599388379206
I0
I1
I-1
tp8069
sS'by,those'
p8070
(F1
F0.00076452599388379206
I0
I1
I-1
tp8071
sS'two,classes'
p8072
(F1
F0.00076452599388379206
I0
I1
I-1
tp8073
sS'subsequently,received'
p8074
(F1
F0.00076452599388379206
I1
I0
I1
tp8075
sS'significantly,increased'
p8076
(F1
F0.0030581039755351682
I4
I0
I4
tp8077
sS'gh,administration'
p8078
(F1
F0.00076452599388379206
I1
I0
I1
tp8079
sS'sunitinib,as'
p8080
(F1
F0.00076452599388379206
I1
I0
I1
tp8081
sS'the,second'
p8082
(F1
F0.00076452599388379206
I1
I0
I1
tp8083
sS'with,other'
p8084
(F0.48148148148148145
F0.0099388379204892966
I20
I7
I13
tp8085
sS'purine,metabolism'
p8086
(F1
F0.00076452599388379206
I1
I0
I1
tp8087
sS'thus,symlin'
p8088
(F1
F0.00076452599388379206
I0
I1
I-1
tp8089
sS'these,nsaids'
p8090
(F1
F0.00076452599388379206
I1
I0
I1
tp8091
sS'were,poor'
p8092
(F1
F0.00076452599388379206
I1
I0
I1
tp8093
sS'observed,increase'
p8094
(F1
F0.00076452599388379206
I0
I1
I-1
tp8095
sS'incoordination,when'
p8096
(F1
F0.00076452599388379206
I1
I0
I1
tp8097
sS'as,suxamethonium'
p8098
(F1
F0.00076452599388379206
I1
I0
I1
tp8099
sS'studies,acetylsalicylic'
p8100
(F1
F0.00076452599388379206
I0
I1
I-1
tp8101
sS'herbal,supplements'
p8102
(F1
F0.00076452599388379206
I0
I1
I-1
tp8103
sS'typical,of'
p8104
(F1
F0.00076452599388379206
I1
I0
I1
tp8105
sS'blocking,action'
p8106
(F1
F0.0015290519877675841
I2
I0
I2
tp8107
sS'supplements,such'
p8108
(F1
F0.00076452599388379206
I0
I1
I-1
tp8109
sS'reported,with'
p8110
(F1
F0.0030581039755351682
I4
I0
I4
tp8111
sS'bronchodilators,and'
p8112
(F1
F0.00076452599388379206
I0
I1
I-1
tp8113
sS'aminosalicylate,derivatives'
p8114
(F1
F0.00076452599388379206
I1
I0
I1
tp8115
sS'of,oxycodone'
p8116
(F1
F0.00076452599388379206
I1
I0
I1
tp8117
sS'of,chickens'
p8118
(F1
F0.00076452599388379206
I0
I1
I-1
tp8119
sS'therapy,mg'
p8120
(F1
F0.00076452599388379206
I1
I0
I1
tp8121
sS'hy-per,parathyroidism'
p8122
(F1
F0.00076452599388379206
I0
I1
I-1
tp8123
sS'with,adrenal'
p8124
(F1
F0.00076452599388379206
I0
I1
I-1
tp8125
sS'we,evaluated'
p8126
(F1
F0.0022935779816513763
I0
I3
I-3
tp8127
sS'methscopolamine,may'
p8128
(F1
F0.00076452599388379206
I1
I0
I1
tp8129
sS'group,of'
p8130
(F1
F0.00076452599388379206
I0
I1
I-1
tp8131
sS'rats,using'
p8132
(F1
F0.00076452599388379206
I0
I1
I-1
tp8133
sS'furoate,during'
p8134
(F1
F0.00076452599388379206
I1
I0
I1
tp8135
sS'cytotoxicity,by'
p8136
(F1
F0.00076452599388379206
I1
I0
I1
tp8137
sS'of,causing'
p8138
(F1
F0.0015290519877675841
I2
I0
I2
tp8139
sS'of,food'
p8140
(F1
F0.00076452599388379206
I1
I0
I1
tp8141
sS'volunteers,ingested'
p8142
(F1
F0.00076452599388379206
I0
I1
I-1
tp8143
sS'levels,and'
p8144
(F1
F0.0038226299694189602
I5
I0
I5
tp8145
sS'sequential,systemic'
p8146
(F1
F0.00076452599388379206
I0
I1
I-1
tp8147
sS'dosage,adjustment'
p8148
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp8149
sS'anafranil,vivactil'
p8150
(F1
F0.00076452599388379206
I0
I1
I-1
tp8151
sS'sensitization,and'
p8152
(F1
F0.0015290519877675841
I0
I2
I-2
tp8153
sS'fecal,fat'
p8154
(F1
F0.00076452599388379206
I0
I1
I-1
tp8155
sS'nsaids,concomitantly'
p8156
(F1
F0.00076452599388379206
I1
I0
I1
tp8157
sS'vehicle,were'
p8158
(F1
F0.00076452599388379206
I0
I1
I-1
tp8159
sS'concurrent,administration'
p8160
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp8161
sS'decreases,gastrointestinal'
p8162
(F1
F0.00076452599388379206
I1
I0
I1
tp8163
sS'lower,rate'
p8164
(F1
F0.00076452599388379206
I1
I0
I1
tp8165
sS'antidiabetic,agents'
p8166
(F1
F0.00076452599388379206
I0
I1
I-1
tp8167
sS'by,altering'
p8168
(F1
F0.00076452599388379206
I1
I0
I1
tp8169
sS'the,occurrence'
p8170
(F1
F0.0015290519877675841
I2
I0
I2
tp8171
sS'pressure,medicines'
p8172
(F1
F0.00076452599388379206
I0
I1
I-1
tp8173
sS'thyroid,hormones'
p8174
(F1
F0.00076452599388379206
I0
I1
I-1
tp8175
sS'week,dietary'
p8176
(F1
F0.0015290519877675841
I0
I2
I-2
tp8177
sS'indicate,that'
p8178
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp8179
sS'topical,application'
p8180
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp8181
sS'when,metrogel'
p8182
(F1
F0.00076452599388379206
I0
I1
I-1
tp8183
sS'drops,before'
p8184
(F1
F0.00076452599388379206
I0
I1
I-1
tp8185
sS'acid,decreases'
p8186
(F1
F0.00076452599388379206
I1
I0
I1
tp8187
sS'clinical,pharmacology'
p8188
(F1
F0.00076452599388379206
I1
I0
I1
tp8189
sS'a,small'
p8190
(F1
F0.00076452599388379206
I1
I0
I1
tp8191
sS'with,sanctura'
p8192
(F1
F0.00076452599388379206
I1
I0
I1
tp8193
sS'or,drug'
p8194
(F1
F0.00076452599388379206
I0
I1
I-1
tp8195
sS'the,fda'
p8196
(F1
F0.00076452599388379206
I1
I0
I1
tp8197
sS'a,promising'
p8198
(F1
F0.00076452599388379206
I0
I1
I-1
tp8199
sS'activity,should'
p8200
(F1
F0.00076452599388379206
I1
I0
I1
tp8201
sS'evidence,of'
p8202
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp8203
sS'with,reduction'
p8204
(F1
F0.00076452599388379206
I0
I1
I-1
tp8205
sS'different,incubation'
p8206
(F1
F0.00076452599388379206
I0
I1
I-1
tp8207
sS'the,chemical'
p8208
(F1
F0.00076452599388379206
I1
I0
I1
tp8209
sS'phases,p'
p8210
(F1
F0.00076452599388379206
I0
I1
I-1
tp8211
sS'sanctura,with'
p8212
(F0
F0
I1
I1
I0
tp8213
sS'women,on'
p8214
(F1
F0.00076452599388379206
I1
I0
I1
tp8215
sS'potential,to'
p8216
(F0
F0
I2
I2
I0
tp8217
sS'are,on'
p8218
(F1
F0.00076452599388379206
I1
I0
I1
tp8219
sS'establish,potential'
p8220
(F1
F0.00076452599388379206
I0
I1
I-1
tp8221
sS'displacement,of'
p8222
(F1
F0.00076452599388379206
I0
I1
I-1
tp8223
sS'highly,protein-bound'
p8224
(F1
F0.00076452599388379206
I1
I0
I1
tp8225
sS'peak,drug'
p8226
(F1
F0.00076452599388379206
I1
I0
I1
tp8227
sS'in,found'
p8228
(F1
F0.00076452599388379206
I1
I0
I1
tp8229
sS'patients,on'
p8230
(F0.33333333333333331
F0.0030581039755351682
I8
I4
I4
tp8231
sS'when,potent'
p8232
(F1
F0.0015290519877675841
I2
I0
I2
tp8233
sS'impair,intestinal'
p8234
(F1
F0.00076452599388379206
I1
I0
I1
tp8235
sS'as,there'
p8236
(F1
F0.00076452599388379206
I1
I0
I1
tp8237
sS'study,healthy'
p8238
(F1
F0.00076452599388379206
I0
I1
I-1
tp8239
sS'clinically,important'
p8240
(F1
F0.0030581039755351682
I0
I4
I-4
tp8241
sS'a5,and'
p8242
(F1
F0.00076452599388379206
I1
I0
I1
tp8243
sS'observation,of'
p8244
(F1
F0.00076452599388379206
I1
I0
I1
tp8245
sS'in,vasospasm'
p8246
(F1
F0.00076452599388379206
I0
I1
I-1
tp8247
sS'from,a'
p8248
(F1
F0.00076452599388379206
I1
I0
I1
tp8249
sS'in,combination'
p8250
(F0.20000000000000001
F0.0022935779816513763
I9
I6
I3
tp8251
sS'of,when'
p8252
(F0.5
F0.0030581039755351682
I6
I2
I4
tp8253
sS'for,other'
p8254
(F0
F0
I1
I1
I0
tp8255
sS'drugs,should'
p8256
(F1
F0.0015290519877675841
I2
I0
I2
tp8257
sS'as,acetylcholine'
p8258
(F1
F0.00076452599388379206
I1
I0
I1
tp8259
sS'a,reaction'
p8260
(F1
F0.00076452599388379206
I1
I0
I1
tp8261
sS'are,fluoroquinolone'
p8262
(F1
F0.00076452599388379206
I0
I1
I-1
tp8263
sS'n,in'
p8264
(F1
F0.00076452599388379206
I0
I1
I-1
tp8265
sS'following,drugs'
p8266
(F0
F0
I1
I1
I0
tp8267
sS'compounds,known'
p8268
(F1
F0.00076452599388379206
I1
I0
I1
tp8269
sS'lithium,in'
p8270
(F1
F0.00076452599388379206
I1
I0
I1
tp8271
sS'to,prolong'
p8272
(F1
F0.00076452599388379206
I1
I0
I1
tp8273
sS'pressure,may'
p8274
(F0
F0
I1
I1
I0
tp8275
sS'demonstrated,with'
p8276
(F1
F0.00076452599388379206
I1
I0
I1
tp8277
sS'hexamethylenimine,mg'
p8278
(F1
F0.00076452599388379206
I0
I1
I-1
tp8279
sS'patient,s'
p8280
(F1
F0.00076452599388379206
I1
I0
I1
tp8281
sS'and,prolonged'
p8282
(F1
F0.00076452599388379206
I1
I0
I1
tp8283
sS'of,cyp1a2'
p8284
(F1
F0.00076452599388379206
I0
I1
I-1
tp8285
sS'xenical,patients'
p8286
(F1
F0.00076452599388379206
I1
I0
I1
tp8287
sS'lyase,heparinase'
p8288
(F1
F0.00076452599388379206
I0
I1
I-1
tp8289
sS'hours,after'
p8290
(F1
F0.0015290519877675841
I2
I0
I2
tp8291
sS'primary,cns'
p8292
(F1
F0.00076452599388379206
I1
I0
I1
tp8293
sS'relative,to'
p8294
(F1
F0.00076452599388379206
I0
I1
I-1
tp8295
sS'assess,the'
p8296
(F1
F0.00076452599388379206
I0
I1
I-1
tp8297
sS'broad,range'
p8298
(F1
F0.00076452599388379206
I0
I1
I-1
tp8299
sS'the,influence'
p8300
(F1
F0.00076452599388379206
I0
I1
I-1
tp8301
sS'tablets,may'
p8302
(F1
F0.0015290519877675841
I0
I2
I-2
tp8303
sS'a,substrate'
p8304
(F1
F0.0030581039755351682
I0
I4
I-4
tp8305
sS'for,therapy'
p8306
(F1
F0.00076452599388379206
I0
I1
I-1
tp8307
sS'fixed,combination'
p8308
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp8309
sS'levonorgestrel-containing,oral'
p8310
(F1
F0.00076452599388379206
I1
I0
I1
tp8311
sS'in,acute'
p8312
(F1
F0.00076452599388379206
I0
I1
I-1
tp8313
sS'or,not'
p8314
(F1
F0.0015290519877675841
I2
I0
I2
tp8315
sS'either,discontinuing'
p8316
(F1
F0.00076452599388379206
I1
I0
I1
tp8317
sS'the,dosage'
p8318
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp8319
sS'mechanism,which'
p8320
(F1
F0.00076452599388379206
I1
I0
I1
tp8321
sS'drug,due'
p8322
(F1
F0.00076452599388379206
I0
I1
I-1
tp8323
sS'metastatic,breast'
p8324
(F1
F0.00076452599388379206
I1
I0
I1
tp8325
sS'adequate,sedation'
p8326
(F1
F0.00076452599388379206
I0
I1
I-1
tp8327
sS'interrupt,enterohepatic'
p8328
(F1
F0.00076452599388379206
I0
I1
I-1
tp8329
sS'and,enterohepatic'
p8330
(F1
F0.00076452599388379206
I1
I0
I1
tp8331
sS'studies,evaluating'
p8332
(F1
F0.00076452599388379206
I0
I1
I-1
tp8333
sS'orally,disintegrating'
p8334
(F1
F0.00076452599388379206
I0
I1
I-1
tp8335
sS'elicit,this'
p8336
(F1
F0.00076452599388379206
I1
I0
I1
tp8337
sS'function,in'
p8338
(F1
F0.00076452599388379206
I1
I0
I1
tp8339
sS'on,two'
p8340
(F1
F0.00076452599388379206
I1
I0
I1
tp8341
sS'following,intravitreal'
p8342
(F1
F0.00076452599388379206
I0
I1
I-1
tp8343
sS'as,to'
p8344
(F1
F0.00076452599388379206
I1
I0
I1
tp8345
sS'other,hepatic'
p8346
(F1
F0.00076452599388379206
I1
I0
I1
tp8347
sS'clinical,circumstances'
p8348
(F1
F0.00076452599388379206
I1
I0
I1
tp8349
sS'oral,or'
p8350
(F1
F0.00076452599388379206
I1
I0
I1
tp8351
sS'also,inhibited'
p8352
(F1
F0.00076452599388379206
I1
I0
I1
tp8353
sS'cyp2c19,so'
p8354
(F1
F0.00076452599388379206
I0
I1
I-1
tp8355
sS'recommended,that'
p8356
(F1
F0.0030581039755351682
I4
I0
I4
tp8357
sS'both,nonheme'
p8358
(F1
F0.00076452599388379206
I1
I0
I1
tp8359
sS'oxidase,mao'
p8360
(F1
F0.00076452599388379206
I0
I1
I-1
tp8361
sS'body,weight'
p8362
(F1
F0.00076452599388379206
I0
I1
I-1
tp8363
sS'administered,after'
p8364
(F1
F0.00076452599388379206
I0
I1
I-1
tp8365
sS'that,low-dose'
p8366
(F1
F0.00076452599388379206
I1
I0
I1
tp8367
sS'interfere,with'
p8368
(F0.55555555555555558
F0.0038226299694189602
I7
I2
I5
tp8369
sS'matulane,exhibits'
p8370
(F1
F0.00076452599388379206
I1
I0
I1
tp8371
sS'the,control'
p8372
(F1
F0.00076452599388379206
I0
I1
I-1
tp8373
sS'of,administered'
p8374
(F1
F0.00076452599388379206
I0
I1
I-1
tp8375
sS'to,metabolize'
p8376
(F1
F0.00076452599388379206
I1
I0
I1
tp8377
sS'fewer,drugs'
p8378
(F1
F0.00076452599388379206
I1
I0
I1
tp8379
sS'experimental,groups'
p8380
(F1
F0.00076452599388379206
I0
I1
I-1
tp8381
sS'antagonist,opioid'
p8382
(F1
F0.00076452599388379206
I1
I0
I1
tp8383
sS'identify,any'
p8384
(F1
F0.00076452599388379206
I0
I1
I-1
tp8385
sS'if,evista'
p8386
(F1
F0.00076452599388379206
I1
I0
I1
tp8387
sS'a,common'
p8388
(F1
F0.00076452599388379206
I1
I0
I1
tp8389
sS'or,following'
p8390
(F1
F0.00076452599388379206
I0
I1
I-1
tp8391
sS'mean,chloride'
p8392
(F1
F0.00076452599388379206
I1
I0
I1
tp8393
sS'adrenergic,blockers'
p8394
(F1
F0.00076452599388379206
I1
I0
I1
tp8395
sS'mechanism,is'
p8396
(F1
F0.00076452599388379206
I1
I0
I1
tp8397
sS'when,studied'
p8398
(F1
F0.00076452599388379206
I0
I1
I-1
tp8399
sS'sensitivity,cell'
p8400
(F1
F0.00076452599388379206
I0
I1
I-1
tp8401
sS'isoflurane,and'
p8402
(F1
F0.00076452599388379206
I0
I1
I-1
tp8403
sS'was,to'
p8404
(F1
F0.0045871559633027525
I0
I6
I-6
tp8405
sS'mg,was'
p8406
(F1
F0.0015290519877675841
I0
I2
I-2
tp8407
sS'cyp2c9,and'
p8408
(F1
F0.00076452599388379206
I0
I1
I-1
tp8409
sS'coeruleus,and'
p8410
(F1
F0.00076452599388379206
I1
I0
I1
tp8411
sS'tachypnea,lethargy'
p8412
(F1
F0.00076452599388379206
I1
I0
I1
tp8413
sS'should,carefully'
p8414
(F1
F0.00076452599388379206
I1
I0
I1
tp8415
sS'characterization,of'
p8416
(F1
F0.00076452599388379206
I1
I0
I1
tp8417
sS'cyp,inhibitors'
p8418
(F1
F0.00076452599388379206
I0
I1
I-1
tp8419
sS'thalidomide,has'
p8420
(F1
F0.00076452599388379206
I1
I0
I1
tp8421
sS'other,eye'
p8422
(F1
F0.00076452599388379206
I1
I0
I1
tp8423
sS'because,the'
p8424
(F1
F0.0015290519877675841
I2
I0
I2
tp8425
sS'inhibitors,during'
p8426
(F1
F0.00076452599388379206
I1
I0
I1
tp8427
sS'least,days'
p8428
(F1
F0.00076452599388379206
I1
I0
I1
tp8429
sS'as,blockers'
p8430
(F1
F0.00076452599388379206
I0
I1
I-1
tp8431
sS'the,small'
p8432
(F1
F0.0015290519877675841
I2
I0
I2
tp8433
sS'sedation,including'
p8434
(F1
F0.00076452599388379206
I0
I1
I-1
tp8435
sS'may,compete'
p8436
(F0
F0
I1
I1
I0
tp8437
sS'enzymes,inhibition'
p8438
(F1
F0.00076452599388379206
I0
I1
I-1
tp8439
sS'with,results'
p8440
(F0
F0
I1
I1
I0
tp8441
sS'and,cyp2c19'
p8442
(F1
F0.00076452599388379206
I0
I1
I-1
tp8443
sS'steroid,therapy'
p8444
(F1
F0.00076452599388379206
I0
I1
I-1
tp8445
sS'lt,and'
p8446
(F1
F0.00076452599388379206
I0
I1
I-1
tp8447
sS'diflucan,and'
p8448
(F1
F0.0030581039755351682
I4
I0
I4
tp8449
sS'reduction,in'
p8450
(F0.20000000000000001
F0.0015290519877675841
I6
I4
I2
tp8451
sS'to,fu'
p8452
(F1
F0.00076452599388379206
I0
I1
I-1
tp8453
sS'cns,depressant'
p8454
(F1
F0.0030581039755351682
I4
I0
I4
tp8455
sS'anticholinergic-like,effects'
p8456
(F1
F0.00076452599388379206
I1
I0
I1
tp8457
sS'and,alpha'
p8458
(F1
F0.00076452599388379206
I0
I1
I-1
tp8459
sS'can,increase'
p8460
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp8461
sS'some,of'
p8462
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp8463
sS'in,adequately'
p8464
(F1
F0.00076452599388379206
I0
I1
I-1
tp8465
sS'cyp3a,activity'
p8466
(F1
F0.00076452599388379206
I0
I1
I-1
tp8467
sS'on,effects'
p8468
(F1
F0.00076452599388379206
I0
I1
I-1
tp8469
sS'little,effect'
p8470
(F1
F0.00076452599388379206
I1
I0
I1
tp8471
sS'appropriateness,of'
p8472
(F1
F0.00076452599388379206
I1
I0
I1
tp8473
sS'only,with'
p8474
(F1
F0.0015290519877675841
I2
I0
I2
tp8475
sS'to,patients'
p8476
(F0.63636363636363635
F0.0053516819571865441
I9
I2
I7
tp8477
sS'protease,or'
p8478
(F1
F0.00076452599388379206
I0
I1
I-1
tp8479
sS'induced,antinociception'
p8480
(F1
F0.00076452599388379206
I0
I1
I-1
tp8481
sS'the,potential'
p8482
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp8483
sS'and,induce'
p8484
(F1
F0.00076452599388379206
I1
I0
I1
tp8485
sS'enterohepatic,recirculation'
p8486
(F0
F0
I1
I1
I0
tp8487
sS'an,is'
p8488
(F1
F0.00076452599388379206
I1
I0
I1
tp8489
sS'an,in'
p8490
(F1
F0.0015290519877675841
I2
I0
I2
tp8491
sS'the,effect'
p8492
(F0.44444444444444442
F0.0061162079510703364
I5
I13
I-8
tp8493
sS'who,were'
p8494
(F1
F0.0015290519877675841
I2
I0
I2
tp8495
sS'kg,g'
p8496
(F1
F0.00076452599388379206
I0
I1
I-1
tp8497
sS'vaccines,should'
p8498
(F1
F0.00076452599388379206
I1
I0
I1
tp8499
sS'coadministered,drug'
p8500
(F1
F0.00076452599388379206
I0
I1
I-1
tp8501
sS'in,the'
p8502
(F0.16
F0.0061162079510703364
I29
I21
I8
tp8503
sS'effective,indicating'
p8504
(F1
F0.00076452599388379206
I0
I1
I-1
tp8505
sS'so,that'
p8506
(F1
F0.00076452599388379206
I0
I1
I-1
tp8507
sS'therapies,thiazide'
p8508
(F1
F0.00076452599388379206
I0
I1
I-1
tp8509
sS'in,stable'
p8510
(F1
F0.00076452599388379206
I0
I1
I-1
tp8511
sS'of,humoral'
p8512
(F1
F0.00076452599388379206
I0
I1
I-1
tp8513
sS'absorption,relative'
p8514
(F1
F0.00076452599388379206
I0
I1
I-1
tp8515
sS'of,effectiveness'
p8516
(F1
F0.00076452599388379206
I1
I0
I1
tp8517
sS'recommended,because'
p8518
(F1
F0.00076452599388379206
I1
I0
I1
tp8519
sS'until,the'
p8520
(F1
F0.00076452599388379206
I0
I1
I-1
tp8521
sS'dznep,and'
p8522
(F1
F0.00076452599388379206
I1
I0
I1
tp8523
sS'determinant,of'
p8524
(F1
F0.0015290519877675841
I2
I0
I2
tp8525
sS'it,appears'
p8526
(F1
F0.00076452599388379206
I1
I0
I1
tp8527
sS'needed,higher'
p8528
(F1
F0.00076452599388379206
I1
I0
I1
tp8529
sS'and,motor'
p8530
(F1
F0.00076452599388379206
I1
I0
I1
tp8531
sS'intracellular,levels'
p8532
(F1
F0.00076452599388379206
I1
I0
I1
tp8533
sS'cholinesterase,resistance'
p8534
(F1
F0.00076452599388379206
I1
I0
I1
tp8535
sS'acid,and'
p8536
(F1
F0.0015290519877675841
I2
I0
I2
tp8537
sS'substances,that'
p8538
(F1
F0.00076452599388379206
I1
I0
I1
tp8539
sS'patients,who'
p8540
(F0.55555555555555558
F0.0038226299694189602
I7
I2
I5
tp8541
sS'following,co-administration'
p8542
(F1
F0.00076452599388379206
I0
I1
I-1
tp8543
sS'inhibitors,resulting'
p8544
(F1
F0.00076452599388379206
I0
I1
I-1
tp8545
sS'otherwise,contraindicated'
p8546
(F1
F0.00076452599388379206
I0
I1
I-1
tp8547
sS'to,inactivated'
p8548
(F1
F0.0015290519877675841
I0
I2
I-2
tp8549
sS'increase,sensitivity'
p8550
(F1
F0.00076452599388379206
I1
I0
I1
tp8551
sS'study,it'
p8552
(F1
F0.00076452599388379206
I1
I0
I1
tp8553
sS'of,mivacron'
p8554
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp8555
sS'considered,for'
p8556
(F1
F0.00076452599388379206
I1
I0
I1
tp8557
sS'was,given'
p8558
(F1
F0.0015290519877675841
I0
I2
I-2
tp8559
sS'enhanced,as'
p8560
(F1
F0.0015290519877675841
I2
I0
I2
tp8561
sS'replication,of'
p8562
(F1
F0.00076452599388379206
I1
I0
I1
tp8563
sS'the,frequency'
p8564
(F1
F0.0015290519877675841
I2
I0
I2
tp8565
sS'study,in'
p8566
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp8567
sS'depo-subq,provera'
p8568
(F1
F0.00076452599388379206
I1
I0
I1
tp8569
sS'measurement,of'
p8570
(F1
F0.00076452599388379206
I0
I1
I-1
tp8571
sS'g,maximum'
p8572
(F1
F0.00076452599388379206
I0
I1
I-1
tp8573
sS'presently,available'
p8574
(F1
F0.00076452599388379206
I0
I1
I-1
tp8575
sS'a,few'
p8576
(F1
F0.00076452599388379206
I0
I1
I-1
tp8577
sS'co-administration,of'
p8578
(F0.75
F0.0045871559633027525
I7
I1
I6
tp8579
sS'iii,and'
p8580
(F1
F0.00076452599388379206
I0
I1
I-1
tp8581
sS'preference,in'
p8582
(F1
F0.00076452599388379206
I0
I1
I-1
tp8583
sS'spontaneous,recovery'
p8584
(F1
F0.00076452599388379206
I1
I0
I1
tp8585
sS'depression-producing,drugs'
p8586
(F1
F0.00076452599388379206
I1
I0
I1
tp8587
sS'decreased,c'
p8588
(F1
F0.00076452599388379206
I1
I0
I1
tp8589
sS'inhibitors,close'
p8590
(F1
F0.00076452599388379206
I0
I1
I-1
tp8591
sS'of,serum'
p8592
(F1
F0.00076452599388379206
I1
I0
I1
tp8593
sS'were,conducted'
p8594
(F1
F0.00076452599388379206
I0
I1
I-1
tp8595
sS'inhibit,ovarian'
p8596
(F1
F0.00076452599388379206
I1
I0
I1
tp8597
sS'by,containing'
p8598
(F1
F0.00076452599388379206
I1
I0
I1
tp8599
sS'include,sympathomimetic'
p8600
(F1
F0.00076452599388379206
I0
I1
I-1
tp8601
sS'the,rate'
p8602
(F0.25
F0.0015290519877675841
I5
I3
I2
tp8603
sS'potential,refer'
p8604
(F1
F0.00076452599388379206
I0
I1
I-1
tp8605
sS'a,monoamine'
p8606
(F1
F0.00076452599388379206
I1
I0
I1
tp8607
sS'potential,interaction'
p8608
(F1
F0.00076452599388379206
I1
I0
I1
tp8609
sS'lithium,renal'
p8610
(F1
F0.00076452599388379206
I1
I0
I1
tp8611
sS'for,t-all'
p8612
(F1
F0.00076452599388379206
I0
I1
I-1
tp8613
sS'in,normal'
p8614
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp8615
sS'followed,by'
p8616
(F1
F0.0015290519877675841
I2
I0
I2
tp8617
sS'the,concomitant'
p8618
(F0
F0
I3
I3
I0
tp8619
sS'fibrosis,leading'
p8620
(F1
F0.00076452599388379206
I0
I1
I-1
tp8621
sS'other,tranquilizers'
p8622
(F1
F0.00076452599388379206
I1
I0
I1
tp8623
sS'that,of'
p8624
(F0
F0
I4
I4
I0
tp8625
sS'with,improved'
p8626
(F1
F0.00076452599388379206
I0
I1
I-1
tp8627
sS'that,on'
p8628
(F1
F0.00076452599388379206
I0
I1
I-1
tp8629
sS'injectable,emulsion'
p8630
(F0
F0
I2
I2
I0
tp8631
sS'on,gastric'
p8632
(F1
F0.00076452599388379206
I1
I0
I1
tp8633
sS'formal,interaction'
p8634
(F1
F0.00076452599388379206
I0
I1
I-1
tp8635
sS'hyaluronidase,hyaluronidase'
p8636
(F1
F0.00076452599388379206
I1
I0
I1
tp8637
sS'metabolism,increasing'
p8638
(F1
F0.00076452599388379206
I1
I0
I1
tp8639
sS'when,taken'
p8640
(F1
F0.0015290519877675841
I2
I0
I2
tp8641
sS'taken,in'
p8642
(F1
F0.00076452599388379206
I1
I0
I1
tp8643
sS'taking,a'
p8644
(F1
F0.00076452599388379206
I0
I1
I-1
tp8645
sS'drugs,that'
p8646
(F0.36363636363636365
F0.0061162079510703364
I15
I7
I8
tp8647
sS'had,indications'
p8648
(F1
F0.00076452599388379206
I0
I1
I-1
tp8649
sS'the,difficulty'
p8650
(F1
F0.00076452599388379206
I0
I1
I-1
tp8651
sS'kinetics,of'
p8652
(F1
F0.0030581039755351682
I0
I4
I-4
tp8653
sS'other,proton'
p8654
(F1
F0.00076452599388379206
I0
I1
I-1
tp8655
sS'kip1,decreased'
p8656
(F1
F0.00076452599388379206
I0
I1
I-1
tp8657
sS'demser,to'
p8658
(F1
F0.00076452599388379206
I1
I0
I1
tp8659
sS'for,an'
p8660
(F1
F0.00076452599388379206
I0
I1
I-1
tp8661
sS'for,sites'
p8662
(F1
F0.00076452599388379206
I1
I0
I1
tp8663
sS'are,resistant'
p8664
(F1
F0.00076452599388379206
I0
I1
I-1
tp8665
sS'compounds,to'
p8666
(F1
F0.00076452599388379206
I1
I0
I1
tp8667
sS'intake,prior'
p8668
(F1
F0.00076452599388379206
I1
I0
I1
tp8669
sS'hcl,mg'
p8670
(F1
F0.0015290519877675841
I0
I2
I-2
tp8671
sS'requirement,in'
p8672
(F1
F0.00076452599388379206
I0
I1
I-1
tp8673
sS'for,or'
p8674
(F1
F0.00076452599388379206
I1
I0
I1
tp8675
sS'impaired,renal'
p8676
(F1
F0.00076452599388379206
I1
I0
I1
tp8677
sS'b6,inhibitor'
p8678
(F1
F0.00076452599388379206
I0
I1
I-1
tp8679
sS'to,when'
p8680
(F1
F0.00076452599388379206
I1
I0
I1
tp8681
sS'interesting,case'
p8682
(F1
F0.00076452599388379206
I1
I0
I1
tp8683
sS'emerge,if'
p8684
(F1
F0.00076452599388379206
I1
I0
I1
tp8685
sS'likely,to'
p8686
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp8687
sS'in,reducing'
p8688
(F1
F0.00076452599388379206
I0
I1
I-1
tp8689
sS'with,acute'
p8690
(F1
F0.00076452599388379206
I1
I0
I1
tp8691
sS'given,until'
p8692
(F1
F0.00076452599388379206
I1
I0
I1
tp8693
sS'marplan,parnate'
p8694
(F1
F0.00076452599388379206
I1
I0
I1
tp8695
sS'but,does'
p8696
(F1
F0.00076452599388379206
I1
I0
I1
tp8697
sS'given,in'
p8698
(F1
F0.00076452599388379206
I0
I1
I-1
tp8699
sS'coadministration,beta'
p8700
(F1
F0.00076452599388379206
I1
I0
I1
tp8701
sS'drug,drug'
p8702
(F1
F0.00076452599388379206
I1
I0
I1
tp8703
sS'serious,cardiac'
p8704
(F1
F0.0022935779816513763
I3
I0
I3
tp8705
sS'calcium-channel,blocking'
p8706
(F1
F0.00076452599388379206
I0
I1
I-1
tp8707
sS'the,development'
p8708
(F1
F0.00076452599388379206
I0
I1
I-1
tp8709
sS'antipsychotic,agents'
p8710
(F1
F0.00076452599388379206
I1
I0
I1
tp8711
sS'diazepam,concomitant'
p8712
(F1
F0.00076452599388379206
I1
I0
I1
tp8713
sS'qd,as'
p8714
(F1
F0.00076452599388379206
I1
I0
I1
tp8715
sS'levels,should'
p8716
(F1
F0.00076452599388379206
I1
I0
I1
tp8717
sS'will,elevate'
p8718
(F1
F0.00076452599388379206
I0
I1
I-1
tp8719
sS'the,metabolism'
p8720
(F0.1111111111111111
F0.0015290519877675841
I10
I8
I2
tp8721
sS'concentrations,by'
p8722
(F1
F0.00076452599388379206
I1
I0
I1
tp8723
sS'mediated,clearance'
p8724
(F1
F0.00076452599388379206
I1
I0
I1
tp8725
sS'cell,surface'
p8726
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp8727
sS'thiazide,may'
p8728
(F1
F0.00076452599388379206
I1
I0
I1
tp8729
sS'as,or'
p8730
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp8731
sS'such,drugs'
p8732
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp8733
sS'of,after'
p8734
(F1
F0.00076452599388379206
I0
I1
I-1
tp8735
sS'ph,is'
p8736
(F1
F0.00076452599388379206
I1
I0
I1
tp8737
sS'if,tolectin'
p8738
(F1
F0.00076452599388379206
I1
I0
I1
tp8739
sS'following,succinylcholine-facilitated'
p8740
(F1
F0.00076452599388379206
I0
I1
I-1
tp8741
sS'of,high-dose'
p8742
(F1
F0.00076452599388379206
I1
I0
I1
tp8743
sS'of,such'
p8744
(F0
F0
I2
I2
I0
tp8745
sS'with,consideration'
p8746
(F1
F0.00076452599388379206
I1
I0
I1
tp8747
sS'useful,especially'
p8748
(F1
F0.00076452599388379206
I0
I1
I-1
tp8749
sS'you,have'
p8750
(F1
F0.00076452599388379206
I1
I0
I1
tp8751
sS'g,had'
p8752
(F1
F0.00076452599388379206
I1
I0
I1
tp8753
sS'probenecid,a'
p8754
(F1
F0.00076452599388379206
I0
I1
I-1
tp8755
sS'timing,of'
p8756
(F1
F0.00076452599388379206
I1
I0
I1
tp8757
sS'agents,h2'
p8758
(F1
F0.00076452599388379206
I0
I1
I-1
tp8759
sS'nevertheless,during'
p8760
(F1
F0.00076452599388379206
I1
I0
I1
tp8761
sS'with,herceptin'
p8762
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp8763
sS'groups,in'
p8764
(F1
F0.00076452599388379206
I1
I0
I1
tp8765
sS'improved,parathyroid'
p8766
(F1
F0.00076452599388379206
I0
I1
I-1
tp8767
sS'through,hydrolysis'
p8768
(F1
F0.00076452599388379206
I0
I1
I-1
tp8769
sS'starting,dose'
p8770
(F1
F0.00076452599388379206
I0
I1
I-1
tp8771
sS'irreversibly,inhibit'
p8772
(F1
F0.00076452599388379206
I1
I0
I1
tp8773
sS'long,lasting'
p8774
(F1
F0.00076452599388379206
I1
I0
I1
tp8775
sS'pain,medicines'
p8776
(F1
F0.00076452599388379206
I0
I1
I-1
tp8777
sS'other,cns'
p8778
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp8779
sS'theophylline,theophylline'
p8780
(F1
F0.00076452599388379206
I0
I1
I-1
tp8781
sS'safety,of'
p8782
(F1
F0.0015290519877675841
I0
I2
I-2
tp8783
sS'bactericidal,effects'
p8784
(F1
F0.00076452599388379206
I1
I0
I1
tp8785
sS'drugs,were'
p8786
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp8787
sS'and,levonorgestrel-containing'
p8788
(F1
F0.00076452599388379206
I1
I0
I1
tp8789
sS'serum,because'
p8790
(F1
F0.0015290519877675841
I0
I2
I-2
tp8791
sS'drugs,where'
p8792
(F1
F0.00076452599388379206
I1
I0
I1
tp8793
sS'between,mycamine'
p8794
(F1
F0.00076452599388379206
I0
I1
I-1
tp8795
sS'containing,should'
p8796
(F1
F0.00076452599388379206
I0
I1
I-1
tp8797
sS'the,depressant'
p8798
(F1
F0.00076452599388379206
I1
I0
I1
tp8799
sS'of,control'
p8800
(F0
F0
I1
I1
I0
tp8801
sS'drugs,capable'
p8802
(F1
F0.00076452599388379206
I0
I1
I-1
tp8803
sS'pharmacokinetic,profile'
p8804
(F1
F0.00076452599388379206
I0
I1
I-1
tp8805
sS'be,taken'
p8806
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp8807
sS'mivacron,include'
p8808
(F1
F0.00076452599388379206
I1
I0
I1
tp8809
sS'subjects,administration'
p8810
(F1
F0.00076452599388379206
I0
I1
I-1
tp8811
sS'n,or'
p8812
(F1
F0.00076452599388379206
I0
I1
I-1
tp8813
sS'required,the'
p8814
(F1
F0.00076452599388379206
I0
I1
I-1
tp8815
sS'with,mg'
p8816
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp8817
sS'content,such'
p8818
(F1
F0.00076452599388379206
I1
I0
I1
tp8819
sS'with,drugs'
p8820
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp8821
sS'plasma,concentration-time'
p8822
(F1
F0.00076452599388379206
I1
I0
I1
tp8823
sS'always,require'
p8824
(F1
F0.00076452599388379206
I0
I1
I-1
tp8825
sS'as,large'
p8826
(F1
F0.00076452599388379206
I0
I1
I-1
tp8827
sS'cyclosporine-treated,as'
p8828
(F1
F0.00076452599388379206
I0
I1
I-1
tp8829
sS'can,potentiate'
p8830
(F1
F0.00076452599388379206
I1
I0
I1
tp8831
sS'elevation,of'
p8832
(F0
F0
I1
I1
I0
tp8833
sS'values,when'
p8834
(F1
F0.00076452599388379206
I1
I0
I1
tp8835
sS'b-acetyldigoxin,administration'
p8836
(F1
F0.00076452599388379206
I0
I1
I-1
tp8837
sS'with,inactivated'
p8838
(F0
F0
I1
I1
I0
tp8839
sS'digoxin,in'
p8840
(F1
F0.00076452599388379206
I0
I1
I-1
tp8841
sS'nutritionally-derived,vitamin'
p8842
(F1
F0.00076452599388379206
I0
I1
I-1
tp8843
sS'brilinta-astrazeneca,an'
p8844
(F1
F0.00076452599388379206
I1
I0
I1
tp8845
sS'they,do'
p8846
(F1
F0.00076452599388379206
I1
I0
I1
tp8847
sS'therefore,caution'
p8848
(F0.5
F0.0015290519877675841
I3
I1
I2
tp8849
sS'and,tail'
p8850
(F1
F0.00076452599388379206
I0
I1
I-1
tp8851
sS'day,for'
p8852
(F1
F0.0053516819571865441
I0
I7
I-7
tp8853
sS'mexitil,is'
p8854
(F1
F0.00076452599388379206
I0
I1
I-1
tp8855
sS'of,bradycardia'
p8856
(F1
F0.00076452599388379206
I1
I0
I1
tp8857
sS'in,monkeys'
p8858
(F1
F0.00076452599388379206
I0
I1
I-1
tp8859
sS'mexitil,if'
p8860
(F1
F0.00076452599388379206
I1
I0
I1
tp8861
sS'maxair,autohaler'
p8862
(F1
F0.00076452599388379206
I1
I0
I1
tp8863
sS'activity,when'
p8864
(F1
F0.00076452599388379206
I1
I0
I1
tp8865
sS'precautions,should'
p8866
(F1
F0.00076452599388379206
I1
I0
I1
tp8867
sS'less,mpa'
p8868
(F1
F0.00076452599388379206
I0
I1
I-1
tp8869
sS'with,co-administered'
p8870
(F1
F0.00076452599388379206
I0
I1
I-1
tp8871
sS'the,virus'
p8872
(F1
F0.00076452599388379206
I1
I0
I1
tp8873
sS'mice,and'
p8874
(F1
F0.00076452599388379206
I0
I1
I-1
tp8875
sS'exposure,when'
p8876
(F1
F0.00076452599388379206
I0
I1
I-1
tp8877
sS'for,several'
p8878
(F1
F0.00076452599388379206
I0
I1
I-1
tp8879
sS'approximately,reduction'
p8880
(F1
F0.00076452599388379206
I0
I1
I-1
tp8881
sS'response,of'
p8882
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp8883
sS'when,not'
p8884
(F1
F0.00076452599388379206
I0
I1
I-1
tp8885
sS'greater,significantly'
p8886
(F1
F0.00076452599388379206
I1
I0
I1
tp8887
sS'reverse,transcriptase'
p8888
(F1
F0.00076452599388379206
I0
I1
I-1
tp8889
sS'oral,in'
p8890
(F1
F0.00076452599388379206
I1
I0
I1
tp8891
sS'cardiac,arrythmias'
p8892
(F1
F0.00076452599388379206
I1
I0
I1
tp8893
sS'either,tolectin'
p8894
(F1
F0.00076452599388379206
I0
I1
I-1
tp8895
sS'clinical,data'
p8896
(F1
F0.00076452599388379206
I0
I1
I-1
tp8897
sS'interactions,are'
p8898
(F1
F0.00076452599388379206
I0
I1
I-1
tp8899
sS'given,to'
p8900
(F1
F0.0015290519877675841
I2
I0
I2
tp8901
sS'oral,is'
p8902
(F1
F0.00076452599388379206
I1
I0
I1
tp8903
sS'causing,cns'
p8904
(F1
F0.00076452599388379206
I1
I0
I1
tp8905
sS'by,after'
p8906
(F1
F0.00076452599388379206
I1
I0
I1
tp8907
sS'or,did'
p8908
(F1
F0.00076452599388379206
I0
I1
I-1
tp8909
sS'decreased,time'
p8910
(F1
F0.00076452599388379206
I1
I0
I1
tp8911
sS'to,cerebral'
p8912
(F1
F0.00076452599388379206
I0
I1
I-1
tp8913
sS'cyclosporine-treated,patients'
p8914
(F1
F0.00076452599388379206
I1
I0
I1
tp8915
sS'no,evidence'
p8916
(F0
F0
I1
I1
I0
tp8917
sS'complications,compared'
p8918
(F1
F0.00076452599388379206
I1
I0
I1
tp8919
sS'when,evista'
p8920
(F1
F0.00076452599388379206
I1
I0
I1
tp8921
sS'alimta,and'
p8922
(F1
F0.00076452599388379206
I1
I0
I1
tp8923
sS'to,inhibit'
p8924
(F1
F0.00076452599388379206
I1
I0
I1
tp8925
sS'known,drug'
p8926
(F1
F0.00076452599388379206
I1
I0
I1
tp8927
sS'recommended,until'
p8928
(F1
F0.00076452599388379206
I1
I0
I1
tp8929
sS'glucose,concentrations'
p8930
(F1
F0.00076452599388379206
I1
I0
I1
tp8931
sS'therefore,when'
p8932
(F0
F0
I1
I1
I0
tp8933
sS'mecamylamine,may'
p8934
(F1
F0.00076452599388379206
I1
I0
I1
tp8935
sS'sympathomimetics,metolazone'
p8936
(F1
F0.00076452599388379206
I1
I0
I1
tp8937
sS'elucidated,the'
p8938
(F1
F0.00076452599388379206
I0
I1
I-1
tp8939
sS'once,daily'
p8940
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp8941
sS'low-dose,was'
p8942
(F1
F0.00076452599388379206
I0
I1
I-1
tp8943
sS'mechanism,of'
p8944
(F1
F0.0015290519877675841
I2
I0
I2
tp8945
sS'other,nondepolarizing'
p8946
(F1
F0.0015290519877675841
I0
I2
I-2
tp8947
sS'in,another'
p8948
(F1
F0.00076452599388379206
I0
I1
I-1
tp8949
sS'anticoagulants,oral'
p8950
(F1
F0.00076452599388379206
I1
I0
I1
tp8951
sS'pharmacokinetic,data'
p8952
(F1
F0.00076452599388379206
I1
I0
I1
tp8953
sS'of,should'
p8954
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp8955
sS'saline,mg'
p8956
(F1
F0.00076452599388379206
I0
I1
I-1
tp8957
sS'known,component'
p8958
(F1
F0.00076452599388379206
I1
I0
I1
tp8959
sS'latter,displayed'
p8960
(F1
F0.00076452599388379206
I0
I1
I-1
tp8961
sS'of,substances'
p8962
(F1
F0.00076452599388379206
I1
I0
I1
tp8963
sS'dasatinib-,and'
p8964
(F1
F0.00076452599388379206
I0
I1
I-1
tp8965
sS'by,whereas'
p8966
(F1
F0.00076452599388379206
I1
I0
I1
tp8967
sS'oral,clearance'
p8968
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp8969
sS'in,s-warfarin'
p8970
(F1
F0.00076452599388379206
I1
I0
I1
tp8971
sS'or,stimulantes'
p8972
(F1
F0.00076452599388379206
I1
I0
I1
tp8973
sS'exercised,with'
p8974
(F1
F0.00076452599388379206
I1
I0
I1
tp8975
sS'anesthetic,agents'
p8976
(F0
F0
I1
I1
I0
tp8977
sS'of,drug'
p8978
(F1
F0.00076452599388379206
I0
I1
I-1
tp8979
sS'rate,requirements'
p8980
(F1
F0.00076452599388379206
I1
I0
I1
tp8981
sS'daily,administration'
p8982
(F1
F0.00076452599388379206
I0
I1
I-1
tp8983
sS'qid,did'
p8984
(F1
F0.00076452599388379206
I0
I1
I-1
tp8985
sS'or,which'
p8986
(F1
F0.00076452599388379206
I1
I0
I1
tp8987
sS'plasma,ace'
p8988
(F1
F0.00076452599388379206
I0
I1
I-1
tp8989
sS'ropivacaine,leading'
p8990
(F1
F0.00076452599388379206
I1
I0
I1
tp8991
sS'if,mexitil'
p8992
(F1
F0.00076452599388379206
I1
I0
I1
tp8993
sS'for,and'
p8994
(F1
F0.00076452599388379206
I0
I1
I-1
tp8995
sS'it,is'
p8996
(F1
F0.0091743119266055051
I12
I0
I12
tp8997
sS'tablets,with'
p8998
(F1
F0.00076452599388379206
I0
I1
I-1
tp8999
sS'severe,thrombocytopenia'
p9000
(F1
F0.00076452599388379206
I1
I0
I1
tp9001
sS'to,moderate'
p9002
(F1
F0.0015290519877675841
I2
I0
I2
tp9003
sS'cholinesterase,activity'
p9004
(F1
F0.00076452599388379206
I1
I0
I1
tp9005
sS'xenograft-bearing,mice'
p9006
(F1
F0.00076452599388379206
I1
I0
I1
tp9007
sS'generally,recommended'
p9008
(F1
F0.00076452599388379206
I1
I0
I1
tp9009
sS'paget,s'
p9010
(F1
F0.00076452599388379206
I1
I0
I1
tp9011
sS'when,megestrol'
p9012
(F1
F0.00076452599388379206
I0
I1
I-1
tp9013
sS'vs,cm3'
p9014
(F1
F0.00076452599388379206
I1
I0
I1
tp9015
sS'dose,response'
p9016
(F1
F0.00076452599388379206
I0
I1
I-1
tp9017
sS'was,conducted'
p9018
(F1
F0.00076452599388379206
I0
I1
I-1
tp9019
sS'mg,ethinyl'
p9020
(F1
F0.00076452599388379206
I0
I1
I-1
tp9021
sS'because,they'
p9022
(F1
F0.0015290519877675841
I2
I0
I2
tp9023
sS'richens,at'
p9024
(F1
F0.00076452599388379206
I1
I0
I1
tp9025
sS'other,agents'
p9026
(F0.5
F0.0015290519877675841
I3
I1
I2
tp9027
sS'the,study'
p9028
(F0
F0
I1
I1
I0
tp9029
sS'simultaneously,with'
p9030
(F1
F0.00076452599388379206
I0
I1
I-1
tp9031
sS'established,there'
p9032
(F1
F0.00076452599388379206
I1
I0
I1
tp9033
sS'skin,of'
p9034
(F1
F0.00076452599388379206
I1
I0
I1
tp9035
sS'are,likely'
p9036
(F0
F0
I1
I1
I0
tp9037
sS'that,vaccinations'
p9038
(F1
F0.00076452599388379206
I1
I0
I1
tp9039
sS'a,non-human'
p9040
(F1
F0.00076452599388379206
I1
I0
I1
tp9041
sS'the,placebo'
p9042
(F1
F0.00076452599388379206
I0
I1
I-1
tp9043
sS'children,receiving'
p9044
(F1
F0.00076452599388379206
I0
I1
I-1
tp9045
sS'or,in'
p9046
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp9047
sS'gfp,under'
p9048
(F1
F0.00076452599388379206
I0
I1
I-1
tp9049
sS'observations,have'
p9050
(F1
F0.00076452599388379206
I1
I0
I1
tp9051
sS'severe,toxicity'
p9052
(F1
F0.00076452599388379206
I1
I0
I1
tp9053
sS'r-warfarin,half-life'
p9054
(F1
F0.00076452599388379206
I1
I0
I1
tp9055
sS'ribs,was'
p9056
(F1
F0.00076452599388379206
I0
I1
I-1
tp9057
sS'or,is'
p9058
(F1
F0.0015290519877675841
I2
I0
I2
tp9059
sS'a,bcl-2'
p9060
(F1
F0.00076452599388379206
I1
I0
I1
tp9061
sS'with,low-dose'
p9062
(F1
F0.00076452599388379206
I1
I0
I1
tp9063
sS'serum,levels'
p9064
(F0.63636363636363635
F0.0053516819571865441
I9
I2
I7
tp9065
sS'the,authors'
p9066
(F1
F0.00076452599388379206
I1
I0
I1
tp9067
sS'of,dosage'
p9068
(F1
F0.00076452599388379206
I1
I0
I1
tp9069
sS'two,separate'
p9070
(F1
F0.00076452599388379206
I1
I0
I1
tp9071
sS'not,displace'
p9072
(F1
F0.0015290519877675841
I0
I2
I-2
tp9073
sS'chronic,stable'
p9074
(F1
F0.00076452599388379206
I1
I0
I1
tp9075
sS'adjustments,for'
p9076
(F1
F0.00076452599388379206
I0
I1
I-1
tp9077
sS'prolonging,effect'
p9078
(F1
F0.00076452599388379206
I0
I1
I-1
tp9079
sS'anticholinergics,because'
p9080
(F1
F0.00076452599388379206
I1
I0
I1
tp9081
sS'muscle,relaxants'
p9082
(F1
F0.0015290519877675841
I0
I2
I-2
tp9083
sS'dosing,for'
p9084
(F1
F0.00076452599388379206
I1
I0
I1
tp9085
sS'a,day'
p9086
(F0.55555555555555558
F0.0038226299694189602
I2
I7
I-5
tp9087
sS'enzymes,would'
p9088
(F1
F0.0015290519877675841
I0
I2
I-2
tp9089
sS'study,of'
p9090
(F0.25
F0.0015290519877675841
I3
I5
I-2
tp9091
sS'been,reports'
p9092
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp9093
sS'agonists,on'
p9094
(F1
F0.00076452599388379206
I1
I0
I1
tp9095
sS'hci,and'
p9096
(F1
F0.00076452599388379206
I0
I1
I-1
tp9097
sS'increasing,salt'
p9098
(F1
F0.00076452599388379206
I0
I1
I-1
tp9099
sS'of,did'
p9100
(F1
F0.0015290519877675841
I0
I2
I-2
tp9101
sS'plasma,profiles'
p9102
(F1
F0.00076452599388379206
I0
I1
I-1
tp9103
sS'have,a'
p9104
(F1
F0.0022935779816513763
I0
I3
I-3
tp9105
sS'not,noticeably'
p9106
(F1
F0.00076452599388379206
I0
I1
I-1
tp9107
sS'amphetamine-paired,context'
p9108
(F1
F0.00076452599388379206
I0
I1
I-1
tp9109
sS'inhibitors,include'
p9110
(F1
F0.0015290519877675841
I0
I2
I-2
tp9111
sS'lower,clinical'
p9112
(F1
F0.00076452599388379206
I1
I0
I1
tp9113
sS'concomitantly,during'
p9114
(F1
F0.00076452599388379206
I1
I0
I1
tp9115
sS'the,toxicity'
p9116
(F1
F0.00076452599388379206
I1
I0
I1
tp9117
sS'injection,before'
p9118
(F1
F0.00076452599388379206
I0
I1
I-1
tp9119
sS'departments,of'
p9120
(F1
F0.00076452599388379206
I0
I1
I-1
tp9121
sS'predominantly,by'
p9122
(F1
F0.00076452599388379206
I1
I0
I1
tp9123
sS'electroretinograms,survived'
p9124
(F1
F0.00076452599388379206
I0
I1
I-1
tp9125
sS'to,urinary'
p9126
(F1
F0.00076452599388379206
I1
I0
I1
tp9127
sS'ratio,of'
p9128
(F0
F0
I1
I1
I0
tp9129
sS'intraperitoneally,not'
p9130
(F1
F0.00076452599388379206
I1
I0
I1
tp9131
sS'mitomycin-c,may'
p9132
(F1
F0.00076452599388379206
I1
I0
I1
tp9133
sS'taking,nsaids'
p9134
(F1
F0.0015290519877675841
I2
I0
I2
tp9135
sS'yet,been'
p9136
(F1
F0.00076452599388379206
I0
I1
I-1
tp9137
sS'the,findings'
p9138
(F1
F0.00076452599388379206
I1
I0
I1
tp9139
sS'gastrointestinal,motility'
p9140
(F1
F0.0022935779816513763
I3
I0
I3
tp9141
sS'approximately,bound'
p9142
(F1
F0.00076452599388379206
I0
I1
I-1
tp9143
sS'transduction,is'
p9144
(F1
F0.00076452599388379206
I1
I0
I1
tp9145
sS'phenothiazine-type,should'
p9146
(F1
F0.00076452599388379206
I0
I1
I-1
tp9147
sS'fluoroquinolone,used'
p9148
(F1
F0.00076452599388379206
I0
I1
I-1
tp9149
sS'chloride,plasma'
p9150
(F1
F0.00076452599388379206
I1
I0
I1
tp9151
sS'therapy,in'
p9152
(F1
F0.0015290519877675841
I2
I0
I2
tp9153
sS'radiotherapy,or'
p9154
(F1
F0.00076452599388379206
I0
I1
I-1
tp9155
sS'or,parenteral'
p9156
(F1
F0.00076452599388379206
I1
I0
I1
tp9157
sS'p450,enzyme'
p9158
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp9159
sS'lenalidomide-cci,interaction'
p9160
(F1
F0.00076452599388379206
I0
I1
I-1
tp9161
sS'on,therapy'
p9162
(F0.5
F0.0015290519877675841
I3
I1
I2
tp9163
sS'diabetic,patients'
p9164
(F1
F0.00076452599388379206
I0
I1
I-1
tp9165
sS'therapy,is'
p9166
(F1
F0.00076452599388379206
I1
I0
I1
tp9167
sS'already,receiving'
p9168
(F1
F0.0015290519877675841
I2
I0
I2
tp9169
sS'combining,with'
p9170
(F1
F0.00076452599388379206
I1
I0
I1
tp9171
sS'promoter,was'
p9172
(F1
F0.00076452599388379206
I0
I1
I-1
tp9173
sS'hypotensive,agents'
p9174
(F1
F0.00076452599388379206
I0
I1
I-1
tp9175
sS'enzyme,induction'
p9176
(F1
F0.00076452599388379206
I1
I0
I1
tp9177
sS'properties,of'
p9178
(F1
F0.00076452599388379206
I0
I1
I-1
tp9179
sS'co-administered,with'
p9180
(F1
F0.00076452599388379206
I0
I1
I-1
tp9181
sS'theophylline,clearance'
p9182
(F1
F0.00076452599388379206
I0
I1
I-1
tp9183
sS'or,acquired'
p9184
(F1
F0.00076452599388379206
I0
I1
I-1
tp9185
sS'acid,against'
p9186
(F1
F0.00076452599388379206
I0
I1
I-1
tp9187
sS'has,not'
p9188
(F0.29411764705882354
F0.0038226299694189602
I6
I11
I-5
tp9189
sS'mean,cmax'
p9190
(F1
F0.00076452599388379206
I1
I0
I1
tp9191
sS'in,conclusion'
p9192
(F1
F0.00076452599388379206
I1
I0
I1
tp9193
sS'as,mivacron'
p9194
(F1
F0.00076452599388379206
I1
I0
I1
tp9195
sS'agents,analgesic'
p9196
(F1
F0.00076452599388379206
I0
I1
I-1
tp9197
sS'pharmacokinetics,pharmacodynamics'
p9198
(F1
F0.00076452599388379206
I0
I1
I-1
tp9199
sS'of,certain'
p9200
(F1
F0.00076452599388379206
I0
I1
I-1
tp9201
sS'for,at'
p9202
(F1
F0.0015290519877675841
I2
I0
I2
tp9203
sS'concurrently,treated'
p9204
(F1
F0.00076452599388379206
I1
I0
I1
tp9205
sS'administration,should'
p9206
(F1
F0.00076452599388379206
I1
I0
I1
tp9207
sS'the,commonly'
p9208
(F1
F0.00076452599388379206
I0
I1
I-1
tp9209
sS'or,inhibit'
p9210
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp9211
sS'exercised,if'
p9212
(F1
F0.00076452599388379206
I0
I1
I-1
tp9213
sS'levels,nonsteroidal'
p9214
(F1
F0.00076452599388379206
I1
I0
I1
tp9215
sS'administered,concurrently'
p9216
(F1
F0.0015290519877675841
I2
I0
I2
tp9217
sS'protease,inhibitors'
p9218
(F0
F0
I1
I1
I0
tp9219
sS'studies,in'
p9220
(F1
F0.00076452599388379206
I0
I1
I-1
tp9221
sS'renal,transplant'
p9222
(F0.5
F0.0015290519877675841
I3
I1
I2
tp9223
sS'glucuronidation,of'
p9224
(F1
F0.00076452599388379206
I1
I0
I1
tp9225
sS'of,extracellular'
p9226
(F1
F0.00076452599388379206
I0
I1
I-1
tp9227
sS'bruising,epistaxis'
p9228
(F1
F0.00076452599388379206
I1
I0
I1
tp9229
sS'decreased,hepatic'
p9230
(F1
F0.0015290519877675841
I0
I2
I-2
tp9231
sS'aspirin,may'
p9232
(F1
F0.00076452599388379206
I1
I0
I1
tp9233
sS'hiv-infected,patients'
p9234
(F1
F0.00076452599388379206
I1
I0
I1
tp9235
sS'i,increased'
p9236
(F1
F0.00076452599388379206
I1
I0
I1
tp9237
sS'with,edema'
p9238
(F1
F0.00076452599388379206
I0
I1
I-1
tp9239
sS'same,time'
p9240
(F1
F0.0015290519877675841
I2
I0
I2
tp9241
sS'hypercholesterolemic,patients'
p9242
(F1
F0.00076452599388379206
I0
I1
I-1
tp9243
sS'dietary,carcinogenicity'
p9244
(F1
F0.0015290519877675841
I0
I2
I-2
tp9245
sS'preventive,impact'
p9246
(F1
F0.00076452599388379206
I0
I1
I-1
tp9247
sS'of,childbearing'
p9248
(F1
F0.00076452599388379206
I0
I1
I-1
tp9249
sS'inhibitors,no'
p9250
(F1
F0.00076452599388379206
I0
I1
I-1
tp9251
sS'be,contributing'
p9252
(F1
F0.00076452599388379206
I0
I1
I-1
tp9253
sS'hematuria,and'
p9254
(F1
F0.00076452599388379206
I1
I0
I1
tp9255
sS'agent,exhibits'
p9256
(F1
F0.00076452599388379206
I1
I0
I1
tp9257
sS'alpha-adrenergic,receptors'
p9258
(F1
F0.00076452599388379206
I1
I0
I1
tp9259
sS'nd,and'
p9260
(F1
F0.00076452599388379206
I0
I1
I-1
tp9261
sS'but,an'
p9262
(F1
F0.0015290519877675841
I2
I0
I2
tp9263
sS'adverse,reaction'
p9264
(F1
F0.00076452599388379206
I1
I0
I1
tp9265
sS'include,grapefruit'
p9266
(F1
F0.00076452599388379206
I0
I1
I-1
tp9267
sS'intramuscularly,injected'
p9268
(F1
F0.00076452599388379206
I0
I1
I-1
tp9269
sS'prolonged,losses'
p9270
(F1
F0.00076452599388379206
I1
I0
I1
tp9271
sS'by,steady'
p9272
(F1
F0.00076452599388379206
I0
I1
I-1
tp9273
sS'of,potent'
p9274
(F1
F0.00076452599388379206
I0
I1
I-1
tp9275
sS'to,bleeding'
p9276
(F1
F0.00076452599388379206
I1
I0
I1
tp9277
sS'include,some'
p9278
(F1
F0.00076452599388379206
I1
I0
I1
tp9279
sS'the,action'
p9280
(F1
F0.0053516819571865441
I7
I0
I7
tp9281
sS'inhibit,cyp450'
p9282
(F1
F0.00076452599388379206
I0
I1
I-1
tp9283
sS'oral,s-ketamine'
p9284
(F0
F0
I1
I1
I0
tp9285
sS'salicylate,competes'
p9286
(F1
F0.00076452599388379206
I1
I0
I1
tp9287
sS'significantly,increasing'
p9288
(F1
F0.00076452599388379206
I1
I0
I1
tp9289
sS'require,downward'
p9290
(F1
F0.00076452599388379206
I1
I0
I1
tp9291
sS'a,effect'
p9292
(F1
F0.00076452599388379206
I1
I0
I1
tp9293
sS'of,to'
p9294
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp9295
sS'of,aggrastat'
p9296
(F1
F0.00076452599388379206
I1
I0
I1
tp9297
sS'valproic,acid'
p9298
(F1
F0.0015290519877675841
I2
I0
I2
tp9299
sS'decreases,in'
p9300
(F1
F0.00076452599388379206
I0
I1
I-1
tp9301
sS'administered,should'
p9302
(F1
F0.00076452599388379206
I1
I0
I1
tp9303
sS'acetylsalicylic,acid'
p9304
(F0
F0
I1
I1
I0
tp9305
sS'oxidase,inhibitor'
p9306
(F1
F0.00076452599388379206
I1
I0
I1
tp9307
sS'induced,by'
p9308
(F1
F0.0015290519877675841
I0
I2
I-2
tp9309
sS'ointment,on'
p9310
(F1
F0.00076452599388379206
I1
I0
I1
tp9311
sS'initiated,the'
p9312
(F1
F0.00076452599388379206
I0
I1
I-1
tp9313
sS'hypertensive,disease'
p9314
(F1
F0.00076452599388379206
I0
I1
I-1
tp9315
sS'adequate,drug-drug'
p9316
(F1
F0.00076452599388379206
I0
I1
I-1
tp9317
sS'because,matulane'
p9318
(F1
F0.00076452599388379206
I1
I0
I1
tp9319
sS'daily,twice'
p9320
(F1
F0.00076452599388379206
I1
I0
I1
tp9321
sS'ticagrelor,brilinta'
p9322
(F1
F0.00076452599388379206
I0
I1
I-1
tp9323
sS'declining,renal'
p9324
(F1
F0.00076452599388379206
I1
I0
I1
tp9325
sS's,metabolism'
p9326
(F1
F0.00076452599388379206
I1
I0
I1
tp9327
sS'adrenergic,antagonists'
p9328
(F1
F0.00076452599388379206
I1
I0
I1
tp9329
sS'administered,in'
p9330
(F1
F0.00076452599388379206
I1
I0
I1
tp9331
sS'total,concentrations'
p9332
(F0
F0
I1
I1
I0
tp9333
sS'pyridine,or'
p9334
(F1
F0.00076452599388379206
I0
I1
I-1
tp9335
sS'inhibitors,may'
p9336
(F1
F0.00076452599388379206
I1
I0
I1
tp9337
sS'pregnancy,category'
p9338
(F1
F0.00076452599388379206
I0
I1
I-1
tp9339
sS'advised,that'
p9340
(F1
F0.00076452599388379206
I1
I0
I1
tp9341
sS'scopolamine,should'
p9342
(F1
F0.00076452599388379206
I1
I0
I1
tp9343
sS'herceptin,serum'
p9344
(F1
F0.00076452599388379206
I1
I0
I1
tp9345
sS'produce,dry'
p9346
(F1
F0.0015290519877675841
I2
I0
I2
tp9347
sS'when,given'
p9348
(F1
F0.0030581039755351682
I4
I0
I4
tp9349
sS'of,using'
p9350
(F1
F0.00076452599388379206
I0
I1
I-1
tp9351
sS'duration,of'
p9352
(F0
F0
I2
I2
I0
tp9353
sS'difference,ci'
p9354
(F1
F0.00076452599388379206
I0
I1
I-1
tp9355
sS'represents,a'
p9356
(F1
F0.00076452599388379206
I1
I0
I1
tp9357
sS'premixed,formulations'
p9358
(F1
F0.00076452599388379206
I1
I0
I1
tp9359
sS'were,consistent'
p9360
(F1
F0.00076452599388379206
I1
I0
I1
tp9361
sS'agonists,inhaled'
p9362
(F1
F0.00076452599388379206
I1
I0
I1
tp9363
sS'with,or'
p9364
(F0.55555555555555558
F0.0038226299694189602
I7
I2
I5
tp9365
sS'disposition,of'
p9366
(F1
F0.00076452599388379206
I0
I1
I-1
tp9367
sS'were,not'
p9368
(F1
F0.0022935779816513763
I0
I3
I-3
tp9369
sS'chelation,therapy'
p9370
(F1
F0.00076452599388379206
I1
I0
I1
tp9371
sS'levels,when'
p9372
(F1
F0.0015290519877675841
I2
I0
I2
tp9373
sS'monitored,when'
p9374
(F1
F0.0015290519877675841
I2
I0
I2
tp9375
sS'or,ergot-type'
p9376
(F1
F0.00076452599388379206
I1
I0
I1
tp9377
sS'ratio,inr'
p9378
(F1
F0.00076452599388379206
I1
I0
I1
tp9379
sS'following,enzyme'
p9380
(F1
F0.00076452599388379206
I0
I1
I-1
tp9381
sS'structurally,related'
p9382
(F1
F0.00076452599388379206
I1
I0
I1
tp9383
sS'feldene,to'
p9384
(F1
F0.00076452599388379206
I1
I0
I1
tp9385
sS'by,anesthesia'
p9386
(F1
F0.00076452599388379206
I1
I0
I1
tp9387
sS'prolonged,the'
p9388
(F1
F0.00076452599388379206
I1
I0
I1
tp9389
sS'were,seen'
p9390
(F1
F0.00076452599388379206
I0
I1
I-1
tp9391
sS'exercised,when'
p9392
(F1
F0.0022935779816513763
I3
I0
I3
tp9393
sS'half-lives,for'
p9394
(F1
F0.00076452599388379206
I1
I0
I1
tp9395
sS'anti-infective,medicines'
p9396
(F1
F0.00076452599388379206
I1
I0
I1
tp9397
sS'mivacron,a'
p9398
(F1
F0.00076452599388379206
I0
I1
I-1
tp9399
sS'net,inducer'
p9400
(F1
F0.00076452599388379206
I1
I0
I1
tp9401
sS'hydrochloride,resulting'
p9402
(F1
F0.00076452599388379206
I1
I0
I1
tp9403
sS'cns,toxicity'
p9404
(F1
F0.00076452599388379206
I1
I0
I1
tp9405
sS'k-ras,mutation'
p9406
(F1
F0.00076452599388379206
I0
I1
I-1
tp9407
sS'azole,antimycotics'
p9408
(F1
F0.00076452599388379206
I1
I0
I1
tp9409
sS'administered,oral'
p9410
(F1
F0.00076452599388379206
I1
I0
I1
tp9411
sS'oral,the'
p9412
(F1
F0.00076452599388379206
I1
I0
I1
tp9413
sS'minimized,by'
p9414
(F0
F0
I1
I1
I0
tp9415
sS'mean,pre-dose'
p9416
(F1
F0.00076452599388379206
I1
I0
I1
tp9417
sS'three,stereoisomers'
p9418
(F1
F0.00076452599388379206
I0
I1
I-1
tp9419
sS'recovery,from'
p9420
(F1
F0.0015290519877675841
I2
I0
I2
tp9421
sS'vascular,system'
p9422
(F1
F0.00076452599388379206
I1
I0
I1
tp9423
sS'antihypertensives,when'
p9424
(F1
F0.00076452599388379206
I1
I0
I1
tp9425
sS'is,primarily'
p9426
(F1
F0.00076452599388379206
I0
I1
I-1
tp9427
sS'analgesics,may'
p9428
(F1
F0.00076452599388379206
I1
I0
I1
tp9429
sS'following,concomitant'
p9430
(F1
F0.0015290519877675841
I0
I2
I-2
tp9431
sS'as,compared'
p9432
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp9433
sS'bicarbonate,to'
p9434
(F1
F0.00076452599388379206
I0
I1
I-1
tp9435
sS'while,there'
p9436
(F1
F0.00076452599388379206
I1
I0
I1
tp9437
sS'inhibition,curve'
p9438
(F1
F0.00076452599388379206
I0
I1
I-1
tp9439
sS'consideration,should'
p9440
(F1
F0.0015290519877675841
I2
I0
I2
tp9441
sS'm2,eloxatin'
p9442
(F0
F0
I1
I1
I0
tp9443
sS'considering,the'
p9444
(F1
F0.0015290519877675841
I0
I2
I-2
tp9445
sS'secretion,and'
p9446
(F0
F0
I1
I1
I0
tp9447
sS'of,attenuating'
p9448
(F1
F0.00076452599388379206
I0
I1
I-1
tp9449
sS'macrolide,and'
p9450
(F1
F0.00076452599388379206
I1
I0
I1
tp9451
sS'non-small,lung'
p9452
(F1
F0.00076452599388379206
I1
I0
I1
tp9453
sS'sulfate,levothyroxine'
p9454
(F1
F0.00076452599388379206
I0
I1
I-1
tp9455
sS'alone,under'
p9456
(F1
F0.00076452599388379206
I1
I0
I1
tp9457
sS'agents,blood'
p9458
(F1
F0.00076452599388379206
I1
I0
I1
tp9459
sS'adverse,events'
p9460
(F1
F0.0015290519877675841
I0
I2
I-2
tp9461
sS'between,purinethol'
p9462
(F1
F0.00076452599388379206
I1
I0
I1
tp9463
sS'of,vesicare'
p9464
(F1
F0.00076452599388379206
I1
I0
I1
tp9465
sS'drug,metabolizing'
p9466
(F0
F0
I1
I1
I0
tp9467
sS'the,myeloproliferative'
p9468
(F1
F0.00076452599388379206
I1
I0
I1
tp9469
sS'have,the'
p9470
(F0
F0
I1
I1
I0
tp9471
sS'of,bacteriostatic'
p9472
(F1
F0.00076452599388379206
I1
I0
I1
tp9473
sS'the,elderly'
p9474
(F1
F0.00076452599388379206
I1
I0
I1
tp9475
sS'are,reports'
p9476
(F1
F0.0015290519877675841
I2
I0
I2
tp9477
sS'p450,enzymes'
p9478
(F1
F0.0015290519877675841
I0
I2
I-2
tp9479
sS'altered,when'
p9480
(F1
F0.00076452599388379206
I1
I0
I1
tp9481
sS'active,histone'
p9482
(F1
F0.00076452599388379206
I0
I1
I-1
tp9483
sS'mephenytoin,may'
p9484
(F1
F0.00076452599388379206
I1
I0
I1
tp9485
sS'for,use'
p9486
(F1
F0.00076452599388379206
I1
I0
I1
tp9487
sS'subjects,who'
p9488
(F1
F0.00076452599388379206
I1
I0
I1
tp9489
sS'controls,conditioned'
p9490
(F1
F0.00076452599388379206
I0
I1
I-1
tp9491
sS'water,wheel'
p9492
(F1
F0.00076452599388379206
I0
I1
I-1
tp9493
sS'had,a'
p9494
(F0.5
F0.0015290519877675841
I3
I1
I2
tp9495
sS'marker,of'
p9496
(F1
F0.00076452599388379206
I0
I1
I-1
tp9497
sS'administered,to'
p9498
(F0.5
F0.0015290519877675841
I3
I1
I2
tp9499
sS'not,recur'
p9500
(F1
F0.00076452599388379206
I0
I1
I-1
tp9501
sS'of,symlin'
p9502
(F0
F0
I1
I1
I0
tp9503
sS'markedly,potentiated'
p9504
(F1
F0.0015290519877675841
I2
I0
I2
tp9505
sS'mydriasis,tachycardia'
p9506
(F1
F0.00076452599388379206
I1
I0
I1
tp9507
sS'ethinyl,estradiol'
p9508
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp9509
sS'and,cns'
p9510
(F1
F0.00076452599388379206
I1
I0
I1
tp9511
sS'other,anti-pseudomonal'
p9512
(F1
F0.00076452599388379206
I1
I0
I1
tp9513
sS'used,only'
p9514
(F1
F0.0015290519877675841
I2
I0
I2
tp9515
sS'taken,hours'
p9516
(F1
F0.00076452599388379206
I1
I0
I1
tp9517
sS'exposed,to'
p9518
(F0
F0
I1
I1
I0
tp9519
sS'with,cholinomimetics'
p9520
(F1
F0.00076452599388379206
I1
I0
I1
tp9521
sS'by,up'
p9522
(F1
F0.00076452599388379206
I1
I0
I1
tp9523
sS'the,concurrent'
p9524
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp9525
sS'time,in'
p9526
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp9527
sS'a,novel'
p9528
(F1
F0.00076452599388379206
I1
I0
I1
tp9529
sS'to,be'
p9530
(F0.80000000000000004
F0.0061162079510703364
I9
I1
I8
tp9531
sS'lyase,had'
p9532
(F1
F0.00076452599388379206
I0
I1
I-1
tp9533
sS's-enantiomers,or'
p9534
(F1
F0.00076452599388379206
I0
I1
I-1
tp9535
sS'a,strong'
p9536
(F1
F0.0015290519877675841
I2
I0
I2
tp9537
sS'as,for'
p9538
(F1
F0.00076452599388379206
I1
I0
I1
tp9539
sS'deoxynucleotidyl,transferase-mediated'
p9540
(F1
F0.00076452599388379206
I0
I1
I-1
tp9541
sS'used,if'
p9542
(F1
F0.00076452599388379206
I1
I0
I1
tp9543
sS'apoptosis,and'
p9544
(F0
F0
I1
I1
I0
tp9545
sS'used,in'
p9546
(F0.7142857142857143
F0.0038226299694189602
I1
I6
I-5
tp9547
sS'not,studied'
p9548
(F0
F0
I1
I1
I0
tp9549
sS'that,approximately'
p9550
(F1
F0.00076452599388379206
I1
I0
I1
tp9551
sS'these,therapeutic'
p9552
(F1
F0.00076452599388379206
I1
I0
I1
tp9553
sS'coumarin-derivative,anticoagulants'
p9554
(F1
F0.00076452599388379206
I1
I0
I1
tp9555
sS'salt-retaining,steroid'
p9556
(F1
F0.00076452599388379206
I0
I1
I-1
tp9557
sS'studies,to'
p9558
(F0
F0
I1
I1
I0
tp9559
sS'be,prolonged'
p9560
(F1
F0.00076452599388379206
I1
I0
I1
tp9561
sS'attenuate,some'
p9562
(F1
F0.00076452599388379206
I0
I1
I-1
tp9563
sS'that,interfere'
p9564
(F1
F0.00076452599388379206
I0
I1
I-1
tp9565
sS'the,prothrombin'
p9566
(F0
F0
I1
I1
I0
tp9567
sS'four,days'
p9568
(F1
F0.00076452599388379206
I1
I0
I1
tp9569
sS'or,of'
p9570
(F1
F0.00076452599388379206
I0
I1
I-1
tp9571
sS'by,about'
p9572
(F1
F0.00076452599388379206
I1
I0
I1
tp9573
sS'provided,with'
p9574
(F1
F0.00076452599388379206
I1
I0
I1
tp9575
sS'or,on'
p9576
(F1
F0.0015290519877675841
I0
I2
I-2
tp9577
sS'which,were'
p9578
(F1
F0.00076452599388379206
I1
I0
I1
tp9579
sS'although,single'
p9580
(F1
F0.00076452599388379206
I1
I0
I1
tp9581
sS'did,cells'
p9582
(F1
F0.00076452599388379206
I1
I0
I1
tp9583
sS'in-vivo,indicate'
p9584
(F1
F0.00076452599388379206
I0
I1
I-1
tp9585
sS'not,cause'
p9586
(F1
F0.0022935779816513763
I0
I3
I-3
tp9587
sS'large,or'
p9588
(F1
F0.00076452599388379206
I1
I0
I1
tp9589
sS'the,highly'
p9590
(F1
F0.00076452599388379206
I0
I1
I-1
tp9591
sS'the,preclinical'
p9592
(F1
F0.00076452599388379206
I1
I0
I1
tp9593
sS'with,ferrous'
p9594
(F1
F0.0015290519877675841
I2
I0
I2
tp9595
sS'kg,and'
p9596
(F1
F0.0015290519877675841
I0
I2
I-2
tp9597
sS'since,the'
p9598
(F1
F0.0022935779816513763
I3
I0
I3
tp9599
sS'study,mg'
p9600
(F1
F0.00076452599388379206
I1
I0
I1
tp9601
sS'by,during'
p9602
(F1
F0.00076452599388379206
I1
I0
I1
tp9603
sS'drugs,no'
p9604
(F1
F0.00076452599388379206
I0
I1
I-1
tp9605
sS'different,origins'
p9606
(F1
F0.00076452599388379206
I0
I1
I-1
tp9607
sS'absence,of'
p9608
(F0
F0
I1
I1
I0
tp9609
sS'cohorts,of'
p9610
(F1
F0.00076452599388379206
I0
I1
I-1
tp9611
sS'by,slowing'
p9612
(F1
F0.00076452599388379206
I1
I0
I1
tp9613
sS'thiazol-4,yl'
p9614
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp9615
sS'drugs,metabolized'
p9616
(F0
F0
I1
I1
I0
tp9617
sS'respond,to'
p9618
(F1
F0.00076452599388379206
I0
I1
I-1
tp9619
sS'one,fatality'
p9620
(F1
F0.00076452599388379206
I1
I0
I1
tp9621
sS'the,antitumor'
p9622
(F1
F0.00076452599388379206
I0
I1
I-1
tp9623
sS'cancer,by'
p9624
(F1
F0.00076452599388379206
I0
I1
I-1
tp9625
sS'to,enhance'
p9626
(F1
F0.00076452599388379206
I1
I0
I1
tp9627
sS'absorption,and'
p9628
(F0
F0
I1
I1
I0
tp9629
sS'can,antagonize'
p9630
(F1
F0.00076452599388379206
I1
I0
I1
tp9631
sS'in,alteration'
p9632
(F1
F0.00076452599388379206
I0
I1
I-1
tp9633
sS'regulatory,agencies'
p9634
(F1
F0.00076452599388379206
I1
I0
I1
tp9635
sS'on,or'
p9636
(F1
F0.00076452599388379206
I0
I1
I-1
tp9637
sS'identified,and'
p9638
(F1
F0.00076452599388379206
I0
I1
I-1
tp9639
sS'salt,intake'
p9640
(F0
F0
I1
I1
I0
tp9641
sS'and,hence'
p9642
(F1
F0.00076452599388379206
I0
I1
I-1
tp9643
sS'taking,oral'
p9644
(F1
F0.00076452599388379206
I1
I0
I1
tp9645
sS'and,prolongation'
p9646
(F1
F0.00076452599388379206
I1
I0
I1
tp9647
sS'of,leukine'
p9648
(F1
F0.00076452599388379206
I1
I0
I1
tp9649
sS'expected,when'
p9650
(F1
F0.0015290519877675841
I2
I0
I2
tp9651
sS'including,and'
p9652
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp9653
sS'pressor,effects'
p9654
(F1
F0.00076452599388379206
I1
I0
I1
tp9655
sS'lithium,serum'
p9656
(F1
F0.00076452599388379206
I0
I1
I-1
tp9657
sS'the,areas'
p9658
(F1
F0.00076452599388379206
I0
I1
I-1
tp9659
sS'a,causal'
p9660
(F1
F0.0015290519877675841
I2
I0
I2
tp9661
sS'of,approximately'
p9662
(F1
F0.0030581039755351682
I0
I4
I-4
tp9663
sS'concomitantly,taking'
p9664
(F1
F0.00076452599388379206
I1
I0
I1
tp9665
sS'and,premixed'
p9666
(F1
F0.00076452599388379206
I1
I0
I1
tp9667
sS'of,mycamine'
p9668
(F1
F0.00076452599388379206
I0
I1
I-1
tp9669
sS'change,the'
p9670
(F1
F0.0022935779816513763
I0
I3
I-3
tp9671
sS'with,univasc'
p9672
(F1
F0.00076452599388379206
I0
I1
I-1
tp9673
sS'tyrosine,hydroxylase'
p9674
(F1
F0.00076452599388379206
I1
I0
I1
tp9675
sS'clearance,and'
p9676
(F1
F0.00076452599388379206
I0
I1
I-1
tp9677
sS'serum,concentration'
p9678
(F0
F0
I1
I1
I0
tp9679
sS'patients,evaluated'
p9680
(F1
F0.00076452599388379206
I0
I1
I-1
tp9681
sS'administration,of'
p9682
(F0.43478260869565216
F0.015290519877675841
I33
I13
I20
tp9683
sS'self,measured'
p9684
(F1
F0.00076452599388379206
I1
I0
I1
tp9685
sS'orthostatic,hypotension'
p9686
(F1
F0.0015290519877675841
I2
I0
I2
tp9687
sS'will,be'
p9688
(F1
F0.00076452599388379206
I1
I0
I1
tp9689
sS'non-competitive,inhibitors'
p9690
(F1
F0.00076452599388379206
I1
I0
I1
tp9691
sS'pharmacokinetics,or'
p9692
(F1
F0.00076452599388379206
I0
I1
I-1
tp9693
sS'by,these'
p9694
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp9695
sS'subjects,studied'
p9696
(F1
F0.00076452599388379206
I1
I0
I1
tp9697
sS'degrading,enzymes'
p9698
(F1
F0.00076452599388379206
I0
I1
I-1
tp9699
sS'a,predictable'
p9700
(F1
F0.00076452599388379206
I1
I0
I1
tp9701
sS'subsequent,sessions'
p9702
(F1
F0.00076452599388379206
I0
I1
I-1
tp9703
sS'and,heme'
p9704
(F0
F0
I1
I1
I0
tp9705
sS'used,during'
p9706
(F1
F0.00076452599388379206
I0
I1
I-1
tp9707
sS'shown,that'
p9708
(F0.5
F0.0015290519877675841
I3
I1
I2
tp9709
sS'has,approved'
p9710
(F1
F0.00076452599388379206
I1
I0
I1
tp9711
sS'acth,may'
p9712
(F1
F0.0015290519877675841
I0
I2
I-2
tp9713
sS'used,to'
p9714
(F1
F0.00076452599388379206
I1
I0
I1
tp9715
sS'expression,transfection'
p9716
(F1
F0.00076452599388379206
I0
I1
I-1
tp9717
sS'acyclovir,ganciclovir'
p9718
(F1
F0.00076452599388379206
I0
I1
I-1
tp9719
sS'when,was'
p9720
(F0
F0
I2
I2
I0
tp9721
sS'vasoconstrictor,agents'
p9722
(F1
F0.00076452599388379206
I0
I1
I-1
tp9723
sS'doses,for'
p9724
(F1
F0.00076452599388379206
I0
I1
I-1
tp9725
sS'also,noted'
p9726
(F1
F0.00076452599388379206
I1
I0
I1
tp9727
sS'have,taken'
p9728
(F1
F0.00076452599388379206
I1
I0
I1
tp9729
sS'were,assessed'
p9730
(F1
F0.00076452599388379206
I0
I1
I-1
tp9731
sS'concentration,in'
p9732
(F1
F0.00076452599388379206
I1
I0
I1
tp9733
sS'ultram,is'
p9734
(F1
F0.00076452599388379206
I0
I1
I-1
tp9735
sS'significant,adverse'
p9736
(F1
F0.0015290519877675841
I0
I2
I-2
tp9737
sS'elimination,are'
p9738
(F1
F0.00076452599388379206
I0
I1
I-1
tp9739
sS'formalin,test'
p9740
(F1
F0.00076452599388379206
I1
I0
I1
tp9741
sS'aceon,tablets'
p9742
(F0
F0
I2
I2
I0
tp9743
sS'to,followed'
p9744
(F1
F0.0015290519877675841
I2
I0
I2
tp9745
sS'may,change'
p9746
(F1
F0.00076452599388379206
I0
I1
I-1
tp9747
sS'control,pills'
p9748
(F0
F0
I1
I1
I0
tp9749
sS'certain,cases'
p9750
(F1
F0.00076452599388379206
I1
I0
I1
tp9751
sS'their,bioavailability'
p9752
(F1
F0.00076452599388379206
I1
I0
I1
tp9753
sS'the,primary'
p9754
(F0
F0
I1
I1
I0
tp9755
sS'administering,feldene'
p9756
(F1
F0.00076452599388379206
I1
I0
I1
tp9757
sS'disease,and'
p9758
(F1
F0.00076452599388379206
I0
I1
I-1
tp9759
sS'and,abl'
p9760
(F0
F0
I1
I1
I0
tp9761
sS'reviewed,the'
p9762
(F1
F0.00076452599388379206
I0
I1
I-1
tp9763
sS'by,anti-vitamin'
p9764
(F1
F0.00076452599388379206
I1
I0
I1
tp9765
sS'acth,in'
p9766
(F1
F0.00076452599388379206
I0
I1
I-1
tp9767
sS'because,there'
p9768
(F1
F0.00076452599388379206
I1
I0
I1
tp9769
sS'tail,suspension'
p9770
(F1
F0.00076452599388379206
I0
I1
I-1
tp9771
sS'as,slowly'
p9772
(F1
F0.00076452599388379206
I1
I0
I1
tp9773
sS'clinical,outcome'
p9774
(F1
F0.00076452599388379206
I0
I1
I-1
tp9775
sS'post-marketing,observations'
p9776
(F1
F0.00076452599388379206
I1
I0
I1
tp9777
sS'with,aceon'
p9778
(F1
F0.00076452599388379206
I1
I0
I1
tp9779
sS'rats,treated'
p9780
(F1
F0.00076452599388379206
I0
I1
I-1
tp9781
sS'increase,levels'
p9782
(F1
F0.00076452599388379206
I1
I0
I1
tp9783
sS'is,effective'
p9784
(F1
F0.00076452599388379206
I0
I1
I-1
tp9785
sS'in,her2-positive'
p9786
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp9787
sS'confusional,states'
p9788
(F1
F0.00076452599388379206
I1
I0
I1
tp9789
sS'derivatives,or'
p9790
(F1
F0.00076452599388379206
I1
I0
I1
tp9791
sS'difficulty,in'
p9792
(F1
F0.00076452599388379206
I0
I1
I-1
tp9793
sS'similarity,of'
p9794
(F1
F0.00076452599388379206
I1
I0
I1
tp9795
sS'anticholinergic,pharmacological'
p9796
(F1
F0.00076452599388379206
I1
I0
I1
tp9797
sS'pilocarpine,should'
p9798
(F1
F0.00076452599388379206
I1
I0
I1
tp9799
sS'out,with'
p9800
(F1
F0.00076452599388379206
I0
I1
I-1
tp9801
sS'is,needed'
p9802
(F1
F0.00076452599388379206
I0
I1
I-1
tp9803
sS'doses,lower'
p9804
(F1
F0.00076452599388379206
I1
I0
I1
tp9805
sS'the,qt'
p9806
(F1
F0.00076452599388379206
I0
I1
I-1
tp9807
sS'the,signaling'
p9808
(F1
F0.00076452599388379206
I1
I0
I1
tp9809
sS'patients,in'
p9810
(F1
F0.0030581039755351682
I0
I4
I-4
tp9811
sS'angina,or'
p9812
(F1
F0.00076452599388379206
I0
I1
I-1
tp9813
sS'pharmacokinetic,steady'
p9814
(F1
F0.0015290519877675841
I0
I2
I-2
tp9815
sS'n,channel'
p9816
(F1
F0.00076452599388379206
I0
I1
I-1
tp9817
sS'metabolite,is'
p9818
(F1
F0.00076452599388379206
I0
I1
I-1
tp9819
sS'took,variable'
p9820
(F1
F0.00076452599388379206
I1
I0
I1
tp9821
sS'therapeutic,doses'
p9822
(F1
F0.00076452599388379206
I1
I0
I1
tp9823
sS'yielded,a'
p9824
(F1
F0.00076452599388379206
I1
I0
I1
tp9825
sS'drugs,used'
p9826
(F1
F0.00076452599388379206
I0
I1
I-1
tp9827
sS'receiving,other'
p9828
(F1
F0.0015290519877675841
I2
I0
I2
tp9829
sS'metabolism,are'
p9830
(F1
F0.00076452599388379206
I0
I1
I-1
tp9831
sS'with,enzymes'
p9832
(F1
F0.00076452599388379206
I0
I1
I-1
tp9833
sS'shorter,durations'
p9834
(F1
F0.00076452599388379206
I1
I0
I1
tp9835
sS'with,peg-intron'
p9836
(F1
F0.00076452599388379206
I1
I0
I1
tp9837
sS'infacol,drops'
p9838
(F1
F0.00076452599388379206
I0
I1
I-1
tp9839
sS'studied,in'
p9840
(F1
F0.0038226299694189602
I0
I5
I-5
tp9841
sS'the,signs'
p9842
(F1
F0.00076452599388379206
I1
I0
I1
tp9843
sS'clearance,from'
p9844
(F1
F0.00076452599388379206
I1
I0
I1
tp9845
sS'is,markedly'
p9846
(F1
F0.0015290519877675841
I2
I0
I2
tp9847
sS'of,that'
p9848
(F1
F0.00076452599388379206
I0
I1
I-1
tp9849
sS'non-specific,cyp'
p9850
(F1
F0.00076452599388379206
I0
I1
I-1
tp9851
sS'fibrates,the'
p9852
(F1
F0.00076452599388379206
I0
I1
I-1
tp9853
sS'hyperreflexia,and'
p9854
(F1
F0.00076452599388379206
I1
I0
I1
tp9855
sS'also,responsible'
p9856
(F1
F0.00076452599388379206
I1
I0
I1
tp9857
sS'tricyclic,antidepressants'
p9858
(F1
F0.0030581039755351682
I4
I0
I4
tp9859
sS'blood,levels'
p9860
(F0.5
F0.0015290519877675841
I3
I1
I2
tp9861
sS'supplements,or'
p9862
(F1
F0.00076452599388379206
I0
I1
I-1
tp9863
sS'of,than'
p9864
(F1
F0.00076452599388379206
I1
I0
I1
tp9865
sS'primary,objective'
p9866
(F1
F0.00076452599388379206
I0
I1
I-1
tp9867
sS'increases,plasma'
p9868
(F1
F0.00076452599388379206
I1
I0
I1
tp9869
sS'fro,days'
p9870
(F1
F0.00076452599388379206
I0
I1
I-1
tp9871
sS'with,herceptin-refractory'
p9872
(F1
F0.00076452599388379206
I1
I0
I1
tp9873
sS'the,mouth'
p9874
(F1
F0.00076452599388379206
I1
I0
I1
tp9875
sS'with,in'
p9876
(F1
F0.0038226299694189602
I5
I0
I5
tp9877
sS'binding,drug'
p9878
(F1
F0.00076452599388379206
I0
I1
I-1
tp9879
sS'proamatine,potential'
p9880
(F1
F0.00076452599388379206
I1
I0
I1
tp9881
sS'weekly,intramuscular'
p9882
(F1
F0.00076452599388379206
I0
I1
I-1
tp9883
sS'animals,displayed'
p9884
(F1
F0.00076452599388379206
I1
I0
I1
tp9885
sS'with,strong'
p9886
(F1
F0.00076452599388379206
I1
I0
I1
tp9887
sS'with,is'
p9888
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp9889
sS'was,no'
p9890
(F1
F0.0022935779816513763
I0
I3
I-3
tp9891
sS'is,antagonistic'
p9892
(F1
F0.00076452599388379206
I1
I0
I1
tp9893
sS'anesthesia,tiva'
p9894
(F1
F0.00076452599388379206
I0
I1
I-1
tp9895
sS'for,active'
p9896
(F1
F0.00076452599388379206
I1
I0
I1
tp9897
sS'pt,and'
p9898
(F1
F0.0022935779816513763
I3
I0
I3
tp9899
sS'cancer,the'
p9900
(F1
F0.00076452599388379206
I1
I0
I1
tp9901
sS'national,formulary'
p9902
(F1
F0.00076452599388379206
I0
I1
I-1
tp9903
sS'weekly,doses'
p9904
(F1
F0.0015290519877675841
I0
I2
I-2
tp9905
sS'univasc,if'
p9906
(F1
F0.00076452599388379206
I0
I1
I-1
tp9907
sS'non-steroidal,anti-inflammatory'
p9908
(F0
F0
I1
I1
I0
tp9909
sS'cardiac,dysrhythmias'
p9910
(F1
F0.00076452599388379206
I1
I0
I1
tp9911
sS'mobic,with'
p9912
(F1
F0.00076452599388379206
I1
I0
I1
tp9913
sS'may,elicit'
p9914
(F1
F0.00076452599388379206
I0
I1
I-1
tp9915
sS'ibuprofen,plasma'
p9916
(F1
F0.00076452599388379206
I1
I0
I1
tp9917
sS'ischemia,and'
p9918
(F1
F0.00076452599388379206
I0
I1
I-1
tp9919
sS'acetazolamide,concurrent'
p9920
(F1
F0.00076452599388379206
I1
I0
I1
tp9921
sS'skelid,is'
p9922
(F1
F0.0015290519877675841
I2
I0
I2
tp9923
sS'not,influence'
p9924
(F1
F0.0015290519877675841
I0
I2
I-2
tp9925
sS'is,also'
p9926
(F1
F0.0015290519877675841
I2
I0
I2
tp9927
sS'did,not'
p9928
(F0.8125
F0.019877675840978593
I3
I29
I-26
tp9929
sS'the,curve'
p9930
(F1
F0.00076452599388379206
I1
I0
I1
tp9931
sS'enzyme,system'
p9932
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp9933
sS'infusion,administered'
p9934
(F1
F0.00076452599388379206
I1
I0
I1
tp9935
sS'after,the'
p9936
(F1
F0.0015290519877675841
I2
I0
I2
tp9937
sS'vitamin,b2'
p9938
(F1
F0.00076452599388379206
I1
I0
I1
tp9939
sS'cana,edta'
p9940
(F1
F0.00076452599388379206
I1
I0
I1
tp9941
sS'ritalin,may'
p9942
(F1
F0.0015290519877675841
I2
I0
I2
tp9943
sS'and,profound'
p9944
(F1
F0.00076452599388379206
I1
I0
I1
tp9945
sS'extended-release,tablets'
p9946
(F1
F0.00076452599388379206
I0
I1
I-1
tp9947
sS'analgesics,agonist'
p9948
(F1
F0.00076452599388379206
I1
I0
I1
tp9949
sS'complications,when'
p9950
(F1
F0.00076452599388379206
I1
I0
I1
tp9951
sS'in,t-all'
p9952
(F1
F0.00076452599388379206
I0
I1
I-1
tp9953
sS'on,often'
p9954
(F1
F0.00076452599388379206
I1
I0
I1
tp9955
sS'appears,possible'
p9956
(F1
F0.00076452599388379206
I1
I0
I1
tp9957
sS'treated,with'
p9958
(F0.5
F0.0045871559633027525
I9
I3
I6
tp9959
sS'supplements,concomitantly'
p9960
(F1
F0.00076452599388379206
I1
I0
I1
tp9961
sS'bowel,may'
p9962
(F1
F0.00076452599388379206
I1
I0
I1
tp9963
sS'channel,blockers'
p9964
(F1
F0.00076452599388379206
I0
I1
I-1
tp9965
sS'aerosol,bronchodilators'
p9966
(F1
F0.0015290519877675841
I2
I0
I2
tp9967
sS'faster,with'
p9968
(F1
F0.00076452599388379206
I1
I0
I1
tp9969
sS'drug-drug,interaction'
p9970
(F0.42857142857142855
F0.0022935779816513763
I2
I5
I-3
tp9971
sS'suitable,chemosensitizer'
p9972
(F1
F0.00076452599388379206
I0
I1
I-1
tp9973
sS'parkinsonian,symptoms'
p9974
(F1
F0.00076452599388379206
I1
I0
I1
tp9975
sS'metabolite,by'
p9976
(F1
F0.00076452599388379206
I1
I0
I1
tp9977
sS'until,recovery'
p9978
(F1
F0.00076452599388379206
I1
I0
I1
tp9979
sS'cholestyramine,causes'
p9980
(F1
F0.00076452599388379206
I1
I0
I1
tp9981
sS'male,or'
p9982
(F1
F0.00076452599388379206
I0
I1
I-1
tp9983
sS'cisapride,astemizole'
p9984
(F1
F0.00076452599388379206
I1
I0
I1
tp9985
sS'intravenous,anesthesia'
p9986
(F1
F0.00076452599388379206
I0
I1
I-1
tp9987
sS'healthy,women'
p9988
(F1
F0.0015290519877675841
I0
I2
I-2
tp9989
sS'dose,or'
p9990
(F1
F0.00076452599388379206
I0
I1
I-1
tp9991
sS'sodium,and'
p9992
(F1
F0.00076452599388379206
I1
I0
I1
tp9993
sS'data,regarding'
p9994
(F1
F0.00076452599388379206
I1
I0
I1
tp9995
sS'subjects,receiving'
p9996
(F0.66666666666666663
F0.0030581039755351682
I1
I5
I-4
tp9997
sS'oral,contraceptives'
p9998
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp9999
sS'tyrosine,hydroxylase-positive'
p10000
(F1
F0.00076452599388379206
I1
I0
I1
tp10001
sS'subjects,in'
p10002
(F1
F0.00076452599388379206
I1
I0
I1
tp10003
sS'k,levels'
p10004
(F1
F0.00076452599388379206
I0
I1
I-1
tp10005
sS'dietary,components'
p10006
(F1
F0.00076452599388379206
I1
I0
I1
tp10007
sS'were,coadministered'
p10008
(F1
F0.00076452599388379206
I0
I1
I-1
tp10009
sS'increased,thrombocytopenia'
p10010
(F1
F0.0015290519877675841
I0
I2
I-2
tp10011
sS'and,elimination'
p10012
(F1
F0.00076452599388379206
I0
I1
I-1
tp10013
sS'mediated,suppression'
p10014
(F1
F0.00076452599388379206
I1
I0
I1
tp10015
sS'dosage,and'
p10016
(F1
F0.00076452599388379206
I1
I0
I1
tp10017
sS'receiving,diflucan'
p10018
(F1
F0.0022935779816513763
I3
I0
I3
tp10019
sS'magnesium-aluminum,hydroxide'
p10020
(F1
F0.00076452599388379206
I1
I0
I1
tp10021
sS'few,spontaneous'
p10022
(F1
F0.00076452599388379206
I0
I1
I-1
tp10023
sS'if,they'
p10024
(F1
F0.00076452599388379206
I0
I1
I-1
tp10025
sS'considered,to'
p10026
(F1
F0.00076452599388379206
I1
I0
I1
tp10027
sS'of,prothrombin'
p10028
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10029
sS'streptozocin,has'
p10030
(F1
F0.00076452599388379206
I1
I0
I1
tp10031
sS'and,xanthine'
p10032
(F1
F0.00076452599388379206
I1
I0
I1
tp10033
sS'is,known'
p10034
(F1
F0.00076452599388379206
I1
I0
I1
tp10035
sS'of,cyclooxygenase-2'
p10036
(F1
F0.00076452599388379206
I0
I1
I-1
tp10037
sS'better,to'
p10038
(F1
F0.00076452599388379206
I1
I0
I1
tp10039
sS'kg,plus'
p10040
(F1
F0.00076452599388379206
I0
I1
I-1
tp10041
sS'synergistic,effect'
p10042
(F1
F0.00076452599388379206
I1
I0
I1
tp10043
sS'the,administration'
p10044
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10045
sS'mobic,may'
p10046
(F1
F0.00076452599388379206
I1
I0
I1
tp10047
sS'of,conducted'
p10048
(F1
F0.00076452599388379206
I0
I1
I-1
tp10049
sS'take,if'
p10050
(F1
F0.00076452599388379206
I1
I0
I1
tp10051
sS'combined,diflucan'
p10052
(F1
F0.00076452599388379206
I1
I0
I1
tp10053
sS'concomitant,mg'
p10054
(F1
F0.00076452599388379206
I1
I0
I1
tp10055
sS'its,metabolism'
p10056
(F1
F0.00076452599388379206
I1
I0
I1
tp10057
sS'additive,effect'
p10058
(F1
F0.0015290519877675841
I2
I0
I2
tp10059
sS'of,diepoxybutane'
p10060
(F1
F0.00076452599388379206
I0
I1
I-1
tp10061
sS'in,mice'
p10062
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp10063
sS'of,other'
p10064
(F0.076923076923076927
F0.00076452599388379206
I7
I6
I1
tp10065
sS'and,this'
p10066
(F1
F0.00076452599388379206
I0
I1
I-1
tp10067
sS'induced,her2'
p10068
(F1
F0.00076452599388379206
I1
I0
I1
tp10069
sS'these,enzymes'
p10070
(F1
F0.0030581039755351682
I0
I4
I-4
tp10071
sS'drug-paired,context'
p10072
(F1
F0.00076452599388379206
I0
I1
I-1
tp10073
sS'in,drs'
p10074
(F1
F0.00076452599388379206
I1
I0
I1
tp10075
sS'you,are'
p10076
(F1
F0.00076452599388379206
I0
I1
I-1
tp10077
sS'or,inhibition'
p10078
(F1
F0.00076452599388379206
I0
I1
I-1
tp10079
sS'serum,to'
p10080
(F1
F0.00076452599388379206
I1
I0
I1
tp10081
sS'hyperthyroid,patients'
p10082
(F1
F0.0015290519877675841
I0
I2
I-2
tp10083
sS'at,its'
p10084
(F1
F0.00076452599388379206
I0
I1
I-1
tp10085
sS'are,eliminated'
p10086
(F0
F0
I1
I1
I0
tp10087
sS'a,bacteriostatic'
p10088
(F1
F0.00076452599388379206
I1
I0
I1
tp10089
sS'can,be'
p10090
(F0.5
F0.0030581039755351682
I6
I2
I4
tp10091
sS'predispose,to'
p10092
(F1
F0.00076452599388379206
I1
I0
I1
tp10093
sS'at,different'
p10094
(F1
F0.00076452599388379206
I0
I1
I-1
tp10095
sS'to,low'
p10096
(F1
F0.00076452599388379206
I0
I1
I-1
tp10097
sS'an,excessive'
p10098
(F1
F0.00076452599388379206
I1
I0
I1
tp10099
sS'to,less'
p10100
(F1
F0.00076452599388379206
I0
I1
I-1
tp10101
sS'significantly,decrease'
p10102
(F1
F0.00076452599388379206
I1
I0
I1
tp10103
sS'after,months'
p10104
(F1
F0.00076452599388379206
I0
I1
I-1
tp10105
sS'an,inhibitor'
p10106
(F0.5
F0.0015290519877675841
I3
I1
I2
tp10107
sS'or,mg'
p10108
(F1
F0.00076452599388379206
I1
I0
I1
tp10109
sS'toxicity,at'
p10110
(F1
F0.00076452599388379206
I0
I1
I-1
tp10111
sS'from,different'
p10112
(F1
F0.00076452599388379206
I0
I1
I-1
tp10113
sS'large,as'
p10114
(F1
F0.00076452599388379206
I0
I1
I-1
tp10115
sS'neuromuscular,blocking'
p10116
(F0.5
F0.0030581039755351682
I6
I2
I4
tp10117
sS'and,potassium-sparing'
p10118
(F1
F0.0015290519877675841
I0
I2
I-2
tp10119
sS'hypotensive,effects'
p10120
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp10121
sS'peak,concentration'
p10122
(F1
F0.00076452599388379206
I1
I0
I1
tp10123
sS'on,studies'
p10124
(F1
F0.00076452599388379206
I0
I1
I-1
tp10125
sS'elucidate,the'
p10126
(F1
F0.00076452599388379206
I0
I1
I-1
tp10127
sS'mexitil,plasma'
p10128
(F1
F0.00076452599388379206
I1
I0
I1
tp10129
sS'the,salt'
p10130
(F1
F0.00076452599388379206
I1
I0
I1
tp10131
sS'alteration,of'
p10132
(F1
F0.00076452599388379206
I0
I1
I-1
tp10133
sS'to,auc'
p10134
(F1
F0.00076452599388379206
I0
I1
I-1
tp10135
sS'can,cause'
p10136
(F1
F0.0015290519877675841
I2
I0
I2
tp10137
sS'and,results'
p10138
(F1
F0.00076452599388379206
I1
I0
I1
tp10139
sS'the,active'
p10140
(F1
F0.00076452599388379206
I0
I1
I-1
tp10141
sS'an,effect'
p10142
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10143
sS'evaluated,the'
p10144
(F1
F0.0038226299694189602
I0
I5
I-5
tp10145
sS'were,altered'
p10146
(F1
F0.00076452599388379206
I1
I0
I1
tp10147
sS'if,confirmed'
p10148
(F1
F0.00076452599388379206
I0
I1
I-1
tp10149
sS'of,sutent'
p10150
(F1
F0.0015290519877675841
I2
I0
I2
tp10151
sS'in,additive'
p10152
(F1
F0.0015290519877675841
I2
I0
I2
tp10153
sS'mpa,available'
p10154
(F1
F0.00076452599388379206
I0
I1
I-1
tp10155
sS'severity,of'
p10156
(F1
F0.0015290519877675841
I2
I0
I2
tp10157
sS'plasma,concentrations'
p10158
(F0.80000000000000004
F0.0061162079510703364
I9
I1
I8
tp10159
sS'who,are'
p10160
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp10161
sS'system,are'
p10162
(F1
F0.00076452599388379206
I1
I0
I1
tp10163
sS'anticholinergic,properties'
p10164
(F1
F0.00076452599388379206
I0
I1
I-1
tp10165
sS'could,proceed'
p10166
(F1
F0.00076452599388379206
I1
I0
I1
tp10167
sS'but,concomitant'
p10168
(F1
F0.00076452599388379206
I1
I0
I1
tp10169
sS'study,showed'
p10170
(F1
F0.00076452599388379206
I1
I0
I1
tp10171
sS'may,cause'
p10172
(F1
F0.0045871559633027525
I6
I0
I6
tp10173
sS'receiving,a'
p10174
(F0
F0
I1
I1
I0
tp10175
sS'studies,have'
p10176
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp10177
sS'displayed,parkinsonian'
p10178
(F1
F0.00076452599388379206
I1
I0
I1
tp10179
sS'monitored,if'
p10180
(F1
F0.0015290519877675841
I2
I0
I2
tp10181
sS'acquired,qt'
p10182
(F1
F0.00076452599388379206
I0
I1
I-1
tp10183
sS'half-life,and'
p10184
(F1
F0.00076452599388379206
I1
I0
I1
tp10185
sS'nardil,in'
p10186
(F1
F0.00076452599388379206
I1
I0
I1
tp10187
sS'cyp450,metabolism'
p10188
(F1
F0.00076452599388379206
I0
I1
I-1
tp10189
sS'the,ratio'
p10190
(F1
F0.00076452599388379206
I0
I1
I-1
tp10191
sS'unaltered,with'
p10192
(F1
F0.00076452599388379206
I0
I1
I-1
tp10193
sS'as,the'
p10194
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp10195
sS'isolate,the'
p10196
(F1
F0.00076452599388379206
I1
I0
I1
tp10197
sS'in,glass'
p10198
(F1
F0.00076452599388379206
I0
I1
I-1
tp10199
sS'ecg,intervals'
p10200
(F1
F0.00076452599388379206
I0
I1
I-1
tp10201
sS'alcohol,in'
p10202
(F1
F0.00076452599388379206
I0
I1
I-1
tp10203
sS'dose,was'
p10204
(F1
F0.0015290519877675841
I0
I2
I-2
tp10205
sS'moderate,renal'
p10206
(F1
F0.0015290519877675841
I2
I0
I2
tp10207
sS'a,cytochrome'
p10208
(F0
F0
I1
I1
I0
tp10209
sS'started,recently'
p10210
(F1
F0.00076452599388379206
I1
I0
I1
tp10211
sS'a,formal'
p10212
(F0
F0
I1
I1
I0
tp10213
sS'course,of'
p10214
(F1
F0.00076452599388379206
I1
I0
I1
tp10215
sS'free,in'
p10216
(F1
F0.00076452599388379206
I0
I1
I-1
tp10217
sS'reported,that'
p10218
(F1
F0.0030581039755351682
I4
I0
I4
tp10219
sS'pharmacodynamics,fecal'
p10220
(F1
F0.00076452599388379206
I0
I1
I-1
tp10221
sS'sympathomimetics,may'
p10222
(F1
F0.00076452599388379206
I1
I0
I1
tp10223
sS'the,locomotor'
p10224
(F1
F0.00076452599388379206
I1
I0
I1
tp10225
sS'that,it'
p10226
(F1
F0.00076452599388379206
I1
I0
I1
tp10227
sS'that,is'
p10228
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp10229
sS'cyclosporine,preliminary'
p10230
(F1
F0.00076452599388379206
I1
I0
I1
tp10231
sS'inhibitors,ssris'
p10232
(F0
F0
I1
I1
I0
tp10233
sS'iiia,inhibitors'
p10234
(F1
F0.00076452599388379206
I1
I0
I1
tp10235
sS'of,concurrent'
p10236
(F1
F0.00076452599388379206
I0
I1
I-1
tp10237
sS'impact,on'
p10238
(F1
F0.00076452599388379206
I0
I1
I-1
tp10239
sS'that,in'
p10240
(F1
F0.00076452599388379206
I0
I1
I-1
tp10241
sS'receiving,these'
p10242
(F1
F0.00076452599388379206
I0
I1
I-1
tp10243
sS'may,decrease'
p10244
(F0.83333333333333337
F0.0076452599388379203
I11
I1
I10
tp10245
sS'generally,should'
p10246
(F1
F0.00076452599388379206
I1
I0
I1
tp10247
sS'other,centrally'
p10248
(F0
F0
I1
I1
I0
tp10249
sS'no,significant'
p10250
(F1
F0.0022935779816513763
I0
I3
I-3
tp10251
sS'cyclooxygenase-2,inhibitors'
p10252
(F1
F0.00076452599388379206
I0
I1
I-1
tp10253
sS'with,diabetes'
p10254
(F1
F0.00076452599388379206
I1
I0
I1
tp10255
sS'and,blood'
p10256
(F1
F0.00076452599388379206
I1
I0
I1
tp10257
sS'not,improve'
p10258
(F1
F0.00076452599388379206
I0
I1
I-1
tp10259
sS'times,the'
p10260
(F1
F0.0038226299694189602
I0
I5
I-5
tp10261
sS'rats,neonatally'
p10262
(F1
F0.00076452599388379206
I0
I1
I-1
tp10263
sS'cisapride,there'
p10264
(F1
F0.00076452599388379206
I1
I0
I1
tp10265
sS'circumstances,consideration'
p10266
(F1
F0.00076452599388379206
I1
I0
I1
tp10267
sS'traditional,therapy'
p10268
(F1
F0.00076452599388379206
I1
I0
I1
tp10269
sS'and,administered'
p10270
(F1
F0.00076452599388379206
I0
I1
I-1
tp10271
sS'metastatic,tumors'
p10272
(F1
F0.00076452599388379206
I1
I0
I1
tp10273
sS'recirculation,or'
p10274
(F1
F0.00076452599388379206
I1
I0
I1
tp10275
sS'by,multiple'
p10276
(F1
F0.00076452599388379206
I0
I1
I-1
tp10277
sS'responsible,for'
p10278
(F1
F0.00076452599388379206
I1
I0
I1
tp10279
sS'cases,which'
p10280
(F1
F0.00076452599388379206
I0
I1
I-1
tp10281
sS'induction,of'
p10282
(F0
F0
I1
I1
I0
tp10283
sS'exceed,a'
p10284
(F1
F0.00076452599388379206
I1
I0
I1
tp10285
sS'concentration,of'
p10286
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp10287
sS'the,reported'
p10288
(F1
F0.00076452599388379206
I0
I1
I-1
tp10289
sS'after,pretreatments'
p10290
(F1
F0.00076452599388379206
I0
I1
I-1
tp10291
sS'pharmacokinetics,and'
p10292
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp10293
sS'induction,or'
p10294
(F1
F0.00076452599388379206
I0
I1
I-1
tp10295
sS'potentiated,by'
p10296
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp10297
sS'antidepressants,and'
p10298
(F1
F0.0022935779816513763
I3
I0
I3
tp10299
sS'of,the'
p10300
(F0.063829787234042548
F0.0022935779816513763
I25
I22
I3
tp10301
sS'anticoagulant,activity'
p10302
(F1
F0.00076452599388379206
I1
I0
I1
tp10303
sS'narcotic,analgesics'
p10304
(F1
F0.0015290519877675841
I2
I0
I2
tp10305
sS'a,background'
p10306
(F1
F0.00076452599388379206
I0
I1
I-1
tp10307
sS'experience,profiles'
p10308
(F1
F0.00076452599388379206
I1
I0
I1
tp10309
sS'of,dose'
p10310
(F1
F0.00076452599388379206
I0
I1
I-1
tp10311
sS'assay,sirna'
p10312
(F1
F0.00076452599388379206
I0
I1
I-1
tp10313
sS'the,isozyme'
p10314
(F1
F0.00076452599388379206
I1
I0
I1
tp10315
sS'a,particular'
p10316
(F1
F0.00076452599388379206
I0
I1
I-1
tp10317
sS'a,increase'
p10318
(F1
F0.0015290519877675841
I2
I0
I2
tp10319
sS'and,was'
p10320
(F0
F0
I1
I1
I0
tp10321
sS'with,against'
p10322
(F1
F0.0015290519877675841
I0
I2
I-2
tp10323
sS'with,cyp3a4'
p10324
(F1
F0.00076452599388379206
I0
I1
I-1
tp10325
sS'between,alimta'
p10326
(F1
F0.00076452599388379206
I1
I0
I1
tp10327
sS'only,was'
p10328
(F1
F0.00076452599388379206
I0
I1
I-1
tp10329
sS'jar,and'
p10330
(F1
F0.00076452599388379206
I0
I1
I-1
tp10331
sS'when,used'
p10332
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10333
sS'two,drugs'
p10334
(F1
F0.00076452599388379206
I0
I1
I-1
tp10335
sS'concurrently,receiving'
p10336
(F0
F0
I1
I1
I0
tp10337
sS'which,depresses'
p10338
(F1
F0.00076452599388379206
I1
I0
I1
tp10339
sS'dasatinib-enhanced,cytotoxicity'
p10340
(F1
F0.00076452599388379206
I1
I0
I1
tp10341
sS'slowly,dissolving'
p10342
(F1
F0.00076452599388379206
I1
I0
I1
tp10343
sS'occur,with'
p10344
(F1
F0.00076452599388379206
I0
I1
I-1
tp10345
sS'randomized,either'
p10346
(F1
F0.00076452599388379206
I0
I1
I-1
tp10347
sS'and,probably'
p10348
(F1
F0.00076452599388379206
I1
I0
I1
tp10349
sS'p4501a2,such'
p10350
(F1
F0.00076452599388379206
I1
I0
I1
tp10351
sS'bradycardia,was'
p10352
(F1
F0.00076452599388379206
I1
I0
I1
tp10353
sS'dependent,in'
p10354
(F1
F0.00076452599388379206
I1
I0
I1
tp10355
sS'with,plus'
p10356
(F1
F0.0015290519877675841
I2
I0
I2
tp10357
sS'hypoglycemia,may'
p10358
(F1
F0.00076452599388379206
I1
I0
I1
tp10359
sS'that,does'
p10360
(F1
F0.0022935779816513763
I0
I3
I-3
tp10361
sS'the,effect-time'
p10362
(F1
F0.00076452599388379206
I0
I1
I-1
tp10363
sS'effects,should'
p10364
(F0
F0
I1
I1
I0
tp10365
sS'blood,concentrations'
p10366
(F1
F0.00076452599388379206
I1
I0
I1
tp10367
sS'anticoagulants,such'
p10368
(F1
F0.00076452599388379206
I1
I0
I1
tp10369
sS'ginseng,stem-and'
p10370
(F1
F0.0015290519877675841
I0
I2
I-2
tp10371
sS'concurrent,and'
p10372
(F1
F0.00076452599388379206
I0
I1
I-1
tp10373
sS'adverse,event'
p10374
(F1
F0.00076452599388379206
I0
I1
I-1
tp10375
sS'coadministered,with'
p10376
(F0.25
F0.0015290519877675841
I5
I3
I2
tp10377
sS'the,and'
p10378
(F1
F0.00076452599388379206
I0
I1
I-1
tp10379
sS'drug,therapies'
p10380
(F1
F0.00076452599388379206
I1
I0
I1
tp10381
sS'anionic,transport'
p10382
(F1
F0.00076452599388379206
I1
I0
I1
tp10383
sS'cns-depressant,effect'
p10384
(F1
F0.00076452599388379206
I1
I0
I1
tp10385
sS'have,suggested'
p10386
(F1
F0.00076452599388379206
I1
I0
I1
tp10387
sS'via,the'
p10388
(F0
F0
I1
I1
I0
tp10389
sS'of,midbrain'
p10390
(F1
F0.00076452599388379206
I1
I0
I1
tp10391
sS'limited,published'
p10392
(F1
F0.00076452599388379206
I1
I0
I1
tp10393
sS'shortness,of'
p10394
(F1
F0.00076452599388379206
I1
I0
I1
tp10395
sS'increased,systemic'
p10396
(F1
F0.00076452599388379206
I1
I0
I1
tp10397
sS'rifampin,rifampin'
p10398
(F1
F0.00076452599388379206
I1
I0
I1
tp10399
sS'acute,model'
p10400
(F1
F0.00076452599388379206
I0
I1
I-1
tp10401
sS'and,chondroitin'
p10402
(F1
F0.00076452599388379206
I0
I1
I-1
tp10403
sS'causal,relationship'
p10404
(F1
F0.0015290519877675841
I2
I0
I2
tp10405
sS'herceptin-sensitive,tumors'
p10406
(F1
F0.00076452599388379206
I0
I1
I-1
tp10407
sS'see,clinical'
p10408
(F1
F0.00076452599388379206
I1
I0
I1
tp10409
sS'most,other'
p10410
(F1
F0.00076452599388379206
I0
I1
I-1
tp10411
sS'in,achieving'
p10412
(F1
F0.00076452599388379206
I0
I1
I-1
tp10413
sS'aruonic,transporter'
p10414
(F1
F0.00076452599388379206
I0
I1
I-1
tp10415
sS'or,oral'
p10416
(F1
F0.0015290519877675841
I2
I0
I2
tp10417
sS'acid,may'
p10418
(F1
F0.00076452599388379206
I1
I0
I1
tp10419
sS'whereas,with'
p10420
(F1
F0.00076452599388379206
I1
I0
I1
tp10421
sS'markedly,inhibits'
p10422
(F1
F0.00076452599388379206
I1
I0
I1
tp10423
sS'mivacron,with'
p10424
(F1
F0.00076452599388379206
I0
I1
I-1
tp10425
sS'anticholinergic,agents'
p10426
(F1
F0.0022935779816513763
I3
I0
I3
tp10427
sS'ci,to'
p10428
(F1
F0.00076452599388379206
I1
I0
I1
tp10429
sS'inhibit,purine'
p10430
(F1
F0.00076452599388379206
I1
I0
I1
tp10431
sS'which,low-dose'
p10432
(F1
F0.00076452599388379206
I0
I1
I-1
tp10433
sS'with,xenical'
p10434
(F0
F0
I1
I1
I0
tp10435
sS'increased,geometric'
p10436
(F1
F0.00076452599388379206
I1
I0
I1
tp10437
sS'alpha,lipoic'
p10438
(F1
F0.00076452599388379206
I0
I1
I-1
tp10439
sS'other,diabetes'
p10440
(F1
F0.00076452599388379206
I1
I0
I1
tp10441
sS'of,oral'
p10442
(F0.45454545454545453
F0.0038226299694189602
I8
I3
I5
tp10443
sS'tiva,but'
p10444
(F1
F0.00076452599388379206
I0
I1
I-1
tp10445
sS'fat-soluble,vitamins'
p10446
(F1
F0.00076452599388379206
I1
I0
I1
tp10447
sS'expression,vectors'
p10448
(F1
F0.00076452599388379206
I0
I1
I-1
tp10449
sS'incompatible,with'
p10450
(F1
F0.00076452599388379206
I1
I0
I1
tp10451
sS'different,conditions'
p10452
(F1
F0.00076452599388379206
I0
I1
I-1
tp10453
sS'non-thalidomide,drug'
p10454
(F1
F0.00076452599388379206
I0
I1
I-1
tp10455
sS'local,anesthetic'
p10456
(F1
F0.00076452599388379206
I0
I1
I-1
tp10457
sS'observed,with'
p10458
(F1
F0.00076452599388379206
I1
I0
I1
tp10459
sS'contradictory,results'
p10460
(F1
F0.00076452599388379206
I0
I1
I-1
tp10461
sS'beta,blockers'
p10462
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp10463
sS'not,appreciably'
p10464
(F1
F0.00076452599388379206
I0
I1
I-1
tp10465
sS'grens,efficacy'
p10466
(F1
F0.00076452599388379206
I0
I1
I-1
tp10467
sS'tobi,concomitantly'
p10468
(F1
F0.00076452599388379206
I1
I0
I1
tp10469
sS'calcitonin,salmon'
p10470
(F1
F0.00076452599388379206
I1
I0
I1
tp10471
sS'or,certain'
p10472
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp10473
sS'function,as'
p10474
(F1
F0.00076452599388379206
I1
I0
I1
tp10475
sS'urinary,and'
p10476
(F1
F0.00076452599388379206
I0
I1
I-1
tp10477
sS'antagonized,by'
p10478
(F1
F0.00076452599388379206
I1
I0
I1
tp10479
sS'diminishing,concealed'
p10480
(F1
F0.00076452599388379206
I1
I0
I1
tp10481
sS'isoform-specific,cyp'
p10482
(F1
F0.00076452599388379206
I0
I1
I-1
tp10483
sS'days,at'
p10484
(F1
F0.00076452599388379206
I0
I1
I-1
tp10485
sS'not,conclusive'
p10486
(F1
F0.00076452599388379206
I1
I0
I1
tp10487
sS'and,additional'
p10488
(F1
F0.00076452599388379206
I1
I0
I1
tp10489
sS'vs,vs'
p10490
(F1
F0.00076452599388379206
I1
I0
I1
tp10491
sS'or,pt'
p10492
(F1
F0.0015290519877675841
I2
I0
I2
tp10493
sS'at,intervals'
p10494
(F1
F0.00076452599388379206
I0
I1
I-1
tp10495
sS'any,effect'
p10496
(F1
F0.00076452599388379206
I0
I1
I-1
tp10497
sS'intensity,or'
p10498
(F1
F0.00076452599388379206
I0
I1
I-1
tp10499
sS'levels,only'
p10500
(F1
F0.00076452599388379206
I0
I1
I-1
tp10501
sS'activities,are'
p10502
(F1
F0.00076452599388379206
I0
I1
I-1
tp10503
sS'the,subject'
p10504
(F1
F0.00076452599388379206
I0
I1
I-1
tp10505
sS'drowsiness,and'
p10506
(F0
F0
I1
I1
I0
tp10507
sS'or,severity'
p10508
(F1
F0.0015290519877675841
I2
I0
I2
tp10509
sS'macrolide,antibiotics'
p10510
(F1
F0.00076452599388379206
I0
I1
I-1
tp10511
sS'not,be'
p10512
(F0.59999999999999998
F0.0068807339449541288
I12
I3
I9
tp10513
sS'its,effect'
p10514
(F1
F0.00076452599388379206
I0
I1
I-1
tp10515
sS'acute,myocardial'
p10516
(F1
F0.00076452599388379206
I0
I1
I-1
tp10517
sS'in,bleeding'
p10518
(F1
F0.00076452599388379206
I1
I0
I1
tp10519
sS'her2-positive,metastatic'
p10520
(F1
F0.00076452599388379206
I1
I0
I1
tp10521
sS'drug,for'
p10522
(F1
F0.00076452599388379206
I1
I0
I1
tp10523
sS'data,no'
p10524
(F1
F0.00076452599388379206
I1
I0
I1
tp10525
sS'to,alter'
p10526
(F1
F0.0022935779816513763
I0
I3
I-3
tp10527
sS'single,dose'
p10528
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp10529
sS'ticlopidine,treatment'
p10530
(F1
F0.00076452599388379206
I1
I0
I1
tp10531
sS'causing,sedation'
p10532
(F1
F0.00076452599388379206
I1
I0
I1
tp10533
sS'by,cyp1a2'
p10534
(F1
F0.00076452599388379206
I0
I1
I-1
tp10535
sS'may,reverse'
p10536
(F1
F0.00076452599388379206
I1
I0
I1
tp10537
sS'pharmacodynamics,blood'
p10538
(F1
F0.00076452599388379206
I0
I1
I-1
tp10539
sS'replacement,is'
p10540
(F1
F0.00076452599388379206
I0
I1
I-1
tp10541
sS'subjects,concurrently'
p10542
(F1
F0.00076452599388379206
I1
I0
I1
tp10543
sS'investigated,in'
p10544
(F1
F0.00076452599388379206
I0
I1
I-1
tp10545
sS'i,metabolite'
p10546
(F1
F0.00076452599388379206
I0
I1
I-1
tp10547
sS'increased,and'
p10548
(F1
F0.00076452599388379206
I1
I0
I1
tp10549
sS'infant,with'
p10550
(F1
F0.00076452599388379206
I1
I0
I1
tp10551
sS'may,bind'
p10552
(F1
F0.00076452599388379206
I1
I0
I1
tp10553
sS'not,administer'
p10554
(F1
F0.00076452599388379206
I1
I0
I1
tp10555
sS'the,agent'
p10556
(F1
F0.00076452599388379206
I1
I0
I1
tp10557
sS'and,potent'
p10558
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10559
sS'the,effectiveness'
p10560
(F1
F0.0022935779816513763
I3
I0
I3
tp10561
sS'a,two-fold'
p10562
(F1
F0.00076452599388379206
I1
I0
I1
tp10563
sS'salicylates,may'
p10564
(F1
F0.00076452599388379206
I1
I0
I1
tp10565
sS'are,also'
p10566
(F1
F0.00076452599388379206
I1
I0
I1
tp10567
sS'or,hours'
p10568
(F1
F0.00076452599388379206
I1
I0
I1
tp10569
sS'theophylline,diflucan'
p10570
(F1
F0.00076452599388379206
I1
I0
I1
tp10571
sS'seven,patients'
p10572
(F1
F0.00076452599388379206
I1
I0
I1
tp10573
sS'concentrations,when'
p10574
(F1
F0.00076452599388379206
I1
I0
I1
tp10575
sS'decreased,by'
p10576
(F1
F0.0030581039755351682
I4
I0
I4
tp10577
sS'a,negative'
p10578
(F1
F0.00076452599388379206
I0
I1
I-1
tp10579
sS'ulceration,or'
p10580
(F1
F0.00076452599388379206
I1
I0
I1
tp10581
sS'be,exercised'
p10582
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp10583
sS'pyridine,reduces'
p10584
(F1
F0.00076452599388379206
I0
I1
I-1
tp10585
sS'actions,and'
p10586
(F1
F0.00076452599388379206
I1
I0
I1
tp10587
sS'in,adolescent'
p10588
(F1
F0.0015290519877675841
I0
I2
I-2
tp10589
sS'administering,demser'
p10590
(F1
F0.00076452599388379206
I1
I0
I1
tp10591
sS'in,pharmacokinetic'
p10592
(F1
F0.00076452599388379206
I0
I1
I-1
tp10593
sS'of,drugs'
p10594
(F0.80000000000000004
F0.0061162079510703364
I9
I1
I8
tp10595
sS'linked,to'
p10596
(F1
F0.00076452599388379206
I0
I1
I-1
tp10597
sS'chloride,supplements'
p10598
(F1
F0.00076452599388379206
I1
I0
I1
tp10599
sS'with,water'
p10600
(F1
F0.00076452599388379206
I0
I1
I-1
tp10601
sS'thc,in'
p10602
(F1
F0.00076452599388379206
I0
I1
I-1
tp10603
sS'be,coadministered'
p10604
(F1
F0.0015290519877675841
I2
I0
I2
tp10605
sS'lines,except'
p10606
(F1
F0.00076452599388379206
I1
I0
I1
tp10607
sS'pharmacokinetic,disposition'
p10608
(F1
F0.00076452599388379206
I0
I1
I-1
tp10609
sS'sympathomimetic,bronchodilators'
p10610
(F1
F0.00076452599388379206
I0
I1
I-1
tp10611
sS'and,seven'
p10612
(F1
F0.00076452599388379206
I1
I0
I1
tp10613
sS'approach,allowing'
p10614
(F1
F0.00076452599388379206
I1
I0
I1
tp10615
sS'while,co-administration'
p10616
(F1
F0.00076452599388379206
I1
I0
I1
tp10617
sS'rate,of'
p10618
(F0.55555555555555558
F0.0038226299694189602
I7
I2
I5
tp10619
sS'insufficiency,creatinine'
p10620
(F1
F0.00076452599388379206
I1
I0
I1
tp10621
sS'hence,the'
p10622
(F1
F0.00076452599388379206
I0
I1
I-1
tp10623
sS'rate,or'
p10624
(F1
F0.00076452599388379206
I0
I1
I-1
tp10625
sS'cimetidine,the'
p10626
(F1
F0.00076452599388379206
I0
I1
I-1
tp10627
sS'general,internal'
p10628
(F1
F0.00076452599388379206
I0
I1
I-1
tp10629
sS'mg,per'
p10630
(F1
F0.00076452599388379206
I1
I0
I1
tp10631
sS'lower,in'
p10632
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp10633
sS'on,platelet'
p10634
(F0
F0
I1
I1
I0
tp10635
sS'the,strains'
p10636
(F1
F0.00076452599388379206
I0
I1
I-1
tp10637
sS'phenotype,by'
p10638
(F1
F0.00076452599388379206
I0
I1
I-1
tp10639
sS'administered,hour'
p10640
(F1
F0.0015290519877675841
I2
I0
I2
tp10641
sS'which,include'
p10642
(F1
F0.00076452599388379206
I1
I0
I1
tp10643
sS'and,selective'
p10644
(F1
F0.00076452599388379206
I1
I0
I1
tp10645
sS'have,clinically'
p10646
(F1
F0.00076452599388379206
I0
I1
I-1
tp10647
sS'treatment,all'
p10648
(F1
F0.00076452599388379206
I1
I0
I1
tp10649
sS'repeatedly,for'
p10650
(F1
F0.00076452599388379206
I0
I1
I-1
tp10651
sS'therapeutically,relevant'
p10652
(F1
F0.00076452599388379206
I1
I0
I1
tp10653
sS'periods,at'
p10654
(F1
F0.00076452599388379206
I0
I1
I-1
tp10655
sS'is,no'
p10656
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp10657
sS'of,resulted'
p10658
(F1
F0.00076452599388379206
I1
I0
I1
tp10659
sS'ace,inhibition'
p10660
(F1
F0.00076452599388379206
I0
I1
I-1
tp10661
sS'least,of'
p10662
(F1
F0.00076452599388379206
I0
I1
I-1
tp10663
sS'antihypertensive,effects'
p10664
(F1
F0.0015290519877675841
I2
I0
I2
tp10665
sS'in,five'
p10666
(F1
F0.00076452599388379206
I1
I0
I1
tp10667
sS'in,acidic'
p10668
(F1
F0.00076452599388379206
I1
I0
I1
tp10669
sS'mild,hepatotoxicity'
p10670
(F1
F0.00076452599388379206
I1
I0
I1
tp10671
sS'intraperitoneally,min'
p10672
(F1
F0.00076452599388379206
I0
I1
I-1
tp10673
sS'first-pass,cyp3a'
p10674
(F1
F0.00076452599388379206
I0
I1
I-1
tp10675
sS'approved,brilinta-astrazeneca'
p10676
(F1
F0.00076452599388379206
I1
I0
I1
tp10677
sS'drugs,may'
p10678
(F0.66666666666666663
F0.0061162079510703364
I10
I2
I8
tp10679
sS'sedative,non-steroidal'
p10680
(F1
F0.00076452599388379206
I0
I1
I-1
tp10681
sS'by,negatively'
p10682
(F1
F0.00076452599388379206
I1
I0
I1
tp10683
sS'even,ileus'
p10684
(F1
F0.00076452599388379206
I1
I0
I1
tp10685
sS'reduces,the'
p10686
(F1
F0.00076452599388379206
I1
I0
I1
tp10687
sS'mtor,inhibitor'
p10688
(F1
F0.00076452599388379206
I1
I0
I1
tp10689
sS'levels,have'
p10690
(F1
F0.0015290519877675841
I2
I0
I2
tp10691
sS'modified,pharmacokinetics'
p10692
(F1
F0.00076452599388379206
I0
I1
I-1
tp10693
sS'dopamine,transporter'
p10694
(F1
F0.00076452599388379206
I1
I0
I1
tp10695
sS'require,increases'
p10696
(F1
F0.00076452599388379206
I1
I0
I1
tp10697
sS'in,patient'
p10698
(F1
F0.00076452599388379206
I1
I0
I1
tp10699
sS'warfarin,a'
p10700
(F1
F0.00076452599388379206
I1
I0
I1
tp10701
sS'of,emergence'
p10702
(F1
F0.00076452599388379206
I0
I1
I-1
tp10703
sS'in,women'
p10704
(F1
F0.00076452599388379206
I1
I0
I1
tp10705
sS'increased,plasma'
p10706
(F1
F0.0030581039755351682
I4
I0
I4
tp10707
sS'require,increased'
p10708
(F1
F0.00076452599388379206
I1
I0
I1
tp10709
sS'controlled,administration'
p10710
(F1
F0.00076452599388379206
I1
I0
I1
tp10711
sS'enhancement,of'
p10712
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10713
sS'medications,included'
p10714
(F1
F0.00076452599388379206
I0
I1
I-1
tp10715
sS'is,better'
p10716
(F1
F0.00076452599388379206
I1
I0
I1
tp10717
sS'no,controlled'
p10718
(F1
F0.00076452599388379206
I0
I1
I-1
tp10719
sS'to,prevent'
p10720
(F1
F0.00076452599388379206
I1
I0
I1
tp10721
sS'neuronal,loss'
p10722
(F0
F0
I1
I1
I0
tp10723
sS'sj,grens'
p10724
(F1
F0.00076452599388379206
I0
I1
I-1
tp10725
sS'dose,should'
p10726
(F1
F0.00076452599388379206
I0
I1
I-1
tp10727
sS'implies,that'
p10728
(F1
F0.00076452599388379206
I0
I1
I-1
tp10729
sS'higher,when'
p10730
(F1
F0.00076452599388379206
I1
I0
I1
tp10731
sS'decreased,serum'
p10732
(F1
F0.0015290519877675841
I2
I0
I2
tp10733
sS'the,desired'
p10734
(F1
F0.00076452599388379206
I1
I0
I1
tp10735
sS'reduced,by'
p10736
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp10737
sS'against,clinical'
p10738
(F1
F0.00076452599388379206
I0
I1
I-1
tp10739
sS'closely,and'
p10740
(F1
F0.00076452599388379206
I1
I0
I1
tp10741
sS'the,area'
p10742
(F1
F0.00076452599388379206
I1
I0
I1
tp10743
sS'the,objective'
p10744
(F1
F0.0015290519877675841
I0
I2
I-2
tp10745
sS'to,fixed'
p10746
(F1
F0.00076452599388379206
I0
I1
I-1
tp10747
sS'that,gh'
p10748
(F1
F0.0015290519877675841
I2
I0
I2
tp10749
sS'no,adverse'
p10750
(F1
F0.00076452599388379206
I0
I1
I-1
tp10751
sS'metabolizing,enzyme'
p10752
(F0
F0
I1
I1
I0
tp10753
sS'ditropan,xl'
p10754
(F1
F0.00076452599388379206
I1
I0
I1
tp10755
sS'not,appear'
p10756
(F0
F0
I1
I1
I0
tp10757
sS'a4,may'
p10758
(F1
F0.00076452599388379206
I1
I0
I1
tp10759
sS'test,fst'
p10760
(F1
F0.00076452599388379206
I0
I1
I-1
tp10761
sS'may,emerge'
p10762
(F1
F0.00076452599388379206
I1
I0
I1
tp10763
sS'or,holed'
p10764
(F1
F0.00076452599388379206
I0
I1
I-1
tp10765
sS'hospitalized,patients'
p10766
(F1
F0.00076452599388379206
I0
I1
I-1
tp10767
sS'in,dasatinib-enhanced'
p10768
(F1
F0.00076452599388379206
I1
I0
I1
tp10769
sS'the,diet'
p10770
(F1
F0.00076452599388379206
I1
I0
I1
tp10771
sS'edema,concomitant'
p10772
(F1
F0.00076452599388379206
I0
I1
I-1
tp10773
sS'sequence,dependent'
p10774
(F1
F0.00076452599388379206
I1
I0
I1
tp10775
sS'cause,intense'
p10776
(F1
F0.00076452599388379206
I1
I0
I1
tp10777
sS'was,previously'
p10778
(F1
F0.00076452599388379206
I1
I0
I1
tp10779
sS'stimulantes,of'
p10780
(F1
F0.00076452599388379206
I1
I0
I1
tp10781
sS'was,evaluated'
p10782
(F1
F0.00076452599388379206
I0
I1
I-1
tp10783
sS'may,add'
p10784
(F1
F0.00076452599388379206
I1
I0
I1
tp10785
sS'interactions,inhibitors'
p10786
(F0
F0
I1
I1
I0
tp10787
sS'and,acute'
p10788
(F1
F0.00076452599388379206
I0
I1
I-1
tp10789
sS'the,apparent'
p10790
(F1
F0.00076452599388379206
I1
I0
I1
tp10791
sS'oxandrolone,may'
p10792
(F1
F0.00076452599388379206
I1
I0
I1
tp10793
sS'absorption,of'
p10794
(F0.36842105263157893
F0.0053516819571865441
I13
I6
I7
tp10795
sS'warfarin,users'
p10796
(F1
F0.0015290519877675841
I2
I0
I2
tp10797
sS'although,specific'
p10798
(F1
F0.00076452599388379206
I1
I0
I1
tp10799
sS'was,also'
p10800
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10801
sS'the,patients'
p10802
(F1
F0.00076452599388379206
I1
I0
I1
tp10803
sS'significantly,altered'
p10804
(F1
F0.00076452599388379206
I1
I0
I1
tp10805
sS'kg,s-ketamine'
p10806
(F1
F0.00076452599388379206
I0
I1
I-1
tp10807
sS'system,caused'
p10808
(F1
F0.00076452599388379206
I1
I0
I1
tp10809
sS'inhibitors,when'
p10810
(F1
F0.00076452599388379206
I0
I1
I-1
tp10811
sS'important,non-thalidomide'
p10812
(F1
F0.00076452599388379206
I0
I1
I-1
tp10813
sS'adrenal,or'
p10814
(F1
F0.00076452599388379206
I0
I1
I-1
tp10815
sS'by,cp450'
p10816
(F1
F0.00076452599388379206
I1
I0
I1
tp10817
sS'eg,may'
p10818
(F1
F0.00076452599388379206
I1
I0
I1
tp10819
sS'antiproliferative,effect'
p10820
(F1
F0.00076452599388379206
I1
I0
I1
tp10821
sS'true,if'
p10822
(F1
F0.00076452599388379206
I0
I1
I-1
tp10823
sS'when,the'
p10824
(F1
F0.0022935779816513763
I3
I0
I3
tp10825
sS'may,result'
p10826
(F0.80000000000000004
F0.0061162079510703364
I9
I1
I8
tp10827
sS'given,at'
p10828
(F1
F0.00076452599388379206
I1
I0
I1
tp10829
sS'elevated,temperature'
p10830
(F1
F0.00076452599388379206
I1
I0
I1
tp10831
sS'given,as'
p10832
(F1
F0.00076452599388379206
I1
I0
I1
tp10833
sS'with,neonatal'
p10834
(F1
F0.00076452599388379206
I0
I1
I-1
tp10835
sS'doses,of'
p10836
(F0.066666666666666666
F0.00076452599388379206
I8
I7
I1
tp10837
sS'myeloproliferative,effects'
p10838
(F1
F0.00076452599388379206
I1
I0
I1
tp10839
sS'by,cyp3a'
p10840
(F1
F0.00076452599388379206
I1
I0
I1
tp10841
sS'increases,of'
p10842
(F1
F0.00076452599388379206
I1
I0
I1
tp10843
sS'markedly,decreased'
p10844
(F1
F0.00076452599388379206
I1
I0
I1
tp10845
sS'cmax,and'
p10846
(F1
F0.0015290519877675841
I2
I0
I2
tp10847
sS'eye,drops'
p10848
(F1
F0.00076452599388379206
I1
I0
I1
tp10849
sS'in,vitro'
p10850
(F0.13043478260869565
F0.0022935779816513763
I10
I13
I-3
tp10851
sS'and,these'
p10852
(F1
F0.00076452599388379206
I1
I0
I1
tp10853
sS'transduction,of'
p10854
(F1
F0.00076452599388379206
I0
I1
I-1
tp10855
sS'trough,concentrations'
p10856
(F1
F0.00076452599388379206
I1
I0
I1
tp10857
sS'during,anesthesia'
p10858
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10859
sS'of,thrombopenia'
p10860
(F1
F0.00076452599388379206
I0
I1
I-1
tp10861
sS'concomitant,administrations'
p10862
(F1
F0.00076452599388379206
I1
I0
I1
tp10863
sS'acids,for'
p10864
(F1
F0.00076452599388379206
I1
I0
I1
tp10865
sS'of,stupor'
p10866
(F1
F0.00076452599388379206
I1
I0
I1
tp10867
sS'a,dopamine'
p10868
(F1
F0.00076452599388379206
I1
I0
I1
tp10869
sS'received,or'
p10870
(F1
F0.00076452599388379206
I1
I0
I1
tp10871
sS'given,with'
p10872
(F1
F0.0015290519877675841
I2
I0
I2
tp10873
sS'narcotics,the'
p10874
(F1
F0.00076452599388379206
I0
I1
I-1
tp10875
sS'efficacy,of'
p10876
(F1
F0.0015290519877675841
I0
I2
I-2
tp10877
sS'with,trental'
p10878
(F1
F0.00076452599388379206
I1
I0
I1
tp10879
sS'were,initially'
p10880
(F1
F0.00076452599388379206
I1
I0
I1
tp10881
sS'slight,increase'
p10882
(F1
F0.00076452599388379206
I1
I0
I1
tp10883
sS'for,protein'
p10884
(F1
F0.00076452599388379206
I1
I0
I1
tp10885
sS'to,approximately'
p10886
(F1
F0.00076452599388379206
I1
I0
I1
tp10887
sS'or,tricyclic'
p10888
(F1
F0.00076452599388379206
I1
I0
I1
tp10889
sS'with,human'
p10890
(F1
F0.00076452599388379206
I0
I1
I-1
tp10891
sS'hey,cells'
p10892
(F1
F0.00076452599388379206
I1
I0
I1
tp10893
sS'in,elderly'
p10894
(F1
F0.00076452599388379206
I0
I1
I-1
tp10895
sS'different,metabolism'
p10896
(F1
F0.00076452599388379206
I0
I1
I-1
tp10897
sS'alkaloids,and'
p10898
(F1
F0.00076452599388379206
I0
I1
I-1
tp10899
sS'curve,auc'
p10900
(F1
F0.00076452599388379206
I1
I0
I1
tp10901
sS'users,contributed'
p10902
(F1
F0.00076452599388379206
I0
I1
I-1
tp10903
sS'to,achieve'
p10904
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp10905
sS'has,a'
p10906
(F1
F0.00076452599388379206
I1
I0
I1
tp10907
sS'of,sodium'
p10908
(F0
F0
I1
I1
I0
tp10909
sS'the,treatment'
p10910
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp10911
sS'childbearing,potential'
p10912
(F1
F0.00076452599388379206
I0
I1
I-1
tp10913
sS'ropivacaine,can'
p10914
(F1
F0.00076452599388379206
I1
I0
I1
tp10915
sS'cells,through'
p10916
(F1
F0.00076452599388379206
I1
I0
I1
tp10917
sS'treatment,although'
p10918
(F1
F0.00076452599388379206
I0
I1
I-1
tp10919
sS'use,decreases'
p10920
(F1
F0.00076452599388379206
I1
I0
I1
tp10921
sS'is,approximately'
p10922
(F1
F0.00076452599388379206
I0
I1
I-1
tp10923
sS'antifungals,in'
p10924
(F1
F0.00076452599388379206
I1
I0
I1
tp10925
sS'if,a'
p10926
(F1
F0.0015290519877675841
I2
I0
I2
tp10927
sS'in,normal-weight'
p10928
(F1
F0.0045871559633027525
I0
I6
I-6
tp10929
sS'currently,recommended'
p10930
(F1
F0.00076452599388379206
I1
I0
I1
tp10931
sS'is,recommended'
p10932
(F1
F0.0061162079510703364
I8
I0
I8
tp10933
sS'secretion,of'
p10934
(F0.5
F0.0015290519877675841
I3
I1
I2
tp10935
sS'origins,to'
p10936
(F1
F0.00076452599388379206
I0
I1
I-1
tp10937
sS'of,nutrients'
p10938
(F1
F0.00076452599388379206
I1
I0
I1
tp10939
sS'and,antiplatelets'
p10940
(F1
F0.00076452599388379206
I0
I1
I-1
tp10941
sS'do,not'
p10942
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp10943
sS'with,eg'
p10944
(F1
F0.00076452599388379206
I1
I0
I1
tp10945
sS'basis,of'
p10946
(F1
F0.0022935779816513763
I3
I0
I3
tp10947
sS'potentiate,the'
p10948
(F1
F0.0053516819571865441
I7
I0
I7
tp10949
sS'by,active'
p10950
(F0
F0
I1
I1
I0
tp10951
sS'with,mixed'
p10952
(F1
F0.00076452599388379206
I1
I0
I1
tp10953
sS'level,increased'
p10954
(F1
F0.00076452599388379206
I1
I0
I1
tp10955
sS'to,stable'
p10956
(F1
F0.00076452599388379206
I1
I0
I1
tp10957
sS'therapy,for'
p10958
(F1
F0.00076452599388379206
I0
I1
I-1
tp10959
sS'serum,creatinine'
p10960
(F1
F0.00076452599388379206
I1
I0
I1
tp10961
sS'patients,taking'
p10962
(F1
F0.0053516819571865441
I7
I0
I7
tp10963
sS'was,associated'
p10964
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp10965
sS'the,half-life'
p10966
(F1
F0.0015290519877675841
I2
I0
I2
tp10967
sS'and,has'
p10968
(F0.25
F0.0015290519877675841
I5
I3
I2
tp10969
sS'and,conditioned'
p10970
(F1
F0.0015290519877675841
I0
I2
I-2
tp10971
sS'thus,strong'
p10972
(F1
F0.00076452599388379206
I1
I0
I1
tp10973
sS'pain,without'
p10974
(F1
F0.00076452599388379206
I1
I0
I1
tp10975
sS'by,compared'
p10976
(F1
F0.00076452599388379206
I1
I0
I1
tp10977
sS'versed,syrup'
p10978
(F1
F0.00076452599388379206
I1
I0
I1
tp10979
sS'significant,alterations'
p10980
(F1
F0.00076452599388379206
I0
I1
I-1
tp10981
sS'as,well'
p10982
(F0.5
F0.0030581039755351682
I6
I2
I4
tp10983
sS'only,enhanced'
p10984
(F1
F0.00076452599388379206
I1
I0
I1
tp10985
sS'and,had'
p10986
(F1
F0.00076452599388379206
I1
I0
I1
tp10987
sS'media,and'
p10988
(F1
F0.00076452599388379206
I1
I0
I1
tp10989
sS'all,patients'
p10990
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp10991
sS'prior,to'
p10992
(F1
F0.0030581039755351682
I4
I0
I4
tp10993
sS'i,antipsychotic'
p10994
(F1
F0.00076452599388379206
I1
I0
I1
tp10995
sS'or,enhancement'
p10996
(F1
F0.00076452599388379206
I1
I0
I1
tp10997
sS'advised,when'
p10998
(F1
F0.00076452599388379206
I1
I0
I1
tp10999
sS'not,altered'
p11000
(F1
F0.00076452599388379206
I0
I1
I-1
tp11001
sS'or,prolonged'
p11002
(F1
F0.0015290519877675841
I2
I0
I2
tp11003
sS'for,d'
p11004
(F1
F0.00076452599388379206
I0
I1
I-1
tp11005
sS'drugs,potentiation'
p11006
(F1
F0.00076452599388379206
I1
I0
I1
tp11007
sS'for,a'
p11008
(F1
F0.0030581039755351682
I4
I0
I4
tp11009
sS'no,protein'
p11010
(F1
F0.00076452599388379206
I0
I1
I-1
tp11011
sS'response,increased'
p11012
(F1
F0.0015290519877675841
I0
I2
I-2
tp11013
sS'the,phosphorylation'
p11014
(F1
F0.00076452599388379206
I1
I0
I1
tp11015
sS'tritec,with'
p11016
(F1
F0.00076452599388379206
I1
I0
I1
tp11017
sS'tetrahydropyridine,treatment'
p11018
(F1
F0.00076452599388379206
I1
I0
I1
tp11019
sS'hydroxylase,immunoreactivity'
p11020
(F1
F0.00076452599388379206
I1
I0
I1
tp11021
sS'the,replication'
p11022
(F1
F0.00076452599388379206
I1
I0
I1
tp11023
sS'contraindicated,selective'
p11024
(F1
F0.00076452599388379206
I1
I0
I1
tp11025
sS'additive,to'
p11026
(F1
F0.00076452599388379206
I1
I0
I1
tp11027
sS'evidence,that'
p11028
(F1
F0.0030581039755351682
I4
I0
I4
tp11029
sS'doses,and'
p11030
(F1
F0.00076452599388379206
I0
I1
I-1
tp11031
sS'of,adverse'
p11032
(F1
F0.00076452599388379206
I1
I0
I1
tp11033
sS'events,in'
p11034
(F0
F0
I1
I1
I0
tp11035
sS'auc,to'
p11036
(F0
F0
I1
I1
I0
tp11037
sS'grapefruit,juice'
p11038
(F1
F0.00076452599388379206
I1
I0
I1
tp11039
sS'anti-inflammatory,drugs'
p11040
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11041
sS'cyp3a,activities'
p11042
(F1
F0.00076452599388379206
I0
I1
I-1
tp11043
sS'monitor,pt'
p11044
(F1
F0.00076452599388379206
I1
I0
I1
tp11045
sS'fertility,a'
p11046
(F1
F0.00076452599388379206
I0
I1
I-1
tp11047
sS'adolescent,male'
p11048
(F1
F0.00076452599388379206
I0
I1
I-1
tp11049
sS's,wort'
p11050
(F1
F0.0015290519877675841
I2
I0
I2
tp11051
sS'seizures,following'
p11052
(F1
F0.00076452599388379206
I1
I0
I1
tp11053
sS'eliminated,by'
p11054
(F0
F0
I1
I1
I0
tp11055
sS'between,flomax'
p11056
(F1
F0.00076452599388379206
I0
I1
I-1
tp11057
sS'reductase,inhibitors'
p11058
(F1
F0.0015290519877675841
I0
I2
I-2
tp11059
sS'arterial,responsiveness'
p11060
(F1
F0.00076452599388379206
I1
I0
I1
tp11061
sS'of,s-adenosylhomocysteine'
p11062
(F1
F0.00076452599388379206
I0
I1
I-1
tp11063
sS'false-positive,urine'
p11064
(F1
F0.00076452599388379206
I0
I1
I-1
tp11065
sS'actions,or'
p11066
(F1
F0.00076452599388379206
I1
I0
I1
tp11067
sS'and,locomotor'
p11068
(F1
F0.00076452599388379206
I0
I1
I-1
tp11069
sS'susceptibility,results'
p11070
(F1
F0.00076452599388379206
I0
I1
I-1
tp11071
sS'induces,hepatic'
p11072
(F1
F0.0015290519877675841
I0
I2
I-2
tp11073
sS'of,nephrotoxicity'
p11074
(F1
F0.00076452599388379206
I1
I0
I1
tp11075
sS'of,exelon'
p11076
(F1
F0.0015290519877675841
I0
I2
I-2
tp11077
sS'under,the'
p11078
(F0
F0
I2
I2
I0
tp11079
sS'multiple,doses'
p11080
(F1
F0.0015290519877675841
I0
I2
I-2
tp11081
sS'fda,has'
p11082
(F1
F0.00076452599388379206
I1
I0
I1
tp11083
sS'and,drug'
p11084
(F1
F0.00076452599388379206
I1
I0
I1
tp11085
sS'more,frequent'
p11086
(F1
F0.00076452599388379206
I1
I0
I1
tp11087
sS'was,the'
p11088
(F1
F0.00076452599388379206
I1
I0
I1
tp11089
sS'this,effect'
p11090
(F0
F0
I1
I1
I0
tp11091
sS'parameters,was'
p11092
(F1
F0.00076452599388379206
I0
I1
I-1
tp11093
sS'of,invega'
p11094
(F1
F0.00076452599388379206
I1
I0
I1
tp11095
sS'when,indicated'
p11096
(F1
F0.00076452599388379206
I0
I1
I-1
tp11097
sS'of,data'
p11098
(F1
F0.00076452599388379206
I1
I0
I1
tp11099
sS'nifedipine,extended-release'
p11100
(F1
F0.00076452599388379206
I0
I1
I-1
tp11101
sS'of,skelid'
p11102
(F1
F0.0022935779816513763
I3
I0
I3
tp11103
sS'with,normal'
p11104
(F1
F0.00076452599388379206
I1
I0
I1
tp11105
sS'aspirin,concomitant'
p11106
(F1
F0.00076452599388379206
I1
I0
I1
tp11107
sS'toxicity,phenytoin'
p11108
(F1
F0.00076452599388379206
I1
I0
I1
tp11109
sS'leukine,such'
p11110
(F1
F0.00076452599388379206
I1
I0
I1
tp11111
sS'different,cancer'
p11112
(F1
F0.00076452599388379206
I0
I1
I-1
tp11113
sS'green,fluorescent'
p11114
(F1
F0.00076452599388379206
I0
I1
I-1
tp11115
sS'or,increase'
p11116
(F1
F0.0015290519877675841
I2
I0
I2
tp11117
sS'nutrients,alpha'
p11118
(F1
F0.00076452599388379206
I1
I0
I1
tp11119
sS'inhibitors,reduce'
p11120
(F1
F0.00076452599388379206
I1
I0
I1
tp11121
sS'phenytoin,diflucan'
p11122
(F1
F0.00076452599388379206
I1
I0
I1
tp11123
sS'and,by'
p11124
(F1
F0.0015290519877675841
I2
I0
I2
tp11125
sS'than,might'
p11126
(F1
F0.00076452599388379206
I1
I0
I1
tp11127
sS'recommended,in'
p11128
(F1
F0.0015290519877675841
I2
I0
I2
tp11129
sS'safely,following'
p11130
(F1
F0.00076452599388379206
I0
I1
I-1
tp11131
sS'a,known'
p11132
(F0
F0
I1
I1
I0
tp11133
sS'prolongation,of'
p11134
(F1
F0.0030581039755351682
I4
I0
I4
tp11135
sS'those,secreted'
p11136
(F1
F0.00076452599388379206
I1
I0
I1
tp11137
sS'depressed,to'
p11138
(F1
F0.00076452599388379206
I1
I0
I1
tp11139
sS'examined,drug-drug'
p11140
(F1
F0.00076452599388379206
I0
I1
I-1
tp11141
sS'fold,by'
p11142
(F1
F0.00076452599388379206
I1
I0
I1
tp11143
sS'exposure,at'
p11144
(F1
F0.0030581039755351682
I0
I4
I-4
tp11145
sS'reactivity,during'
p11146
(F1
F0.00076452599388379206
I1
I0
I1
tp11147
sS'prolongation,or'
p11148
(F1
F0.00076452599388379206
I1
I0
I1
tp11149
sS'a,therapeutic'
p11150
(F1
F0.00076452599388379206
I0
I1
I-1
tp11151
sS'a,is'
p11152
(F1
F0.00076452599388379206
I1
I0
I1
tp11153
sS'whereas,the'
p11154
(F1
F0.0015290519877675841
I2
I0
I2
tp11155
sS'experience,we'
p11156
(F1
F0.00076452599388379206
I1
I0
I1
tp11157
sS'of,hypotensive'
p11158
(F0
F0
I1
I1
I0
tp11159
sS'cyclosporine,rifampin'
p11160
(F1
F0.00076452599388379206
I1
I0
I1
tp11161
sS'with,interaction'
p11162
(F1
F0.00076452599388379206
I1
I0
I1
tp11163
sS'the,kinetics'
p11164
(F1
F0.0022935779816513763
I0
I3
I-3
tp11165
sS'pindolol,has'
p11166
(F0
F0
I1
I1
I0
tp11167
sS'a6,c9'
p11168
(F1
F0.00076452599388379206
I0
I1
I-1
tp11169
sS'inhibit,its'
p11170
(F1
F0.00076452599388379206
I1
I0
I1
tp11171
sS'some,aluminum-'
p11172
(F1
F0.00076452599388379206
I1
I0
I1
tp11173
sS'effects,and'
p11174
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11175
sS'cell,groups'
p11176
(F1
F0.0015290519877675841
I2
I0
I2
tp11177
sS'particular,caution'
p11178
(F1
F0.00076452599388379206
I1
I0
I1
tp11179
sS'depressants,effects'
p11180
(F1
F0.00076452599388379206
I1
I0
I1
tp11181
sS'enzyme,such'
p11182
(F1
F0.00076452599388379206
I0
I1
I-1
tp11183
sS'adverse,experience'
p11184
(F1
F0.00076452599388379206
I1
I0
I1
tp11185
sS'effectiveness,such'
p11186
(F1
F0.00076452599388379206
I1
I0
I1
tp11187
sS'primate,study'
p11188
(F1
F0.00076452599388379206
I1
I0
I1
tp11189
sS'hour,prior'
p11190
(F1
F0.00076452599388379206
I1
I0
I1
tp11191
sS'of,succinate'
p11192
(F1
F0.00076452599388379206
I1
I0
I1
tp11193
sS'when,and'
p11194
(F1
F0.0030581039755351682
I4
I0
I4
tp11195
sS'tests,were'
p11196
(F1
F0.00076452599388379206
I0
I1
I-1
tp11197
sS'and,bananas'
p11198
(F1
F0.00076452599388379206
I1
I0
I1
tp11199
sS'not,a'
p11200
(F1
F0.0030581039755351682
I0
I4
I-4
tp11201
sS'a,case'
p11202
(F1
F0.00076452599388379206
I1
I0
I1
tp11203
sS'depressant,medications'
p11204
(F1
F0.00076452599388379206
I1
I0
I1
tp11205
sS'of,concealed'
p11206
(F1
F0.00076452599388379206
I1
I0
I1
tp11207
sS'while,appeared'
p11208
(F1
F0.00076452599388379206
I1
I0
I1
tp11209
sS'one,controlled'
p11210
(F1
F0.00076452599388379206
I1
I0
I1
tp11211
sS'been,performed'
p11212
(F1
F0.0015290519877675841
I0
I2
I-2
tp11213
sS'and,death'
p11214
(F1
F0.00076452599388379206
I1
I0
I1
tp11215
sS'is,a'
p11216
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp11217
sS'astemizole,rifabutin'
p11218
(F1
F0.00076452599388379206
I1
I0
I1
tp11219
sS'is,accentuated'
p11220
(F1
F0.00076452599388379206
I1
I0
I1
tp11221
sS'be,an'
p11222
(F0
F0
I1
I1
I0
tp11223
sS'been,associated'
p11224
(F1
F0.0022935779816513763
I3
I0
I3
tp11225
sS'probenecid,probenecid'
p11226
(F1
F0.00076452599388379206
I0
I1
I-1
tp11227
sS'a6,and'
p11228
(F1
F0.00076452599388379206
I0
I1
I-1
tp11229
sS'study,we'
p11230
(F1
F0.00076452599388379206
I0
I1
I-1
tp11231
sS'each,other'
p11232
(F1
F0.00076452599388379206
I1
I0
I1
tp11233
sS'drugs,to'
p11234
(F1
F0.00076452599388379206
I0
I1
I-1
tp11235
sS'for,changes'
p11236
(F1
F0.00076452599388379206
I1
I0
I1
tp11237
sS'with,reduced'
p11238
(F1
F0.00076452599388379206
I1
I0
I1
tp11239
sS'of,metopirone'
p11240
(F1
F0.00076452599388379206
I1
I0
I1
tp11241
sS'apparent,oral'
p11242
(F1
F0.00076452599388379206
I1
I0
I1
tp11243
sS'when,mykrox'
p11244
(F1
F0.00076452599388379206
I1
I0
I1
tp11245
sS's,response'
p11246
(F1
F0.00076452599388379206
I1
I0
I1
tp11247
sS'studies,show'
p11248
(F1
F0.0015290519877675841
I0
I2
I-2
tp11249
sS'or,or'
p11250
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp11251
sS'is,reasonable'
p11252
(F1
F0.0015290519877675841
I2
I0
I2
tp11253
sS'related,to'
p11254
(F1
F0.00076452599388379206
I1
I0
I1
tp11255
sS'on,in'
p11256
(F1
F0.00076452599388379206
I0
I1
I-1
tp11257
sS'blinded,crossover'
p11258
(F1
F0.00076452599388379206
I0
I1
I-1
tp11259
sS'dna,strand'
p11260
(F1
F0.00076452599388379206
I0
I1
I-1
tp11261
sS'locomotor,inhibitor'
p11262
(F1
F0.00076452599388379206
I0
I1
I-1
tp11263
sS'depressants,meperidine'
p11264
(F1
F0.00076452599388379206
I1
I0
I1
tp11265
sS'total,clearance'
p11266
(F1
F0.00076452599388379206
I1
I0
I1
tp11267
sS'retinal,ganglion'
p11268
(F1
F0.00076452599388379206
I0
I1
I-1
tp11269
sS'the,observed'
p11270
(F1
F0.00076452599388379206
I0
I1
I-1
tp11271
sS'an,additive'
p11272
(F1
F0.0015290519877675841
I2
I0
I2
tp11273
sS'and,evaluated'
p11274
(F1
F0.00076452599388379206
I0
I1
I-1
tp11275
sS'inhibition,studies'
p11276
(F1
F0.00076452599388379206
I0
I1
I-1
tp11277
sS'with,daily'
p11278
(F1
F0.00076452599388379206
I0
I1
I-1
tp11279
sS'of,can'
p11280
(F1
F0.00076452599388379206
I1
I0
I1
tp11281
sS'to,interaction'
p11282
(F1
F0.00076452599388379206
I1
I0
I1
tp11283
sS'this,implies'
p11284
(F1
F0.00076452599388379206
I0
I1
I-1
tp11285
sS'azole,antifungals'
p11286
(F1
F0.0022935779816513763
I3
I0
I3
tp11287
sS'of,a'
p11288
(F0.33333333333333331
F0.0045871559633027525
I6
I12
I-6
tp11289
sS'toxicity,since'
p11290
(F1
F0.00076452599388379206
I1
I0
I1
tp11291
sS'of,g'
p11292
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp11293
sS'be,enhanced'
p11294
(F1
F0.0015290519877675841
I2
I0
I2
tp11295
sS'emulsion,has'
p11296
(F1
F0.00076452599388379206
I0
I1
I-1
tp11297
sS'physicians,should'
p11298
(F1
F0.0022935779816513763
I3
I0
I3
tp11299
sS'in,human'
p11300
(F0.5
F0.0015290519877675841
I3
I1
I2
tp11301
sS'may,significantly'
p11302
(F1
F0.0015290519877675841
I2
I0
I2
tp11303
sS'with,sodium'
p11304
(F1
F0.00076452599388379206
I1
I0
I1
tp11305
sS'approximately,fold'
p11306
(F1
F0.00076452599388379206
I1
I0
I1
tp11307
sS'the,rapid'
p11308
(F1
F0.00076452599388379206
I1
I0
I1
tp11309
sS'its,combination'
p11310
(F1
F0.0015290519877675841
I0
I2
I-2
tp11311
sS'be,kept'
p11312
(F0
F0
I1
I1
I0
tp11313
sS'slight,but'
p11314
(F1
F0.00076452599388379206
I1
I0
I1
tp11315
sS'noticeably,effective'
p11316
(F1
F0.00076452599388379206
I0
I1
I-1
tp11317
sS'we,have'
p11318
(F1
F0.00076452599388379206
I1
I0
I1
tp11319
sS'invega,paliperidone'
p11320
(F1
F0.00076452599388379206
I0
I1
I-1
tp11321
sS'corresponding,decrease'
p11322
(F1
F0.00076452599388379206
I1
I0
I1
tp11323
sS'alcohol,barbiturates'
p11324
(F1
F0.00076452599388379206
I0
I1
I-1
tp11325
sS'and,mexitil'
p11326
(F1
F0.00076452599388379206
I1
I0
I1
tp11327
sS'cancer,cell'
p11328
(F0
F0
I1
I1
I0
tp11329
sS'k-ras,mutations'
p11330
(F1
F0.00076452599388379206
I1
I0
I1
tp11331
sS'oral,certain'
p11332
(F1
F0.00076452599388379206
I1
I0
I1
tp11333
sS'beta,agonists'
p11334
(F1
F0.00076452599388379206
I1
I0
I1
tp11335
sS'acetylcholine,chloride'
p11336
(F1
F0.00076452599388379206
I1
I0
I1
tp11337
sS'alkeran,vaccinations'
p11338
(F1
F0.00076452599388379206
I1
I0
I1
tp11339
sS'have,identified'
p11340
(F1
F0.00076452599388379206
I0
I1
I-1
tp11341
sS'proamatine,therefore'
p11342
(F1
F0.00076452599388379206
I1
I0
I1
tp11343
sS'proamatine,alpha-adrenergic'
p11344
(F1
F0.00076452599388379206
I1
I0
I1
tp11345
sS'sites,of'
p11346
(F1
F0.00076452599388379206
I1
I0
I1
tp11347
sS'lowered,mexitil'
p11348
(F1
F0.00076452599388379206
I1
I0
I1
tp11349
sS'no,changes'
p11350
(F1
F0.00076452599388379206
I0
I1
I-1
tp11351
sS'angiotensin-converting,enzyme'
p11352
(F1
F0.00076452599388379206
I1
I0
I1
tp11353
sS'nonheme,or'
p11354
(F1
F0.00076452599388379206
I0
I1
I-1
tp11355
sS'groups,n'
p11356
(F1
F0.00076452599388379206
I0
I1
I-1
tp11357
sS'surface,of'
p11358
(F1
F0.00076452599388379206
I1
I0
I1
tp11359
sS'drugs,affecting'
p11360
(F1
F0.00076452599388379206
I0
I1
I-1
tp11361
sS'to,pre-mexitil'
p11362
(F1
F0.00076452599388379206
I1
I0
I1
tp11363
sS'the,activity'
p11364
(F1
F0.0015290519877675841
I2
I0
I2
tp11365
sS'anticoagulants,phenytoin'
p11366
(F1
F0.00076452599388379206
I1
I0
I1
tp11367
sS'example,bile'
p11368
(F1
F0.00076452599388379206
I1
I0
I1
tp11369
sS'were,noted'
p11370
(F1
F0.00076452599388379206
I0
I1
I-1
tp11371
sS'bacteriostatic,drugs'
p11372
(F1
F0.00076452599388379206
I1
I0
I1
tp11373
sS'doses,mg'
p11374
(F1
F0.00076452599388379206
I1
I0
I1
tp11375
sS'sharply,increase'
p11376
(F1
F0.00076452599388379206
I1
I0
I1
tp11377
sS'cyp3a4,inhibitors'
p11378
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11379
sS'increase,decrease'
p11380
(F1
F0.00076452599388379206
I1
I0
I1
tp11381
sS'histamine-like,flushing'
p11382
(F1
F0.00076452599388379206
I1
I0
I1
tp11383
sS'available,data'
p11384
(F1
F0.00076452599388379206
I1
I0
I1
tp11385
sS'thrombotic,cardiovascular'
p11386
(F1
F0.00076452599388379206
I1
I0
I1
tp11387
sS'derivatives,is'
p11388
(F1
F0.00076452599388379206
I1
I0
I1
tp11389
sS'of,hypokalemia'
p11390
(F1
F0.00076452599388379206
I0
I1
I-1
tp11391
sS'since,patients'
p11392
(F1
F0.00076452599388379206
I1
I0
I1
tp11393
sS'of,acetyl-l'
p11394
(F1
F0.00076452599388379206
I0
I1
I-1
tp11395
sS'but,is'
p11396
(F1
F0.00076452599388379206
I1
I0
I1
tp11397
sS'convert,herceptin-refractory'
p11398
(F1
F0.00076452599388379206
I0
I1
I-1
tp11399
sS'loop,given'
p11400
(F1
F0.00076452599388379206
I1
I0
I1
tp11401
sS'when,mobic'
p11402
(F1
F0.00076452599388379206
I1
I0
I1
tp11403
sS'calcineurin,inhibitor-free'
p11404
(F1
F0.00076452599388379206
I0
I1
I-1
tp11405
sS'tolerability,of'
p11406
(F1
F0.00076452599388379206
I0
I1
I-1
tp11407
sS'pyrimethamine,may'
p11408
(F1
F0.00076452599388379206
I0
I1
I-1
tp11409
sS'the,pressor'
p11410
(F1
F0.0045871559633027525
I6
I0
I6
tp11411
sS'agents,radiotherapy'
p11412
(F1
F0.00076452599388379206
I0
I1
I-1
tp11413
sS'ng,hr'
p11414
(F1
F0.00076452599388379206
I1
I0
I1
tp11415
sS'and,neuromuscular'
p11416
(F1
F0.00076452599388379206
I1
I0
I1
tp11417
sS'children,due'
p11418
(F1
F0.00076452599388379206
I1
I0
I1
tp11419
sS'not,expected'
p11420
(F1
F0.0015290519877675841
I0
I2
I-2
tp11421
sS'and,narcotics'
p11422
(F1
F0.00076452599388379206
I0
I1
I-1
tp11423
sS'the,drugs'
p11424
(F0
F0
I1
I1
I0
tp11425
sS'blockers,antidiabetic'
p11426
(F1
F0.00076452599388379206
I0
I1
I-1
tp11427
sS'rocuronium,bromide'
p11428
(F1
F0.00076452599388379206
I0
I1
I-1
tp11429
sS'macrolide,hiv'
p11430
(F1
F0.00076452599388379206
I0
I1
I-1
tp11431
sS'rifabutin,tacrolimus'
p11432
(F1
F0.00076452599388379206
I1
I0
I1
tp11433
sS'inhibition,of'
p11434
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp11435
sS'disease,hospitalized'
p11436
(F1
F0.00076452599388379206
I0
I1
I-1
tp11437
sS'of,chronic'
p11438
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp11439
sS'dose-dependent,antinociceptive'
p11440
(F1
F0.00076452599388379206
I1
I0
I1
tp11441
sS'inhibition,on'
p11442
(F1
F0.00076452599388379206
I0
I1
I-1
tp11443
sS'inhibition,or'
p11444
(F1
F0.00076452599388379206
I0
I1
I-1
tp11445
sS'relationship,has'
p11446
(F1
F0.00076452599388379206
I1
I0
I1
tp11447
sS'the,mean'
p11448
(F0.5
F0.0015290519877675841
I3
I1
I2
tp11449
sS'on,this'
p11450
(F1
F0.00076452599388379206
I1
I0
I1
tp11451
sS'to,either'
p11452
(F1
F0.00076452599388379206
I0
I1
I-1
tp11453
sS'although,undercarboxylated'
p11454
(F1
F0.00076452599388379206
I0
I1
I-1
tp11455
sS'vitamin,e'
p11456
(F1
F0.00076452599388379206
I1
I0
I1
tp11457
sS'and,long'
p11458
(F1
F0.00076452599388379206
I1
I0
I1
tp11459
sS'vitamin,a'
p11460
(F1
F0.00076452599388379206
I0
I1
I-1
tp11461
sS'one,of'
p11462
(F1
F0.00076452599388379206
I0
I1
I-1
tp11463
sS'be,similar'
p11464
(F1
F0.00076452599388379206
I1
I0
I1
tp11465
sS'any,change'
p11466
(F1
F0.00076452599388379206
I0
I1
I-1
tp11467
sS'sulfate,usp'
p11468
(F1
F0.00076452599388379206
I1
I0
I1
tp11469
sS'thiazide-like,may'
p11470
(F1
F0.00076452599388379206
I1
I0
I1
tp11471
sS'of,onset'
p11472
(F1
F0.00076452599388379206
I1
I0
I1
tp11473
sS'trilostane,may'
p11474
(F1
F0.00076452599388379206
I1
I0
I1
tp11475
sS'with,cerezyme'
p11476
(F1
F0.00076452599388379206
I1
I0
I1
tp11477
sS't790m,mutation'
p11478
(F1
F0.00076452599388379206
I0
I1
I-1
tp11479
sS'safety,and'
p11480
(F1
F0.00076452599388379206
I0
I1
I-1
tp11481
sS'pharmacokinetic,parameters'
p11482
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp11483
sS'potentiating,cns'
p11484
(F1
F0.00076452599388379206
I1
I0
I1
tp11485
sS'in,seven'
p11486
(F1
F0.00076452599388379206
I0
I1
I-1
tp11487
sS'to,whom'
p11488
(F1
F0.0022935779816513763
I3
I0
I3
tp11489
sS'catecholamines,in'
p11490
(F1
F0.00076452599388379206
I1
I0
I1
tp11491
sS'hplc,system'
p11492
(F1
F0.00076452599388379206
I0
I1
I-1
tp11493
sS'is,feasible'
p11494
(F1
F0.00076452599388379206
I0
I1
I-1
tp11495
sS'administered,at'
p11496
(F1
F0.0015290519877675841
I2
I0
I2
tp11497
sS'administered,as'
p11498
(F1
F0.00076452599388379206
I0
I1
I-1
tp11499
sS'and,lower'
p11500
(F1
F0.00076452599388379206
I1
I0
I1
tp11501
sS'function,creatinine'
p11502
(F1
F0.00076452599388379206
I1
I0
I1
tp11503
sS'cells,and'
p11504
(F0
F0
I1
I1
I0
tp11505
sS'prevention,of'
p11506
(F0
F0
I1
I1
I0
tp11507
sS'known,high'
p11508
(F1
F0.00076452599388379206
I1
I0
I1
tp11509
sS'of,pharmacokinetics'
p11510
(F1
F0.00076452599388379206
I0
I1
I-1
tp11511
sS'these,cells'
p11512
(F1
F0.00076452599388379206
I0
I1
I-1
tp11513
sS'cause,orthostatic'
p11514
(F1
F0.00076452599388379206
I1
I0
I1
tp11515
sS'achievement,of'
p11516
(F0
F0
I1
I1
I0
tp11517
sS'carefully,monitored'
p11518
(F1
F0.0015290519877675841
I2
I0
I2
tp11519
sS'and,cmax'
p11520
(F1
F0.0015290519877675841
I2
I0
I2
tp11521
sS'other,macrolide'
p11522
(F1
F0.00076452599388379206
I1
I0
I1
tp11523
sS'with,type'
p11524
(F1
F0.00076452599388379206
I1
I0
I1
tp11525
sS'reported,from'
p11526
(F1
F0.00076452599388379206
I1
I0
I1
tp11527
sS'of,cyp2c19'
p11528
(F1
F0.00076452599388379206
I1
I0
I1
tp11529
sS'chronic,or'
p11530
(F1
F0.00076452599388379206
I1
I0
I1
tp11531
sS'with,these'
p11532
(F1
F0.00076452599388379206
I1
I0
I1
tp11533
sS'except,for'
p11534
(F1
F0.00076452599388379206
I1
I0
I1
tp11535
sS'of,cytochrome'
p11536
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp11537
sS'by,drugs'
p11538
(F1
F0.00076452599388379206
I1
I0
I1
tp11539
sS'the,expression'
p11540
(F1
F0.00076452599388379206
I0
I1
I-1
tp11541
sS'novel,combination'
p11542
(F1
F0.00076452599388379206
I1
I0
I1
tp11543
sS'myocardial,infarction'
p11544
(F1
F0.00076452599388379206
I0
I1
I-1
tp11545
sS'counteract,the'
p11546
(F1
F0.00076452599388379206
I1
I0
I1
tp11547
sS'is,contraindicated'
p11548
(F1
F0.0015290519877675841
I2
I0
I2
tp11549
sS'receiving,ace'
p11550
(F1
F0.00076452599388379206
I1
I0
I1
tp11551
sS'is,advisable'
p11552
(F1
F0.00076452599388379206
I1
I0
I1
tp11553
sS'listed,in'
p11554
(F1
F0.00076452599388379206
I0
I1
I-1
tp11555
sS'induced,apoptosis'
p11556
(F1
F0.0015290519877675841
I2
I0
I2
tp11557
sS'kip1,mediated'
p11558
(F1
F0.00076452599388379206
I1
I0
I1
tp11559
sS'gh,treatment'
p11560
(F1
F0.00076452599388379206
I1
I0
I1
tp11561
sS'other,containing'
p11562
(F1
F0.00076452599388379206
I1
I0
I1
tp11563
sS'should,not'
p11564
(F0.81818181818181823
F0.0068807339449541288
I10
I1
I9
tp11565
sS'longer,half-lives'
p11566
(F1
F0.00076452599388379206
I1
I0
I1
tp11567
sS'or,to'
p11568
(F1
F0.0015290519877675841
I0
I2
I-2
tp11569
sS'category,and'
p11570
(F1
F0.00076452599388379206
I0
I1
I-1
tp11571
sS'increased,nephrotoxicity'
p11572
(F1
F0.0015290519877675841
I0
I2
I-2
tp11573
sS'study,n'
p11574
(F0
F0
I1
I1
I0
tp11575
sS'inhibitor,in'
p11576
(F1
F0.00076452599388379206
I0
I1
I-1
tp11577
sS'studied,with'
p11578
(F1
F0.00076452599388379206
I0
I1
I-1
tp11579
sS'of,central'
p11580
(F1
F0.00076452599388379206
I1
I0
I1
tp11581
sS'of,acetate'
p11582
(F1
F0.00076452599388379206
I0
I1
I-1
tp11583
sS'authors,report'
p11584
(F1
F0.00076452599388379206
I1
I0
I1
tp11585
sS'other,antihypertensives'
p11586
(F1
F0.00076452599388379206
I1
I0
I1
tp11587
sS'cautiously,increasing'
p11588
(F1
F0.00076452599388379206
I0
I1
I-1
tp11589
sS'believed,to'
p11590
(F1
F0.00076452599388379206
I1
I0
I1
tp11591
sS'provera,may'
p11592
(F1
F0.00076452599388379206
I1
I0
I1
tp11593
sS'drugs,with'
p11594
(F0
F0
I1
I1
I0
tp11595
sS'adohcy,hydrolase'
p11596
(F1
F0.00076452599388379206
I0
I1
I-1
tp11597
sS'hcl,hcl'
p11598
(F1
F0.00076452599388379206
I1
I0
I1
tp11599
sS'tacrolimus,there'
p11600
(F1
F0.00076452599388379206
I1
I0
I1
tp11601
sS'before,test'
p11602
(F1
F0.00076452599388379206
I0
I1
I-1
tp11603
sS'may,interfere'
p11604
(F1
F0.0045871559633027525
I6
I0
I6
tp11605
sS'dose,in'
p11606
(F1
F0.00076452599388379206
I1
I0
I1
tp11607
sS'kg,was'
p11608
(F1
F0.00076452599388379206
I0
I1
I-1
tp11609
sS'trial,of'
p11610
(F1
F0.00076452599388379206
I0
I1
I-1
tp11611
sS'after,initiation'
p11612
(F1
F0.00076452599388379206
I1
I0
I1
tp11613
sS'dose,is'
p11614
(F1
F0.00076452599388379206
I1
I0
I1
tp11615
sS'and,qt'
p11616
(F1
F0.00076452599388379206
I0
I1
I-1
tp11617
sS'medication,tell'
p11618
(F1
F0.00076452599388379206
I0
I1
I-1
tp11619
sS'and,therefore'
p11620
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11621
sS'in,addition'
p11622
(F1
F0.0022935779816513763
I3
I0
I3
tp11623
sS'myeloma,evidence'
p11624
(F1
F0.00076452599388379206
I0
I1
I-1
tp11625
sS'lines,leading'
p11626
(F1
F0.00076452599388379206
I1
I0
I1
tp11627
sS'in,intracellular'
p11628
(F1
F0.00076452599388379206
I1
I0
I1
tp11629
sS'during,organogenesis'
p11630
(F1
F0.00076452599388379206
I0
I1
I-1
tp11631
sS'because,amplifies'
p11632
(F1
F0.00076452599388379206
I1
I0
I1
tp11633
sS'the,concentrations'
p11634
(F1
F0.00076452599388379206
I0
I1
I-1
tp11635
sS'by,competing'
p11636
(F1
F0.00076452599388379206
I1
I0
I1
tp11637
sS'the,intestinal'
p11638
(F1
F0.0015290519877675841
I2
I0
I2
tp11639
sS'between,any'
p11640
(F1
F0.00076452599388379206
I0
I1
I-1
tp11641
sS'nonmatched,tacrolimus-treated'
p11642
(F1
F0.00076452599388379206
I0
I1
I-1
tp11643
sS'sequential,administration'
p11644
(F0
F0
I1
I1
I0
tp11645
sS'and,respiratory'
p11646
(F0
F0
I1
I1
I0
tp11647
sS'no,clinically'
p11648
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp11649
sS'administered,zolinza'
p11650
(F1
F0.00076452599388379206
I1
I0
I1
tp11651
sS'between,and'
p11652
(F0.1111111111111111
F0.00076452599388379206
I4
I5
I-1
tp11653
sS'system,depressants'
p11654
(F1
F0.0022935779816513763
I3
I0
I3
tp11655
sS'antimycotics,protease'
p11656
(F1
F0.00076452599388379206
I1
I0
I1
tp11657
sS'human,pharmacologic'
p11658
(F1
F0.00076452599388379206
I1
I0
I1
tp11659
sS'meq,results'
p11660
(F1
F0.00076452599388379206
I1
I0
I1
tp11661
sS'their,combination'
p11662
(F1
F0.00076452599388379206
I1
I0
I1
tp11663
sS'of,equivalent'
p11664
(F1
F0.00076452599388379206
I1
I0
I1
tp11665
sS'tacrolimus-treated,renal'
p11666
(F1
F0.00076452599388379206
I0
I1
I-1
tp11667
sS'of,ethinyl'
p11668
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp11669
sS'the,synergistic'
p11670
(F1
F0.00076452599388379206
I1
I0
I1
tp11671
sS'or,prothrombin'
p11672
(F1
F0.00076452599388379206
I1
I0
I1
tp11673
sS'weaker,effect'
p11674
(F1
F0.00076452599388379206
I1
I0
I1
tp11675
sS'upon,initiation'
p11676
(F1
F0.00076452599388379206
I1
I0
I1
tp11677
sS'shown,no'
p11678
(F1
F0.00076452599388379206
I1
I0
I1
tp11679
sS'drug,interactions'
p11680
(F0.1111111111111111
F0.00076452599388379206
I4
I5
I-1
tp11681
sS'calcium,doses'
p11682
(F1
F0.00076452599388379206
I1
I0
I1
tp11683
sS'in,overall'
p11684
(F1
F0.00076452599388379206
I1
I0
I1
tp11685
sS'pyridine-treated,animals'
p11686
(F1
F0.00076452599388379206
I1
I0
I1
tp11687
sS'alkyating,agent'
p11688
(F1
F0.00076452599388379206
I0
I1
I-1
tp11689
sS'p450,inducers'
p11690
(F1
F0.00076452599388379206
I1
I0
I1
tp11691
sS'approximately,of'
p11692
(F1
F0.00076452599388379206
I1
I0
I1
tp11693
sS'in,supplement'
p11694
(F1
F0.00076452599388379206
I1
I0
I1
tp11695
sS'the,more'
p11696
(F1
F0.00076452599388379206
I0
I1
I-1
tp11697
sS'auc,t'
p11698
(F1
F0.00076452599388379206
I1
I0
I1
tp11699
sS'particularly,with'
p11700
(F1
F0.00076452599388379206
I1
I0
I1
tp11701
sS'was,and'
p11702
(F1
F0.00076452599388379206
I1
I0
I1
tp11703
sS'orally,administered'
p11704
(F1
F0.00076452599388379206
I1
I0
I1
tp11705
sS'terfenadine,because'
p11706
(F1
F0.00076452599388379206
I1
I0
I1
tp11707
sS'chemosensitizer,for'
p11708
(F1
F0.00076452599388379206
I0
I1
I-1
tp11709
sS'proamatine,is'
p11710
(F1
F0.00076452599388379206
I1
I0
I1
tp11711
sS'and,phases'
p11712
(F1
F0.0015290519877675841
I0
I2
I-2
tp11713
sS'although,does'
p11714
(F1
F0.00076452599388379206
I1
I0
I1
tp11715
sS'strong,inhibitors'
p11716
(F1
F0.0015290519877675841
I2
I0
I2
tp11717
sS'cimetidine,concomitant'
p11718
(F1
F0.00076452599388379206
I0
I1
I-1
tp11719
sS'alkaloids,including'
p11720
(F1
F0.00076452599388379206
I0
I1
I-1
tp11721
sS'to,increasing'
p11722
(F1
F0.00076452599388379206
I1
I0
I1
tp11723
sS'colonies,than'
p11724
(F1
F0.00076452599388379206
I1
I0
I1
tp11725
sS'rats,times'
p11726
(F1
F0.00076452599388379206
I0
I1
I-1
tp11727
sS'results,from'
p11728
(F1
F0.00076452599388379206
I0
I1
I-1
tp11729
sS'a,risk'
p11730
(F1
F0.00076452599388379206
I0
I1
I-1
tp11731
sS'mg,daily'
p11732
(F0.25
F0.0015290519877675841
I3
I5
I-2
tp11733
sS'used,as'
p11734
(F1
F0.00076452599388379206
I1
I0
I1
tp11735
sS'the,median'
p11736
(F1
F0.00076452599388379206
I0
I1
I-1
tp11737
sS'when,cholinesterase'
p11738
(F1
F0.00076452599388379206
I1
I0
I1
tp11739
sS'intensity,and'
p11740
(F1
F0.00076452599388379206
I1
I0
I1
tp11741
sS'other,salicylate'
p11742
(F1
F0.00076452599388379206
I1
I0
I1
tp11743
sS'symptoms,whereas'
p11744
(F1
F0.00076452599388379206
I1
I0
I1
tp11745
sS'investigates,the'
p11746
(F1
F0.00076452599388379206
I0
I1
I-1
tp11747
sS'most,proton'
p11748
(F1
F0.00076452599388379206
I0
I1
I-1
tp11749
sS'inhibitors,narcotic'
p11750
(F1
F0.00076452599388379206
I1
I0
I1
tp11751
sS'treatment,periods'
p11752
(F1
F0.00076452599388379206
I0
I1
I-1
tp11753
sS'aids,patients'
p11754
(F1
F0.00076452599388379206
I1
I0
I1
tp11755
sS'pretreatments,with'
p11756
(F1
F0.00076452599388379206
I0
I1
I-1
tp11757
sS'cancer,with'
p11758
(F0
F0
I1
I1
I0
tp11759
sS'which,respond'
p11760
(F1
F0.00076452599388379206
I0
I1
I-1
tp11761
sS'before,the'
p11762
(F1
F0.0022935779816513763
I3
I0
I3
tp11763
sS'this,synergism'
p11764
(F1
F0.00076452599388379206
I1
I0
I1
tp11765
sS'dose,pharmacokinetic'
p11766
(F1
F0.00076452599388379206
I0
I1
I-1
tp11767
sS'the,antihypertensive'
p11768
(F1
F0.0015290519877675841
I2
I0
I2
tp11769
sS'apoptosis,of'
p11770
(F1
F0.00076452599388379206
I1
I0
I1
tp11771
sS'with,cyp3a'
p11772
(F1
F0.0015290519877675841
I0
I2
I-2
tp11773
sS'sensitization,compared'
p11774
(F1
F0.00076452599388379206
I1
I0
I1
tp11775
sS'although,studies'
p11776
(F1
F0.00076452599388379206
I1
I0
I1
tp11777
sS'alcohol,due'
p11778
(F1
F0.00076452599388379206
I1
I0
I1
tp11779
sS'of,methyl-4'
p11780
(F0
F0
I1
I1
I0
tp11781
sS'adults,was'
p11782
(F1
F0.00076452599388379206
I1
I0
I1
tp11783
sS'of,methyl-1'
p11784
(F1
F0.00076452599388379206
I0
I1
I-1
tp11785
sS'avoid,prescribing'
p11786
(F1
F0.00076452599388379206
I1
I0
I1
tp11787
sS'pheochromocytoma,by'
p11788
(F1
F0.00076452599388379206
I0
I1
I-1
tp11789
sS'receiving,the'
p11790
(F1
F0.0015290519877675841
I2
I0
I2
tp11791
sS'mutations,but'
p11792
(F1
F0.00076452599388379206
I1
I0
I1
tp11793
sS'cholinergic,agonists'
p11794
(F1
F0.00076452599388379206
I1
I0
I1
tp11795
sS'there,was'
p11796
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp11797
sS'gi,ulceration'
p11798
(F1
F0.00076452599388379206
I1
I0
I1
tp11799
sS'may,produce'
p11800
(F1
F0.00076452599388379206
I0
I1
I-1
tp11801
sS'a,clinically'
p11802
(F1
F0.0015290519877675841
I0
I2
I-2
tp11803
sS'also,interact'
p11804
(F1
F0.0015290519877675841
I0
I2
I-2
tp11805
sS'a,marker'
p11806
(F1
F0.00076452599388379206
I0
I1
I-1
tp11807
sS'respectively,lower'
p11808
(F1
F0.0015290519877675841
I2
I0
I2
tp11809
sS'poisoning,although'
p11810
(F1
F0.00076452599388379206
I1
I0
I1
tp11811
sS'of,gi'
p11812
(F1
F0.0015290519877675841
I2
I0
I2
tp11813
sS'reaction,has'
p11814
(F1
F0.00076452599388379206
I1
I0
I1
tp11815
sS'a,cyp450'
p11816
(F1
F0.00076452599388379206
I1
I0
I1
tp11817
sS'p,and'
p11818
(F1
F0.00076452599388379206
I1
I0
I1
tp11819
sS'or,ordinarily'
p11820
(F1
F0.00076452599388379206
I1
I0
I1
tp11821
sS'develop,delirium'
p11822
(F1
F0.00076452599388379206
I1
I0
I1
tp11823
sS'of,tnkase'
p11824
(F1
F0.00076452599388379206
I0
I1
I-1
tp11825
sS'serious,effect'
p11826
(F1
F0.00076452599388379206
I1
I0
I1
tp11827
sS'daily,for'
p11828
(F1
F0.0015290519877675841
I0
I2
I-2
tp11829
sS'c,patients'
p11830
(F1
F0.00076452599388379206
I1
I0
I1
tp11831
sS'results,suggest'
p11832
(F1
F0.00076452599388379206
I0
I1
I-1
tp11833
sS'some,monoamine'
p11834
(F1
F0.00076452599388379206
I1
I0
I1
tp11835
sS'taking,tobi'
p11836
(F1
F0.00076452599388379206
I1
I0
I1
tp11837
sS'are,increased'
p11838
(F1
F0.00076452599388379206
I0
I1
I-1
tp11839
sS'significant,hypoglycemia'
p11840
(F1
F0.00076452599388379206
I1
I0
I1
tp11841
sS'dutp,nick-end'
p11842
(F1
F0.00076452599388379206
I0
I1
I-1
tp11843
sS'n,did'
p11844
(F1
F0.00076452599388379206
I0
I1
I-1
tp11845
sS'administered,concomitantly'
p11846
(F0.7142857142857143
F0.0038226299694189602
I6
I1
I5
tp11847
sS'lung,cancer'
p11848
(F1
F0.00076452599388379206
I1
I0
I1
tp11849
sS'concomitantly,the'
p11850
(F1
F0.00076452599388379206
I1
I0
I1
tp11851
sS'alter,platelet'
p11852
(F1
F0.0015290519877675841
I2
I0
I2
tp11853
sS'formal,single-dose'
p11854
(F1
F0.00076452599388379206
I1
I0
I1
tp11855
sS'studies,conducted'
p11856
(F1
F0.00076452599388379206
I0
I1
I-1
tp11857
sS'certain,actions'
p11858
(F1
F0.00076452599388379206
I1
I0
I1
tp11859
sS'are,metabolized'
p11860
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11861
sS'either,component'
p11862
(F1
F0.00076452599388379206
I0
I1
I-1
tp11863
sS'dose,studies'
p11864
(F1
F0.00076452599388379206
I0
I1
I-1
tp11865
sS'hypertensive,crisis'
p11866
(F1
F0.00076452599388379206
I1
I0
I1
tp11867
sS'failed,to'
p11868
(F0
F0
I1
I1
I0
tp11869
sS'secretion,may'
p11870
(F0
F0
I1
I1
I0
tp11871
sS'inhibitors,are'
p11872
(F1
F0.00076452599388379206
I1
I0
I1
tp11873
sS'hypokalemia,can'
p11874
(F1
F0.00076452599388379206
I1
I0
I1
tp11875
sS'from,foreign'
p11876
(F1
F0.00076452599388379206
I1
I0
I1
tp11877
sS'cyp3a,inhibitor'
p11878
(F1
F0.00076452599388379206
I0
I1
I-1
tp11879
sS'administration,with'
p11880
(F1
F0.00076452599388379206
I0
I1
I-1
tp11881
sS'of,demonstrated'
p11882
(F1
F0.00076452599388379206
I1
I0
I1
tp11883
sS'between,proton'
p11884
(F1
F0.00076452599388379206
I0
I1
I-1
tp11885
sS'with,egfr'
p11886
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11887
sS'oral,antiplatelet'
p11888
(F1
F0.00076452599388379206
I1
I0
I1
tp11889
sS'the,mechanism'
p11890
(F1
F0.0015290519877675841
I2
I0
I2
tp11891
sS'mutation,and'
p11892
(F1
F0.00076452599388379206
I0
I1
I-1
tp11893
sS'higher,in'
p11894
(F1
F0.00076452599388379206
I1
I0
I1
tp11895
sS'in,in'
p11896
(F1
F0.00076452599388379206
I1
I0
I1
tp11897
sS'time,induced'
p11898
(F1
F0.00076452599388379206
I0
I1
I-1
tp11899
sS'is,metabolized'
p11900
(F1
F0.0015290519877675841
I0
I2
I-2
tp11901
sS'to,adding'
p11902
(F1
F0.00076452599388379206
I1
I0
I1
tp11903
sS'to,augment'
p11904
(F1
F0.00076452599388379206
I1
I0
I1
tp11905
sS'auc,was'
p11906
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11907
sS'concentration,cmax'
p11908
(F1
F0.00076452599388379206
I1
I0
I1
tp11909
sS'of,coumarin'
p11910
(F1
F0.00076452599388379206
I1
I0
I1
tp11911
sS'zadaxin,therapy'
p11912
(F1
F0.00076452599388379206
I1
I0
I1
tp11913
sS'organic,acids'
p11914
(F1
F0.00076452599388379206
I0
I1
I-1
tp11915
sS'those,receiving'
p11916
(F1
F0.0015290519877675841
I0
I2
I-2
tp11917
sS'by,inhibition'
p11918
(F1
F0.00076452599388379206
I1
I0
I1
tp11919
sS'of,breath'
p11920
(F1
F0.00076452599388379206
I1
I0
I1
tp11921
sS'recirculation,and'
p11922
(F1
F0.00076452599388379206
I0
I1
I-1
tp11923
sS'as,may'
p11924
(F1
F0.0015290519877675841
I2
I0
I2
tp11925
sS'of,demonstrate'
p11926
(F1
F0.00076452599388379206
I1
I0
I1
tp11927
sS'in,increased'
p11928
(F1
F0.0030581039755351682
I4
I0
I4
tp11929
sS'of,hepatic'
p11930
(F1
F0.00076452599388379206
I1
I0
I1
tp11931
sS'zemplar,capsules'
p11932
(F1
F0.00076452599388379206
I1
I0
I1
tp11933
sS'antitumor,activities'
p11934
(F1
F0.00076452599388379206
I0
I1
I-1
tp11935
sS'local,such'
p11936
(F1
F0.00076452599388379206
I0
I1
I-1
tp11937
sS'in,conjunction'
p11938
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp11939
sS'with,live'
p11940
(F1
F0.00076452599388379206
I1
I0
I1
tp11941
sS'the,intracellular'
p11942
(F1
F0.00076452599388379206
I1
I0
I1
tp11943
sS'concomitant,orally'
p11944
(F1
F0.00076452599388379206
I1
I0
I1
tp11945
sS'noradrenergic,neuronal'
p11946
(F1
F0.00076452599388379206
I0
I1
I-1
tp11947
sS'of,mexitil'
p11948
(F1
F0.00076452599388379206
I1
I0
I1
tp11949
sS'in,these'
p11950
(F1
F0.00076452599388379206
I0
I1
I-1
tp11951
sS'sympathomimetic,amines'
p11952
(F1
F0.00076452599388379206
I1
I0
I1
tp11953
sS'similar,agents'
p11954
(F1
F0.00076452599388379206
I1
I0
I1
tp11955
sS'control,seizures'
p11956
(F1
F0.00076452599388379206
I0
I1
I-1
tp11957
sS'antianginal,and'
p11958
(F1
F0.00076452599388379206
I0
I1
I-1
tp11959
sS'other,nonsteroidal'
p11960
(F1
F0.00076452599388379206
I1
I0
I1
tp11961
sS'treatment,with'
p11962
(F0.27272727272727271
F0.0022935779816513763
I7
I4
I3
tp11963
sS'cyclosporine,diflucan'
p11964
(F1
F0.00076452599388379206
I1
I0
I1
tp11965
sS'locus,coeruleus'
p11966
(F1
F0.0015290519877675841
I2
I0
I2
tp11967
sS'human,exposure'
p11968
(F1
F0.0030581039755351682
I0
I4
I-4
tp11969
sS'blocks,the'
p11970
(F1
F0.00076452599388379206
I1
I0
I1
tp11971
sS'the,cyp3a4'
p11972
(F1
F0.0015290519877675841
I2
I0
I2
tp11973
sS'and,s-enantiomers'
p11974
(F1
F0.00076452599388379206
I0
I1
I-1
tp11975
sS'in,connection'
p11976
(F1
F0.00076452599388379206
I0
I1
I-1
tp11977
sS'evaluating,possible'
p11978
(F1
F0.00076452599388379206
I0
I1
I-1
tp11979
sS'of,combined'
p11980
(F1
F0.0015290519877675841
I0
I2
I-2
tp11981
sS'or,macrolide'
p11982
(F1
F0.0015290519877675841
I2
I0
I2
tp11983
sS'cytochromes,p450'
p11984
(F1
F0.00076452599388379206
I0
I1
I-1
tp11985
sS'administered,agent'
p11986
(F1
F0.00076452599388379206
I1
I0
I1
tp11987
sS'other,belladonna'
p11988
(F1
F0.00076452599388379206
I0
I1
I-1
tp11989
sS'to,further'
p11990
(F1
F0.0015290519877675841
I0
I2
I-2
tp11991
sS'shown,not'
p11992
(F1
F0.00076452599388379206
I0
I1
I-1
tp11993
sS'patients,concomitantly'
p11994
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11995
sS'or,after'
p11996
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp11997
sS'pretreatment,for'
p11998
(F1
F0.00076452599388379206
I1
I0
I1
tp11999
sS'pre-mexitil,values'
p12000
(F1
F0.00076452599388379206
I1
I0
I1
tp12001
sS'a,slight'
p12002
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp12003
sS'avoid,while'
p12004
(F1
F0.00076452599388379206
I1
I0
I1
tp12005
sS'fat,excretion'
p12006
(F1
F0.00076452599388379206
I0
I1
I-1
tp12007
sS'women,and'
p12008
(F1
F0.00076452599388379206
I1
I0
I1
tp12009
sS'determine,whether'
p12010
(F1
F0.00076452599388379206
I0
I1
I-1
tp12011
sS'drugs,periodic'
p12012
(F1
F0.00076452599388379206
I1
I0
I1
tp12013
sS'prothrombin,time'
p12014
(F0.46666666666666667
F0.0053516819571865441
I11
I4
I7
tp12015
sS'certain,given'
p12016
(F1
F0.00076452599388379206
I0
I1
I-1
tp12017
sS'and,le'
p12018
(F1
F0.00076452599388379206
I1
I0
I1
tp12019
sS'pharmacology,variability'
p12020
(F1
F0.00076452599388379206
I1
I0
I1
tp12021
sS'cholestyramine,concomitant'
p12022
(F1
F0.00076452599388379206
I1
I0
I1
tp12023
sS'a,net'
p12024
(F1
F0.00076452599388379206
I1
I0
I1
tp12025
sS'a,new'
p12026
(F1
F0.00076452599388379206
I1
I0
I1
tp12027
sS'inhibition,in'
p12028
(F1
F0.00076452599388379206
I0
I1
I-1
tp12029
sS'such,occurrences'
p12030
(F1
F0.00076452599388379206
I0
I1
I-1
tp12031
sS'metabolizers,of'
p12032
(F1
F0.00076452599388379206
I0
I1
I-1
tp12033
sS'are,used'
p12034
(F1
F0.0015290519877675841
I2
I0
I2
tp12035
sS'other,inhibitors'
p12036
(F1
F0.00076452599388379206
I1
I0
I1
tp12037
sS'in,dosage'
p12038
(F1
F0.0022935779816513763
I3
I0
I3
tp12039
sS'seven,groups'
p12040
(F1
F0.00076452599388379206
I0
I1
I-1
tp12041
sS'gastrointestinal,bleeding'
p12042
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp12043
sS'ergotamine-containing,or'
p12044
(F1
F0.00076452599388379206
I1
I0
I1
tp12045
sS'concentration,and'
p12046
(F1
F0.0015290519877675841
I2
I0
I2
tp12047
sS'breast,but'
p12048
(F1
F0.00076452599388379206
I1
I0
I1
tp12049
sS'of,this'
p12050
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp12051
sS'not,lead'
p12052
(F1
F0.00076452599388379206
I0
I1
I-1
tp12053
sS'are,taking'
p12054
(F1
F0.00076452599388379206
I0
I1
I-1
tp12055
sS'subjects,coadministration'
p12056
(F1
F0.00076452599388379206
I0
I1
I-1
tp12057
sS'including,ergot'
p12058
(F1
F0.00076452599388379206
I0
I1
I-1
tp12059
sS'severe,constipation'
p12060
(F1
F0.00076452599388379206
I1
I0
I1
tp12061
sS'acid,writhing'
p12062
(F1
F0.00076452599388379206
I1
I0
I1
tp12063
sS'of,provided'
p12064
(F1
F0.00076452599388379206
I1
I0
I1
tp12065
sS'macrolides,clinical'
p12066
(F1
F0.00076452599388379206
I1
I0
I1
tp12067
sS'of,concurrently'
p12068
(F1
F0.00076452599388379206
I1
I0
I1
tp12069
sS'clinical,drug'
p12070
(F1
F0.00076452599388379206
I1
I0
I1
tp12071
sS'the,inr'
p12072
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp12073
sS'agents,has'
p12074
(F1
F0.0015290519877675841
I2
I0
I2
tp12075
sS'enzyme,cyp3a4'
p12076
(F1
F0.00076452599388379206
I1
I0
I1
tp12077
sS'by,following'
p12078
(F1
F0.00076452599388379206
I1
I0
I1
tp12079
sS'pharmacokinetics,of'
p12080
(F1
F0.0084097859327217118
I0
I11
I-11
tp12081
sS'a,bioenhancer'
p12082
(F1
F0.00076452599388379206
I1
I0
I1
tp12083
sS'potentiation,occurs'
p12084
(F1
F0.00076452599388379206
I0
I1
I-1
tp12085
sS'with,an'
p12086
(F0
F0
I2
I2
I0
tp12087
sS'states,may'
p12088
(F1
F0.00076452599388379206
I1
I0
I1
tp12089
sS'addition,dznep'
p12090
(F1
F0.00076452599388379206
I1
I0
I1
tp12091
sS'accentuated,by'
p12092
(F1
F0.00076452599388379206
I1
I0
I1
tp12093
sS'to,accelerate'
p12094
(F1
F0.00076452599388379206
I1
I0
I1
tp12095
sS'coexistence,may'
p12096
(F1
F0.00076452599388379206
I0
I1
I-1
tp12097
sS'the,use'
p12098
(F0.33333333333333331
F0.0038226299694189602
I10
I5
I5
tp12099
sS'of,there'
p12100
(F1
F0.00076452599388379206
I1
I0
I1
tp12101
sS'drugs,and'
p12102
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp12103
sS'evaluated,for'
p12104
(F1
F0.00076452599388379206
I0
I1
I-1
tp12105
sS'secretion,although'
p12106
(F1
F0.00076452599388379206
I1
I0
I1
tp12107
sS'for,gastrointestinal'
p12108
(F1
F0.00076452599388379206
I0
I1
I-1
tp12109
sS'alfa,pulmozyme'
p12110
(F1
F0.00076452599388379206
I1
I0
I1
tp12111
sS'interactions,that'
p12112
(F1
F0.00076452599388379206
I0
I1
I-1
tp12113
sS'vitro,testing'
p12114
(F1
F0.00076452599388379206
I0
I1
I-1
tp12115
sS'together,the'
p12116
(F1
F0.00076452599388379206
I1
I0
I1
tp12117
sS'other,strong'
p12118
(F1
F0.00076452599388379206
I1
I0
I1
tp12119
sS'of,nondepolarizing'
p12120
(F1
F0.0015290519877675841
I2
I0
I2
tp12121
sS'congenital,or'
p12122
(F1
F0.00076452599388379206
I0
I1
I-1
tp12123
sS'rabbits,during'
p12124
(F1
F0.00076452599388379206
I0
I1
I-1
tp12125
sS'must,be'
p12126
(F0
F0
I1
I1
I0
tp12127
sS'blockers,oral'
p12128
(F1
F0.00076452599388379206
I0
I1
I-1
tp12129
sS'ability,of'
p12130
(F1
F0.00076452599388379206
I0
I1
I-1
tp12131
sS'therefore,do'
p12132
(F1
F0.00076452599388379206
I1
I0
I1
tp12133
sS'c,max'
p12134
(F1
F0.0022935779816513763
I3
I0
I3
tp12135
sS'system,such'
p12136
(F1
F0.00076452599388379206
I1
I0
I1
tp12137
sS'marrow,fibrosis'
p12138
(F1
F0.00076452599388379206
I0
I1
I-1
tp12139
sS'breakdown,of'
p12140
(F1
F0.00076452599388379206
I1
I0
I1
tp12141
sS'thoracic,ribs'
p12142
(F1
F0.00076452599388379206
I0
I1
I-1
tp12143
sS'with,proton'
p12144
(F1
F0.00076452599388379206
I1
I0
I1
tp12145
sS'is,prescribed'
p12146
(F1
F0.00076452599388379206
I0
I1
I-1
tp12147
sS'was,combined'
p12148
(F1
F0.0015290519877675841
I2
I0
I2
tp12149
sS'the,non-specific'
p12150
(F1
F0.00076452599388379206
I0
I1
I-1
tp12151
sS'of,hiv-infected'
p12152
(F1
F0.00076452599388379206
I1
I0
I1
tp12153
sS'anticoagulants,and'
p12154
(F1
F0.00076452599388379206
I1
I0
I1
tp12155
sS'days,or'
p12156
(F1
F0.00076452599388379206
I0
I1
I-1
tp12157
sS'other,sedating'
p12158
(F1
F0.00076452599388379206
I1
I0
I1
tp12159
sS'system,particularly'
p12160
(F1
F0.00076452599388379206
I1
I0
I1
tp12161
sS'antagonistic,in'
p12162
(F1
F0.00076452599388379206
I1
I0
I1
tp12163
sS'of,general'
p12164
(F1
F0.00076452599388379206
I0
I1
I-1
tp12165
sS'with,spent'
p12166
(F1
F0.00076452599388379206
I0
I1
I-1
tp12167
sS'in,concentrations'
p12168
(F1
F0.00076452599388379206
I1
I0
I1
tp12169
sS'metabolizers,see'
p12170
(F1
F0.00076452599388379206
I1
I0
I1
tp12171
sS'these,two'
p12172
(F1
F0.0015290519877675841
I0
I2
I-2
tp12173
sS'and,carbonic'
p12174
(F1
F0.00076452599388379206
I1
I0
I1
tp12175
sS'drugs,beta'
p12176
(F1
F0.00076452599388379206
I0
I1
I-1
tp12177
sS'as,acetylsalicylic'
p12178
(F1
F0.00076452599388379206
I1
I0
I1
tp12179
sS'normal,volunteer'
p12180
(F1
F0.00076452599388379206
I0
I1
I-1
tp12181
sS'study,were'
p12182
(F1
F0.00076452599388379206
I0
I1
I-1
tp12183
sS'and,further'
p12184
(F1
F0.00076452599388379206
I0
I1
I-1
tp12185
sS't,returned'
p12186
(F1
F0.00076452599388379206
I0
I1
I-1
tp12187
sS'tablets,coadministered'
p12188
(F1
F0.00076452599388379206
I1
I0
I1
tp12189
sS'effect,would'
p12190
(F1
F0.00076452599388379206
I1
I0
I1
tp12191
sS'are,co-'
p12192
(F1
F0.00076452599388379206
I1
I0
I1
tp12193
sS'with,tiva'
p12194
(F1
F0.00076452599388379206
I0
I1
I-1
tp12195
sS'drug,therapy'
p12196
(F1
F0.00076452599388379206
I0
I1
I-1
tp12197
sS'day,the'
p12198
(F1
F0.00076452599388379206
I1
I0
I1
tp12199
sS'paroxetine,and'
p12200
(F1
F0.00076452599388379206
I1
I0
I1
tp12201
sS'noradrenaline,cell'
p12202
(F1
F0.00076452599388379206
I1
I0
I1
tp12203
sS'drug,interaction'
p12204
(F0.25
F0.0015290519877675841
I3
I5
I-2
tp12205
sS'a,mixture'
p12206
(F1
F0.00076452599388379206
I0
I1
I-1
tp12207
sS'equivalent,to'
p12208
(F1
F0.00076452599388379206
I1
I0
I1
tp12209
sS'also,taking'
p12210
(F1
F0.00076452599388379206
I1
I0
I1
tp12211
sS'bleeding,compared'
p12212
(F1
F0.00076452599388379206
I1
I0
I1
tp12213
sS'before,for'
p12214
(F1
F0.00076452599388379206
I0
I1
I-1
tp12215
sS'objective,was'
p12216
(F1
F0.0015290519877675841
I0
I2
I-2
tp12217
sS'that,aminosalicylate'
p12218
(F1
F0.00076452599388379206
I1
I0
I1
tp12219
sS'oncology,patients'
p12220
(F1
F0.00076452599388379206
I0
I1
I-1
tp12221
sS'protein-bound,drugs'
p12222
(F1
F0.00076452599388379206
I1
I0
I1
tp12223
sS'to,control'
p12224
(F1
F0.00076452599388379206
I0
I1
I-1
tp12225
sS'questioning,revealed'
p12226
(F1
F0.00076452599388379206
I0
I1
I-1
tp12227
sS'unlikely,to'
p12228
(F1
F0.0015290519877675841
I0
I2
I-2
tp12229
sS'the,enhancement'
p12230
(F1
F0.00076452599388379206
I1
I0
I1
tp12231
sS'acting,alpha-2'
p12232
(F1
F0.00076452599388379206
I0
I1
I-1
tp12233
sS'inhibitory,activity'
p12234
(F1
F0.00076452599388379206
I1
I0
I1
tp12235
sS'to,minimize'
p12236
(F1
F0.00076452599388379206
I0
I1
I-1
tp12237
sS'administer,myfortic'
p12238
(F1
F0.00076452599388379206
I1
I0
I1
tp12239
sS'alter,gastrointestinal'
p12240
(F1
F0.0015290519877675841
I2
I0
I2
tp12241
sS'affect,mexitil'
p12242
(F1
F0.00076452599388379206
I0
I1
I-1
tp12243
sS'vitro,rat'
p12244
(F1
F0.00076452599388379206
I1
I0
I1
tp12245
sS'the,combined'
p12246
(F1
F0.0022935779816513763
I3
I0
I3
tp12247
sS'conditions,and'
p12248
(F1
F0.00076452599388379206
I0
I1
I-1
tp12249
sS'mice,in'
p12250
(F1
F0.0015290519877675841
I0
I2
I-2
tp12251
sS'following,all'
p12252
(F1
F0.00076452599388379206
I1
I0
I1
tp12253
sS'levels,but'
p12254
(F0
F0
I1
I1
I0
tp12255
sS'marketing,therefore'
p12256
(F1
F0.00076452599388379206
I1
I0
I1
tp12257
sS'antibody,response'
p12258
(F1
F0.00076452599388379206
I1
I0
I1
tp12259
sS'insufficiency,should'
p12260
(F1
F0.00076452599388379206
I1
I0
I1
tp12261
sS'patients,had'
p12262
(F1
F0.00076452599388379206
I0
I1
I-1
tp12263
sS'a,may'
p12264
(F1
F0.00076452599388379206
I0
I1
I-1
tp12265
sS'inhibit,this'
p12266
(F1
F0.00076452599388379206
I0
I1
I-1
tp12267
sS'of,zavesca'
p12268
(F1
F0.00076452599388379206
I1
I0
I1
tp12269
sS'target,inr'
p12270
(F1
F0.00076452599388379206
I1
I0
I1
tp12271
sS'discontinues,therapy'
p12272
(F1
F0.00076452599388379206
I1
I0
I1
tp12273
sS'other,azole-type'
p12274
(F1
F0.00076452599388379206
I1
I0
I1
tp12275
sS'diffusion,rate'
p12276
(F1
F0.00076452599388379206
I1
I0
I1
tp12277
sS'but,to'
p12278
(F1
F0.00076452599388379206
I1
I0
I1
tp12279
sS'xenical,did'
p12280
(F1
F0.0030581039755351682
I0
I4
I-4
tp12281
sS'hypoglycemia,in'
p12282
(F1
F0.00076452599388379206
I1
I0
I1
tp12283
sS'in,digitalized'
p12284
(F1
F0.00076452599388379206
I1
I0
I1
tp12285
sS'with,great'
p12286
(F1
F0.0022935779816513763
I3
I0
I3
tp12287
sS'and,that'
p12288
(F0
F0
I1
I1
I0
tp12289
sS'that,these'
p12290
(F1
F0.00076452599388379206
I1
I0
I1
tp12291
sS'in,one'
p12292
(F1
F0.0022935779816513763
I3
I0
I3
tp12293
sS'pk,parameters'
p12294
(F1
F0.00076452599388379206
I0
I1
I-1
tp12295
sS'oral,administration'
p12296
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp12297
sS'psychostimulant,drug'
p12298
(F1
F0.00076452599388379206
I0
I1
I-1
tp12299
sS'onset,but'
p12300
(F1
F0.00076452599388379206
I1
I0
I1
tp12301
sS'of,with'
p12302
(F0.5
F0.0076452599388379203
I15
I5
I10
tp12303
sS'cause,a'
p12304
(F0
F0
I1
I1
I0
tp12305
sS'analysis,with'
p12306
(F1
F0.00076452599388379206
I0
I1
I-1
tp12307
sS'decreasing,the'
p12308
(F1
F0.00076452599388379206
I1
I0
I1
tp12309
sS'appropriate,model'
p12310
(F1
F0.00076452599388379206
I0
I1
I-1
tp12311
sS'breath,and'
p12312
(F1
F0.00076452599388379206
I1
I0
I1
tp12313
sS'a7,noradrenaline'
p12314
(F1
F0.0015290519877675841
I2
I0
I2
tp12315
sS'other,chelation'
p12316
(F1
F0.00076452599388379206
I1
I0
I1
tp12317
sS'a,potent'
p12318
(F0
F0
I2
I2
I0
tp12319
sS'additive,use'
p12320
(F1
F0.00076452599388379206
I1
I0
I1
tp12321
sS'dose,adjustment'
p12322
(F1
F0.00076452599388379206
I1
I0
I1
tp12323
sS'antiplatelet,agents'
p12324
(F1
F0.00076452599388379206
I1
I0
I1
tp12325
sS'in,clinical'
p12326
(F0
F0
I4
I4
I0
tp12327
sS'not,inhibit'
p12328
(F1
F0.0015290519877675841
I0
I2
I-2
tp12329
sS'were,ingested'
p12330
(F1
F0.00076452599388379206
I0
I1
I-1
tp12331
sS'its,binding'
p12332
(F1
F0.00076452599388379206
I0
I1
I-1
tp12333
sS'substantial,increases'
p12334
(F1
F0.00076452599388379206
I1
I0
I1
tp12335
sS'unaffected,by'
p12336
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp12337
sS'was,reduced'
p12338
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp12339
sS'e,acetate'
p12340
(F1
F0.00076452599388379206
I1
I0
I1
tp12341
sS'of,s-ketamine'
p12342
(F1
F0.00076452599388379206
I1
I0
I1
tp12343
sS'mg,bid'
p12344
(F1
F0.0030581039755351682
I4
I0
I4
tp12345
sS'how,interacts'
p12346
(F1
F0.00076452599388379206
I0
I1
I-1
tp12347
sS'animals,than'
p12348
(F1
F0.00076452599388379206
I1
I0
I1
tp12349
sS'co-injection,of'
p12350
(F0
F0
I1
I1
I0
tp12351
sS'systemic,toxicity'
p12352
(F1
F0.00076452599388379206
I1
I0
I1
tp12353
sS'evaluate,potential'
p12354
(F1
F0.00076452599388379206
I0
I1
I-1
tp12355
sS'active,metabolite'
p12356
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp12357
sS'because,may'
p12358
(F1
F0.00076452599388379206
I1
I0
I1
tp12359
sS'as,antimycotic'
p12360
(F1
F0.00076452599388379206
I1
I0
I1
tp12361
sS'of,plasma'
p12362
(F1
F0.00076452599388379206
I1
I0
I1
tp12363
sS'showed,resistances'
p12364
(F1
F0.00076452599388379206
I0
I1
I-1
tp12365
sS'mainly,comes'
p12366
(F1
F0.00076452599388379206
I1
I0
I1
tp12367
sS'all,possible'
p12368
(F1
F0.00076452599388379206
I1
I0
I1
tp12369
sS'neonatal,enhanced'
p12370
(F1
F0.00076452599388379206
I0
I1
I-1
tp12371
sS'drugs,hcl'
p12372
(F1
F0.00076452599388379206
I1
I0
I1
tp12373
sS'increased,hydroxy-'
p12374
(F1
F0.00076452599388379206
I1
I0
I1
tp12375
sS'immune,response'
p12376
(F1
F0.00076452599388379206
I0
I1
I-1
tp12377
sS'this,randomized'
p12378
(F1
F0.00076452599388379206
I0
I1
I-1
tp12379
sS'regimen,of'
p12380
(F1
F0.00076452599388379206
I1
I0
I1
tp12381
sS'that,bind'
p12382
(F1
F0.00076452599388379206
I0
I1
I-1
tp12383
sS'hb-egf,is'
p12384
(F1
F0.00076452599388379206
I0
I1
I-1
tp12385
sS'cerezyme,and'
p12386
(F1
F0.00076452599388379206
I1
I0
I1
tp12387
sS'to,an'
p12388
(F1
F0.00076452599388379206
I1
I0
I1
tp12389
sS'conditioned,with'
p12390
(F0
F0
I1
I1
I0
tp12391
sS'also,used'
p12392
(F1
F0.00076452599388379206
I1
I0
I1
tp12393
sS'cells,from'
p12394
(F1
F0.00076452599388379206
I0
I1
I-1
tp12395
sS'the,incubations'
p12396
(F1
F0.00076452599388379206
I0
I1
I-1
tp12397
sS'hb-egf,in'
p12398
(F1
F0.00076452599388379206
I0
I1
I-1
tp12399
sS'synergistic,action'
p12400
(F1
F0.00076452599388379206
I0
I1
I-1
tp12401
sS'cyp2c8,such'
p12402
(F1
F0.00076452599388379206
I1
I0
I1
tp12403
sS'of,ea'
p12404
(F1
F0.00076452599388379206
I1
I0
I1
tp12405
sS'to,decreasing'
p12406
(F1
F0.00076452599388379206
I1
I0
I1
tp12407
sS'chloride,concurrent'
p12408
(F1
F0.00076452599388379206
I1
I0
I1
tp12409
sS'to,severe'
p12410
(F1
F0.00076452599388379206
I1
I0
I1
tp12411
sS'capable,of'
p12412
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp12413
sS'ssri,is'
p12414
(F1
F0.00076452599388379206
I1
I0
I1
tp12415
sS'noted,when'
p12416
(F1
F0.00076452599388379206
I1
I0
I1
tp12417
sS'slight,decrease'
p12418
(F1
F0.00076452599388379206
I0
I1
I-1
tp12419
sS'potentiation,hypotensive'
p12420
(F1
F0.00076452599388379206
I0
I1
I-1
tp12421
sS'mao-is,type'
p12422
(F1
F0.00076452599388379206
I0
I1
I-1
tp12423
sS'which,produce'
p12424
(F1
F0.00076452599388379206
I1
I0
I1
tp12425
sS'basis,that'
p12426
(F1
F0.00076452599388379206
I1
I0
I1
tp12427
sS'excessive,reductions'
p12428
(F1
F0.00076452599388379206
I0
I1
I-1
tp12429
sS'not,sufficient'
p12430
(F1
F0.00076452599388379206
I1
I0
I1
tp12431
sS'anti-parkinsonian,drug'
p12432
(F1
F0.00076452599388379206
I0
I1
I-1
tp12433
sS'artificial,tears'
p12434
(F1
F0.00076452599388379206
I0
I1
I-1
tp12435
sS'also,conducted'
p12436
(F1
F0.00076452599388379206
I0
I1
I-1
tp12437
sS'information,available'
p12438
(F1
F0.00076452599388379206
I0
I1
I-1
tp12439
sS'during,maintenance'
p12440
(F0
F0
I1
I1
I0
tp12441
sS'mice,at'
p12442
(F1
F0.00076452599388379206
I0
I1
I-1
tp12443
sS'with,quinpirole-free'
p12444
(F0
F0
I1
I1
I0
tp12445
sS'with,has'
p12446
(F1
F0.0015290519877675841
I0
I2
I-2
tp12447
sS'enhanced,transduction'
p12448
(F1
F0.00076452599388379206
I0
I1
I-1
tp12449
sS'of,given'
p12450
(F0
F0
I1
I1
I0
tp12451
sS'that,an'
p12452
(F1
F0.00076452599388379206
I0
I1
I-1
tp12453
sS'kg,dose'
p12454
(F1
F0.00076452599388379206
I0
I1
I-1
tp12455
sS'improve,their'
p12456
(F1
F0.00076452599388379206
I0
I1
I-1
tp12457
sS'amantadine,population'
p12458
(F1
F0.00076452599388379206
I0
I1
I-1
tp12459
sS'survival,rate'
p12460
(F1
F0.00076452599388379206
I1
I0
I1
tp12461
sS'cimetidine,a'
p12462
(F1
F0.00076452599388379206
I1
I0
I1
tp12463
sS'than,did'
p12464
(F1
F0.00076452599388379206
I1
I0
I1
tp12465
sS'leukemia,model'
p12466
(F1
F0.00076452599388379206
I1
I0
I1
tp12467
sS'where,gastric'
p12468
(F1
F0.00076452599388379206
I1
I0
I1
tp12469
sS'times,in'
p12470
(F1
F0.00076452599388379206
I1
I0
I1
tp12471
sS'of,panobinostat-related'
p12472
(F1
F0.00076452599388379206
I0
I1
I-1
tp12473
sS'be,mixed'
p12474
(F1
F0.00076452599388379206
I0
I1
I-1
tp12475
sS'possible,potentiation'
p12476
(F1
F0.00076452599388379206
I0
I1
I-1
tp12477
sS'routinely,treated'
p12478
(F1
F0.00076452599388379206
I0
I1
I-1
tp12479
sS'polymyxin,b'
p12480
(F1
F0.0015290519877675841
I0
I2
I-2
tp12481
sS'chemical,similarity'
p12482
(F1
F0.00076452599388379206
I1
I0
I1
tp12483
sS'gsls,on'
p12484
(F1
F0.00076452599388379206
I0
I1
I-1
tp12485
sS'wales,reported'
p12486
(F1
F0.00076452599388379206
I1
I0
I1
tp12487
sS'qtc,rr'
p12488
(F1
F0.00076452599388379206
I0
I1
I-1
tp12489
sS'twice,the'
p12490
(F1
F0.00076452599388379206
I1
I0
I1
tp12491
sS'cautiously,in'
p12492
(F1
F0.0022935779816513763
I3
I0
I3
tp12493
sS'therefore,use'
p12494
(F1
F0.00076452599388379206
I1
I0
I1
tp12495
sS'cautiously,if'
p12496
(F1
F0.00076452599388379206
I1
I0
I1
tp12497
sS'high,content'
p12498
(F1
F0.00076452599388379206
I1
I0
I1
tp12499
sS'normal,values'
p12500
(F1
F0.00076452599388379206
I1
I0
I1
tp12501
sS'or,female'
p12502
(F1
F0.00076452599388379206
I0
I1
I-1
tp12503
sS'abc,lyase'
p12504
(F1
F0.0015290519877675841
I0
I2
I-2
tp12505
sS'carnitine,and'
p12506
(F1
F0.00076452599388379206
I0
I1
I-1
tp12507
sS'dznep,one'
p12508
(F1
F0.00076452599388379206
I0
I1
I-1
tp12509
sS'conjugated,estrogens'
p12510
(F1
F0.00076452599388379206
I0
I1
I-1
tp12511
sS'of,single'
p12512
(F1
F0.0015290519877675841
I0
I2
I-2
tp12513
sS'without,or'
p12514
(F1
F0.00076452599388379206
I1
I0
I1
tp12515
sS'results,regarding'
p12516
(F1
F0.00076452599388379206
I0
I1
I-1
tp12517
sS'acetyl-l,carnitine'
p12518
(F0
F0
I1
I1
I0
tp12519
sS'eloxatin,and'
p12520
(F1
F0.00076452599388379206
I0
I1
I-1
tp12521
sS'with,may'
p12522
(F1
F0.00076452599388379206
I1
I0
I1
tp12523
sS'ml,of'
p12524
(F1
F0.00076452599388379206
I0
I1
I-1
tp12525
sS'agents,which'
p12526
(F1
F0.00076452599388379206
I1
I0
I1
tp12527
sS'mexitil,and'
p12528
(F1
F0.0015290519877675841
I2
I0
I2
tp12529
sS'warfarin,the'
p12530
(F1
F0.00076452599388379206
I0
I1
I-1
tp12531
sS'hot,flushes'
p12532
(F1
F0.00076452599388379206
I0
I1
I-1
tp12533
sS'side,effects'
p12534
(F0
F0
I2
I2
I0
tp12535
sS'important,drug-drug'
p12536
(F1
F0.00076452599388379206
I0
I1
I-1
tp12537
sS'wort,with'
p12538
(F1
F0.00076452599388379206
I1
I0
I1
tp12539
sS'although,it'
p12540
(F1
F0.00076452599388379206
I1
I0
I1
tp12541
sS'of,acute'
p12542
(F1
F0.0015290519877675841
I0
I2
I-2
tp12543
sS'auc,of'
p12544
(F0.5
F0.0030581039755351682
I6
I2
I4
tp12545
sS'caused,a'
p12546
(F1
F0.0030581039755351682
I4
I0
I4
tp12547
sS'of,serious'
p12548
(F0
F0
I1
I1
I0
tp12549
sS'increases,in'
p12550
(F1
F0.0038226299694189602
I5
I0
I5
tp12551
sS'zerit,should'
p12552
(F1
F0.00076452599388379206
I1
I0
I1
tp12553
sS'are,given'
p12554
(F1
F0.0015290519877675841
I2
I0
I2
tp12555
sS'tablets,but'
p12556
(F1
F0.00076452599388379206
I1
I0
I1
tp12557
sS'of,vma'
p12558
(F1
F0.00076452599388379206
I0
I1
I-1
tp12559
sS'of,pth'
p12560
(F1
F0.00076452599388379206
I1
I0
I1
tp12561
sS'drugs,tramadol'
p12562
(F1
F0.00076452599388379206
I1
I0
I1
tp12563
sS'with,coumarin-type'
p12564
(F1
F0.00076452599388379206
I1
I0
I1
tp12565
sS'patients,dosage'
p12566
(F1
F0.00076452599388379206
I0
I1
I-1
tp12567
sS'acute,coronary'
p12568
(F1
F0.00076452599388379206
I1
I0
I1
tp12569
sS'or,leave'
p12570
(F1
F0.00076452599388379206
I1
I0
I1
tp12571
sS'remeron,were'
p12572
(F1
F0.00076452599388379206
I1
I0
I1
tp12573
sS'agents,streptase'
p12574
(F1
F0.00076452599388379206
I1
I0
I1
tp12575
sS'oral,hypoglycemic'
p12576
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp12577
sS'when,it'
p12578
(F1
F0.0030581039755351682
I4
I0
I4
tp12579
sS'levels,in'
p12580
(F0.5
F0.0015290519877675841
I3
I1
I2
tp12581
sS'and,during'
p12582
(F1
F0.00076452599388379206
I0
I1
I-1
tp12583
sS'affected,by'
p12584
(F1
F0.0038226299694189602
I0
I5
I-5
tp12585
sS'spent,more'
p12586
(F1
F0.00076452599388379206
I0
I1
I-1
tp12587
sS'data,presently'
p12588
(F1
F0.00076452599388379206
I0
I1
I-1
tp12589
sS'reduce,mpa'
p12590
(F1
F0.00076452599388379206
I0
I1
I-1
tp12591
sS'increase,the'
p12592
(F0.75
F0.01834862385321101
I28
I4
I24
tp12593
sS'administering,concurrently'
p12594
(F1
F0.00076452599388379206
I1
I0
I1
tp12595
sS'reduce,clearance'
p12596
(F1
F0.00076452599388379206
I1
I0
I1
tp12597
sS'state,study'
p12598
(F1
F0.00076452599388379206
I0
I1
I-1
tp12599
sS'therefore,the'
p12600
(F1
F0.0015290519877675841
I2
I0
I2
tp12601
sS'k,is'
p12602
(F1
F0.00076452599388379206
I0
I1
I-1
tp12603
sS'diflucan,with'
p12604
(F1
F0.00076452599388379206
I1
I0
I1
tp12605
sS'during,which'
p12606
(F1
F0.00076452599388379206
I0
I1
I-1
tp12607
sS'day,approximately'
p12608
(F1
F0.00076452599388379206
I0
I1
I-1
tp12609
sS'an,interaction'
p12610
(F1
F0.00076452599388379206
I0
I1
I-1
tp12611
sS'as,amphotericin'
p12612
(F1
F0.00076452599388379206
I0
I1
I-1
tp12613
sS'some,individual'
p12614
(F1
F0.00076452599388379206
I0
I1
I-1
tp12615
sS'or,chondroitin'
p12616
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp12617
sS'gentamicin,animal'
p12618
(F1
F0.00076452599388379206
I1
I0
I1
tp12619
sS'present,a'
p12620
(F1
F0.00076452599388379206
I1
I0
I1
tp12621
sS'drugs,will'
p12622
(F1
F0.00076452599388379206
I1
I0
I1
tp12623
sS'of,supplemental'
p12624
(F0
F0
I1
I1
I0
tp12625
sS'auc,from'
p12626
(F1
F0.00076452599388379206
I1
I0
I1
tp12627
sS'reduced,dosage'
p12628
(F1
F0.00076452599388379206
I1
I0
I1
tp12629
sS'of,recombinant'
p12630
(F1
F0.00076452599388379206
I1
I0
I1
tp12631
sS'accounts,of'
p12632
(F1
F0.00076452599388379206
I0
I1
I-1
tp12633
sS'nsclc,cell'
p12634
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp12635
sS'receiving,multiple'
p12636
(F1
F0.00076452599388379206
I1
I0
I1
tp12637
sS'some,other'
p12638
(F1
F0.00076452599388379206
I1
I0
I1
tp12639
sS'unknown,slightly'
p12640
(F1
F0.00076452599388379206
I1
I0
I1
tp12641
sS'are,antagonized'
p12642
(F1
F0.00076452599388379206
I1
I0
I1
tp12643
sS'with,most'
p12644
(F1
F0.00076452599388379206
I0
I1
I-1
tp12645
sS'strong,cyp3a4'
p12646
(F1
F0.00076452599388379206
I1
I0
I1
tp12647
sS'the,contraception'
p12648
(F1
F0.00076452599388379206
I1
I0
I1
tp12649
sS'urinary,retention'
p12650
(F1
F0.00076452599388379206
I1
I0
I1
tp12651
sS'significantly,decreased'
p12652
(F1
F0.00076452599388379206
I0
I1
I-1
tp12653
sS'occur,in'
p12654
(F1
F0.00076452599388379206
I0
I1
I-1
tp12655
sS'hdac,inhibitors'
p12656
(F1
F0.00076452599388379206
I1
I0
I1
tp12657
sS'either,oral'
p12658
(F1
F0.00076452599388379206
I0
I1
I-1
tp12659
sS'inducers,or'
p12660
(F1
F0.00076452599388379206
I0
I1
I-1
tp12661
sS'in,subjects'
p12662
(F0
F0
I1
I1
I0
tp12663
sS'bioavailability,eg'
p12664
(F1
F0.00076452599388379206
I1
I0
I1
tp12665
sS'not,significantly'
p12666
(F0.66666666666666663
F0.0030581039755351682
I1
I5
I-4
tp12667
sS'xenical,administration'
p12668
(F1
F0.00076452599388379206
I0
I1
I-1
tp12669
sS'of,abt-737'
p12670
(F1
F0.00076452599388379206
I1
I0
I1
tp12671
sS'determined,by'
p12672
(F1
F0.00076452599388379206
I0
I1
I-1
tp12673
sS'reduced,the'
p12674
(F1
F0.00076452599388379206
I1
I0
I1
tp12675
sS'co-,administered'
p12676
(F1
F0.00076452599388379206
I1
I0
I1
tp12677
sS'concentration,profile'
p12678
(F1
F0.0015290519877675841
I0
I2
I-2
tp12679
sS'concentrations,were'
p12680
(F1
F0.00076452599388379206
I1
I0
I1
tp12681
sS'sedative-hypnotics,including'
p12682
(F1
F0.00076452599388379206
I1
I0
I1
tp12683
sS'in,apoptosis'
p12684
(F1
F0.00076452599388379206
I0
I1
I-1
tp12685
sS'kip1,sirna'
p12686
(F1
F0.00076452599388379206
I0
I1
I-1
tp12687
sS'sub-g1,fraction'
p12688
(F1
F0.00076452599388379206
I0
I1
I-1
tp12689
sS'in,dose'
p12690
(F1
F0.0015290519877675841
I2
I0
I2
tp12691
sS'plus,mg'
p12692
(F1
F0.00076452599388379206
I0
I1
I-1
tp12693
sS'plus,inhibited'
p12694
(F1
F0.00076452599388379206
I1
I0
I1
tp12695
sS'level,determinations'
p12696
(F1
F0.00076452599388379206
I1
I0
I1
tp12697
sS'cyp2a6,cyp2c9'
p12698
(F1
F0.00076452599388379206
I0
I1
I-1
tp12699
sS'have,shown'
p12700
(F0.5
F0.0015290519877675841
I3
I1
I2
tp12701
sS'receiving,monoamine'
p12702
(F1
F0.0022935779816513763
I3
I0
I3
tp12703
sS'decreased,renal'
p12704
(F1
F0.0015290519877675841
I0
I2
I-2
tp12705
sS'nifedipine,auc'
p12706
(F1
F0.00076452599388379206
I1
I0
I1
tp12707
sS'on,clinical'
p12708
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp12709
sS'remeron,soltab'
p12710
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp12711
sS'replacement,therapies'
p12712
(F1
F0.00076452599388379206
I0
I1
I-1
tp12713
sS'to,infinity'
p12714
(F1
F0.00076452599388379206
I1
I0
I1
tp12715
sS'mycamine,on'
p12716
(F1
F0.00076452599388379206
I0
I1
I-1
tp12717
sS'was,increased'
p12718
(F1
F0.0015290519877675841
I2
I0
I2
tp12719
sS'as,vitamin'
p12720
(F1
F0.00076452599388379206
I1
I0
I1
tp12721
sS'cyclosporine,when'
p12722
(F1
F0.00076452599388379206
I0
I1
I-1
tp12723
sS'to,interact'
p12724
(F0
F0
I1
I1
I0
tp12725
sS'neuromuscular,block'
p12726
(F1
F0.00076452599388379206
I1
I0
I1
tp12727
sS'enhancing,the'
p12728
(F1
F0.00076452599388379206
I1
I0
I1
tp12729
sS'or,the'
p12730
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp12731
sS'contraceptives,given'
p12732
(F1
F0.00076452599388379206
I0
I1
I-1
tp12733
sS'the,intestines'
p12734
(F1
F0.00076452599388379206
I1
I0
I1
tp12735
sS'gp,iib'
p12736
(F1
F0.00076452599388379206
I1
I0
I1
tp12737
sS'than,mg'
p12738
(F1
F0.00076452599388379206
I1
I0
I1
tp12739
sS'vitro,did'
p12740
(F1
F0.0015290519877675841
I0
I2
I-2
tp12741
sS'for,mpa'
p12742
(F1
F0.00076452599388379206
I1
I0
I1
tp12743
sS'like,or'
p12744
(F1
F0.00076452599388379206
I1
I0
I1
tp12745
sS'eg,chloral'
p12746
(F1
F0.00076452599388379206
I0
I1
I-1
tp12747
sS'dopamine,agonist'
p12748
(F1
F0.00076452599388379206
I1
I0
I1
tp12749
sS'for,invega'
p12750
(F1
F0.00076452599388379206
I0
I1
I-1
tp12751
sS'a,patient'
p12752
(F1
F0.0022935779816513763
I3
I0
I3
tp12753
sS'liver,thus'
p12754
(F1
F0.00076452599388379206
I1
I0
I1
tp12755
sS'according,to'
p12756
(F0
F0
I1
I1
I0
tp12757
sS'be,associated'
p12758
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp12759
sS'inhibitor,cci-779'
p12760
(F1
F0.00076452599388379206
I1
I0
I1
tp12761
sS'following,and'
p12762
(F1
F0.00076452599388379206
I0
I1
I-1
tp12763
sS'premedication,particularly'
p12764
(F1
F0.00076452599388379206
I1
I0
I1
tp12765
sS'described,in'
p12766
(F1
F0.0015290519877675841
I2
I0
I2
tp12767
sS'substrate,of'
p12768
(F1
F0.0022935779816513763
I0
I3
I-3
tp12769
sS'inducer,of'
p12770
(F1
F0.0015290519877675841
I2
I0
I2
tp12771
sS'eliminated,predominantly'
p12772
(F1
F0.00076452599388379206
I1
I0
I1
tp12773
sS'mind,in'
p12774
(F1
F0.00076452599388379206
I1
I0
I1
tp12775
sS'in,combining'
p12776
(F1
F0.00076452599388379206
I1
I0
I1
tp12777
sS'observed,following'
p12778
(F1
F0.0015290519877675841
I0
I2
I-2
tp12779
sS'from,its'
p12780
(F1
F0.0015290519877675841
I0
I2
I-2
tp12781
sS'its,potential'
p12782
(F1
F0.00076452599388379206
I0
I1
I-1
tp12783
sS'of,false-positive'
p12784
(F1
F0.00076452599388379206
I0
I1
I-1
tp12785
sS'with,intramuscular'
p12786
(F1
F0.00076452599388379206
I1
I0
I1
tp12787
sS'and,increase'
p12788
(F1
F0.00076452599388379206
I0
I1
I-1
tp12789
sS'both,r-'
p12790
(F1
F0.00076452599388379206
I0
I1
I-1
tp12791
sS'with,agents'
p12792
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp12793
sS'be,decreased'
p12794
(F1
F0.0015290519877675841
I2
I0
I2
tp12795
sS'retention,and'
p12796
(F1
F0.00076452599388379206
I1
I0
I1
tp12797
sS'practice,is'
p12798
(F1
F0.00076452599388379206
I0
I1
I-1
tp12799
sS'with,elevations'
p12800
(F1
F0.00076452599388379206
I1
I0
I1
tp12801
sS'are,at'
p12802
(F1
F0.00076452599388379206
I1
I0
I1
tp12803
sS'qrs,qtc'
p12804
(F1
F0.00076452599388379206
I0
I1
I-1
tp12805
sS'oral,produced'
p12806
(F1
F0.00076452599388379206
I1
I0
I1
tp12807
sS'prolongation,in'
p12808
(F1
F0.00076452599388379206
I0
I1
I-1
tp12809
sS'average,tumor'
p12810
(F1
F0.00076452599388379206
I1
I0
I1
tp12811
sS'self-reported,drowsiness'
p12812
(F1
F0.00076452599388379206
I0
I1
I-1
tp12813
sS'is,especially'
p12814
(F1
F0.00076452599388379206
I0
I1
I-1
tp12815
sS'grams,of'
p12816
(F1
F0.00076452599388379206
I0
I1
I-1
tp12817
sS'interactions,were'
p12818
(F1
F0.00076452599388379206
I0
I1
I-1
tp12819
sS'mixed,and'
p12820
(F1
F0.00076452599388379206
I0
I1
I-1
tp12821
sS'permax,a'
p12822
(F1
F0.00076452599388379206
I1
I0
I1
tp12823
sS'for,combination'
p12824
(F1
F0.00076452599388379206
I0
I1
I-1
tp12825
sS'adjusting,and'
p12826
(F1
F0.00076452599388379206
I1
I0
I1
tp12827
sS'enhanced,but'
p12828
(F1
F0.00076452599388379206
I1
I0
I1
tp12829
sS'ranging,from'
p12830
(F1
F0.00076452599388379206
I1
I0
I1
tp12831
sS'responses,to'
p12832
(F1
F0.00076452599388379206
I0
I1
I-1
tp12833
sS'flushing,mydriasis'
p12834
(F1
F0.00076452599388379206
I1
I0
I1
tp12835
sS'a,history'
p12836
(F1
F0.00076452599388379206
I1
I0
I1
tp12837
sS'improved,by'
p12838
(F1
F0.00076452599388379206
I1
I0
I1
tp12839
sS'therapy,which'
p12840
(F1
F0.00076452599388379206
I0
I1
I-1
tp12841
sS'available,indicate'
p12842
(F1
F0.00076452599388379206
I0
I1
I-1
tp12843
sS'diuretic-induced,hypokalemia'
p12844
(F1
F0.0015290519877675841
I2
I0
I2
tp12845
sS'and,nsaids'
p12846
(F1
F0.00076452599388379206
I1
I0
I1
tp12847
sS'controlled,week'
p12848
(F1
F0.00076452599388379206
I0
I1
I-1
tp12849
sS'that,at'
p12850
(F1
F0.00076452599388379206
I0
I1
I-1
tp12851
sS'incubations,were'
p12852
(F1
F0.00076452599388379206
I0
I1
I-1
tp12853
sS'predominantly,metabolized'
p12854
(F1
F0.00076452599388379206
I0
I1
I-1
tp12855
sS'values,in'
p12856
(F1
F0.00076452599388379206
I1
I0
I1
tp12857
sS'the,coadministration'
p12858
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp12859
sS'therapeutic,range'
p12860
(F1
F0.00076452599388379206
I1
I0
I1
tp12861
sS'were,potent'
p12862
(F1
F0.00076452599388379206
I1
I0
I1
tp12863
sS'of,zemuron'
p12864
(F1
F0.0022935779816513763
I0
I3
I-3
tp12865
sS'and,infusional'
p12866
(F1
F0.00076452599388379206
I0
I1
I-1
tp12867
sS'patients,suffering'
p12868
(F1
F0.0015290519877675841
I2
I0
I2
tp12869
sS'studies,and'
p12870
(F1
F0.0015290519877675841
I0
I2
I-2
tp12871
sS'ml,similar'
p12872
(F1
F0.00076452599388379206
I1
I0
I1
tp12873
sS'a,high'
p12874
(F1
F0.00076452599388379206
I1
I0
I1
tp12875
sS'drugs,has'
p12876
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp12877
sS'is,typical'
p12878
(F1
F0.00076452599388379206
I1
I0
I1
tp12879
sS'focus,on'
p12880
(F1
F0.00076452599388379206
I0
I1
I-1
tp12881
sS'liver,s'
p12882
(F1
F0.00076452599388379206
I1
I0
I1
tp12883
sS'close,monitoring'
p12884
(F1
F0.00076452599388379206
I0
I1
I-1
tp12885
sS'administered,prior'
p12886
(F1
F0.0015290519877675841
I2
I0
I2
tp12887
sS'to,following'
p12888
(F1
F0.00076452599388379206
I0
I1
I-1
tp12889
sS'reduction,due'
p12890
(F1
F0.00076452599388379206
I1
I0
I1
tp12891
sS'activated,by'
p12892
(F1
F0.00076452599388379206
I1
I0
I1
tp12893
sS'neurotoxic,medications'
p12894
(F1
F0.00076452599388379206
I1
I0
I1
tp12895
sS'minimal,effect'
p12896
(F1
F0.0015290519877675841
I2
I0
I2
tp12897
sS'therapy,having'
p12898
(F1
F0.00076452599388379206
I1
I0
I1
tp12899
sS'infarction,the'
p12900
(F1
F0.00076452599388379206
I0
I1
I-1
tp12901
sS'approximately,resulting'
p12902
(F1
F0.00076452599388379206
I0
I1
I-1
tp12903
sS'usually,complete'
p12904
(F1
F0.00076452599388379206
I1
I0
I1
tp12905
sS'interacts,with'
p12906
(F1
F0.00076452599388379206
I0
I1
I-1
tp12907
sS'found,to'
p12908
(F1
F0.00076452599388379206
I1
I0
I1
tp12909
sS'medications,concurrent'
p12910
(F1
F0.00076452599388379206
I1
I0
I1
tp12911
sS'that,might'
p12912
(F1
F0.00076452599388379206
I1
I0
I1
tp12913
sS'vivo,or'
p12914
(F1
F0.00076452599388379206
I0
I1
I-1
tp12915
sS'containing,hydroxide'
p12916
(F1
F0.00076452599388379206
I0
I1
I-1
tp12917
sS'threshold,has'
p12918
(F1
F0.00076452599388379206
I1
I0
I1
tp12919
sS'indication,that'
p12920
(F1
F0.00076452599388379206
I0
I1
I-1
tp12921
sS'order,of'
p12922
(F1
F0.00076452599388379206
I0
I1
I-1
tp12923
sS'suppressed,by'
p12924
(F1
F0.00076452599388379206
I1
I0
I1
tp12925
sS'occur,when'
p12926
(F1
F0.00076452599388379206
I1
I0
I1
tp12927
sS'important,pharmacokinetic'
p12928
(F1
F0.0015290519877675841
I0
I2
I-2
tp12929
sS'can,interact'
p12930
(F1
F0.0022935779816513763
I3
I0
I3
tp12931
sS'approximately,doubled'
p12932
(F1
F0.00076452599388379206
I1
I0
I1
tp12933
sS'or,these'
p12934
(F1
F0.00076452599388379206
I1
I0
I1
tp12935
sS'with,concurrently'
p12936
(F1
F0.00076452599388379206
I1
I0
I1
tp12937
sS'topical,use'
p12938
(F1
F0.00076452599388379206
I0
I1
I-1
tp12939
sS'than,milligrams'
p12940
(F1
F0.00076452599388379206
I0
I1
I-1
tp12941
sS'trials,the'
p12942
(F1
F0.00076452599388379206
I0
I1
I-1
tp12943
sS'gastric,emptying'
p12944
(F1
F0.00076452599388379206
I1
I0
I1
tp12945
sS'this,could'
p12946
(F1
F0.0015290519877675841
I2
I0
I2
tp12947
sS'when,therapy'
p12948
(F1
F0.00076452599388379206
I1
I0
I1
tp12949
sS'clinical,monitoring'
p12950
(F1
F0.0015290519877675841
I2
I0
I2
tp12951
sS'for,increased'
p12952
(F1
F0.0015290519877675841
I2
I0
I2
tp12953
sS'for,increases'
p12954
(F1
F0.00076452599388379206
I1
I0
I1
tp12955
sS'glycosides,serum'
p12956
(F1
F0.00076452599388379206
I0
I1
I-1
tp12957
sS'the,combination'
p12958
(F0.75
F0.0045871559633027525
I7
I1
I6
tp12959
sS'to,herceptin-sensitive'
p12960
(F1
F0.00076452599388379206
I0
I1
I-1
tp12961
sS'that,nsaids'
p12962
(F1
F0.0015290519877675841
I2
I0
I2
tp12963
sS'a,possible'
p12964
(F1
F0.00076452599388379206
I1
I0
I1
tp12965
sS'increased,serum'
p12966
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp12967
sS'or,systemic'
p12968
(F1
F0.00076452599388379206
I0
I1
I-1
tp12969
sS'limited,effect'
p12970
(F1
F0.00076452599388379206
I0
I1
I-1
tp12971
sS'available,from'
p12972
(F1
F0.00076452599388379206
I0
I1
I-1
tp12973
sS'affect,elimination'
p12974
(F1
F0.00076452599388379206
I0
I1
I-1
tp12975
sS'of,absorption'
p12976
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp12977
sS'meloxicam,did'
p12978
(F1
F0.00076452599388379206
I0
I1
I-1
tp12979
sS'tetrahydropyridine,vehicle-treated'
p12980
(F1
F0.0015290519877675841
I2
I0
I2
tp12981
sS'enzyme,inducers'
p12982
(F1
F0.0022935779816513763
I3
I0
I3
tp12983
sS'sedation,and'
p12984
(F1
F0.0022935779816513763
I3
I0
I3
tp12985
sS'potassium,supplements'
p12986
(F1
F0.0015290519877675841
I0
I2
I-2
tp12987
sS'sinequan,pamelor'
p12988
(F1
F0.00076452599388379206
I0
I1
I-1
tp12989
sS'be,synergistic'
p12990
(F1
F0.00076452599388379206
I1
I0
I1
tp12991
sS'insensitive,cells'
p12992
(F1
F0.00076452599388379206
I1
I0
I1
tp12993
sS'mouth,constipation'
p12994
(F1
F0.0015290519877675841
I2
I0
I2
tp12995
sS'and,drugs'
p12996
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp12997
sS'standard,hormone'
p12998
(F1
F0.00076452599388379206
I0
I1
I-1
tp12999
sS'diflucan,when'
p13000
(F1
F0.00076452599388379206
I1
I0
I1
tp13001
sS'cyp1a2,inducers'
p13002
(F1
F0.00076452599388379206
I0
I1
I-1
tp13003
sS'medical,supervision'
p13004
(F1
F0.00076452599388379206
I1
I0
I1
tp13005
sS'nonheme,as'
p13006
(F0
F0
I1
I1
I0
tp13007
sS'of,taken'
p13008
(F1
F0.00076452599388379206
I0
I1
I-1
tp13009
sS'antinociception,activity'
p13010
(F1
F0.00076452599388379206
I1
I0
I1
tp13011
sS'since,are'
p13012
(F1
F0.00076452599388379206
I1
I0
I1
tp13013
sS'milligrams,of'
p13014
(F1
F0.00076452599388379206
I0
I1
I-1
tp13015
sS'a,range'
p13016
(F1
F0.00076452599388379206
I0
I1
I-1
tp13017
sS'classes,of'
p13018
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13019
sS'the,locus'
p13020
(F1
F0.00076452599388379206
I1
I0
I1
tp13021
sS'rats,at'
p13022
(F1
F0.00076452599388379206
I0
I1
I-1
tp13023
sS'ethynyl,pyridine'
p13024
(F0
F0
I2
I2
I0
tp13025
sS'therefore,may'
p13026
(F1
F0.00076452599388379206
I0
I1
I-1
tp13027
sS'should,have'
p13028
(F1
F0.00076452599388379206
I1
I0
I1
tp13029
sS'gavage,fertility'
p13030
(F1
F0.00076452599388379206
I0
I1
I-1
tp13031
sS'kg,day'
p13032
(F1
F0.0030581039755351682
I0
I4
I-4
tp13033
sS'predominantly,a'
p13034
(F1
F0.00076452599388379206
I0
I1
I-1
tp13035
sS'concomitant,and'
p13036
(F1
F0.00076452599388379206
I0
I1
I-1
tp13037
sS'and,auc'
p13038
(F0.77777777777777779
F0.0053516819571865441
I8
I1
I7
tp13039
sS'univasc,was'
p13040
(F1
F0.00076452599388379206
I0
I1
I-1
tp13041
sS'comparable,with'
p13042
(F1
F0.00076452599388379206
I0
I1
I-1
tp13043
sS'other,anticholinergic'
p13044
(F1
F0.0022935779816513763
I3
I0
I3
tp13045
sS'stomach,may'
p13046
(F1
F0.00076452599388379206
I1
I0
I1
tp13047
sS'potentially,result'
p13048
(F1
F0.00076452599388379206
I1
I0
I1
tp13049
sS'secreted,by'
p13050
(F1
F0.00076452599388379206
I1
I0
I1
tp13051
sS'mg,than'
p13052
(F1
F0.00076452599388379206
I0
I1
I-1
tp13053
sS'torsade,de'
p13054
(F1
F0.00076452599388379206
I1
I0
I1
tp13055
sS'if,the'
p13056
(F1
F0.00076452599388379206
I0
I1
I-1
tp13057
sS'elderly,patients'
p13058
(F1
F0.00076452599388379206
I0
I1
I-1
tp13059
sS'to,calcitonin'
p13060
(F1
F0.00076452599388379206
I1
I0
I1
tp13061
sS'case,of'
p13062
(F1
F0.0022935779816513763
I3
I0
I3
tp13063
sS'increase,seizure'
p13064
(F1
F0.00076452599388379206
I1
I0
I1
tp13065
sS'antagonists,because'
p13066
(F1
F0.00076452599388379206
I1
I0
I1
tp13067
sS'monkeys,were'
p13068
(F1
F0.00076452599388379206
I1
I0
I1
tp13069
sS'several,studies'
p13070
(F1
F0.00076452599388379206
I1
I0
I1
tp13071
sS'day,to'
p13072
(F1
F0.00076452599388379206
I0
I1
I-1
tp13073
sS'dosage,of'
p13074
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13075
sS'fold,whereas'
p13076
(F1
F0.00076452599388379206
I1
I0
I1
tp13077
sS'since,marketing'
p13078
(F1
F0.00076452599388379206
I1
I0
I1
tp13079
sS'by,anticholinergic'
p13080
(F1
F0.00076452599388379206
I1
I0
I1
tp13081
sS'myelotoxicity,radiation'
p13082
(F1
F0.00076452599388379206
I1
I0
I1
tp13083
sS'dosage,or'
p13084
(F1
F0.00076452599388379206
I1
I0
I1
tp13085
sS'of,patients'
p13086
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13087
sS'combination,to'
p13088
(F1
F0.00076452599388379206
I0
I1
I-1
tp13089
sS'inhibited,absorption'
p13090
(F1
F0.00076452599388379206
I1
I0
I1
tp13091
sS'other,beta'
p13092
(F1
F0.00076452599388379206
I1
I0
I1
tp13093
sS'total,dose'
p13094
(F1
F0.00076452599388379206
I0
I1
I-1
tp13095
sS'have,an'
p13096
(F1
F0.0015290519877675841
I2
I0
I2
tp13097
sS'as,necessary'
p13098
(F1
F0.00076452599388379206
I1
I0
I1
tp13099
sS'with,higher'
p13100
(F1
F0.0015290519877675841
I0
I2
I-2
tp13101
sS'human,ovarian'
p13102
(F1
F0.00076452599388379206
I1
I0
I1
tp13103
sS'delayed,clearance'
p13104
(F1
F0.00076452599388379206
I1
I0
I1
tp13105
sS'k,nutritional'
p13106
(F1
F0.00076452599388379206
I0
I1
I-1
tp13107
sS'commonly,prescribed'
p13108
(F1
F0.00076452599388379206
I0
I1
I-1
tp13109
sS'concurrently,blood'
p13110
(F1
F0.00076452599388379206
I1
I0
I1
tp13111
sS'signs,of'
p13112
(F1
F0.0015290519877675841
I2
I0
I2
tp13113
sS'adjusted,according'
p13114
(F1
F0.00076452599388379206
I1
I0
I1
tp13115
sS'xenical,and'
p13116
(F0
F0
I1
I1
I0
tp13117
sS'fresh,human'
p13118
(F1
F0.00076452599388379206
I1
I0
I1
tp13119
sS'appreciably,metabolized'
p13120
(F1
F0.00076452599388379206
I0
I1
I-1
tp13121
sS'that,induce'
p13122
(F0
F0
I2
I2
I0
tp13123
sS'contraceptives,concomitant'
p13124
(F1
F0.00076452599388379206
I0
I1
I-1
tp13125
sS'and,decrease'
p13126
(F1
F0.00076452599388379206
I1
I0
I1
tp13127
sS'are,to'
p13128
(F1
F0.00076452599388379206
I1
I0
I1
tp13129
sS'coadministration,of'
p13130
(F0.375
F0.0045871559633027525
I11
I5
I6
tp13131
sS'contributing,to'
p13132
(F1
F0.00076452599388379206
I0
I1
I-1
tp13133
sS'parkinsonian,motor'
p13134
(F1
F0.00076452599388379206
I0
I1
I-1
tp13135
sS'proteins,is'
p13136
(F1
F0.00076452599388379206
I0
I1
I-1
tp13137
sS'receiving,zolinza'
p13138
(F1
F0.00076452599388379206
I1
I0
I1
tp13139
sS'and,may'
p13140
(F0.78947368421052633
F0.011467889908256881
I17
I2
I15
tp13141
sS'as,anorexia'
p13142
(F1
F0.00076452599388379206
I1
I0
I1
tp13143
sS'dosage,increased'
p13144
(F1
F0.00076452599388379206
I1
I0
I1
tp13145
sS'death,have'
p13146
(F1
F0.00076452599388379206
I1
I0
I1
tp13147
sS'of,beta'
p13148
(F1
F0.00076452599388379206
I1
I0
I1
tp13149
sS'the,progression-free'
p13150
(F1
F0.00076452599388379206
I1
I0
I1
tp13151
sS'with,regular'
p13152
(F1
F0.00076452599388379206
I1
I0
I1
tp13153
sS'adamantyl,hexamethylenimine'
p13154
(F1
F0.00076452599388379206
I0
I1
I-1
tp13155
sS'inhibitor,on'
p13156
(F1
F0.00076452599388379206
I0
I1
I-1
tp13157
sS'following,administration'
p13158
(F0
F0
I2
I2
I0
tp13159
sS'inhibitor,of'
p13160
(F0.20000000000000001
F0.0015290519877675841
I6
I4
I2
tp13161
sS'least,two'
p13162
(F1
F0.00076452599388379206
I1
I0
I1
tp13163
sS'tumor,volume'
p13164
(F1
F0.00076452599388379206
I1
I0
I1
tp13165
sS'days,before'
p13166
(F1
F0.0015290519877675841
I2
I0
I2
tp13167
sS'including,barbiturates'
p13168
(F1
F0.00076452599388379206
I1
I0
I1
tp13169
sS'as,chloride'
p13170
(F0
F0
I1
I1
I0
tp13171
sS'metaproterenol,sulfate'
p13172
(F1
F0.00076452599388379206
I1
I0
I1
tp13173
sS'pathways,that'
p13174
(F1
F0.00076452599388379206
I1
I0
I1
tp13175
sS'univasc,can'
p13176
(F1
F0.0015290519877675841
I0
I2
I-2
tp13177
sS'cyp3a4,family'
p13178
(F1
F0.0015290519877675841
I2
I0
I2
tp13179
sS'a,decreased'
p13180
(F1
F0.00076452599388379206
I1
I0
I1
tp13181
sS'enzymes,in'
p13182
(F1
F0.00076452599388379206
I0
I1
I-1
tp13183
sS'in,locus'
p13184
(F1
F0.00076452599388379206
I1
I0
I1
tp13185
sS'cyp3a4,mg'
p13186
(F1
F0.00076452599388379206
I1
I0
I1
tp13187
sS'of,followed'
p13188
(F1
F0.00076452599388379206
I1
I0
I1
tp13189
sS'intramuscular,or'
p13190
(F1
F0.00076452599388379206
I1
I0
I1
tp13191
sS'symlin,on'
p13192
(F1
F0.00076452599388379206
I0
I1
I-1
tp13193
sS'of,fixed'
p13194
(F0
F0
I2
I2
I0
tp13195
sS'growth,inhibition'
p13196
(F1
F0.0015290519877675841
I0
I2
I-2
tp13197
sS'the,absence'
p13198
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13199
sS'potent,non-competitive'
p13200
(F1
F0.00076452599388379206
I1
I0
I1
tp13201
sS'pharmacokinetic,properties'
p13202
(F1
F0.00076452599388379206
I0
I1
I-1
tp13203
sS'atropinization,flushing'
p13204
(F1
F0.00076452599388379206
I1
I0
I1
tp13205
sS'deazaneplanocin,a'
p13206
(F1
F0.00076452599388379206
I0
I1
I-1
tp13207
sS'requirements,of'
p13208
(F1
F0.00076452599388379206
I1
I0
I1
tp13209
sS'vaccines,and'
p13210
(F1
F0.00076452599388379206
I1
I0
I1
tp13211
sS'local,or'
p13212
(F1
F0.00076452599388379206
I1
I0
I1
tp13213
sS'or,should'
p13214
(F0
F0
I1
I1
I0
tp13215
sS'hr,ml'
p13216
(F1
F0.00076452599388379206
I1
I0
I1
tp13217
sS'administrations,not'
p13218
(F1
F0.00076452599388379206
I1
I0
I1
tp13219
sS'the,hypotensive'
p13220
(F0
F0
I1
I1
I0
tp13221
sS'human,a375'
p13222
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13223
sS'not,generally'
p13224
(F1
F0.00076452599388379206
I1
I0
I1
tp13225
sS'antitumor,effects'
p13226
(F1
F0.00076452599388379206
I0
I1
I-1
tp13227
sS'coumarin-type,and'
p13228
(F1
F0.00076452599388379206
I1
I0
I1
tp13229
sS'other,potassium'
p13230
(F1
F0.00076452599388379206
I1
I0
I1
tp13231
sS'single,mg'
p13232
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp13233
sS'interaction,was'
p13234
(F1
F0.00076452599388379206
I0
I1
I-1
tp13235
sS'of,increased'
p13236
(F1
F0.0015290519877675841
I2
I0
I2
tp13237
sS'metolazone,may'
p13238
(F1
F0.00076452599388379206
I1
I0
I1
tp13239
sS'chronic,use'
p13240
(F1
F0.00076452599388379206
I0
I1
I-1
tp13241
sS'appropriate,igf-i'
p13242
(F1
F0.00076452599388379206
I1
I0
I1
tp13243
sS'not,influenced'
p13244
(F1
F0.00076452599388379206
I0
I1
I-1
tp13245
sS'humans,and'
p13246
(F1
F0.00076452599388379206
I0
I1
I-1
tp13247
sS'an,inr'
p13248
(F1
F0.00076452599388379206
I0
I1
I-1
tp13249
sS'before,feeds'
p13250
(F1
F0.00076452599388379206
I0
I1
I-1
tp13251
sS'drugs,paliperidone'
p13252
(F1
F0.00076452599388379206
I0
I1
I-1
tp13253
sS'following,coadministration'
p13254
(F1
F0.00076452599388379206
I1
I0
I1
tp13255
sS'type,b'
p13256
(F1
F0.00076452599388379206
I0
I1
I-1
tp13257
sS'seven,children'
p13258
(F1
F0.00076452599388379206
I0
I1
I-1
tp13259
sS'some,patients'
p13260
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13261
sS'mivacron,and'
p13262
(F1
F0.00076452599388379206
I0
I1
I-1
tp13263
sS'either,phenotype'
p13264
(F1
F0.00076452599388379206
I0
I1
I-1
tp13265
sS'the,humoral'
p13266
(F1
F0.00076452599388379206
I0
I1
I-1
tp13267
sS'dysrhythmias,secondary'
p13268
(F1
F0.00076452599388379206
I1
I0
I1
tp13269
sS'dosage,should'
p13270
(F1
F0.0015290519877675841
I2
I0
I2
tp13271
sS'found,in'
p13272
(F1
F0.00076452599388379206
I1
I0
I1
tp13273
sS'a,multiple-dose'
p13274
(F1
F0.00076452599388379206
I0
I1
I-1
tp13275
sS'thus,increasing'
p13276
(F1
F0.00076452599388379206
I1
I0
I1
tp13277
sS'prescribed,medications'
p13278
(F1
F0.00076452599388379206
I0
I1
I-1
tp13279
sS'acids,these'
p13280
(F1
F0.00076452599388379206
I0
I1
I-1
tp13281
sS'kg,intraperitoneally'
p13282
(F0
F0
I1
I1
I0
tp13283
sS'and,melena'
p13284
(F1
F0.00076452599388379206
I1
I0
I1
tp13285
sS'systemic,or'
p13286
(F1
F0.00076452599388379206
I0
I1
I-1
tp13287
sS'pressor,agent'
p13288
(F1
F0.00076452599388379206
I1
I0
I1
tp13289
sS'topical,administration'
p13290
(F1
F0.00076452599388379206
I0
I1
I-1
tp13291
sS'bleeding,and'
p13292
(F1
F0.00076452599388379206
I1
I0
I1
tp13293
sS'carbamazepine,and'
p13294
(F1
F0.00076452599388379206
I1
I0
I1
tp13295
sS'possible,that'
p13296
(F1
F0.0015290519877675841
I2
I0
I2
tp13297
sS'than,of'
p13298
(F1
F0.00076452599388379206
I1
I0
I1
tp13299
sS'enzymes,has'
p13300
(F1
F0.00076452599388379206
I0
I1
I-1
tp13301
sS'purinethol,and'
p13302
(F1
F0.00076452599388379206
I1
I0
I1
tp13303
sS'motility,anticholinergic'
p13304
(F1
F0.00076452599388379206
I1
I0
I1
tp13305
sS'produced,a'
p13306
(F1
F0.00076452599388379206
I1
I0
I1
tp13307
sS'the,metabotropic'
p13308
(F1
F0.00076452599388379206
I1
I0
I1
tp13309
sS'bid,in'
p13310
(F1
F0.00076452599388379206
I1
I0
I1
tp13311
sS'furafylline,and'
p13312
(F1
F0.00076452599388379206
I1
I0
I1
tp13313
sS'categories,blood'
p13314
(F1
F0.00076452599388379206
I1
I0
I1
tp13315
sS'tablets,are'
p13316
(F1
F0.00076452599388379206
I1
I0
I1
tp13317
sS'diflucan,may'
p13318
(F1
F0.00076452599388379206
I1
I0
I1
tp13319
sS'dry,mouth'
p13320
(F1
F0.0015290519877675841
I2
I0
I2
tp13321
sS'and,pharmacokinetics'
p13322
(F1
F0.0015290519877675841
I0
I2
I-2
tp13323
sS'to,interfere'
p13324
(F1
F0.00076452599388379206
I1
I0
I1
tp13325
sS'measured,in'
p13326
(F1
F0.00076452599388379206
I0
I1
I-1
tp13327
sS'a,fold'
p13328
(F0
F0
I1
I1
I0
tp13329
sS'precocene,i'
p13330
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13331
sS'suxamethonium,chloride'
p13332
(F1
F0.00076452599388379206
I1
I0
I1
tp13333
sS'the,co-injection'
p13334
(F1
F0.00076452599388379206
I0
I1
I-1
tp13335
sS'of,respiratory'
p13336
(F1
F0.00076452599388379206
I1
I0
I1
tp13337
sS'carefully,monitor'
p13338
(F1
F0.00076452599388379206
I1
I0
I1
tp13339
sS'mexitil,theophylline'
p13340
(F1
F0.00076452599388379206
I1
I0
I1
tp13341
sS'approximately,in'
p13342
(F1
F0.00076452599388379206
I1
I0
I1
tp13343
sS'as,general'
p13344
(F1
F0.00076452599388379206
I0
I1
I-1
tp13345
sS'pharmacokinetics,were'
p13346
(F1
F0.0015290519877675841
I0
I2
I-2
tp13347
sS'and,catecholamines'
p13348
(F1
F0.00076452599388379206
I0
I1
I-1
tp13349
sS'an,overall'
p13350
(F1
F0.00076452599388379206
I1
I0
I1
tp13351
sS'hcl,and'
p13352
(F1
F0.00076452599388379206
I1
I0
I1
tp13353
sS'to,although'
p13354
(F1
F0.00076452599388379206
I0
I1
I-1
tp13355
sS'hypokalemia,may'
p13356
(F0
F0
I1
I1
I0
tp13357
sS'recommended,clinical'
p13358
(F1
F0.00076452599388379206
I0
I1
I-1
tp13359
sS'family,and'
p13360
(F1
F0.00076452599388379206
I1
I0
I1
tp13361
sS'to,its'
p13362
(F1
F0.00076452599388379206
I1
I0
I1
tp13363
sS'for,cmax'
p13364
(F1
F0.00076452599388379206
I1
I0
I1
tp13365
sS'if,indicated'
p13366
(F1
F0.00076452599388379206
I1
I0
I1
tp13367
sS'or,ischemia'
p13368
(F1
F0.00076452599388379206
I0
I1
I-1
tp13369
sS'is,associated'
p13370
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13371
sS'of,mecamylamine'
p13372
(F1
F0.00076452599388379206
I1
I0
I1
tp13373
sS'nsaids,can'
p13374
(F1
F0.00076452599388379206
I1
I0
I1
tp13375
sS'tacrolimus,short-acting'
p13376
(F1
F0.00076452599388379206
I1
I0
I1
tp13377
sS'cytotoxicity,in'
p13378
(F1
F0.0015290519877675841
I2
I0
I2
tp13379
sS'with,inducers'
p13380
(F1
F0.00076452599388379206
I1
I0
I1
tp13381
sS'the,depth'
p13382
(F1
F0.00076452599388379206
I0
I1
I-1
tp13383
sS'abt,decreased'
p13384
(F1
F0.00076452599388379206
I1
I0
I1
tp13385
sS'information,on'
p13386
(F1
F0.00076452599388379206
I0
I1
I-1
tp13387
sS'xenical,inhibited'
p13388
(F1
F0.00076452599388379206
I1
I0
I1
tp13389
sS'drugs,at'
p13390
(F1
F0.0015290519877675841
I0
I2
I-2
tp13391
sS'demonstrate,a'
p13392
(F1
F0.00076452599388379206
I1
I0
I1
tp13393
sS'study,with'
p13394
(F1
F0.0015290519877675841
I0
I2
I-2
tp13395
sS'cycling,of'
p13396
(F1
F0.00076452599388379206
I1
I0
I1
tp13397
sS'by,concurrent'
p13398
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13399
sS'simultaneous,use'
p13400
(F1
F0.00076452599388379206
I1
I0
I1
tp13401
sS'with,short'
p13402
(F1
F0.00076452599388379206
I1
I0
I1
tp13403
sS'secondary,to'
p13404
(F1
F0.00076452599388379206
I1
I0
I1
tp13405
sS'mg,twice'
p13406
(F0
F0
I1
I1
I0
tp13407
sS'and,and'
p13408
(F0
F0
I1
I1
I0
tp13409
sS'with,maxair'
p13410
(F1
F0.00076452599388379206
I1
I0
I1
tp13411
sS'warfarin,in'
p13412
(F1
F0.00076452599388379206
I0
I1
I-1
tp13413
sS'in,responsiveness'
p13414
(F1
F0.00076452599388379206
I0
I1
I-1
tp13415
sS'and,against'
p13416
(F1
F0.00076452599388379206
I0
I1
I-1
tp13417
sS'inhibitors,mao-is'
p13418
(F1
F0.00076452599388379206
I0
I1
I-1
tp13419
sS'mixture,of'
p13420
(F1
F0.00076452599388379206
I0
I1
I-1
tp13421
sS'lowering,serum'
p13422
(F1
F0.00076452599388379206
I1
I0
I1
tp13423
sS'this,is'
p13424
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13425
sS'a,period'
p13426
(F1
F0.00076452599388379206
I1
I0
I1
tp13427
sS'temperature,were'
p13428
(F1
F0.00076452599388379206
I0
I1
I-1
tp13429
sS'drugs,was'
p13430
(F1
F0.00076452599388379206
I0
I1
I-1
tp13431
sS'as,that'
p13432
(F1
F0.0015290519877675841
I0
I2
I-2
tp13433
sS'a,critical'
p13434
(F1
F0.00076452599388379206
I1
I0
I1
tp13435
sS'were,interpreted'
p13436
(F1
F0.00076452599388379206
I0
I1
I-1
tp13437
sS'increase,steady'
p13438
(F1
F0.00076452599388379206
I1
I0
I1
tp13439
sS'it,can'
p13440
(F1
F0.00076452599388379206
I1
I0
I1
tp13441
sS'may,diminish'
p13442
(F1
F0.0022935779816513763
I3
I0
I3
tp13443
sS'was,significantly'
p13444
(F0
F0
I1
I1
I0
tp13445
sS'responsiveness,to'
p13446
(F1
F0.00076452599388379206
I1
I0
I1
tp13447
sS'methods,which'
p13448
(F1
F0.00076452599388379206
I0
I1
I-1
tp13449
sS'pro-oxidant,in'
p13450
(F1
F0.00076452599388379206
I0
I1
I-1
tp13451
sS'eloxatin,dosed'
p13452
(F1
F0.00076452599388379206
I1
I0
I1
tp13453
sS'preliminary,data'
p13454
(F1
F0.00076452599388379206
I1
I0
I1
tp13455
sS'the,cationic'
p13456
(F1
F0.0015290519877675841
I2
I0
I2
tp13457
sS'metabolite,levels'
p13458
(F1
F0.00076452599388379206
I1
I0
I1
tp13459
sS'of,at'
p13460
(F1
F0.0015290519877675841
I2
I0
I2
tp13461
sS'of,as'
p13462
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13463
sS'appear,to'
p13464
(F1
F0.00076452599388379206
I1
I0
I1
tp13465
sS'discontinuation,of'
p13466
(F1
F0.00076452599388379206
I1
I0
I1
tp13467
sS'of,an'
p13468
(F0
F0
I3
I3
I0
tp13469
sS'mexitil,has'
p13470
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13471
sS'on,an'
p13472
(F0
F0
I1
I1
I0
tp13473
sS'vumon,injection'
p13474
(F1
F0.00076452599388379206
I0
I1
I-1
tp13475
sS'metabolites,possibly'
p13476
(F1
F0.00076452599388379206
I1
I0
I1
tp13477
sS'curariform,drugs'
p13478
(F1
F0.00076452599388379206
I1
I0
I1
tp13479
sS'including,some'
p13480
(F1
F0.00076452599388379206
I1
I0
I1
tp13481
sS'of,resulting'
p13482
(F1
F0.00076452599388379206
I1
I0
I1
tp13483
sS'if,pergolide'
p13484
(F1
F0.00076452599388379206
I0
I1
I-1
tp13485
sS'daily,dosed'
p13486
(F1
F0.0015290519877675841
I0
I2
I-2
tp13487
sS'study,mean'
p13488
(F1
F0.00076452599388379206
I1
I0
I1
tp13489
sS'other,medications'
p13490
(F1
F0.00076452599388379206
I1
I0
I1
tp13491
sS'bactericidal,effect'
p13492
(F1
F0.00076452599388379206
I1
I0
I1
tp13493
sS'other,drugs'
p13494
(F0.047619047619047616
F0.00076452599388379206
I10
I11
I-1
tp13495
sS'from,should'
p13496
(F1
F0.00076452599388379206
I1
I0
I1
tp13497
sS'blocking,effect'
p13498
(F1
F0.00076452599388379206
I1
I0
I1
tp13499
sS'less,likely'
p13500
(F1
F0.00076452599388379206
I0
I1
I-1
tp13501
sS'prescribed,for'
p13502
(F1
F0.00076452599388379206
I0
I1
I-1
tp13503
sS'hey,xenograft-bearing'
p13504
(F1
F0.00076452599388379206
I1
I0
I1
tp13505
sS'myfortic,not'
p13506
(F1
F0.00076452599388379206
I1
I0
I1
tp13507
sS'vitamin,b1'
p13508
(F1
F0.00076452599388379206
I1
I0
I1
tp13509
sS'or,placebo'
p13510
(F1
F0.00076452599388379206
I0
I1
I-1
tp13511
sS'for,vitamin'
p13512
(F1
F0.0015290519877675841
I2
I0
I2
tp13513
sS'avoided,except'
p13514
(F1
F0.00076452599388379206
I0
I1
I-1
tp13515
sS'of,cyp'
p13516
(F1
F0.00076452599388379206
I0
I1
I-1
tp13517
sS'because,patients'
p13518
(F1
F0.00076452599388379206
I1
I0
I1
tp13519
sS'application,of'
p13520
(F0
F0
I1
I1
I0
tp13521
sS'and,prothrombin'
p13522
(F1
F0.00076452599388379206
I1
I0
I1
tp13523
sS'ai,vaccines'
p13524
(F1
F0.00076452599388379206
I1
I0
I1
tp13525
sS'and,ipth'
p13526
(F1
F0.00076452599388379206
I1
I0
I1
tp13527
sS'human,immediately'
p13528
(F1
F0.00076452599388379206
I1
I0
I1
tp13529
sS'with,proamatine'
p13530
(F1
F0.00076452599388379206
I1
I0
I1
tp13531
sS'verified,for'
p13532
(F1
F0.00076452599388379206
I0
I1
I-1
tp13533
sS'curve,extrapolated'
p13534
(F1
F0.00076452599388379206
I1
I0
I1
tp13535
sS'prolongation,with'
p13536
(F1
F0.00076452599388379206
I0
I1
I-1
tp13537
sS'fold,higher'
p13538
(F1
F0.00076452599388379206
I1
I0
I1
tp13539
sS'whereas,none'
p13540
(F1
F0.00076452599388379206
I1
I0
I1
tp13541
sS'and,rabbits'
p13542
(F1
F0.00076452599388379206
I0
I1
I-1
tp13543
sS'when,hyperthyroid'
p13544
(F1
F0.0015290519877675841
I0
I2
I-2
tp13545
sS'model,is'
p13546
(F1
F0.00076452599388379206
I1
I0
I1
tp13547
sS'significant,effect'
p13548
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13549
sS'in,matched'
p13550
(F1
F0.00076452599388379206
I1
I0
I1
tp13551
sS'with,erythema'
p13552
(F1
F0.00076452599388379206
I1
I0
I1
tp13553
sS'controlled,studies'
p13554
(F1
F0.00076452599388379206
I0
I1
I-1
tp13555
sS'with,failed'
p13556
(F1
F0.00076452599388379206
I0
I1
I-1
tp13557
sS'precipitated,by'
p13558
(F1
F0.00076452599388379206
I1
I0
I1
tp13559
sS'usp,because'
p13560
(F1
F0.00076452599388379206
I1
I0
I1
tp13561
sS'salicylates,and'
p13562
(F1
F0.00076452599388379206
I1
I0
I1
tp13563
sS'cm3,confidence'
p13564
(F1
F0.00076452599388379206
I1
I0
I1
tp13565
sS'combined,use'
p13566
(F1
F0.0015290519877675841
I2
I0
I2
tp13567
sS'preclinical,combination'
p13568
(F1
F0.00076452599388379206
I1
I0
I1
tp13569
sS'vivo,hepatic'
p13570
(F1
F0.00076452599388379206
I0
I1
I-1
tp13571
sS'of,qrs'
p13572
(F1
F0.00076452599388379206
I0
I1
I-1
tp13573
sS'accentuate,the'
p13574
(F1
F0.00076452599388379206
I1
I0
I1
tp13575
sS'a,limited'
p13576
(F1
F0.00076452599388379206
I0
I1
I-1
tp13577
sS'schedules,and'
p13578
(F1
F0.00076452599388379206
I1
I0
I1
tp13579
sS'electrocardiographic,parameters'
p13580
(F1
F0.00076452599388379206
I0
I1
I-1
tp13581
sS'wine,yogurt'
p13582
(F1
F0.00076452599388379206
I1
I0
I1
tp13583
sS'estradiol,and'
p13584
(F0
F0
I1
I1
I0
tp13585
sS'in,immunocompromised'
p13586
(F1
F0.00076452599388379206
I1
I0
I1
tp13587
sS'in,their'
p13588
(F1
F0.00076452599388379206
I1
I0
I1
tp13589
sS'administered,until'
p13590
(F1
F0.00076452599388379206
I0
I1
I-1
tp13591
sS'monitored,for'
p13592
(F1
F0.0022935779816513763
I3
I0
I3
tp13593
sS'eg,esters'
p13594
(F1
F0.00076452599388379206
I1
I0
I1
tp13595
sS'concentration-time,curve'
p13596
(F1
F0.00076452599388379206
I1
I0
I1
tp13597
sS'significantly,alter'
p13598
(F1
F0.00076452599388379206
I0
I1
I-1
tp13599
sS'although,mg'
p13600
(F1
F0.00076452599388379206
I1
I0
I1
tp13601
sS'although,there'
p13602
(F1
F0.00076452599388379206
I1
I0
I1
tp13603
sS'be,interrupted'
p13604
(F1
F0.00076452599388379206
I1
I0
I1
tp13605
sS'organic,bases'
p13606
(F1
F0.00076452599388379206
I1
I0
I1
tp13607
sS'was,necessary'
p13608
(F1
F0.00076452599388379206
I0
I1
I-1
tp13609
sS'significantly,lower'
p13610
(F1
F0.0022935779816513763
I0
I3
I-3
tp13611
sS'with,ganglionic'
p13612
(F1
F0.00076452599388379206
I0
I1
I-1
tp13613
sS'a,decrease'
p13614
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp13615
sS'studied,on'
p13616
(F0
F0
I1
I1
I0
tp13617
sS'in,doses'
p13618
(F1
F0.00076452599388379206
I1
I0
I1
tp13619
sS'high-dose,intravenous'
p13620
(F1
F0.0015290519877675841
I2
I0
I2
tp13621
sS'lines,and'
p13622
(F1
F0.0015290519877675841
I0
I2
I-2
tp13623
sS'inhibited,growth'
p13624
(F1
F0.00076452599388379206
I1
I0
I1
tp13625
sS'taking,beta'
p13626
(F1
F0.00076452599388379206
I1
I0
I1
tp13627
sS'weekly,for'
p13628
(F1
F0.00076452599388379206
I1
I0
I1
tp13629
sS'receiving,or'
p13630
(F1
F0.0030581039755351682
I4
I0
I4
tp13631
sS'of,cyp3a4'
p13632
(F1
F0.0030581039755351682
I4
I0
I4
tp13633
sS'and,nondepolarizing'
p13634
(F1
F0.00076452599388379206
I0
I1
I-1
tp13635
sS'hormone,treatment'
p13636
(F1
F0.00076452599388379206
I0
I1
I-1
tp13637
sS'maoi,such'
p13638
(F1
F0.00076452599388379206
I1
I0
I1
tp13639
sS'with,either'
p13640
(F0.5
F0.0015290519877675841
I3
I1
I2
tp13641
sS'this,activity'
p13642
(F1
F0.00076452599388379206
I1
I0
I1
tp13643
sS'of,zemplar'
p13644
(F1
F0.00076452599388379206
I1
I0
I1
tp13645
sS'same,regimen'
p13646
(F1
F0.00076452599388379206
I1
I0
I1
tp13647
sS'mice,co-administration'
p13648
(F1
F0.00076452599388379206
I1
I0
I1
tp13649
sS'aav2-mediated,retinal'
p13650
(F1
F0.00076452599388379206
I1
I0
I1
tp13651
sS'in,post-marketing'
p13652
(F1
F0.00076452599388379206
I1
I0
I1
tp13653
sS'may,affect'
p13654
(F1
F0.0022935779816513763
I3
I0
I3
tp13655
sS'associated,gastrointestinal'
p13656
(F1
F0.00076452599388379206
I0
I1
I-1
tp13657
sS'arthritis,patients'
p13658
(F1
F0.0015290519877675841
I0
I2
I-2
tp13659
sS'concomitant,tolectin'
p13660
(F1
F0.00076452599388379206
I1
I0
I1
tp13661
sS'interaction,of'
p13662
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp13663
sS'to,healthy'
p13664
(F1
F0.00076452599388379206
I1
I0
I1
tp13665
sS'nsaids,with'
p13666
(F1
F0.0015290519877675841
I2
I0
I2
tp13667
sS'plasma,clearance'
p13668
(F1
F0.00076452599388379206
I1
I0
I1
tp13669
sS'gemfibrozil,in'
p13670
(F1
F0.00076452599388379206
I0
I1
I-1
tp13671
sS'group,mg'
p13672
(F1
F0.00076452599388379206
I0
I1
I-1
tp13673
sS'sedative,effect'
p13674
(F1
F0.00076452599388379206
I1
I0
I1
tp13675
sS'a,large'
p13676
(F1
F0.00076452599388379206
I0
I1
I-1
tp13677
sS'be,more'
p13678
(F1
F0.00076452599388379206
I1
I0
I1
tp13679
sS'days,with'
p13680
(F1
F0.0015290519877675841
I2
I0
I2
tp13681
sS'aggrastat,has'
p13682
(F1
F0.00076452599388379206
I0
I1
I-1
tp13683
sS'on,plasma'
p13684
(F1
F0.0030581039755351682
I4
I0
I4
tp13685
sS'sensitivity,was'
p13686
(F1
F0.00076452599388379206
I0
I1
I-1
tp13687
sS'with,concomitant'
p13688
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp13689
sS'interaction,studies'
p13690
(F0.55555555555555558
F0.0038226299694189602
I2
I7
I-5
tp13691
sS'after,discontinuation'
p13692
(F1
F0.00076452599388379206
I1
I0
I1
tp13693
sS'together,with'
p13694
(F1
F0.00076452599388379206
I1
I0
I1
tp13695
sS'a,number'
p13696
(F1
F0.00076452599388379206
I1
I0
I1
tp13697
sS'inhibitors,a'
p13698
(F1
F0.00076452599388379206
I1
I0
I1
tp13699
sS'to,or'
p13700
(F0.5
F0.0015290519877675841
I3
I1
I2
tp13701
sS'alkaloid,drugs'
p13702
(F1
F0.00076452599388379206
I0
I1
I-1
tp13703
sS'other,local'
p13704
(F1
F0.00076452599388379206
I1
I0
I1
tp13705
sS'changing,mobic'
p13706
(F1
F0.00076452599388379206
I1
I0
I1
tp13707
sS'to,of'
p13708
(F1
F0.00076452599388379206
I0
I1
I-1
tp13709
sS'bcl-2,and'
p13710
(F0.5
F0.0015290519877675841
I3
I1
I2
tp13711
sS'higher,dose'
p13712
(F1
F0.00076452599388379206
I1
I0
I1
tp13713
sS'with,implanon'
p13714
(F1
F0.00076452599388379206
I1
I0
I1
tp13715
sS'added,to'
p13716
(F1
F0.00076452599388379206
I1
I0
I1
tp13717
sS'the,experiments'
p13718
(F1
F0.00076452599388379206
I0
I1
I-1
tp13719
sS'cyp,d6'
p13720
(F1
F0.00076452599388379206
I1
I0
I1
tp13721
sS'min,before'
p13722
(F1
F0.00076452599388379206
I0
I1
I-1
tp13723
sS'trental,with'
p13724
(F1
F0.00076452599388379206
I1
I0
I1
tp13725
sS'mycophenolate,mofetil'
p13726
(F0
F0
I1
I1
I0
tp13727
sS'especially,true'
p13728
(F1
F0.00076452599388379206
I0
I1
I-1
tp13729
sS'interactions,drugs'
p13730
(F1
F0.00076452599388379206
I0
I1
I-1
tp13731
sS'and,did'
p13732
(F1
F0.0022935779816513763
I0
I3
I-3
tp13733
sS'in,nsclc'
p13734
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13735
sS'live,vaccines'
p13736
(F1
F0.00076452599388379206
I1
I0
I1
tp13737
sS'of,adeno-associated'
p13738
(F1
F0.00076452599388379206
I0
I1
I-1
tp13739
sS'substitute,for'
p13740
(F1
F0.00076452599388379206
I0
I1
I-1
tp13741
sS'a,substitute'
p13742
(F1
F0.00076452599388379206
I0
I1
I-1
tp13743
sS'days,xenical'
p13744
(F1
F0.0030581039755351682
I0
I4
I-4
tp13745
sS'cause,weakness'
p13746
(F1
F0.00076452599388379206
I1
I0
I1
tp13747
sS'and,temperature'
p13748
(F1
F0.00076452599388379206
I0
I1
I-1
tp13749
sS'steroid,medications'
p13750
(F1
F0.00076452599388379206
I1
I0
I1
tp13751
sS'addition,of'
p13752
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp13753
sS'hepatic,cyp3a'
p13754
(F1
F0.00076452599388379206
I1
I0
I1
tp13755
sS'healthy,subjects'
p13756
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13757
sS'or,without'
p13758
(F0
F0
I1
I1
I0
tp13759
sS'of,anti-parkinsonian'
p13760
(F1
F0.00076452599388379206
I0
I1
I-1
tp13761
sS'demser,with'
p13762
(F1
F0.00076452599388379206
I1
I0
I1
tp13763
sS'the,liver'
p13764
(F1
F0.0015290519877675841
I2
I0
I2
tp13765
sS'receiving,daily'
p13766
(F1
F0.00076452599388379206
I0
I1
I-1
tp13767
sS'single,or'
p13768
(F1
F0.00076452599388379206
I1
I0
I1
tp13769
sS'whether,hb-egf'
p13770
(F1
F0.00076452599388379206
I0
I1
I-1
tp13771
sS'the,binding'
p13772
(F1
F0.00076452599388379206
I0
I1
I-1
tp13773
sS'probably,other'
p13774
(F1
F0.00076452599388379206
I1
I0
I1
tp13775
sS'administered,antiepileptic'
p13776
(F1
F0.00076452599388379206
I1
I0
I1
tp13777
sS'doubled,auc0-'
p13778
(F1
F0.00076452599388379206
I1
I0
I1
tp13779
sS'vitro,binding'
p13780
(F1
F0.00076452599388379206
I0
I1
I-1
tp13781
sS'significant,inhibitory'
p13782
(F1
F0.00076452599388379206
I0
I1
I-1
tp13783
sS'an,orally'
p13784
(F1
F0.00076452599388379206
I0
I1
I-1
tp13785
sS'significant,inhibitors'
p13786
(F1
F0.00076452599388379206
I1
I0
I1
tp13787
sS'clearance,may'
p13788
(F1
F0.00076452599388379206
I0
I1
I-1
tp13789
sS'auc,values'
p13790
(F0
F0
I1
I1
I0
tp13791
sS'clinical,drug-drug'
p13792
(F1
F0.00076452599388379206
I0
I1
I-1
tp13793
sS'should,interrupt'
p13794
(F1
F0.00076452599388379206
I1
I0
I1
tp13795
sS'receiving,cylert'
p13796
(F1
F0.00076452599388379206
I1
I0
I1
tp13797
sS'glycosides,diuretic-induced'
p13798
(F1
F0.00076452599388379206
I1
I0
I1
tp13799
sS'xenical,mg'
p13800
(F1
F0.0045871559633027525
I0
I6
I-6
tp13801
sS'mycamine,should'
p13802
(F1
F0.00076452599388379206
I1
I0
I1
tp13803
sS'clearance,significantly'
p13804
(F1
F0.00076452599388379206
I1
I0
I1
tp13805
sS'myfortic,was'
p13806
(F1
F0.00076452599388379206
I1
I0
I1
tp13807
sS'rifampin,enhances'
p13808
(F1
F0.00076452599388379206
I1
I0
I1
tp13809
sS'approximately,have'
p13810
(F1
F0.00076452599388379206
I1
I0
I1
tp13811
sS'influence,locomotion'
p13812
(F1
F0.00076452599388379206
I1
I0
I1
tp13813
sS'close,medical'
p13814
(F1
F0.00076452599388379206
I1
I0
I1
tp13815
sS'midbrain,dopaminergic'
p13816
(F1
F0.00076452599388379206
I1
I0
I1
tp13817
sS'also,tubularly'
p13818
(F1
F0.00076452599388379206
I1
I0
I1
tp13819
sS'igf-i,suppression'
p13820
(F1
F0.00076452599388379206
I1
I0
I1
tp13821
sS'nephrotoxicity,agents'
p13822
(F1
F0.0015290519877675841
I0
I2
I-2
tp13823
sS'a,suitable'
p13824
(F1
F0.00076452599388379206
I0
I1
I-1
tp13825
sS'c9,cl9'
p13826
(F1
F0.00076452599388379206
I0
I1
I-1
tp13827
sS'the,susceptibility'
p13828
(F1
F0.00076452599388379206
I0
I1
I-1
tp13829
sS'panobinostat-related,adverse'
p13830
(F1
F0.00076452599388379206
I0
I1
I-1
tp13831
sS'eg,and'
p13832
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13833
sS'highly,specific'
p13834
(F1
F0.00076452599388379206
I0
I1
I-1
tp13835
sS'oral,agents'
p13836
(F1
F0.00076452599388379206
I1
I0
I1
tp13837
sS'and,concomitantly'
p13838
(F1
F0.0030581039755351682
I4
I0
I4
tp13839
sS'assessed,using'
p13840
(F1
F0.00076452599388379206
I0
I1
I-1
tp13841
sS'were,resistant'
p13842
(F1
F0.00076452599388379206
I0
I1
I-1
tp13843
sS'of,parkinsonian'
p13844
(F1
F0.00076452599388379206
I0
I1
I-1
tp13845
sS'receiving,mao-a'
p13846
(F1
F0.00076452599388379206
I1
I0
I1
tp13847
sS'doses,less'
p13848
(F1
F0.00076452599388379206
I0
I1
I-1
tp13849
sS'rate,compared'
p13850
(F1
F0.00076452599388379206
I1
I0
I1
tp13851
sS'alterations,in'
p13852
(F1
F0.00076452599388379206
I0
I1
I-1
tp13853
sS'potent,cyp3a4'
p13854
(F1
F0.00076452599388379206
I1
I0
I1
tp13855
sS'induce,hepatic'
p13856
(F1
F0.0015290519877675841
I2
I0
I2
tp13857
sS'for,patients'
p13858
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp13859
sS'digoxin,a'
p13860
(F1
F0.00076452599388379206
I1
I0
I1
tp13861
sS'addition,to'
p13862
(F0
F0
I1
I1
I0
tp13863
sS'the,tpmt'
p13864
(F1
F0.00076452599388379206
I1
I0
I1
tp13865
sS'fatality,has'
p13866
(F1
F0.00076452599388379206
I1
I0
I1
tp13867
sS'strains,were'
p13868
(F1
F0.00076452599388379206
I0
I1
I-1
tp13869
sS'selective,and'
p13870
(F1
F0.0015290519877675841
I2
I0
I2
tp13871
sS'vitro,and'
p13872
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp13873
sS'molecular,basis'
p13874
(F1
F0.00076452599388379206
I1
I0
I1
tp13875
sS'and,were'
p13876
(F0.42857142857142855
F0.0022935779816513763
I2
I5
I-3
tp13877
sS'considered,when'
p13878
(F0
F0
I1
I1
I0
tp13879
sS'and,elevated'
p13880
(F1
F0.0015290519877675841
I2
I0
I2
tp13881
sS'the,recommended'
p13882
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13883
sS'co,administration'
p13884
(F1
F0.00076452599388379206
I1
I0
I1
tp13885
sS'diminished,effects'
p13886
(F1
F0.0015290519877675841
I2
I0
I2
tp13887
sS'whether,initiation'
p13888
(F1
F0.00076452599388379206
I0
I1
I-1
tp13889
sS'dose,of'
p13890
(F0.20000000000000001
F0.0030581039755351682
I12
I8
I4
tp13891
sS'administration,increased'
p13892
(F0
F0
I1
I1
I0
tp13893
sS'no,clinical'
p13894
(F1
F0.00076452599388379206
I0
I1
I-1
tp13895
sS'sedating,drugs'
p13896
(F1
F0.00076452599388379206
I1
I0
I1
tp13897
sS'pronounced,following'
p13898
(F1
F0.00076452599388379206
I1
I0
I1
tp13899
sS'risk,in'
p13900
(F1
F0.00076452599388379206
I0
I1
I-1
tp13901
sS'and,should'
p13902
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp13903
sS'patients,receiving'
p13904
(F0.72222222222222221
F0.019877675840978593
I31
I5
I26
tp13905
sS'these,changes'
p13906
(F1
F0.00076452599388379206
I1
I0
I1
tp13907
sS'sympathomimetic,drugs'
p13908
(F1
F0.00076452599388379206
I1
I0
I1
tp13909
sS'following,topical'
p13910
(F1
F0.0015290519877675841
I0
I2
I-2
tp13911
sS'general,anesthetics'
p13912
(F1
F0.00076452599388379206
I1
I0
I1
tp13913
sS'combined,administration'
p13914
(F1
F0.00076452599388379206
I1
I0
I1
tp13915
sS'been,the'
p13916
(F1
F0.0015290519877675841
I0
I2
I-2
tp13917
sS'greatly,enhanced'
p13918
(F1
F0.00076452599388379206
I0
I1
I-1
tp13919
sS'on,induced'
p13920
(F1
F0.00076452599388379206
I0
I1
I-1
tp13921
sS'other,loop'
p13922
(F1
F0.00076452599388379206
I1
I0
I1
tp13923
sS'inr,were'
p13924
(F1
F0.00076452599388379206
I1
I0
I1
tp13925
sS'congenital,hypothyroidism'
p13926
(F1
F0.00076452599388379206
I1
I0
I1
tp13927
sS'acetic,acid'
p13928
(F1
F0.00076452599388379206
I1
I0
I1
tp13929
sS'of,angiotensin-converting'
p13930
(F1
F0.00076452599388379206
I1
I0
I1
tp13931
sS'minimize,cns'
p13932
(F1
F0.00076452599388379206
I0
I1
I-1
tp13933
sS'mg,dose'
p13934
(F1
F0.00076452599388379206
I1
I0
I1
tp13935
sS'volunteer,subjects'
p13936
(F1
F0.00076452599388379206
I0
I1
I-1
tp13937
sS'mivacron,are'
p13938
(F1
F0.00076452599388379206
I1
I0
I1
tp13939
sS'be,necessary'
p13940
(F1
F0.0022935779816513763
I3
I0
I3
tp13941
sS'anticholinesterase,poisoning'
p13942
(F1
F0.00076452599388379206
I1
I0
I1
tp13943
sS'the,incidence'
p13944
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp13945
sS'including,torsade'
p13946
(F1
F0.00076452599388379206
I1
I0
I1
tp13947
sS'to,pharmacokinetic'
p13948
(F1
F0.0015290519877675841
I0
I2
I-2
tp13949
sS'employ,appropriate'
p13950
(F1
F0.0015290519877675841
I2
I0
I2
tp13951
sS'that,produce'
p13952
(F1
F0.00076452599388379206
I1
I0
I1
tp13953
sS'the,immune'
p13954
(F1
F0.00076452599388379206
I0
I1
I-1
tp13955
sS'of,or'
p13956
(F0.20000000000000001
F0.0015290519877675841
I4
I6
I-2
tp13957
sS'ergot,alkaloid'
p13958
(F1
F0.00076452599388379206
I0
I1
I-1
tp13959
sS'of,on'
p13960
(F0.45454545454545453
F0.0038226299694189602
I3
I8
I-5
tp13961
sS'a,higher'
p13962
(F1
F0.00076452599388379206
I1
I0
I1
tp13963
sS'to,both'
p13964
(F1
F0.00076452599388379206
I0
I1
I-1
tp13965
sS'study,aimed'
p13966
(F1
F0.00076452599388379206
I0
I1
I-1
tp13967
sS'has,caused'
p13968
(F1
F0.00076452599388379206
I1
I0
I1
tp13969
sS'of,zetia'
p13970
(F1
F0.00076452599388379206
I1
I0
I1
tp13971
sS'cycle,apoptosis'
p13972
(F1
F0.00076452599388379206
I0
I1
I-1
tp13973
sS'of,toxicity'
p13974
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp13975
sS'bleeding,hematuria'
p13976
(F1
F0.00076452599388379206
I1
I0
I1
tp13977
sS'with,respect'
p13978
(F1
F0.0015290519877675841
I0
I2
I-2
tp13979
sS'rare,reports'
p13980
(F1
F0.00076452599388379206
I0
I1
I-1
tp13981
sS'drugs,care'
p13982
(F1
F0.00076452599388379206
I1
I0
I1
tp13983
sS'no,supporting'
p13984
(F1
F0.00076452599388379206
I1
I0
I1
tp13985
sS'proof,opioid'
p13986
(F1
F0.00076452599388379206
I1
I0
I1
tp13987
sS'given,concurrently'
p13988
(F1
F0.0015290519877675841
I2
I0
I2
tp13989
sS'improved,control'
p13990
(F1
F0.00076452599388379206
I0
I1
I-1
tp13991
sS'with,calcium-channel'
p13992
(F1
F0.00076452599388379206
I0
I1
I-1
tp13993
sS'abt,and'
p13994
(F1
F0.00076452599388379206
I0
I1
I-1
tp13995
sS'be,discontinued'
p13996
(F1
F0.00076452599388379206
I1
I0
I1
tp13997
sS'poor,metabolizers'
p13998
(F0
F0
I1
I1
I0
tp13999
sS'estradiol-,and'
p14000
(F1
F0.00076452599388379206
I1
I0
I1
tp14001
sS'were,approximately'
p14002
(F1
F0.00076452599388379206
I1
I0
I1
tp14003
sS'motor,symptoms'
p14004
(F1
F0.00076452599388379206
I0
I1
I-1
tp14005
sS'for,these'
p14006
(F1
F0.00076452599388379206
I0
I1
I-1
tp14007
sS'be,affected'
p14008
(F1
F0.00076452599388379206
I0
I1
I-1
tp14009
sS'combination,n'
p14010
(F1
F0.00076452599388379206
I0
I1
I-1
tp14011
sS'cp450,liver'
p14012
(F1
F0.00076452599388379206
I1
I0
I1
tp14013
sS'warrant,dosage'
p14014
(F1
F0.00076452599388379206
I0
I1
I-1
tp14015
sS'with,permax'
p14016
(F1
F0.00076452599388379206
I1
I0
I1
tp14017
sS'international,normalized'
p14018
(F0
F0
I1
I1
I0
tp14019
sS'performance,were'
p14020
(F1
F0.00076452599388379206
I0
I1
I-1
tp14021
sS'dosage,may'
p14022
(F1
F0.00076452599388379206
I1
I0
I1
tp14023
sS'the,vascular'
p14024
(F1
F0.00076452599388379206
I1
I0
I1
tp14025
sS'significant,decrease'
p14026
(F1
F0.00076452599388379206
I1
I0
I1
tp14027
sS'mg,had'
p14028
(F1
F0.00076452599388379206
I1
I0
I1
tp14029
sS'has,shown'
p14030
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp14031
sS'of,hiv-protease'
p14032
(F1
F0.00076452599388379206
I0
I1
I-1
tp14033
sS'reductase,inhibitor'
p14034
(F1
F0.00076452599388379206
I0
I1
I-1
tp14035
sS'the,different'
p14036
(F1
F0.00076452599388379206
I0
I1
I-1
tp14037
sS'including,general'
p14038
(F1
F0.00076452599388379206
I0
I1
I-1
tp14039
sS'components,because'
p14040
(F1
F0.00076452599388379206
I1
I0
I1
tp14041
sS'in,pk'
p14042
(F1
F0.00076452599388379206
I0
I1
I-1
tp14043
sS'with,can'
p14044
(F1
F0.0022935779816513763
I3
I0
I3
tp14045
sS'effect-time,curves'
p14046
(F1
F0.00076452599388379206
I0
I1
I-1
tp14047
sS'these,behavioural'
p14048
(F1
F0.00076452599388379206
I1
I0
I1
tp14049
sS'the,bactericidal'
p14050
(F1
F0.0022935779816513763
I3
I0
I3
tp14051
sS'was,not'
p14052
(F1
F0.0015290519877675841
I0
I2
I-2
tp14053
sS'hypotension,its'
p14054
(F1
F0.00076452599388379206
I1
I0
I1
tp14055
sS'receiving,certain'
p14056
(F1
F0.00076452599388379206
I0
I1
I-1
tp14057
sS'vaccinations,may'
p14058
(F1
F0.00076452599388379206
I1
I0
I1
tp14059
sS'status,was'
p14060
(F1
F0.00076452599388379206
I0
I1
I-1
tp14061
sS'activity,chronically'
p14062
(F1
F0.00076452599388379206
I1
I0
I1
tp14063
sS'by,the'
p14064
(F0.46666666666666667
F0.0053516819571865441
I11
I4
I7
tp14065
sS'have,been'
p14066
(F0.41935483870967744
F0.0099388379204892966
I22
I9
I13
tp14067
sS'serum,and'
p14068
(F1
F0.0015290519877675841
I0
I2
I-2
tp14069
sS'be,closely'
p14070
(F1
F0.0015290519877675841
I2
I0
I2
tp14071
sS'acetaminophen,rimantadine'
p14072
(F1
F0.00076452599388379206
I0
I1
I-1
tp14073
sS'concentrations,should'
p14074
(F1
F0.0015290519877675841
I2
I0
I2
tp14075
sS'was,comparable'
p14076
(F1
F0.00076452599388379206
I0
I1
I-1
tp14077
sS'effects,the'
p14078
(F1
F0.00076452599388379206
I1
I0
I1
tp14079
sS'response,to'
p14080
(F1
F0.0030581039755351682
I4
I0
I4
tp14081
sS'coumarin-type,anticoagulants'
p14082
(F1
F0.0022935779816513763
I3
I0
I3
tp14083
sS'medications,like'
p14084
(F1
F0.00076452599388379206
I1
I0
I1
tp14085
sS'pressure,has'
p14086
(F1
F0.00076452599388379206
I1
I0
I1
tp14087
sS'blockers,and'
p14088
(F1
F0.00076452599388379206
I0
I1
I-1
tp14089
sS'digitalis,glycosides'
p14090
(F0
F0
I1
I1
I0
tp14091
sS'of,myfortic'
p14092
(F0
F0
I1
I1
I0
tp14093
sS'experimental,evidence'
p14094
(F1
F0.00076452599388379206
I1
I0
I1
tp14095
sS'acetate,supplement'
p14096
(F1
F0.00076452599388379206
I1
I0
I1
tp14097
sS'pills,medicines'
p14098
(F1
F0.00076452599388379206
I0
I1
I-1
tp14099
sS'less,than'
p14100
(F1
F0.00076452599388379206
I0
I1
I-1
tp14101
sS'if,at'
p14102
(F1
F0.0015290519877675841
I2
I0
I2
tp14103
sS'clearance,were'
p14104
(F1
F0.00076452599388379206
I1
I0
I1
tp14105
sS'all,in'
p14106
(F1
F0.00076452599388379206
I1
I0
I1
tp14107
sS'if,concomitant'
p14108
(F1
F0.00076452599388379206
I1
I0
I1
tp14109
sS'study,concomitant'
p14110
(F0
F0
I1
I1
I0
tp14111
sS'with,compounds'
p14112
(F1
F0.00076452599388379206
I1
I0
I1
tp14113
sS'with,mild'
p14114
(F1
F0.0015290519877675841
I2
I0
I2
tp14115
sS'receiving,mg'
p14116
(F1
F0.00076452599388379206
I0
I1
I-1
tp14117
sS'in,an'
p14118
(F1
F0.0045871559633027525
I6
I0
I6
tp14119
sS'until,use'
p14120
(F1
F0.00076452599388379206
I1
I0
I1
tp14121
sS'absorbent-type,anti-diarrhea'
p14122
(F1
F0.00076452599388379206
I1
I0
I1
tp14123
sS'mean,auc'
p14124
(F1
F0.0022935779816513763
I3
I0
I3
tp14125
sS'are,incompatible'
p14126
(F1
F0.00076452599388379206
I1
I0
I1
tp14127
sS'individuals,nalidixic'
p14128
(F1
F0.00076452599388379206
I1
I0
I1
tp14129
sS'the,other'
p14130
(F1
F0.00076452599388379206
I0
I1
I-1
tp14131
sS'with,female'
p14132
(F1
F0.00076452599388379206
I0
I1
I-1
tp14133
sS'in,at'
p14134
(F1
F0.00076452599388379206
I0
I1
I-1
tp14135
sS'package,labeling'
p14136
(F1
F0.00076452599388379206
I0
I1
I-1
tp14137
sS'total,level'
p14138
(F1
F0.00076452599388379206
I1
I0
I1
tp14139
sS'on,concomitant'
p14140
(F1
F0.00076452599388379206
I1
I0
I1
tp14141
sS'is,that'
p14142
(F1
F0.00076452599388379206
I1
I0
I1
tp14143
sS'and,do'
p14144
(F1
F0.00076452599388379206
I0
I1
I-1
tp14145
sS'more,pronounced'
p14146
(F1
F0.00076452599388379206
I1
I0
I1
tp14147
sS'diminution,is'
p14148
(F1
F0.00076452599388379206
I1
I0
I1
tp14149
sS'which,is'
p14150
(F1
F0.00076452599388379206
I1
I0
I1
tp14151
sS'metopirone,inhibits'
p14152
(F1
F0.00076452599388379206
I1
I0
I1
tp14153
sS'clinically,warranted'
p14154
(F1
F0.00076452599388379206
I1
I0
I1
tp14155
sS'test,when'
p14156
(F1
F0.00076452599388379206
I1
I0
I1
tp14157
sS'levels,of'
p14158
(F1
F0.0076452599388379203
I10
I0
I10
tp14159
sS'when,administering'
p14160
(F1
F0.0061162079510703364
I8
I0
I8
tp14161
sS'levels,or'
p14162
(F1
F0.0015290519877675841
I2
I0
I2
tp14163
sS'mind,when'
p14164
(F1
F0.00076452599388379206
I0
I1
I-1
tp14165
sS'approximately,half'
p14166
(F1
F0.00076452599388379206
I1
I0
I1
tp14167
sS'corticosteroids,may'
p14168
(F1
F0.00076452599388379206
I1
I0
I1
tp14169
sS'mouse,leukemia'
p14170
(F1
F0.00076452599388379206
I1
I0
I1
tp14171
sS'to,decreased'
p14172
(F1
F0.0015290519877675841
I2
I0
I2
tp14173
sS'the,dose-dependent'
p14174
(F1
F0.00076452599388379206
I1
I0
I1
tp14175
sS'a,mg'
p14176
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp14177
sS'before,initiation'
p14178
(F1
F0.00076452599388379206
I0
I1
I-1
tp14179
sS'substrates,for'
p14180
(F1
F0.00076452599388379206
I0
I1
I-1
tp14181
sS'tears,conjugated'
p14182
(F1
F0.00076452599388379206
I0
I1
I-1
tp14183
sS'sequestrates,or'
p14184
(F1
F0.00076452599388379206
I1
I0
I1
tp14185
sS'control,by'
p14186
(F1
F0.00076452599388379206
I0
I1
I-1
tp14187
sS'including,torsades'
p14188
(F1
F0.00076452599388379206
I0
I1
I-1
tp14189
sS'metrogel,gel'
p14190
(F1
F0.00076452599388379206
I0
I1
I-1
tp14191
sS'may,inhibit'
p14192
(F1
F0.0053516819571865441
I7
I0
I7
tp14193
sS'most,serious'
p14194
(F1
F0.00076452599388379206
I1
I0
I1
tp14195
sS'qt,prolonging'
p14196
(F1
F0.00076452599388379206
I0
I1
I-1
tp14197
sS'the,sensitivity'
p14198
(F0
F0
I1
I1
I0
tp14199
sS'a,result'
p14200
(F1
F0.0015290519877675841
I2
I0
I2
tp14201
sS'saponins,gsls'
p14202
(F1
F0.00076452599388379206
I0
I1
I-1
tp14203
sS'mg,and'
p14204
(F1
F0.0015290519877675841
I2
I0
I2
tp14205
sS'short-acting,benzodiazepines'
p14206
(F1
F0.0022935779816513763
I3
I0
I3
tp14207
sS'require,reduced'
p14208
(F1
F0.00076452599388379206
I1
I0
I1
tp14209
sS'the,latter'
p14210
(F1
F0.00076452599388379206
I0
I1
I-1
tp14211
sS'terminal,deoxynucleotidyl'
p14212
(F1
F0.00076452599388379206
I0
I1
I-1
tp14213
sS'excessive,reduction'
p14214
(F1
F0.00076452599388379206
I1
I0
I1
tp14215
sS'found,throughout'
p14216
(F1
F0.00076452599388379206
I0
I1
I-1
tp14217
sS'initiated,in'
p14218
(F1
F0.00076452599388379206
I1
I0
I1
tp14219
sS'starting,mexitil'
p14220
(F1
F0.00076452599388379206
I1
I0
I1
tp14221
sS'individual,ethinyl'
p14222
(F1
F0.00076452599388379206
I0
I1
I-1
tp14223
sS'mixed,agonist'
p14224
(F1
F0.00076452599388379206
I1
I0
I1
tp14225
sS'to,mg'
p14226
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp14227
sS'be,minimized'
p14228
(F0
F0
I1
I1
I0
tp14229
sS'sirolimus,auc'
p14230
(F1
F0.00076452599388379206
I1
I0
I1
tp14231
sS'or,toxicity'
p14232
(F1
F0.00076452599388379206
I1
I0
I1
tp14233
sS'in,blood'
p14234
(F1
F0.00076452599388379206
I0
I1
I-1
tp14235
sS'potent,inhalational'
p14236
(F1
F0.00076452599388379206
I0
I1
I-1
tp14237
sS'ventricular,arrhythmia'
p14238
(F1
F0.00076452599388379206
I0
I1
I-1
tp14239
sS'others,can'
p14240
(F1
F0.00076452599388379206
I0
I1
I-1
tp14241
sS'via,competitive'
p14242
(F1
F0.00076452599388379206
I0
I1
I-1
tp14243
sS'these,patients'
p14244
(F1
F0.00076452599388379206
I1
I0
I1
tp14245
sS'the,sedative'
p14246
(F1
F0.0022935779816513763
I3
I0
I3
tp14247
sS'those,include'
p14248
(F1
F0.00076452599388379206
I0
I1
I-1
tp14249
sS'oral,dose'
p14250
(F1
F0.00076452599388379206
I0
I1
I-1
tp14251
sS'or,by'
p14252
(F1
F0.00076452599388379206
I1
I0
I1
tp14253
sS'concomitant,use'
p14254
(F0.20000000000000001
F0.0022935779816513763
I9
I6
I3
tp14255
sS'is,unlikely'
p14256
(F1
F0.0015290519877675841
I0
I2
I-2
tp14257
sS'be,monitored'
p14258
(F1
F0.0061162079510703364
I8
I0
I8
tp14259
sS'large,compassionate'
p14260
(F1
F0.00076452599388379206
I0
I1
I-1
tp14261
sS'significantly,affected'
p14262
(F1
F0.00076452599388379206
I0
I1
I-1
tp14263
sS'ethinyl,following'
p14264
(F1
F0.00076452599388379206
I0
I1
I-1
tp14265
sS'inr,in'
p14266
(F1
F0.00076452599388379206
I1
I0
I1
tp14267
sS'as,a'
p14268
(F1
F0.0030581039755351682
I4
I0
I4
tp14269
sS'oral,may'
p14270
(F1
F0.0030581039755351682
I4
I0
I4
tp14271
sS'and,furthermore'
p14272
(F1
F0.00076452599388379206
I1
I0
I1
tp14273
sS'as,n'
p14274
(F1
F0.00076452599388379206
I0
I1
I-1
tp14275
sS'soltab,orally'
p14276
(F1
F0.00076452599388379206
I0
I1
I-1
tp14277
sS'overexpressed,in'
p14278
(F1
F0.00076452599388379206
I1
I0
I1
tp14279
sS'contraceptives,stavudine'
p14280
(F1
F0.00076452599388379206
I1
I0
I1
tp14281
sS'with,similar'
p14282
(F1
F0.00076452599388379206
I1
I0
I1
tp14283
sS'or,inhibitors'
p14284
(F1
F0.00076452599388379206
I0
I1
I-1
tp14285
sS'tetrahydropyridine-induced,loss'
p14286
(F1
F0.00076452599388379206
I1
I0
I1
tp14287
sS'displayed,clearances'
p14288
(F1
F0.00076452599388379206
I0
I1
I-1
tp14289
sS'effects,can'
p14290
(F1
F0.0015290519877675841
I2
I0
I2
tp14291
sS'diet,that'
p14292
(F1
F0.00076452599388379206
I1
I0
I1
tp14293
sS'used,simultaneously'
p14294
(F1
F0.00076452599388379206
I0
I1
I-1
tp14295
sS'may,prolong'
p14296
(F1
F0.00076452599388379206
I1
I0
I1
tp14297
sS'experience,changes'
p14298
(F1
F0.00076452599388379206
I1
I0
I1
tp14299
sS'bleeding,if'
p14300
(F1
F0.0015290519877675841
I2
I0
I2
tp14301
sS'conclusive,evidence'
p14302
(F1
F0.00076452599388379206
I0
I1
I-1
tp14303
sS'sulfate,and'
p14304
(F1
F0.00076452599388379206
I1
I0
I1
tp14305
sS'and,neulasta'
p14306
(F1
F0.00076452599388379206
I1
I0
I1
tp14307
sS'saline,g'
p14308
(F1
F0.00076452599388379206
I0
I1
I-1
tp14309
sS'of,folic'
p14310
(F1
F0.00076452599388379206
I1
I0
I1
tp14311
sS'of,vitamin'
p14312
(F1
F0.00076452599388379206
I0
I1
I-1
tp14313
sS'patient,already'
p14314
(F1
F0.00076452599388379206
I1
I0
I1
tp14315
sS'antifungals,eg'
p14316
(F1
F0.00076452599388379206
I1
I0
I1
tp14317
sS'oral,containing'
p14318
(F1
F0.00076452599388379206
I0
I1
I-1
tp14319
sS'the,currently'
p14320
(F1
F0.00076452599388379206
I1
I0
I1
tp14321
sS'total,of'
p14322
(F1
F0.00076452599388379206
I0
I1
I-1
tp14323
sS'the,toxic'
p14324
(F1
F0.00076452599388379206
I1
I0
I1
tp14325
sS'other,anticholinergic-like'
p14326
(F1
F0.00076452599388379206
I1
I0
I1
tp14327
sS'the,doses'
p14328
(F1
F0.00076452599388379206
I0
I1
I-1
tp14329
sS'qrs,and'
p14330
(F1
F0.00076452599388379206
I0
I1
I-1
tp14331
sS'o,as'
p14332
(F1
F0.00076452599388379206
I0
I1
I-1
tp14333
sS'when,daily'
p14334
(F1
F0.00076452599388379206
I0
I1
I-1
tp14335
sS'drugs,leads'
p14336
(F1
F0.00076452599388379206
I1
I0
I1
tp14337
sS'the,specific'
p14338
(F1
F0.00076452599388379206
I1
I0
I1
tp14339
sS'therapy,was'
p14340
(F1
F0.00076452599388379206
I1
I0
I1
tp14341
sS'animal,model'
p14342
(F1
F0.00076452599388379206
I1
I0
I1
tp14343
sS'that,ascorbic'
p14344
(F1
F0.00076452599388379206
I1
I0
I1
tp14345
sS'being,treated'
p14346
(F1
F0.0015290519877675841
I2
I0
I2
tp14347
sS'a,stable'
p14348
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp14349
sS'study,conducted'
p14350
(F1
F0.00076452599388379206
I1
I0
I1
tp14351
sS'their,mechanism'
p14352
(F1
F0.00076452599388379206
I1
I0
I1
tp14353
sS'other,or'
p14354
(F1
F0.00076452599388379206
I1
I0
I1
tp14355
sS'leading,to'
p14356
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp14357
sS'of,evista'
p14358
(F1
F0.00076452599388379206
I0
I1
I-1
tp14359
sS'layer,and'
p14360
(F1
F0.00076452599388379206
I0
I1
I-1
tp14361
sS'diuretics,oral'
p14362
(F1
F0.00076452599388379206
I1
I0
I1
tp14363
sS'cylert,concomitantly'
p14364
(F1
F0.00076452599388379206
I1
I0
I1
tp14365
sS'may,render'
p14366
(F1
F0.0015290519877675841
I2
I0
I2
tp14367
sS'transport,system'
p14368
(F1
F0.0015290519877675841
I2
I0
I2
tp14369
sS'adjoining,a5'
p14370
(F1
F0.00076452599388379206
I1
I0
I1
tp14371
sS'drugs,eliminated'
p14372
(F1
F0.0015290519877675841
I2
I0
I2
tp14373
sS'hydrolase,inhibitors'
p14374
(F1
F0.00076452599388379206
I0
I1
I-1
tp14375
sS'increased,levels'
p14376
(F1
F0.00076452599388379206
I1
I0
I1
tp14377
sS'methysergide,may'
p14378
(F1
F0.00076452599388379206
I1
I0
I1
tp14379
sS'and,weekly'
p14380
(F1
F0.0015290519877675841
I0
I2
I-2
tp14381
sS'other,thiazide-like'
p14382
(F1
F0.00076452599388379206
I1
I0
I1
tp14383
sS'penicillin,blood'
p14384
(F1
F0.00076452599388379206
I1
I0
I1
tp14385
sS'mg,four'
p14386
(F1
F0.0015290519877675841
I2
I0
I2
tp14387
sS'found,that'
p14388
(F1
F0.0022935779816513763
I3
I0
I3
tp14389
sS'bleeding,have'
p14390
(F1
F0.0015290519877675841
I2
I0
I2
tp14391
sS'presence,of'
p14392
(F0.5
F0.0030581039755351682
I6
I2
I4
tp14393
sS'drugs,interrupt'
p14394
(F1
F0.00076452599388379206
I0
I1
I-1
tp14395
sS'stimulate,alpha-adrenergic'
p14396
(F1
F0.00076452599388379206
I1
I0
I1
tp14397
sS'nonheme,and'
p14398
(F1
F0.00076452599388379206
I0
I1
I-1
tp14399
sS'phenytoin,can'
p14400
(F1
F0.00076452599388379206
I1
I0
I1
tp14401
sS'antagonist,is'
p14402
(F1
F0.00076452599388379206
I0
I1
I-1
tp14403
sS'renal,insufficiency'
p14404
(F1
F0.0015290519877675841
I2
I0
I2
tp14405
sS'additive,cns'
p14406
(F1
F0.00076452599388379206
I0
I1
I-1
tp14407
sS'parkinsonian,by'
p14408
(F1
F0.00076452599388379206
I0
I1
I-1
tp14409
sS'to,investigate'
p14410
(F1
F0.0015290519877675841
I0
I2
I-2
tp14411
sS'causes,bone'
p14412
(F1
F0.00076452599388379206
I0
I1
I-1
tp14413
sS'the,ability'
p14414
(F1
F0.00076452599388379206
I0
I1
I-1
tp14415
sS'cause,shortness'
p14416
(F1
F0.00076452599388379206
I1
I0
I1
tp14417
sS'bromide,injection'
p14418
(F1
F0.00076452599388379206
I0
I1
I-1
tp14419
sS'by,fold'
p14420
(F1
F0.00076452599388379206
I1
I0
I1
tp14421
sS'of,neuronal'
p14422
(F1
F0.00076452599388379206
I1
I0
I1
tp14423
sS'metabolized,through'
p14424
(F1
F0.00076452599388379206
I0
I1
I-1
tp14425
sS'low-dose,with'
p14426
(F1
F0.00076452599388379206
I1
I0
I1
tp14427
sS'controlled,pharmacokinetic'
p14428
(F1
F0.00076452599388379206
I1
I0
I1
tp14429
sS'mixed,effects'
p14430
(F1
F0.00076452599388379206
I0
I1
I-1
tp14431
sS'oral,anticoagulants'
p14432
(F1
F0.00076452599388379206
I0
I1
I-1
tp14433
sS'inactivated,nd'
p14434
(F1
F0.0015290519877675841
I0
I2
I-2
tp14435
sS'the,patient'
p14436
(F1
F0.0015290519877675841
I2
I0
I2
tp14437
sS'b,polymyxin'
p14438
(F1
F0.00076452599388379206
I0
I1
I-1
tp14439
sS'who,experienced'
p14440
(F1
F0.00076452599388379206
I1
I0
I1
tp14441
sS'displayed,synergy'
p14442
(F1
F0.00076452599388379206
I1
I0
I1
tp14443
sS'half-life,by'
p14444
(F1
F0.00076452599388379206
I1
I0
I1
tp14445
sS'of,xenical'
p14446
(F1
F0.0022935779816513763
I0
I3
I-3
tp14447
sS'been,taken'
p14448
(F1
F0.00076452599388379206
I1
I0
I1
tp14449
sS'were,efficiently'
p14450
(F1
F0.00076452599388379206
I1
I0
I1
tp14451
sS'profound,sedation'
p14452
(F1
F0.00076452599388379206
I1
I0
I1
tp14453
sS'oral,activated'
p14454
(F1
F0.00076452599388379206
I1
I0
I1
tp14455
sS'results,for'
p14456
(F1
F0.00076452599388379206
I0
I1
I-1
tp14457
sS'may,be'
p14458
(F0.55000000000000004
F0.016819571865443424
I31
I9
I22
tp14459
sS'cyp2c19,inhibitors'
p14460
(F1
F0.00076452599388379206
I1
I0
I1
tp14461
sS'bismuth,trough'
p14462
(F1
F0.00076452599388379206
I1
I0
I1
tp14463
sS'patients,showed'
p14464
(F1
F0.00076452599388379206
I0
I1
I-1
tp14465
sS'antagonists,and'
p14466
(F1
F0.00076452599388379206
I1
I0
I1
tp14467
sS'therefore,should'
p14468
(F1
F0.0015290519877675841
I2
I0
I2
tp14469
sS'cells,were'
p14470
(F1
F0.00076452599388379206
I1
I0
I1
tp14471
sS'been,demonstrated'
p14472
(F1
F0.0015290519877675841
I2
I0
I2
tp14473
sS'symlin,therapy'
p14474
(F1
F0.00076452599388379206
I1
I0
I1
tp14475
sS'its,human'
p14476
(F1
F0.00076452599388379206
I0
I1
I-1
tp14477
sS'with,traditional'
p14478
(F1
F0.00076452599388379206
I1
I0
I1
tp14479
sS'efficacy,studies'
p14480
(F1
F0.00076452599388379206
I0
I1
I-1
tp14481
sS'appropriate,clinical'
p14482
(F1
F0.0015290519877675841
I2
I0
I2
tp14483
sS'medications,such'
p14484
(F0
F0
I1
I1
I0
tp14485
sS'have,little'
p14486
(F1
F0.00076452599388379206
I1
I0
I1
tp14487
sS'by,disc'
p14488
(F1
F0.00076452599388379206
I1
I0
I1
tp14489
sS'observed,before'
p14490
(F1
F0.00076452599388379206
I1
I0
I1
tp14491
sS'evaluation,of'
p14492
(F1
F0.00076452599388379206
I0
I1
I-1
tp14493
sS'a,base'
p14494
(F1
F0.00076452599388379206
I1
I0
I1
tp14495
sS'with,for'
p14496
(F0.20000000000000001
F0.00076452599388379206
I3
I2
I1
tp14497
sS'by,co-injection'
p14498
(F1
F0.00076452599388379206
I1
I0
I1
tp14499
sS'bw,for'
p14500
(F1
F0.00076452599388379206
I0
I1
I-1
tp14501
sS'an,hiv-positive'
p14502
(F1
F0.0015290519877675841
I2
I0
I2
tp14503
sS'the,tubular'
p14504
(F1
F0.00076452599388379206
I1
I0
I1
tp14505
sS'no,formal'
p14506
(F1
F0.0015290519877675841
I0
I2
I-2
tp14507
sS'diminished,absorption'
p14508
(F1
F0.00076452599388379206
I1
I0
I1
tp14509
sS'female,subjects'
p14510
(F1
F0.00076452599388379206
I0
I1
I-1
tp14511
sS'max,and'
p14512
(F1
F0.0022935779816513763
I3
I0
I3
tp14513
sS'flushes,linked'
p14514
(F1
F0.00076452599388379206
I0
I1
I-1
tp14515
sS'risk,of'
p14516
(F0.69230769230769229
F0.0068807339449541288
I11
I2
I9
tp14517
sS'ethynyl,pyridine-treated'
p14518
(F1
F0.0015290519877675841
I2
I0
I2
tp14519
sS'or,greater'
p14520
(F1
F0.0015290519877675841
I2
I0
I2
tp14521
sS'vehicle-treated,animals'
p14522
(F1
F0.0015290519877675841
I2
I0
I2
tp14523
sS'onset,of'
p14524
(F1
F0.00076452599388379206
I1
I0
I1
tp14525
sS'vitro,perfusion'
p14526
(F1
F0.00076452599388379206
I1
I0
I1
tp14527
sS'plasma,concentration'
p14528
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp14529
sS'hypoglycemic,agents'
p14530
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp14531
sS'oxycodone,hydrochloride'
p14532
(F1
F0.00076452599388379206
I1
I0
I1
tp14533
sS'of,ml'
p14534
(F1
F0.00076452599388379206
I0
I1
I-1
tp14535
sS'of,mg'
p14536
(F0
F0
I10
I10
I0
tp14537
sS'inhibitory,effect'
p14538
(F0
F0
I1
I1
I0
tp14539
sS'holed,open'
p14540
(F1
F0.00076452599388379206
I0
I1
I-1
tp14541
sS'p450,a'
p14542
(F1
F0.00076452599388379206
I1
I0
I1
tp14543
sS'days,did'
p14544
(F1
F0.0022935779816513763
I0
I3
I-3
tp14545
sS'vivo,in'
p14546
(F0
F0
I1
I1
I0
tp14547
sS'activity,patients'
p14548
(F1
F0.00076452599388379206
I1
I0
I1
tp14549
sS'diuretics,univasc'
p14550
(F1
F0.00076452599388379206
I0
I1
I-1
tp14551
sS'when,myfortic'
p14552
(F1
F0.00076452599388379206
I1
I0
I1
tp14553
sS'delivered,by'
p14554
(F1
F0.00076452599388379206
I0
I1
I-1
tp14555
sS'enhance,neuromuscular'
p14556
(F1
F0.00076452599388379206
I1
I0
I1
tp14557
sS'if,zemuron'
p14558
(F1
F0.00076452599388379206
I1
I0
I1
tp14559
sS'retinal,transduction'
p14560
(F0
F0
I1
I1
I0
tp14561
sS'dose,drug-drug'
p14562
(F1
F0.00076452599388379206
I1
I0
I1
tp14563
sS'doctor,if'
p14564
(F1
F0.00076452599388379206
I0
I1
I-1
tp14565
sS'catecholamine-depleting,drugs'
p14566
(F1
F0.0015290519877675841
I2
I0
I2
tp14567
sS'present,study'
p14568
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp14569
sS'for,pharmacokinetic'
p14570
(F1
F0.00076452599388379206
I1
I0
I1
tp14571
sS'food,to'
p14572
(F1
F0.00076452599388379206
I1
I0
I1
tp14573
sS'prolonged,sedation'
p14574
(F1
F0.00076452599388379206
I1
I0
I1
tp14575
sS'tacrolimus-treated,patients'
p14576
(F1
F0.00076452599388379206
I0
I1
I-1
tp14577
sS'depending,on'
p14578
(F1
F0.00076452599388379206
I1
I0
I1
tp14579
sS'to,sharply'
p14580
(F1
F0.00076452599388379206
I1
I0
I1
tp14581
sS'exert,an'
p14582
(F1
F0.00076452599388379206
I1
I0
I1
tp14583
sS'such,as'
p14584
(F0.61904761904761907
F0.019877675840978593
I34
I8
I26
tp14585
sS'of,bismuth'
p14586
(F1
F0.00076452599388379206
I1
I0
I1
tp14587
sS'or,nardil'
p14588
(F1
F0.00076452599388379206
I1
I0
I1
tp14589
sS'in,prothrombin'
p14590
(F1
F0.0015290519877675841
I2
I0
I2
tp14591
sS'however,as'
p14592
(F1
F0.00076452599388379206
I1
I0
I1
tp14593
sS'model,day'
p14594
(F1
F0.00076452599388379206
I0
I1
I-1
tp14595
sS'important,determinant'
p14596
(F1
F0.00076452599388379206
I1
I0
I1
tp14597
sS'soltab,diazepam'
p14598
(F1
F0.00076452599388379206
I1
I0
I1
tp14599
sS'on,hot'
p14600
(F1
F0.00076452599388379206
I0
I1
I-1
tp14601
sS'and,beta'
p14602
(F1
F0.00076452599388379206
I1
I0
I1
tp14603
sS'be,advisable'
p14604
(F1
F0.00076452599388379206
I1
I0
I1
tp14605
sS'assess,drug-drug'
p14606
(F1
F0.00076452599388379206
I1
I0
I1
tp14607
sS'single-dose,interaction'
p14608
(F1
F0.00076452599388379206
I1
I0
I1
tp14609
sS'in,fatal'
p14610
(F1
F0.00076452599388379206
I1
I0
I1
tp14611
sS'improved,the'
p14612
(F1
F0.00076452599388379206
I1
I0
I1
tp14613
sS'other,dietary'
p14614
(F1
F0.00076452599388379206
I1
I0
I1
tp14615
sS'incidence,of'
p14616
(F0
F0
I3
I3
I0
tp14617
sS'limited,in'
p14618
(F1
F0.00076452599388379206
I0
I1
I-1
tp14619
sS'is,superior'
p14620
(F1
F0.00076452599388379206
I1
I0
I1
tp14621
sS'screening,tests'
p14622
(F1
F0.00076452599388379206
I0
I1
I-1
tp14623
sS'the,hot'
p14624
(F1
F0.00076452599388379206
I1
I0
I1
tp14625
sS'food,does'
p14626
(F1
F0.00076452599388379206
I0
I1
I-1
tp14627
sS'immune,responses'
p14628
(F1
F0.0015290519877675841
I0
I2
I-2
tp14629
sS'and,proton'
p14630
(F1
F0.00076452599388379206
I0
I1
I-1
tp14631
sS'while,in'
p14632
(F1
F0.00076452599388379206
I0
I1
I-1
tp14633
sS'opioid,analgesics'
p14634
(F1
F0.0015290519877675841
I2
I0
I2
tp14635
sS'and,first-pass'
p14636
(F1
F0.00076452599388379206
I0
I1
I-1
tp14637
sS'bcl-2,was'
p14638
(F1
F0.00076452599388379206
I1
I0
I1
tp14639
sS'on,sensitivity'
p14640
(F1
F0.00076452599388379206
I0
I1
I-1
tp14641
sS'remarkably,enhanced'
p14642
(F1
F0.00076452599388379206
I1
I0
I1
tp14643
sS'single,intravenous'
p14644
(F1
F0.00076452599388379206
I0
I1
I-1
tp14645
sS'maintenance,with'
p14646
(F1
F0.00076452599388379206
I0
I1
I-1
tp14647
sS'increased,total'
p14648
(F0
F0
I1
I1
I0
tp14649
sS'concentrations,to'
p14650
(F1
F0.00076452599388379206
I1
I0
I1
tp14651
sS'in,vivo'
p14652
(F0.40000000000000002
F0.0030581039755351682
I3
I7
I-4
tp14653
sS'the,maximum'
p14654
(F1
F0.00076452599388379206
I0
I1
I-1
tp14655
sS'taking,infacol'
p14656
(F1
F0.00076452599388379206
I0
I1
I-1
tp14657
sS'the,amphetamine-paired'
p14658
(F1
F0.00076452599388379206
I0
I1
I-1
tp14659
sS'isoenzyme,cyp'
p14660
(F1
F0.00076452599388379206
I1
I0
I1
tp14661
sS'furosemide,single'
p14662
(F1
F0.00076452599388379206
I0
I1
I-1
tp14663
sS'drug-metabolizing,enzymes'
p14664
(F1
F0.00076452599388379206
I0
I1
I-1
tp14665
sS'advised,to'
p14666
(F1
F0.0015290519877675841
I2
I0
I2
tp14667
sS'alpha-2,agonists'
p14668
(F1
F0.00076452599388379206
I0
I1
I-1
tp14669
sS'roles,of'
p14670
(F1
F0.00076452599388379206
I0
I1
I-1
tp14671
sS'in,auc'
p14672
(F1
F0.00076452599388379206
I1
I0
I1
tp14673
sS'inhalational,agents'
p14674
(F1
F0.0015290519877675841
I0
I2
I-2
tp14675
sS'with,commonly'
p14676
(F1
F0.0015290519877675841
I0
I2
I-2
tp14677
sS'metabolism,by'
p14678
(F1
F0.0015290519877675841
I2
I0
I2
tp14679
sS'of,salicylic'
p14680
(F1
F0.00076452599388379206
I1
I0
I1
tp14681
sS'cyp1a2,enzymes'
p14682
(F1
F0.00076452599388379206
I0
I1
I-1
tp14683
sS'could,possibly'
p14684
(F1
F0.00076452599388379206
I1
I0
I1
tp14685
sS'with,should'
p14686
(F1
F0.00076452599388379206
I1
I0
I1
tp14687
sS'recommended,pending'
p14688
(F1
F0.00076452599388379206
I1
I0
I1
tp14689
sS'other,azole'
p14690
(F1
F0.0015290519877675841
I2
I0
I2
tp14691
sS'a,study'
p14692
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp14693
sS'is,given'
p14694
(F1
F0.0022935779816513763
I3
I0
I3
tp14695
sS'with,inhibitors'
p14696
(F1
F0.00076452599388379206
I0
I1
I-1
tp14697
sS'case,report'
p14698
(F1
F0.00076452599388379206
I1
I0
I1
tp14699
sS'in,fresh'
p14700
(F1
F0.00076452599388379206
I1
I0
I1
tp14701
sS'a,mean'
p14702
(F1
F0.0015290519877675841
I2
I0
I2
tp14703
sS'or,and'
p14704
(F1
F0.0015290519877675841
I2
I0
I2
tp14705
sS'nervous,system'
p14706
(F1
F0.0030581039755351682
I4
I0
I4
tp14707
sS'receiving,treatment'
p14708
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp14709
sS'and,tabloid'
p14710
(F1
F0.00076452599388379206
I1
I0
I1
tp14711
sS'dosage,if'
p14712
(F1
F0.00076452599388379206
I1
I0
I1
tp14713
sS'potassium,chloride'
p14714
(F1
F0.00076452599388379206
I1
I0
I1
tp14715
sS'produced,by'
p14716
(F1
F0.0015290519877675841
I2
I0
I2
tp14717
sS'dosage,in'
p14718
(F1
F0.00076452599388379206
I1
I0
I1
tp14719
sS'parameters,changes'
p14720
(F1
F0.00076452599388379206
I0
I1
I-1
tp14721
sS'inhospital,administration'
p14722
(F1
F0.00076452599388379206
I1
I0
I1
tp14723
sS'of,steady-state'
p14724
(F1
F0.0015290519877675841
I2
I0
I2
tp14725
sS'or,heme'
p14726
(F1
F0.00076452599388379206
I0
I1
I-1
tp14727
sS'alimta,to'
p14728
(F1
F0.00076452599388379206
I1
I0
I1
tp14729
sS'of,remeron'
p14730
(F1
F0.0015290519877675841
I0
I2
I-2
tp14731
sS'sensitivity,of'
p14732
(F1
F0.0015290519877675841
I2
I0
I2
tp14733
sS'single,and'
p14734
(F1
F0.00076452599388379206
I0
I1
I-1
tp14735
sS'decrease,patient'
p14736
(F1
F0.00076452599388379206
I1
I0
I1
tp14737
sS'to,determine'
p14738
(F1
F0.00076452599388379206
I0
I1
I-1
tp14739
sS'disease,prior'
p14740
(F1
F0.00076452599388379206
I1
I0
I1
tp14741
sS'study,was'
p14742
(F1
F0.0038226299694189602
I0
I5
I-5
tp14743
sS'three,doses'
p14744
(F1
F0.00076452599388379206
I0
I1
I-1
tp14745
sS'increasing,the'
p14746
(F1
F0.0022935779816513763
I3
I0
I3
tp14747
sS'that,were'
p14748
(F1
F0.00076452599388379206
I1
I0
I1
tp14749
sS'on,chronic'
p14750
(F1
F0.00076452599388379206
I1
I0
I1
tp14751
sS'diflucan,is'
p14752
(F1
F0.00076452599388379206
I1
I0
I1
tp14753
sS'day,with'
p14754
(F1
F0.00076452599388379206
I1
I0
I1
tp14755
sS'sedation,may'
p14756
(F1
F0.00076452599388379206
I0
I1
I-1
tp14757
sS'increases,the'
p14758
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp14759
sS'in,mind'
p14760
(F0
F0
I1
I1
I0
tp14761
sS'is,the'
p14762
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp14763
sS'ergot-type,medications'
p14764
(F1
F0.00076452599388379206
I1
I0
I1
tp14765
sS'suggest,that'
p14766
(F0.66666666666666663
F0.0030581039755351682
I5
I1
I4
tp14767
sS'and,flomax'
p14768
(F0
F0
I1
I1
I0
tp14769
sS'exposure,auc'
p14770
(F1
F0.00076452599388379206
I1
I0
I1
tp14771
sS'spontaneous,adverse'
p14772
(F1
F0.00076452599388379206
I1
I0
I1
tp14773
sS'neurologic,toxicity'
p14774
(F1
F0.00076452599388379206
I1
I0
I1
tp14775
sS'additive,effects'
p14776
(F1
F0.00076452599388379206
I1
I0
I1
tp14777
sS'or,inducers'
p14778
(F1
F0.00076452599388379206
I0
I1
I-1
tp14779
sS'normal,subjects'
p14780
(F1
F0.00076452599388379206
I1
I0
I1
tp14781
sS'depression,and'
p14782
(F1
F0.00076452599388379206
I0
I1
I-1
tp14783
sS'lower,than'
p14784
(F1
F0.0015290519877675841
I2
I0
I2
tp14785
sS'and,please'
p14786
(F1
F0.00076452599388379206
I1
I0
I1
tp14787
sS'analgesics,and'
p14788
(F1
F0.00076452599388379206
I1
I0
I1
tp14789
sS'test,in'
p14790
(F1
F0.00076452599388379206
I1
I0
I1
tp14791
sS'the,co'
p14792
(F1
F0.00076452599388379206
I1
I0
I1
tp14793
sS'and,infusion'
p14794
(F1
F0.00076452599388379206
I1
I0
I1
tp14795
sS'stable,target'
p14796
(F1
F0.00076452599388379206
I1
I0
I1
tp14797
sS'calcium,channel'
p14798
(F1
F0.00076452599388379206
I1
I0
I1
tp14799
sS'it,decreases'
p14800
(F1
F0.00076452599388379206
I0
I1
I-1
tp14801
sS'symptoms,due'
p14802
(F1
F0.00076452599388379206
I1
I0
I1
tp14803
sS'imaging,data'
p14804
(F1
F0.00076452599388379206
I1
I0
I1
tp14805
sS'be,increased'
p14806
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp14807
sS'system,and'
p14808
(F1
F0.00076452599388379206
I1
I0
I1
tp14809
sS'or,peripheral'
p14810
(F1
F0.00076452599388379206
I0
I1
I-1
tp14811
sS'there,is'
p14812
(F0.33333333333333331
F0.0022935779816513763
I6
I3
I3
tp14813
sS'vivo,positron'
p14814
(F1
F0.00076452599388379206
I1
I0
I1
tp14815
sS'of,inhospital'
p14816
(F1
F0.00076452599388379206
I1
I0
I1
tp14817
sS'labeling,tunel'
p14818
(F1
F0.00076452599388379206
I0
I1
I-1
tp14819
sS'concurrent,or'
p14820
(F1
F0.00076452599388379206
I0
I1
I-1
tp14821
sS'with,monoamine'
p14822
(F1
F0.00076452599388379206
I1
I0
I1
tp14823
sS'phenytoin,cyclosporine'
p14824
(F1
F0.00076452599388379206
I1
I0
I1
tp14825
sS'treatment,following'
p14826
(F1
F0.00076452599388379206
I1
I0
I1
tp14827
sS'data,have'
p14828
(F1
F0.00076452599388379206
I1
I0
I1
tp14829
sS'shrinkage,of'
p14830
(F1
F0.00076452599388379206
I1
I0
I1
tp14831
sS'of,cell'
p14832
(F1
F0.00076452599388379206
I1
I0
I1
tp14833
sS'reproductive,toxicity'
p14834
(F1
F0.00076452599388379206
I0
I1
I-1
tp14835
sS'therapy,such'
p14836
(F1
F0.00076452599388379206
I1
I0
I1
tp14837
sS'aramine,should'
p14838
(F1
F0.00076452599388379206
I1
I0
I1
tp14839
sS'or,acth'
p14840
(F1
F0.0015290519877675841
I0
I2
I-2
tp14841
sS'sometimes,with'
p14842
(F1
F0.00076452599388379206
I0
I1
I-1
tp14843
sS'not,listed'
p14844
(F1
F0.00076452599388379206
I0
I1
I-1
tp14845
sS'profile,only'
p14846
(F1
F0.00076452599388379206
I0
I1
I-1
tp14847
sS'univasc,has'
p14848
(F1
F0.00076452599388379206
I0
I1
I-1
tp14849
sS'are,described'
p14850
(F1
F0.00076452599388379206
I1
I0
I1
tp14851
sS'feldene,have'
p14852
(F1
F0.00076452599388379206
I1
I0
I1
tp14853
sS'lapatinib,enhances'
p14854
(F1
F0.00076452599388379206
I1
I0
I1
tp14855
sS'context,compared'
p14856
(F1
F0.00076452599388379206
I0
I1
I-1
tp14857
sS'ordinarily,should'
p14858
(F1
F0.00076452599388379206
I1
I0
I1
tp14859
sS'an,increase'
p14860
(F1
F0.0053516819571865441
I7
I0
I7
tp14861
sS'of,hydrochloride'
p14862
(F1
F0.0038226299694189602
I5
I0
I5
tp14863
sS'the,effects'
p14864
(F0.33333333333333331
F0.0053516819571865441
I14
I7
I7
tp14865
sS'these,results'
p14866
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp14867
sS'antidepressant-warfarin,interaction'
p14868
(F1
F0.00076452599388379206
I0
I1
I-1
tp14869
sS'internal,medicine'
p14870
(F1
F0.00076452599388379206
I0
I1
I-1
tp14871
sS'an,interesting'
p14872
(F1
F0.00076452599388379206
I1
I0
I1
tp14873
sS'except,where'
p14874
(F1
F0.00076452599388379206
I0
I1
I-1
tp14875
sS'responses,of'
p14876
(F1
F0.00076452599388379206
I0
I1
I-1
tp14877
sS'hct116,hepg2'
p14878
(F1
F0.00076452599388379206
I0
I1
I-1
tp14879
sS'higher,than'
p14880
(F1
F0.00076452599388379206
I0
I1
I-1
tp14881
sS'potentially,neurotoxic'
p14882
(F1
F0.00076452599388379206
I0
I1
I-1
tp14883
sS'studies,with'
p14884
(F0.33333333333333331
F0.0015290519877675841
I2
I4
I-2
tp14885
sS'synergistically,inhibited'
p14886
(F1
F0.00076452599388379206
I1
I0
I1
tp14887
sS'bp,and'
p14888
(F1
F0.00076452599388379206
I1
I0
I1
tp14889
sS'however,a'
p14890
(F1
F0.0015290519877675841
I2
I0
I2
tp14891
sS'effect,of'
p14892
(F0.081081081081081086
F0.0022935779816513763
I17
I20
I-3
tp14893
sS'initiated,or'
p14894
(F1
F0.00076452599388379206
I1
I0
I1
tp14895
sS'with,particularly'
p14896
(F1
F0.00076452599388379206
I1
I0
I1
tp14897
sS'effect,on'
p14898
(F0.29999999999999999
F0.0045871559633027525
I13
I7
I6
tp14899
sS'adjuvant,to'
p14900
(F1
F0.00076452599388379206
I0
I1
I-1
tp14901
sS'caution,or'
p14902
(F1
F0.0015290519877675841
I2
I0
I2
tp14903
sS'dosage,adjustments'
p14904
(F1
F0.00076452599388379206
I0
I1
I-1
tp14905
sS'of,spontaneous'
p14906
(F1
F0.00076452599388379206
I1
I0
I1
tp14907
sS'azathioprine,mycophenolate'
p14908
(F1
F0.00076452599388379206
I1
I0
I1
tp14909
sS'drugs,while'
p14910
(F1
F0.00076452599388379206
I1
I0
I1
tp14911
sS'drugs,antidepressant'
p14912
(F1
F0.00076452599388379206
I1
I0
I1
tp14913
sS'for,breast'
p14914
(F0
F0
I1
I1
I0
tp14915
sS'much,weaker'
p14916
(F1
F0.00076452599388379206
I1
I0
I1
tp14917
sS'area,under'
p14918
(F1
F0.0015290519877675841
I2
I0
I2
tp14919
sS'that,slow'
p14920
(F1
F0.00076452599388379206
I1
I0
I1
tp14921
sS'sulfonamides,can'
p14922
(F1
F0.00076452599388379206
I1
I0
I1
tp14923
sS'generally,used'
p14924
(F1
F0.00076452599388379206
I0
I1
I-1
tp14925
sS'therapies,may'
p14926
(F1
F0.00076452599388379206
I1
I0
I1
tp14927
sS'it,may'
p14928
(F0
F0
I2
I2
I0
tp14929
sS'particularly,may'
p14930
(F1
F0.0015290519877675841
I2
I0
I2
tp14931
sS'monitored,closely'
p14932
(F1
F0.0015290519877675841
I2
I0
I2
tp14933
sS'for,pain'
p14934
(F1
F0.00076452599388379206
I0
I1
I-1
tp14935
sS'hydroxide,and'
p14936
(F1
F0.00076452599388379206
I0
I1
I-1
tp14937
sS'monitored,particularly'
p14938
(F1
F0.0015290519877675841
I2
I0
I2
tp14939
sS'chloride,in'
p14940
(F1
F0.00076452599388379206
I0
I1
I-1
tp14941
sS'total,users'
p14942
(F1
F0.00076452599388379206
I0
I1
I-1
tp14943
sS'elicit,important'
p14944
(F1
F0.00076452599388379206
I0
I1
I-1
tp14945
sS'based,on'
p14946
(F0.55555555555555558
F0.0038226299694189602
I2
I7
I-5
tp14947
sS'anticholinergic,drugs'
p14948
(F1
F0.0045871559633027525
I6
I0
I6
tp14949
sS'triprolidine,may'
p14950
(F1
F0.00076452599388379206
I1
I0
I1
tp14951
sS'two,larger'
p14952
(F1
F0.00076452599388379206
I0
I1
I-1
tp14953
sS'intervals,pr'
p14954
(F1
F0.00076452599388379206
I0
I1
I-1
tp14955
sS'excretion,of'
p14956
(F1
F0.0015290519877675841
I0
I2
I-2
tp14957
sS'by,in'
p14958
(F1
F0.00076452599388379206
I1
I0
I1
tp14959
sS'some,anti-proliferative'
p14960
(F1
F0.00076452599388379206
I1
I0
I1
tp14961
sS'of,drug-metab'
p14962
(F1
F0.00076452599388379206
I0
I1
I-1
tp14963
sS'were,and'
p14964
(F1
F0.00076452599388379206
I1
I0
I1
tp14965
sS'but,did'
p14966
(F0
F0
I1
I1
I0
tp14967
sS'tetrahydropyridine,mptp'
p14968
(F1
F0.00076452599388379206
I0
I1
I-1
tp14969
sS'excretion,or'
p14970
(F1
F0.00076452599388379206
I0
I1
I-1
tp14971
sS'by,is'
p14972
(F0
F0
I2
I2
I0
tp14973
sS'therapy,should'
p14974
(F1
F0.00076452599388379206
I1
I0
I1
tp14975
sS'oral,have'
p14976
(F1
F0.00076452599388379206
I1
I0
I1
tp14977
sS'when,both'
p14978
(F1
F0.00076452599388379206
I1
I0
I1
tp14979
sS'results,are'
p14980
(F1
F0.00076452599388379206
I1
I0
I1
tp14981
sS'certain,heart'
p14982
(F1
F0.00076452599388379206
I1
I0
I1
tp14983
sS'cci-779,has'
p14984
(F1
F0.00076452599388379206
I1
I0
I1
tp14985
sS'not,verified'
p14986
(F1
F0.00076452599388379206
I0
I1
I-1
tp14987
sS'xenical,was'
p14988
(F1
F0.00076452599388379206
I1
I0
I1
tp14989
sS'inhibitors,ketoconazole'
p14990
(F1
F0.00076452599388379206
I1
I0
I1
tp14991
sS'not,affected'
p14992
(F1
F0.0030581039755351682
I0
I4
I-4
tp14993
sS'that,may'
p14994
(F0.5
F0.0030581039755351682
I6
I2
I4
tp14995
sS'vesicare,when'
p14996
(F1
F0.00076452599388379206
I1
I0
I1
tp14997
sS'doses,higher'
p14998
(F1
F0.00076452599388379206
I1
I0
I1
tp14999
sS'increased,by'
p15000
(F1
F0.0030581039755351682
I4
I0
I4
tp15001
sS'demonstrated,that'
p15002
(F0.5
F0.0015290519877675841
I3
I1
I2
tp15003
sS'of,available'
p15004
(F1
F0.00076452599388379206
I1
I0
I1
tp15005
sS'kg,saline'
p15006
(F1
F0.00076452599388379206
I0
I1
I-1
tp15007
sS'are,substrates'
p15008
(F1
F0.00076452599388379206
I0
I1
I-1
tp15009
sS'signs,were'
p15010
(F1
F0.00076452599388379206
I0
I1
I-1
tp15011
sS'action,of'
p15012
(F0.5
F0.0045871559633027525
I9
I3
I6
tp15013
sS'sodium,bicarbonate'
p15014
(F1
F0.00076452599388379206
I0
I1
I-1
tp15015
sS'blood,dyscrasia'
p15016
(F1
F0.00076452599388379206
I1
I0
I1
tp15017
sS'study,population'
p15018
(F1
F0.00076452599388379206
I1
I0
I1
tp15019
sS'or,multiple'
p15020
(F1
F0.00076452599388379206
I0
I1
I-1
tp15021
sS'inhibitors,in'
p15022
(F1
F0.00076452599388379206
I0
I1
I-1
tp15023
sS'could,lead'
p15024
(F1
F0.0015290519877675841
I2
I0
I2
tp15025
sS'is,not'
p15026
(F0.29999999999999999
F0.0045871559633027525
I7
I13
I-6
tp15027
sS'inactivated,newcastle'
p15028
(F1
F0.00076452599388379206
I0
I1
I-1
tp15029
sS'inhibitors,is'
p15030
(F0
F0
I1
I1
I0
tp15031
sS'vitro,data'
p15032
(F1
F0.00076452599388379206
I1
I0
I1
tp15033
sS'anticoagulation,test'
p15034
(F1
F0.00076452599388379206
I1
I0
I1
tp15035
sS'recommended,doses'
p15036
(F1
F0.0015290519877675841
I2
I0
I2
tp15037
sS'concentrations,in'
p15038
(F1
F0.0022935779816513763
I3
I0
I3
tp15039
sS'chickens,to'
p15040
(F1
F0.00076452599388379206
I0
I1
I-1
tp15041
sS'of,therapy'
p15042
(F1
F0.0015290519877675841
I2
I0
I2
tp15043
sS'increased,when'
p15044
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp15045
sS'yogurt,ripe'
p15046
(F1
F0.00076452599388379206
I1
I0
I1
tp15047
sS'containing,drugs'
p15048
(F1
F0.00076452599388379206
I1
I0
I1
tp15049
sS'further,increase'
p15050
(F1
F0.0015290519877675841
I0
I2
I-2
tp15051
sS'neurons,as'
p15052
(F1
F0.00076452599388379206
I1
I0
I1
tp15053
sS'phenothiazines,are'
p15054
(F1
F0.00076452599388379206
I1
I0
I1
tp15055
sS'induction,dose'
p15056
(F1
F0.00076452599388379206
I1
I0
I1
tp15057
sS'receiving,azole'
p15058
(F1
F0.00076452599388379206
I1
I0
I1
tp15059
sS'may,further'
p15060
(F1
F0.00076452599388379206
I0
I1
I-1
tp15061
sS'concurrently,taking'
p15062
(F1
F0.00076452599388379206
I1
I0
I1
tp15063
sS'at,relevant'
p15064
(F1
F0.00076452599388379206
I1
I0
I1
tp15065
sS'to,active'
p15066
(F1
F0.00076452599388379206
I1
I0
I1
tp15067
sS'zavesca,is'
p15068
(F1
F0.00076452599388379206
I1
I0
I1
tp15069
sS'hypotension,that'
p15070
(F1
F0.00076452599388379206
I1
I0
I1
tp15071
sS'in,patients'
p15072
(F0.5357142857142857
F0.022935779816513763
I43
I13
I30
tp15073
sS'cheese,and'
p15074
(F1
F0.00076452599388379206
I1
I0
I1
tp15075
sS'and,combinations'
p15076
(F1
F0.00076452599388379206
I0
I1
I-1
tp15077
sS'enhances,sensitivity'
p15078
(F1
F0.00076452599388379206
I1
I0
I1
tp15079
sS'containing,ml'
p15080
(F1
F0.00076452599388379206
I1
I0
I1
tp15081
sS'lower,the'
p15082
(F1
F0.00076452599388379206
I0
I1
I-1
tp15083
sS'containing,mg'
p15084
(F1
F0.0015290519877675841
I0
I2
I-2
tp15085
sS'inhibitors,and'
p15086
(F0.33333333333333331
F0.0015290519877675841
I4
I2
I2
tp15087
sS'apoptosis,induced'
p15088
(F1
F0.00076452599388379206
I0
I1
I-1
tp15089
sS'two,hours'
p15090
(F1
F0.00076452599388379206
I1
I0
I1
tp15091
sS'initiation,of'
p15092
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp15093
sS'and,coadministration'
p15094
(F1
F0.00076452599388379206
I1
I0
I1
tp15095
sS'acute,administration'
p15096
(F1
F0.00076452599388379206
I1
I0
I1
tp15097
sS'arthritis,ra'
p15098
(F1
F0.00076452599388379206
I0
I1
I-1
tp15099
sS'stem-and,leaf'
p15100
(F1
F0.0015290519877675841
I0
I2
I-2
tp15101
sS'the,alkyating'
p15102
(F1
F0.00076452599388379206
I0
I1
I-1
tp15103
sS'testing,found'
p15104
(F1
F0.00076452599388379206
I0
I1
I-1
tp15105
sS'the,subsequent'
p15106
(F1
F0.00076452599388379206
I1
I0
I1
tp15107
sS'and,possible'
p15108
(F1
F0.00076452599388379206
I0
I1
I-1
tp15109
sS'of,motor'
p15110
(F1
F0.00076452599388379206
I1
I0
I1
tp15111
sS'may,alter'
p15112
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp15113
sS'assessed,under'
p15114
(F1
F0.00076452599388379206
I0
I1
I-1
tp15115
sS'n,n'
p15116
(F1
F0.00076452599388379206
I0
I1
I-1
tp15117
sS'phase,whereas'
p15118
(F1
F0.00076452599388379206
I0
I1
I-1
tp15119
sS'intraocular,pressure'
p15120
(F1
F0.00076452599388379206
I1
I0
I1
tp15121
sS'mg,tid'
p15122
(F1
F0.00076452599388379206
I1
I0
I1
tp15123
sS'by,an'
p15124
(F1
F0.00076452599388379206
I1
I0
I1
tp15125
sS'high,dose'
p15126
(F1
F0.00076452599388379206
I1
I0
I1
tp15127
sS'with,ropivacaine'
p15128
(F1
F0.00076452599388379206
I1
I0
I1
tp15129
sS'drugs,without'
p15130
(F1
F0.00076452599388379206
I0
I1
I-1
tp15131
sS'interactions,associated'
p15132
(F1
F0.00076452599388379206
I0
I1
I-1
tp15133
sS'class,i'
p15134
(F1
F0.00076452599388379206
I1
I0
I1
tp15135
sS'treat,gastrointestinal'
p15136
(F1
F0.00076452599388379206
I1
I0
I1
tp15137
sS'cdk1,expression'
p15138
(F1
F0.00076452599388379206
I0
I1
I-1
tp15139
sS'hydrolysis,may'
p15140
(F1
F0.00076452599388379206
I0
I1
I-1
tp15141
sS'however,on'
p15142
(F1
F0.00076452599388379206
I1
I0
I1
tp15143
sS'the,renal'
p15144
(F1
F0.0015290519877675841
I2
I0
I2
tp15145
sS'secretion,by'
p15146
(F1
F0.00076452599388379206
I1
I0
I1
tp15147
sS'normal,renal'
p15148
(F1
F0.00076452599388379206
I1
I0
I1
tp15149
sS'in,aids'
p15150
(F1
F0.00076452599388379206
I1
I0
I1
tp15151
sS'delivery,of'
p15152
(F0
F0
I1
I1
I0
tp15153
sS'and,presence'
p15154
(F1
F0.00076452599388379206
I0
I1
I-1
tp15155
sS'the,present'
p15156
(F0.5
F0.0015290519877675841
I1
I3
I-2
tp15157
sS'cases,an'
p15158
(F1
F0.00076452599388379206
I1
I0
I1
tp15159
sS'given,consideration'
p15160
(F1
F0.00076452599388379206
I1
I0
I1
tp15161
sS'protein,gfp'
p15162
(F1
F0.00076452599388379206
I0
I1
I-1
tp15163
sS'the,only'
p15164
(F1
F0.00076452599388379206
I1
I0
I1
tp15165
sS'depression,apnea'
p15166
(F1
F0.00076452599388379206
I1
I0
I1
tp15167
sS'to,convert'
p15168
(F1
F0.00076452599388379206
I0
I1
I-1
tp15169
sS'or,pharmacokinetics'
p15170
(F1
F0.00076452599388379206
I0
I1
I-1
tp15171
sS'agents,of'
p15172
(F1
F0.00076452599388379206
I1
I0
I1
tp15173
sS'positive,control'
p15174
(F1
F0.00076452599388379206
I0
I1
I-1
tp15175
sS'is,changed'
p15176
(F1
F0.00076452599388379206
I1
I0
I1
tp15177
sS'humoral,immune'
p15178
(F1
F0.0015290519877675841
I0
I2
I-2
tp15179
sS'agents,or'
p15180
(F0
F0
I1
I1
I0
tp15181
sS'fold,decrease'
p15182
(F1
F0.00076452599388379206
I0
I1
I-1
tp15183
sS'of,evaluated'
p15184
(F1
F0.00076452599388379206
I1
I0
I1
tp15185
sS'macrolide,eg'
p15186
(F1
F0.00076452599388379206
I1
I0
I1
tp15187
sS'with,mexitil'
p15188
(F1
F0.00076452599388379206
I1
I0
I1
tp15189
sS'with,hormonal'
p15190
(F0
F0
I1
I1
I0
tp15191
sS'itself,cause'
p15192
(F1
F0.00076452599388379206
I1
I0
I1
tp15193
sS'pth,by'
p15194
(F1
F0.00076452599388379206
I1
I0
I1
tp15195
sS'spiriva,with'
p15196
(F1
F0.00076452599388379206
I1
I0
I1
tp15197
sS'plate,or'
p15198
(F1
F0.00076452599388379206
I0
I1
I-1
tp15199
sS'combination,as'
p15200
(F1
F0.00076452599388379206
I1
I0
I1
tp15201
sS'of,from'
p15202
(F0
F0
I1
I1
I0
tp15203
sS'the,diffusion'
p15204
(F1
F0.00076452599388379206
I1
I0
I1
tp15205
sS'subjects,and'
p15206
(F1
F0.00076452599388379206
I1
I0
I1
tp15207
sS'leave,unchanged'
p15208
(F1
F0.00076452599388379206
I1
I0
I1
tp15209
sS'inhibitors,to'
p15210
(F0
F0
I1
I1
I0
tp15211
sS'for,angina'
p15212
(F1
F0.00076452599388379206
I0
I1
I-1
tp15213
sS'normal,hematopoiesis'
p15214
(F1
F0.00076452599388379206
I0
I1
I-1
tp15215
sS'system,ie'
p15216
(F1
F0.00076452599388379206
I1
I0
I1
tp15217
sS'on,absorption'
p15218
(F0.20000000000000001
F0.00076452599388379206
I2
I3
I-1
tp15219
sS'does,not'
p15220
(F0.53846153846153844
F0.0053516819571865441
I3
I10
I-7
tp15221
sS'of,auc'
p15222
(F1
F0.00076452599388379206
I0
I1
I-1
tp15223
sS'high,renal'
p15224
(F1
F0.00076452599388379206
I1
I0
I1
tp15225
sS'an,indication'
p15226
(F1
F0.00076452599388379206
I0
I1
I-1
tp15227
sS'activity,is'
p15228
(F1
F0.00076452599388379206
I0
I1
I-1
tp15229
sS'were,shown'
p15230
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp15231
sS'not,affect'
p15232
(F1
F0.0030581039755351682
I0
I4
I-4
tp15233
sS'delirium,high'
p15234
(F1
F0.00076452599388379206
I1
I0
I1
tp15235
sS'and,induced'
p15236
(F1
F0.00076452599388379206
I1
I0
I1
tp15237
sS'impaired,by'
p15238
(F1
F0.00076452599388379206
I1
I0
I1
tp15239
sS'groups,methyl-4'
p15240
(F1
F0.00076452599388379206
I0
I1
I-1
tp15241
sS'of,muscle'
p15242
(F1
F0.00076452599388379206
I0
I1
I-1
tp15243
sS'that,and'
p15244
(F1
F0.0022935779816513763
I3
I0
I3
tp15245
sS'in,herceptin'
p15246
(F1
F0.00076452599388379206
I1
I0
I1
tp15247
sS'abt-737,and'
p15248
(F1
F0.00076452599388379206
I1
I0
I1
tp15249
sS'on,may'
p15250
(F1
F0.00076452599388379206
I1
I0
I1
tp15251
sS'following,different'
p15252
(F1
F0.00076452599388379206
I0
I1
I-1
tp15253
sS'aim,of'
p15254
(F1
F0.00076452599388379206
I0
I1
I-1
tp15255
sS'in,substantial'
p15256
(F1
F0.00076452599388379206
I1
I0
I1
tp15257
sS'cytochrome,p450'
p15258
(F0.41176470588235292
F0.0053516819571865441
I12
I5
I7
tp15259
sS'the,dose'
p15260
(F0.14285714285714285
F0.00076452599388379206
I4
I3
I1
tp15261
sS'or,reduce'
p15262
(F1
F0.00076452599388379206
I1
I0
I1
tp15263
sS'with,myfortic'
p15264
(F1
F0.0015290519877675841
I2
I0
I2
tp15265
sS'between,the'
p15266
(F1
F0.00076452599388379206
I0
I1
I-1
tp15267
sS'and,eldepryl'
p15268
(F1
F0.00076452599388379206
I1
I0
I1
tp15269
sS'interference,of'
p15270
(F1
F0.00076452599388379206
I0
I1
I-1
tp15271
sS'by,both'
p15272
(F1
F0.00076452599388379206
I1
I0
I1
tp15273
sS'and,k-ras'
p15274
(F0
F0
I1
I1
I0
tp15275
sS'potent,inducers'
p15276
(F1
F0.00076452599388379206
I1
I0
I1
tp15277
sS'doses,ranging'
p15278
(F1
F0.00076452599388379206
I1
I0
I1
tp15279
sS'chemet,with'
p15280
(F1
F0.00076452599388379206
I1
I0
I1
tp15281
sS'adverse,effect'
p15282
(F1
F0.00076452599388379206
I0
I1
I-1
tp15283
sS'expected,to'
p15284
(F0.59999999999999998
F0.0022935779816513763
I1
I4
I-3
tp15285
sS'johns,wort'
p15286
(F1
F0.00076452599388379206
I1
I0
I1
tp15287
sS'of,doses'
p15288
(F1
F0.0015290519877675841
I0
I2
I-2
tp15289
sS'or,cardiac'
p15290
(F1
F0.00076452599388379206
I1
I0
I1
tp15291
sS'or,since'
p15292
(F1
F0.00076452599388379206
I1
I0
I1
tp15293
sS'k,antagonists'
p15294
(F1
F0.0015290519877675841
I2
I0
I2
tp15295
sS'cannot,take'
p15296
(F1
F0.00076452599388379206
I1
I0
I1
tp15297
sS'centrally,acting'
p15298
(F0
F0
I1
I1
I0
tp15299
sS'subjects,did'
p15300
(F1
F0.00076452599388379206
I0
I1
I-1
tp15301
sS'affect,gastrointestinal'
p15302
(F1
F0.00076452599388379206
I1
I0
I1
tp15303
sS'time,the'
p15304
(F1
F0.00076452599388379206
I1
I0
I1
tp15305
sS'serotonin,reuptake'
p15306
(F0.33333333333333331
F0.00076452599388379206
I2
I1
I1
tp15307
sS'to,prolongation'
p15308
(F1
F0.00076452599388379206
I1
I0
I1
tp15309
sS'normal-weight,female'
p15310
(F1
F0.00076452599388379206
I0
I1
I-1
tp15311
sS'some,steroid'
p15312
(F1
F0.00076452599388379206
I1
I0
I1
tp15313
sS'interrupt,dosing'
p15314
(F1
F0.00076452599388379206
I1
I0
I1
tp15315
sS'given,orally'
p15316
(F1
F0.00076452599388379206
I0
I1
I-1
tp15317
sS'inhibitors,tested'
p15318
(F1
F0.00076452599388379206
I0
I1
I-1
tp15319
sS'contributed,person-years'
p15320
(F1
F0.00076452599388379206
I0
I1
I-1
tp15321
sS'all,studies'
p15322
(F1
F0.00076452599388379206
I0
I1
I-1
tp15323
sS'metabolize,some'
p15324
(F1
F0.00076452599388379206
I1
I0
I1
tp15325
sS'high,levels'
p15326
(F1
F0.00076452599388379206
I0
I1
I-1
tp15327
sS'a,vitamin'
p15328
(F1
F0.00076452599388379206
I1
I0
I1
tp15329
sS'metabolite,an'
p15330
(F1
F0.00076452599388379206
I0
I1
I-1
tp15331
sS'in,female'
p15332
(F1
F0.00076452599388379206
I1
I0
I1
tp15333
sS'the,elimination'
p15334
(F1
F0.0015290519877675841
I2
I0
I2
tp15335
sS'iii,or'
p15336
(F0.33333333333333331
F0.00076452599388379206
I1
I2
I-1
tp15337
sS'retrospectively,reviewed'
p15338
(F1
F0.00076452599388379206
I0
I1
I-1
tp15339
sS'nitrogen,substituted'
p15340
(F1
F0.00076452599388379206
I1
I0
I1
tp15341
sS'in,higher'
p15342
(F1
F0.00076452599388379206
I0
I1
I-1
tp15343
sS'role,of'
p15344
(F0
F0
I1
I1
I0
tp15345
sS'hydroxide,hydroxide'
p15346
(F1
F0.00076452599388379206
I0
I1
I-1
tp15347
sS'with,those'
p15348
(F1
F0.0015290519877675841
I2
I0
I2
tp15349
sS'any,clinically'
p15350
(F1
F0.0015290519877675841
I0
I2
I-2
tp15351
sS'taking,these'
p15352
(F1
F0.00076452599388379206
I1
I0
I1
tp15353
sS'time,pt'
p15354
(F1
F0.0015290519877675841
I2
I0
I2
tp15355
sS'cardiovascular,events'
p15356
(F1
F0.00076452599388379206
I1
I0
I1
tp15357
sS'cyp,b6'
p15358
(F1
F0.00076452599388379206
I0
I1
I-1
tp15359
sS'unpredictable,myelotoxicity'
p15360
(F1
F0.00076452599388379206
I1
I0
I1
tp15361
sS'ketoconazole-mediated,cyp3a4'
p15362
(F1
F0.00076452599388379206
I0
I1
I-1
tp15363
sS'occur,earlier'
p15364
(F1
F0.00076452599388379206
I1
I0
I1
tp15365
sS'use,with'
p15366
(F0.59999999999999998
F0.0022935779816513763
I4
I1
I3
tp15367
sS'and,antiplatelet'
p15368
(F1
F0.00076452599388379206
I1
I0
I1
tp15369
sS'blocking,agents'
p15370
(F0.14285714285714285
F0.00076452599388379206
I4
I3
I1
tp15371
sS'achieving,adequate'
p15372
(F1
F0.00076452599388379206
I0
I1
I-1
tp15373
sS'within,hours'
p15374
(F1
F0.0015290519877675841
I2
I0
I2
tp15375
sS'cholinesterase,inhibitors'
p15376
(F1
F0.0015290519877675841
I2
I0
I2
tp15377
sS'in,cases'
p15378
(F1
F0.00076452599388379206
I0
I1
I-1
tp15379
sS'd,on'
p15380
(F1
F0.00076452599388379206
I0
I1
I-1
tp15381
sS'that,administering'
p15382
(F1
F0.00076452599388379206
I1
I0
I1
tp15383
sS'shown,a'
p15384
(F1
F0.00076452599388379206
I1
I0
I1
tp15385
sS'of,ropivacaine'
p15386
(F1
F0.00076452599388379206
I1
I0
I1
tp15387
sS'to,rheumatoid'
p15388
(F1
F0.0015290519877675841
I0
I2
I-2
tp15389
sS'patients,are'
p15390
(F1
F0.00076452599388379206
I1
I0
I1
tp15391
sS'inhibitors,can'
p15392
(F1
F0.00076452599388379206
I1
I0
I1
tp15393
sS'glycosides,may'
p15394
(F1
F0.00076452599388379206
I1
I0
I1
tp15395
sS'supplements,absorbent-type'
p15396
(F1
F0.00076452599388379206
I1
I0
I1
tp15397
sS'transfection,with'
p15398
(F1
F0.00076452599388379206
I0
I1
I-1
tp15399
sS'on,and'
p15400
(F1
F0.00076452599388379206
I1
I0
I1
tp15401
sS'similar,drugs'
p15402
(F1
F0.00076452599388379206
I1
I0
I1
tp15403
sS'not,produce'
p15404
(F1
F0.00076452599388379206
I1
I0
I1
tp15405
sS'promising,oral'
p15406
(F1
F0.00076452599388379206
I0
I1
I-1
tp15407
sS'in,each'
p15408
(F1
F0.00076452599388379206
I0
I1
I-1
tp15409
sS'who,subsequently'
p15410
(F1
F0.00076452599388379206
I1
I0
I1
tp15411
sS'respect,to'
p15412
(F1
F0.0015290519877675841
I0
I2
I-2
tp15413
sS'reactivity,and'
p15414
(F1
F0.00076452599388379206
I0
I1
I-1
tp15415
sS'activity,in'
p15416
(F1
F0.00076452599388379206
I0
I1
I-1
tp15417
sS'glass,jar'
p15418
(F1
F0.00076452599388379206
I0
I1
I-1
tp15419
sS'patients,also'
p15420
(F1
F0.00076452599388379206
I1
I0
I1
tp15421
sS'is,administered'
p15422
(F0.42857142857142855
F0.0022935779816513763
I5
I2
I3
tp15423
sS'compounds,predominantly'
p15424
(F1
F0.00076452599388379206
I0
I1
I-1
tp15425
sS'requirements,when'
p15426
(F1
F0.0015290519877675841
I2
I0
I2
tp15427
sS'and,monoamine'
p15428
(F1
F0.00076452599388379206
I0
I1
I-1
tp15429
sS'great,caution'
p15430
(F1
F0.0022935779816513763
I3
I0
I3
tp15431
sS'necessary,during'
p15432
(F1
F0.00076452599388379206
I1
I0
I1
tp15433
sS'both,and'
p15434
(F0
F0
I1
I1
I0
tp15435
sS'this,experience'
p15436
(F1
F0.00076452599388379206
I1
I0
I1
tp15437
sS'primarily,an'
p15438
(F1
F0.00076452599388379206
I0
I1
I-1
tp15439
sS'cysteine,with'
p15440
(F1
F0.00076452599388379206
I0
I1
I-1
tp15441
s.